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As result of progress, endoscopy has became more complex, using more sophisticated 
devices and has claimed a special form. In this moment, the gastroenterologist 
performing endoscopy has to be an expert in macroscopic view of the lesions in the gut, 
with good skills for using standard endoscopes, with good experience in ultrasound 
(for performing endoscopic ultrasound), with pathology experience for confocal 
examination. It is compulsory to get experience and to have patience and attention for 
the follow-up of thousands of images transmitted during capsule endoscopy or to have 
knowledge in physics necessary for autofluorescence imaging endoscopy. Therefore, the 
idea of an endoscopist has changed. Examinations mentioned need a special formation, 
a superior level of instruction, accessible to those who have already gained enough 
experience in basic diagnostic endoscopy. This is the reason for what these new issues of 
endoscopy are presented in this book of New techniques in Gastrointestinal Endoscopy.
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Several decades have passed since endoscopy was introduced as a diagnostic method. 
Based on continuous cooperation between engineers and endoscopists, the 
standardization of endoscopic procedures in both diagnostic and therapeutic methods 
has been achieved. Furthermore, we assisted the uniting of academic and industrial 
research for obtaining further advances in GI endoscopy.  
As result of this progress, endoscopy has became more complex, using more 
sophisticated devices and it has claimed a special form. At this moment, the 
gastroenterologist performing endoscopy has to be an expert in the macrosopic view 
of lesions in the gut, with good skills for using standard endoscopes, good experience 
in ultrasound (for performing endoscopic ultrasound), pathology experience for 
confocal examination. It is compulsory to get experience and to have patience and 
attention for the follow-up of thousands of images transmitted during capsule 
endoscopy as well as to have knowledge in physics necessary for autofluorescence 
imaging endoscopy. 
Therefore, the idea of the endoscopist has changed. Examinations mentioned need a 
special formation, a superior level of instruction, accessible to those who have already 
gained enough experience in basic, diagnostic endoscopy. This is the reason for what 
these new issues of endoscopy are presented in this book New techniques in 
Gastrointestinal Endoscopy.  
The real benefit brought by this book is the presentation of latest developments in this 
field, as capsule endoscopy, confocal laser endomicroscopy, autofluorescence imaging 
endoscopy, endoscopic ultrasonography, advanced techniques for resection or 
stenting. Different issues are not presented only as general information, harvesting 
knowledge in literature, but highlight personal experiences of authors from all over 
the world. 
We are convinced that this book will be very useful to doctors who are performing 
these techniques, because there are many chapters written by impressive 
gastroenterologists with large experience in their area, but also to young fellows in 
formation who want to perform them in the future. Reasons for utility of the book are 
the didactic, complete and detailed presentation, with indications, contraindications, 
risks and complications for every method described.  
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1. Introduction 
Endoscopic ultrasound (EUS) has revolutionized the field of gastrointestinal endoscopy, and 
it plays a pivotal role in the staging of tumors of the upper gastrointestinal (GI) tract. EUS 
provides high-resolution imaging of both intraluminal and extraluminal structures, 
allowing for the detection and staging of even the smallest tumors in a minimally invasive 
manner. The accuracy of EUS in assessing depth of invasion of luminal tumors (T stage) is 
greater than other imaging modalities, including multi-detector CT and MRI. The addition 
of fine needle aspiration (FNA) allows for assessment of nodal involvement (N stage), and 
although the quality of images obtained by CT and MRI continue to rapidly advance, EUS 
remains essential for obtaining tissue samples and for the definitive diagnosis of lesions 
within or adjacent to the upper GI tract.  
This chapter aims to serve as an evidence-based and comprehensive review used to guide 
endosonographers involved in the care of patients with upper GI tract malignancies. We 
will outline the goals, challenges, and pitfalls encountered during the EUS evaluation for 
cancer staging. Furthermore, we will discuss the endoscopic technique best utilized for 
assessing cancers of the esophagus, stomach, ampulla and duodenum. 
2. Basic EUS principles for staging upper GI tumors 
The expertise of the endosonographer is considered one of the most important aspects in the 
staging of upper GI tract malignancy. A complete understanding of the normal anatomy 
and common congenital anomalies of the organ studied is a prerequisite for an accurate 
examination. Experience in identifying local and regional lymph nodes, and precisely 
assessing the level of tumor invasion, is critical for directing patients into the appropriate 
treatment algorithm; as often the choice of surgical procedure relies upon this information. 
There are several classification systems currently in use for defining GI cancers, predicting 
prognosis and determining treatment. Most commonly used is the tumor, node, metastasis 
(TNM) staging system as described by the American Joint Committee on Cancer (AJCC) [1]. 
The basic technique for performing endoscopic ultrasound for staging is similar for tumors 
located in the esophagus, stomach, and duodenum. We usually begin with standard upper 
endoscopy to visually assess the lesion, to determine whether the larger echoendoscope will 
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be able to traverse the lesion, and to dilate any luminal malignant strictures if necessary. The 
location of the tumor being studied will often direct the choice of radial or linear 
echoendoscope, or whether a   high-frequency ultrasound (HFUS) probe is needed. HFUS 
probes are ultrasound transducers located at the tip of a small-caliber (2 to 2.9 mm) catheter 
that can pass through the working channel of a standard endoscope. They are available in 
frequencies between 12-30 MHz and yield high-resolution images of the gastrointestinal 
wall layers. They are typically used in the evaluation and T staging of small or superficial 
masses. Several studies have shown equivalency to conventional EUS for T staging although 
conventional EUS is superior for nodal staging[2].  
In order to assess depth of invasion (T stage) for luminal tumors, it is necessary to identify 5 
layers of wall structure that correspond to the histological layers (Image 1). HFUS allows for 
the visualization of up to nine layers. Using an echoendoscope at a frequency between 7.5 
and 10 MHz, the 5 layers appear as alternating hyperechoic and hypoechoic bands as 
follows [3, 4]: 
 
 
1st hyperechoic layer: surface mucosa 
2nd hypoechoic layer: deep mucosa 
3rd hyperechoic layer: submucosa 
4th hypoechoic layer: muscularis propria 
5th hyperechoic layer: serosa (or adventitia in the esophagus) 
Image 1. High-frequency probe demonstrating the layers of the gastric wall. 
The EUS characteristics of lymph nodes for prediction of lymph node metastases (N stage) 
were originally described in patients with esophageal cancer. Features suggestive of 
metastatic lymph nodes are size greater than 1 cm, sharp borders, rounded shape, and 
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homogenous hypoechoic echo pattern. When all four of these predictive features were 
found in a single lymph node, lymph node metastases were found in 100% of cases [5]. EUS 
fine-needle aspiration (FNA) adds to the evaluation for malignant lymph nodes by safely 
and accurately providing tissue samples which can influence patient management [6]. 
3. Staging of esophageal tumors 
Esophageal tumors commonly present with symptoms of dysphagia and are often initially 
diagnosed by upper endoscopy. EUS provides superior loco-regional staging compared to 
other imaging modalities, and combined with FNA improves decision making regarding 
surgery and neo-adjuvant therapy [7, 8]. The role of EUS in early esophageal neoplasia is 
more controversial as endoscopic mucosal resection (EMR) may play an important role. 
CT is usually performed early in the staging of esophageal cancers to evaluate for evidence 
of metastatic disease. EUS is indicated for staging of esophageal cancers in the absence of 
distant metastases on initial CT scan or MRI. Determining a T stage is accomplished by EUS 
and the first step for the endosonographer is repeating the standard upper endoscopy. This 
will allow the endosonographer to document the location of the tumor, measure the extent 
of stricture and assess whether the echoendoscope will easily pass the tumor if a stricture 
exists. Inability to pass the echoendoscope beyond a stricture is generally associated with a 
poorer prognosis as it may suggest advanced disease, but an effort should be made to 
traverse strictures as a more accurate T and N stage can be determined [9, 10]. Dilation may 
be performed with either a Savary dilator over the wire, or with a through-the-scope (TTS) 
controlled radial expansion (CRE) dilation balloon. A higher rate of esophageal perforation 
has been reported with dilation of malignant esophageal strictures, but it is generally 
regarded as safe [11, 12]. In our practice, if we experience resistance due to a malignant 
stricture precluding passage of a standard EGD scope or echoendoscope, we dilate with a 
TTS CRE balloon up to 14-16 mm so as to then allow for a complete and thorough staging 
EUS exam. If a high-grade stricture is present, serial dilations may be necessary prior to the 
EUS staging. 
3.1 Determining the T stage 
Assessment of the depth of invasion of the tumor is necessary for determination of a T stage. 
CT and MRI lack the sensitivity to accurately distinguish between the different layers of the 
esophageal wall. EUS has excellent sensitivity and specificity in assessing depth of invasion 
that increases with more advanced tumors (T4 tumors) [13]. The T stage for primary 
adenocarcinomas of the esophagus, esophagogastric junction (EGJ), and esophageal 
squamous cell cancers (SCC) are the same according to the 7th Edition of the TNM staging 
manual of the American Joint Committee on Cancer (AJCC). EGJ tumors are those within 
the first 5 cm of the stomach that extend into the esophagogastric junction or distal thoracic 
esophagus. Non-anatomic classifications (histopathological cell type, histologic grade and 
tumor location) were identified in the latest revision of the manual for stage grouping [14].  
Once the tumor has been identified endoscopically, the echoendoscope should be carefully 
advanced beyond the most distal portion of the tumor. Minimal balloon distention should 
be utilized to minimize compression of the tumor and esophageal wall. Esophageal tumors 
appear as hypoechoic masses with irregular borders and penetration beyond the esophageal 
layers should be described. Measurement of the mass thickness should be noted as it can 
predict extra-esophageal extension [15]. Early esophageal cancers are defined as tumors 
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limited to the mucosa and/or submucosa but not extending into the muscular wall of the 
esophagus (T1)[16]. Tis is the earliest tumor stage and defined as high-grade dysplasia. It 
was previously known as carcinoma-in-situ and includes all noninvasive neoplastic 
epithelium [1, 14]. EUS is not accurate for mucosal evaluation and staging of these early 
lesions, even with the use of high-frequency endoscopic ultrasound probes. Tis lesions are 
best diagnosed by other means, such as endoscopic mucosal resection (EMR) [17]. 
Once a tumor has invaded the lamina propria, muscularis mucosa or submucosa but not 
the muscularis propria, it considered a stage T1 tumor. This stage is further sub-divided 
to T1a (also known as T1m and further subdivided to m1: limited to the epithelial layer, 
m2: invading lamina propria and m3: invading into but not through muscularis mucosa) 
for tumors that invade the lamina propria or muscularis mucosa;  and T1b (also known as 
T1sm and further subdivided into thirds to sm1, sm2 and sm3: deepest one third of the 
submucosa) for tumors that invade the submucosa [1, 13, 18]. The depth of invasion 
predicts the probability of lymph node metastasis, vascular invasion and long-term 
survival [19]. There has been much debate and controversy regarding the staging 
modality for early esophageal cancers. Although EUS can distinguish between stages T1 
and >T1, recent data has shown that EUS is not sufficiently accurate in distinguishing 
between T1a and T1b tumors and pathological staging by EMR should be performed [17, 
20, 21]. Whether EUS should be performed prior to EMR is another debatable topic and 
beyond the scope of this chapter. Small caliber high-frequency EUS probes are able to 
visualize nine esophageal layers and may be able to accurately identify depth of invasion 
to guide therapy [18, 22, 23]. 
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Stage T2 tumors have invaded the fourth hypoechoic layer, the muscularis propria. In a 
recent meta-analysis, the diagnostic accuracy of EUS in staging of a T2 tumor was found to 
have a sensitivity of 81.4% and specificity of 96.3% [13]. The distinction between a T2 and T3 
tumor is important in the decision for neoadjuvant therapy [24]. The endosonographer 
needs to be cautioned that overstaging of T2 tumors can lead to the inappropriate use of 
neoadjuvant therapy instead of immediate surgery [25]. 
EUS has its highest accuracy in staging advanced tumors. The distinction between a T3 
(tumor invading adventitia, or going through the muscularis propria) and a T4 (tumor 
invading adjacent structures) is important in that it can determine resectability [1, 7, 14]. In 
the latest revision of the AJCC Staging Manual, T4 tumors were divided into resectable 
tumors (T4a) and unresectable (T4b). Those tumors invading pleura, pericardium and 
diaphragm are considered resectable and those invading other structures such as the trachea 
and aorta are considered unresectable [1, 26]. 
 
 
Image 3. T2 N1 Esophageal tumor; the mass can be seen invading through 4 of 5 esophageal 
layers. The adventitia is intact and there is no infiltration of tumor into adjacent structures. 
A recent meta-analysis and systematic review of 49 studies showed EUS to have a high 
pooled sensitivity for T staging between 81-90% with a pooled specificity of approximately 
99%. The pooled sensitivity and specificity of EUS for assessing tumor depth per T stage 
were 81.6% and 99.4% for T1, 81.4% and 96.3% for T2, 91.4% and 94.4% for T3, and 92.4% 
and 97.4% for T4 [13]. 
3.2 Determining the N stage 
EUS has a high accuracy for detecting regional lymph node involvement with a high 
sensitivity and specificity (85% and 85% respectively in a recent meta-analysis). FNA 
significantly improves the diagnostic capability of EUS for detecting malignant lymph nodes 
(sensitivity of 97% and specificity of 96%) by adding cytological analysis [13]. The 
 
New Techniques in Gastrointestinal Endoscopy 6 
limited to the mucosa and/or submucosa but not extending into the muscular wall of the 
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was previously known as carcinoma-in-situ and includes all noninvasive neoplastic 
epithelium [1, 14]. EUS is not accurate for mucosal evaluation and staging of these early 
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characteristics of a malignant node are size greater than 1 cm, rounded shape, sharp 
borders, and homogenous hypoechogenicity [5]. Malignant lymph nodes are usually in close 
proximity to the esophageal mass and often FNA can be impeded by the mass if in the 
trajectory of the needle. A selective approach to EUS-FNA may be applied by use of the 
modified EUS criteria for lymph node staging (standard characteristics plus EUS identified 
celiac lymph nodes, >5 lymph nodes, or EUS T3/4 tumor) for increased accuracy and 
decreased need for FNA (and cost) [27]. 
Regional lymph nodes are defined as any para-esophageal node extending from cervical 
nodes to celiac nodes. The number of involved lymph nodes--instead of their location--has 
been found to have prognostic implications [28-30]. This led to a revision of the N 
classification to support groupings of number of positive nodes as follows:  N0 (none), N1 
(1–2), N2 (3–6), and N3 (≥7) [14]. The examination for metastatic lymph nodes begins with 
examination of the celiac axis and the diaphragmatic crurae and continues as the scope is 
withdrawn through the esophagus. Peri-tumoral lymph nodes should be noted during 
determination of the T stage and the remainder of the mediastinum should be carefully 
examined as the scope is withdrawn.  
3.3 Determining the M stage 
The liver is the most common site of distant metastases of esophageal cancer. EUS can 
accurately evaluate the medial two thirds of the liver for metastases but cannot reliably 
exclude metastases in the entire liver [7]. CT and PET are most commonly used to evaluate 
for distant metastases. The role of EUS is greatest in confirming the presence of metastases 
in distant lymph nodes or lesions in the liver. The accuracy is increased by FNA and 
cytological evaluation of liver lesions as small as 4 mm [31-33]. Careful examination of the 
liver should be performed during staging for occult metastases not identified by other 
imaging studies. Identification of occult lesions may be low but can change the management 
of the patient. Any focal, discrete hypoechoic lesion of the liver identified should be 
sampled by EUS [34].  
Malignant celiac lymph nodes are no longer considered metastatic and are grouped with 
regional lymph nodes. M classification is simply designated as M0 for no distant metastases, 
and M1 for presence of distant metastases [14]. 
4. Restaging following neoadjuvant therapy 
The overall accuracy of EUS to assess the response to neoadjuvant chemotherapy or 
chemoradiotherapy is much less accurate than for initial staging and its role for this purpose 
is debatable [35, 36]. The presence of inflammation and fibrosis that remains following 
neoadjuvant therapy can be indistinguishable from residual tumor and may result in 
overstaging by EUS. Alternatively, residual microfoci of tumor in the esophageal wall may 
result in understaging [37]. Reduction of tumor thickness by > 50% is associated with a 
response to therapy and nodal status following neoadjuvant therapy has been shown to 
predict survival [36, 38, 39]. 
5. Staging of gastric tumors 
Patients with gastric cancer often present with advanced disease at the time of diagnosis, 
which is usually unresectable. Distant metastases and/or involvement of major blood 
vessels usually indicate unresectability. EUS is one of the primary means for loco-regional 
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staging of gastric cancers. Patients typically present with abdominal pain, nausea, early 
satiety, anorexia and weight loss that warrants an initial upper endoscopic evaluation. In 
addition, gastric cancers are often diagnosed endoscopically when a CT scan is performed 
and notes a thickened gastric fold or a non-healing ulcer. EUS is then performed for further 
loco-regional staging.  
The choice of echoendoscope for evaluation of gastric tumors is dependent on the location of 
the tumor and often a personal preference of the endosonographer. Obtaining adequate 
acoustic coupling between the gastric wall and the transducer can present a challenge. It is 
critical to remove all of the air from the stomach and instill up to 500 mL of water in order to 
adequately evaluate lesions (especially if the lesion is small). Changing the patient’s 
position, such as placing the patient in a reverse Trendelenberg position to evaluate a lesion 
in the antrum, is often necessary to allow the water to pool in the targeted area. Care must 
be taken in preventing aspiration as these patients are sedated and thus possess a 
diminished gag reflex. A radial echoendoscope operating between 7.5 and 10 MHz allows 
for adequate sonographic views of the gut wall with visualization of all 5 wall layers. Some 
endosonographers prefer a linear echoendoscope since it allows for FNA of lymph nodes 
without having to change endoscopes. Lastly, if a smaller lesion such as an early gastric 
cancer is encountered, a high-frequency ultrasound probe may provide the highest 
resolution to determine depth of invasion. 
5.1 Determining the T Stage 
EUS remains as the diagnostic tool of choice for evaluation of tumor depth in gastric cancer. 
This holds true especially in differentiating between early to intermediate (T1-2) and 
advanced (T3-4) primary tumors [40]. Gastric masses usually appear as irregular, poorly-
circumscribed hypoechoic masses. The depth of invasion is determined by the penetration 
into one of the sonographic layers. It is important to note the integrity of each of these layers 
as described below. 
The 7th edition of the AJCC gastric cancer staging system applies to tumors arising in the 
more distal stomach, and those arising in the proximal 5 cm without crossing the 
esophagogastric junction [41]. Tumors confined to the mucosa and submucosa (T1), 
regardless of the N stage, are considered early gastric cancer [42]. Tis is the earliest stage and 
reserved for intraepithelial tumors without invasion of the lamina propria [1]. The T1 
category is further subdivided into T1a for invasion of lamina propria or muscularis 
mucosa, and T1b for invasion of submucosa [41]. The distinction between Tis, T1a and T1b 
is important in deciding whether endoscopic resection is feasible. Contrary to staging in 
other parts of the GI tract, invasion of the lamina propria is classified as T1a rather than Tis 
since there is an abundance of lymphatic channels in the gastric mucosa, and thus associated 
lymph node metastases are possible when the tumor is confined to the lamina propria [41]. 
In areas with a high prevalence of gastric cancers, such as Japan and Korea, endoscopic 
mucosal resection (EMR) and endoscopic submucosal dissection (ESD) is widely employed 
as a safe and minimally invasive curative technique [43-46]. 
Invasion of the muscularis propria by tumor is considered T2 [1]. Sonographically, these 
lesions will involve the fourth layer (muscularis propria) without penetrating the fifth layer 
(serosa). Distinguishing between a T2  and T3 tumor can be difficult at times due to the 
subtle differences in the visualized gastric layers. Once the tumor has penetrated the fifth 
sonographic layer without invasion of visceral peritoneum or adjacent structures, it is 
classified as T3. In contrast to a T2 tumor, a T3 tumor will have irregular margins, often 
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staging of gastric cancers. Patients typically present with abdominal pain, nausea, early 
satiety, anorexia and weight loss that warrants an initial upper endoscopic evaluation. In 
addition, gastric cancers are often diagnosed endoscopically when a CT scan is performed 
and notes a thickened gastric fold or a non-healing ulcer. EUS is then performed for further 
loco-regional staging.  
The choice of echoendoscope for evaluation of gastric tumors is dependent on the location of 
the tumor and often a personal preference of the endosonographer. Obtaining adequate 
acoustic coupling between the gastric wall and the transducer can present a challenge. It is 
critical to remove all of the air from the stomach and instill up to 500 mL of water in order to 
adequately evaluate lesions (especially if the lesion is small). Changing the patient’s 
position, such as placing the patient in a reverse Trendelenberg position to evaluate a lesion 
in the antrum, is often necessary to allow the water to pool in the targeted area. Care must 
be taken in preventing aspiration as these patients are sedated and thus possess a 
diminished gag reflex. A radial echoendoscope operating between 7.5 and 10 MHz allows 
for adequate sonographic views of the gut wall with visualization of all 5 wall layers. Some 
endosonographers prefer a linear echoendoscope since it allows for FNA of lymph nodes 
without having to change endoscopes. Lastly, if a smaller lesion such as an early gastric 
cancer is encountered, a high-frequency ultrasound probe may provide the highest 
resolution to determine depth of invasion. 
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This holds true especially in differentiating between early to intermediate (T1-2) and 
advanced (T3-4) primary tumors [40]. Gastric masses usually appear as irregular, poorly-
circumscribed hypoechoic masses. The depth of invasion is determined by the penetration 
into one of the sonographic layers. It is important to note the integrity of each of these layers 
as described below. 
The 7th edition of the AJCC gastric cancer staging system applies to tumors arising in the 
more distal stomach, and those arising in the proximal 5 cm without crossing the 
esophagogastric junction [41]. Tumors confined to the mucosa and submucosa (T1), 
regardless of the N stage, are considered early gastric cancer [42]. Tis is the earliest stage and 
reserved for intraepithelial tumors without invasion of the lamina propria [1]. The T1 
category is further subdivided into T1a for invasion of lamina propria or muscularis 
mucosa, and T1b for invasion of submucosa [41]. The distinction between Tis, T1a and T1b 
is important in deciding whether endoscopic resection is feasible. Contrary to staging in 
other parts of the GI tract, invasion of the lamina propria is classified as T1a rather than Tis 
since there is an abundance of lymphatic channels in the gastric mucosa, and thus associated 
lymph node metastases are possible when the tumor is confined to the lamina propria [41]. 
In areas with a high prevalence of gastric cancers, such as Japan and Korea, endoscopic 
mucosal resection (EMR) and endoscopic submucosal dissection (ESD) is widely employed 
as a safe and minimally invasive curative technique [43-46]. 
Invasion of the muscularis propria by tumor is considered T2 [1]. Sonographically, these 
lesions will involve the fourth layer (muscularis propria) without penetrating the fifth layer 
(serosa). Distinguishing between a T2  and T3 tumor can be difficult at times due to the 
subtle differences in the visualized gastric layers. Once the tumor has penetrated the fifth 
sonographic layer without invasion of visceral peritoneum or adjacent structures, it is 
classified as T3. In contrast to a T2 tumor, a T3 tumor will have irregular margins, often 
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appearing as finger-like projections, or pseudopodia, extending into the gastrocolic or 
gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the 
visceral peritoneum covering these structures. T4 tumors are defined as those invading the 
serosa or adjacent structures, and they are divided into T4a for tumors invading the serosa 
(visceral peritoneum) and T4b for tumors invading adjacent structures such as spleen, 
transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small 
intestine, and retroperitoneum [1, 41].  
 
 
Image 4. T3 gastric adenocarcinoma with infiltration of the tumor beyond the 4th 
sonographic layer without penetration of the visceral peritoneum. 
A recent meta-analysis reviewed the available literature for the performance of EUS in 
staging of gastric cancer. The overall sensitivity for individual T stages ranged from 86% (for 
T3) to 65% for T2), and specificity of 96% (for T1) to 85% (for T3). An important observation 
of this meta-analysis was the high performance rates for differentiating between early to 
intermediate (T1-2) and advanced (T3-4) primary gastric tumors which may guide 
therapeutic management [40].  
5.2 Determining the N stage 
Similar to the newly adopted definition for N stage in staging of esophageal cancer, gastric 
cancer N stage classification is based on the number of regional lymph nodes as follows: N0 
(none), N1 (1-2), N2 (3-6), N3 (7 or greater). The necessity to count the number of lymph 
nodes, as well as the heterogeneity in the criterion for nodes regarded as malignant, present 
a difficult challenge in assessing for nodal involvement. Scanning for peri-gastric lymph 
serosa 
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nodes should begin from the antrum to the gastroesophageal junction with the balloon 
distended and the gastric lumen compressed. Water can be instilled to aid in the 
visualization if a large amount of air artifact is seen. Malignant lymph nodes are usually 
regarded as round, hypoechoic, sharp and greater than 1 cm [5]. Although one study of 
resected gastrectomy specimens showed that 55% of metastasis-containing nodes were less 
than 5 mm, suggesting that lymph node size is not a reliable predictor of metastases in 
gastric cancer [47]. 
5.3 Determining the M stage 
EUS is not suitable for detecting distant metastases but is sensitive in evaluating portions of 
the liver for metastatic disease and for malignant ascites. Various studies have shown that 
the detection of ascites by EUS in patients with gastric cancer is associated with peritoneal 
metastases [48-50]. Ascites appears as anechoic, triangular shaped collections of fluid in the 
peri-hepatic or peri-gastric regions. FNA can be formed for cytological evaluation. Care 
must be taken not to cross the tumor in order to obtain the fluid. This may produce a falsely 
positive result and also contaminate the fluid with malignant cells. Prophylactic antibiotics 
should be administered and continued post-procedure. Positive peritoneal cytology is 
classified as M1 [41].   
6. Infiltrating gastric malignancies 
Infiltrating malignancies of the stomach include the diffuse type of gastric adenocarcinoma 
(linitis plastica) and primary gastric lymphomas (PGL). EUS is important in determining the 
depth of involvement of these lesions. The normal gastric thickness is between 3 to 5 mm 
and appears thickened in infiltrating tumors. Sonographic images in linitis plastica will 
either show a homogenous appearance across all the layers of the gastric wall making the 
individual layers indistinguishable, or will appear as thickening of the third and fourth 
sonographic layer (submucosa and muscularis propria).   
Benign conditions can often mimic malignant conditions by presenting with thickened 
gastric folds, such as in protein-losing hypertrophic gastropathy (Ménétrier's disease), 
amyloidosis and Zollinger-Ellison syndrome. EUS will usually reveal thickening limited to 
the first and second sonographic layer indicating a mucosal disease. Large capacity and 
jumbo forceps biopsy can often provide sufficient tissue to aid in the diagnosis of these 
disorders. For lesions involving the third and fourth sonographic layers, deep endoscopic 
biopsies (using a bite-on-bite technique) or full-thickness surgical biopsies are often 
necessary to make a diagnosis. A few case reports and studies have shown EUS-FNA as a 
feasible technique for obtaining tissue samples from thickened folds or other lesions within 
the GI tract wall, especially when endoscopic biopsies are negative. One retrospective study 
of EUS-FNA in evaluating intramural and extramural GI tract lesions showed the 
sensitivity, specificity, and diagnostic accuracy of EUS-FNA in diagnosing GI tract 
neoplastic lesions were 89%, 88%, and 89%, respectively[51]. 
The staging of PGL is different than for gastric adenocarcinoma and utilizes either the 
modified Ann Arbor staging system or the modified TNM staging system named the Paris 
classification [52, 53]. Sonographic appearance of PGL varies and can mimic other 
infiltrative diseases both benign and malignant. The appearance may be of a focal nodular 
infiltration of the mucosa, or as diffuse hypoechoic thickening of the mucosal layers (first 
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resected gastrectomy specimens showed that 55% of metastasis-containing nodes were less 
than 5 mm, suggesting that lymph node size is not a reliable predictor of metastases in 
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classified as M1 [41].   
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depth of involvement of these lesions. The normal gastric thickness is between 3 to 5 mm 
and appears thickened in infiltrating tumors. Sonographic images in linitis plastica will 
either show a homogenous appearance across all the layers of the gastric wall making the 
individual layers indistinguishable, or will appear as thickening of the third and fourth 
sonographic layer (submucosa and muscularis propria).   
Benign conditions can often mimic malignant conditions by presenting with thickened 
gastric folds, such as in protein-losing hypertrophic gastropathy (Ménétrier's disease), 
amyloidosis and Zollinger-Ellison syndrome. EUS will usually reveal thickening limited to 
the first and second sonographic layer indicating a mucosal disease. Large capacity and 
jumbo forceps biopsy can often provide sufficient tissue to aid in the diagnosis of these 
disorders. For lesions involving the third and fourth sonographic layers, deep endoscopic 
biopsies (using a bite-on-bite technique) or full-thickness surgical biopsies are often 
necessary to make a diagnosis. A few case reports and studies have shown EUS-FNA as a 
feasible technique for obtaining tissue samples from thickened folds or other lesions within 
the GI tract wall, especially when endoscopic biopsies are negative. One retrospective study 
of EUS-FNA in evaluating intramural and extramural GI tract lesions showed the 
sensitivity, specificity, and diagnostic accuracy of EUS-FNA in diagnosing GI tract 
neoplastic lesions were 89%, 88%, and 89%, respectively[51]. 
The staging of PGL is different than for gastric adenocarcinoma and utilizes either the 
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classification [52, 53]. Sonographic appearance of PGL varies and can mimic other 
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and second sonographic layers) with fusion of these layers as the tumor extends [7, 54]. 
There is limited data in the literature regarding EUS for staging gastric lymphoma but it is 
generally accepted as the most accurate method to determine local stage. T stage accuracy 
has been reported between 80-92% and N stage between 77-90% [55]. FNA with flow-
cytometry of the aspirate may aid in the detection of metastatic lymph nodes and guide 
further management. The role of EUS in the follow-up of gastric lymphomas is not well-




Image 5. Infiltrating gastric adenocarcinoma with thickening of the submucosa and 
muscularis propria. 
7. Staging of ampullary tumors 
Carcinomas of the ampulla of Vater are rare and can arise from the major papilla, pancreas, 
duodenum and the common bile duct. EUS is useful in evaluating the depth of invasion of 
ampullary tumors and it aids in determining whether endoscopic resection is feasible. Like 
colon polyps, these lesions follow the adenoma-carcinoma sequence. Benign adenomas of 
the ampulla should be removed entirely by endoscopic ampullectomy. Conversely, 
malignant or invasive lesions should be removed surgically, often requiring a 
pancreaticoduodenectomy for complete resection. Patients with ampullary carcinomas 
typically present with obstructive jaundice or pancreatitis. Occasionally they are found 
incidentally by upper endoscopy. 
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Classification according to the 7th Edition of the AJCC staging system for tumors of the 
ampulla of Vater is as follows: Tis corresponds to carcinoma in situ, T1 tumors are limited to 
the ampulla of Vater or sphincter of Oddi, T2 tumors invade the duodenal wall, T3 tumors 
invade the pancreas, and T4 tumors invade peri-pancreatic soft tissues or other adjacent 
organs or structures other than the pancreas[1].  
Sonographic imaging of the ampulla of Vater can be performed either with a radial or 
linear-array echoendoscope. Once the echoendoscope is advanced to the second portion of 
the duodenum, it should be withdrawn slowly while scanning for the ampullary lesion. The 
balloon should be filled just enough as not to press on the ampullary lesion and water 
should be instilled into the duodenum for improved echogenic coupling. An alternative 
method is to visualize the ampullary lesion endoscopically and place the water-filled 
balloon directly on the lesion. A combination of both approaches may yield the best results. 
The ampulla appears as a hypoechoic structure arising from the wall of the duodenum 
usually measuring 8 to 12 mm. Ampullary tumors are hypoechoic masses at the ampulla 
which create loss of interface between the different echogenic layers of the duodenal wall. 
The sphincter of Oddi may be difficult to visualize but would appear as a thin hypoechoic 
layer surrounding the pancreaticobiliary duct. Extension of the hypoechoic mass within the 
biliary or pancreatic duct lumen, or wall thickening of the duct, suggests ductal infiltration 
[7, 56].  
The diagnostic accuracy of EUS in ampullary tumor staging is reportedly 0–100% for T1, 45–
100% for T2, and 75–100% for T3–T4 lesions with an overall accuracy in tumor staging from 
62 and 90% [57]. Decreased accuracy and understaging has been reported when a biliary 
stent is present. 
Intraductal ultrasound (IDUS) is yet another method of visualizing ampullary tumors by 
use of a high-frequency ultrasound probe (20-30 MHz) inserted into the bile duct during 
ERCP. Various studies have shown superior T staging for IDUS compared to EUS [56, 58, 
59], with overall accuracy for tumor staging ranging between 78-88% for IDUS. Limitations 
of IDUS include the necessity of ERCP for staging and cannulation of the bile duct (which 
may be difficult with larger tumors), cost of the probe, potential damage to the probe by the 
duodenoscope elevator, and its limited availability.  
Nodal metastases are best evaluated by EUS as it has been shown to have superior 
accuracy for detection of malignant lymph nodes compared to transabdominal ultrasound 
and CT [60-62]. MRI may show equal or improved lymph node detection. CT is superior 
for detection of distant metastases. The technique for malignant lymph node detection 
involves scanning the peri-pancreatic regions for any suspicious nodes. Regional lymph 
nodes (N1) are peri-pancreatic nodes including:  hepatic, hepatic artery, epiploic, omental, 
peri-portal,  infra-pyloric,  celiac, superior mesenteric, retroperitoneal, and lateral aortic 
(lumbar) nodes. Tumor involvement of other nodal groups such as splenic and para-aortic 
lymph nodes and those at the tail of the pancreas are not regional and classified as distant 
metastases (M1) [1]. FNA can be performed of any malignant appearing lymph nodes for 
cytological analysis. 
8. Staging of duodenal tumors 
Non-ampullary duodenal adenocarcinomas are exceedingly rare accounting for 1-2% of all 
GI malignancies and 25-50% of all small intestinal cancers. Adenocarcinomas are the most 
common followed by carcinoid tumors [1, 63, 64].  
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and second sonographic layers) with fusion of these layers as the tumor extends [7, 54]. 
There is limited data in the literature regarding EUS for staging gastric lymphoma but it is 
generally accepted as the most accurate method to determine local stage. T stage accuracy 
has been reported between 80-92% and N stage between 77-90% [55]. FNA with flow-
cytometry of the aspirate may aid in the detection of metastatic lymph nodes and guide 
further management. The role of EUS in the follow-up of gastric lymphomas is not well-




Image 5. Infiltrating gastric adenocarcinoma with thickening of the submucosa and 
muscularis propria. 
7. Staging of ampullary tumors 
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typically present with obstructive jaundice or pancreatitis. Occasionally they are found 
incidentally by upper endoscopy. 
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Duodenal tumors are staged using the 7th edition of the AJCC for Small Intestine Cancer.[1]  
The role of EUS in staging these tumors is not well-defined and has not been widely studied. 
Depending on the size of the tumor, a radial echoendoscope or a high-frequency ultrasound 
probe can be utilized to assess depth of invasion for T staging. In order to obtain accurate 
imaging of the 5 sonographic layers of the duodenal wall, all of the air should be aspirated 
out of the lumen and the tumor should be submerged in water. 
Nodal status is an important predictive factor for recurrence and survival in patients with 
resectable duodenal adenocarcinoma [64]. EUS can aid in the assessment of regional lymph 
nodes by counting and possibly performing FNA of suspicious nodes. 
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1. Introduction  
Surgery is the accepted standard treatment of early gastrointestinal cancer, defined as cancer 
with involvement confined to the mucosa or submucosa, regardless of the size or the 
presence of regional lymph-node metastases. However, recent progress in endoscopic 
technique has made it possible to treat gastrointestinal neoplasm. For example, early gastric 
cancer confined to the mucosa can be treated successfully with endoscopic resection alone. 
Endoscopic resection of early gastric cancer originated with the development of a 
polypectomy technique using high-frequency current for gastric polyps in 1968 (Niwa 1968), 
and has become popular as endoscopic mucosal resection (EMR) since the birth of the strip 
biopsy method in 1984 (Tada et al. 1984). Endoscopic submucosal dissection (ESD) is a new 
endoscopic technique using cutting devices that developed from one of the EMR techniques, 
namely endoscopic resection after local injection of a solution of hypertonic saline-
epinephrine (Hirano et al. 1988). EMR has recently been replaced by endoscopic submucosal 
dissection (ESD), because en bloc resection of specimens >20 mm in diameter is difficult to 
achieve with EMR, and piecemeal resection is associated with increased rates of local 
recurrence to about 15% (Muto et al. 2005, Oka et al. 2006). The technique of ESD was 
introduced to resect large specimens of early gastric cancer in a single piece. But, the 
question remains as to whether ESD is superior to EMR in all regards. This chapter provides 
an overview of EMR and ESD.  
2. Indication for EMR and ESD 
2.1 Esophagus 
Epithelial cancer (m1) and proper mucosal cancer (m2) are not associated with lymph-node 
metastasis. Cancer invaiding into the muscularis mucosae (m3) and to the upper third of the 
submucosal layer (sm1) are associated with lymph-node metastases in 10-15% of cases. 
However, when the cancer invades more deeply into the submucosal layer (sm2-sm3), 
lymph-node metastasis is present in 40-50% of cases. Cases of m1-m2 cancer are therefore 
absolute indications for EMR and ESD and cases of m3-sm1 cancer are relative indications 
(Makuuchi. 1996, Oyama et al. 2005). 
2.2 Stomach 
The indication for EMR is considered as intestinal well differentiated mucosal cancer 
without ulcer and less than 20 mm in diameter, because en bloc resection of specimens >20 
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mm in diameter is difficult to achieve with EMR. On the other hands, in the stomach no 
lymph-node metastasis were seen in large series of patients with intestinal well 
differentiated mucosal cancer without ulcer and no size limit, with ulcer with size less than 
30 mm, and in patients with submucosal cancer limited to sm1 infiltration (<500 μm deep 
in the submucosa starting from the muscularis mucosae) and less than 30 mm in diameter 
(Gotoda. 2007). Therefore, the indication for ESD is considered as above. 
2.3 Colon 
From the large numbers of surgically resected colorectal cases, intramucosal carcinomas and 
those with sm1 infiltration (< 1000μm deep in the submucosa starting from the muscularis 
mucosae) without lymphovascular infiltration have little risk of nodal metastasis (Kitajima 
et al. 2004). Tumor morphology and surface pit pattern are good endoscopic indicators for 
submucosal invasion. From this aspect, depressed lesions, laterally spreading tumors of 
non-granular type (LST-NG) and large protruding tumors are considered as good 
candidates for ESD because these lesions have a high risk of submucosal invasion, which 
may be difficult to diagnose preoperatively, and a thorough histopathological assessment of 
the resected specimen is essential. It is controversial whether one should perform ESD or 
piecemeal EMR for laterally spreading tumors of granular type (LST-G), because most 
lesions are intramucosal and the endoscopic prediction of invasiveness is highly feasible 
(Uraoka et al. 2006). 
3. EMR 
Various devices and techniques of EMR have been described. EMR is classified into 
techniques without an aspiration cap and techniques with an aspiration cap (Soetikno et al. 
2003). Strip biopsy methods using a single-channel scope or double-channel scope are 
included as techniques without an aspiration cap. Cap-assisted endoscopic mucosal 
resection (EMRC), endoscopic aspiration mucosectomy (EAM), endoscopic mucosal 





m:mucosa, sm: submucosa, mp: muscularis propria, se:serosa.  
Fig. 1. Four types of commonly used EMR techniques: (a) Strip biopsy method using a single-
channel scope, (b) Strip biopsy method using a double-channel scope, (c) Cap-assisted 
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3.1 Standard EMR: Strip biopsy method using a single-channel scope 
The lesion is raised off the muscularis propia by the creation of a submucosal bleb, 




Fig. 2. Technique of strip biopsy method: (a) The lesion is examined carefully and the border 
is defined. Electrocoagulation is used to mark the border of the lesion. (b) The submucosa is 
injected with saline solution with a sclerotherapy needle. The lesion must lift during and 
after injection before attempting resection. (c) The snare loop is placed at the base of the 
lesion. (d) The snare is closed. If the snare appears to entrap the muscularis propria, 
maneuvers to release the muscle are performed before the lesion is cut with blended current. 
(e) The specimen is removed.  
3.2 Strip biopsy method using a double-channel scope 
Submucosal injection is performed in standard fashion. Both the snare and grasping forceps 
are advanced through the channels. In preparation for EMR, the snare is opened to capture 
the forceps, then closed snugly. The lesion is grasped by the forceps and pulled gently into 
the now-opened snare. The snare is then closed and the lesion is resected (Tada et al. 1993, 
Takekoshi et al. 1994, Karita et al. 1992). 
 
 
Fig. 3. A double-channel scope 
3.3 EMRC 
EMRC has methods using a standard cap and my original devices. 
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Fig. 3. A double-channel scope 
3.3 EMRC 
EMRC has methods using a standard cap and my original devices. 
 




                                           (a)                                                              (b)  
  
                                         (c)                                                            (d) 
  
                                         (e)                                                          (f) 
Fig. 4. EMRC device: (a) Transparent plastic cap, (b) Soft 18-mm diameter cap, (c) EMRC-UI 
cap, (d) 2-channel prelooped cap, (e) IRS cap, (f) EMRC-C device; (c)-(f):Each devices placed 
at the top of the scope. 
3.3.1 EMRC (standard) 
EMRC is a simpler and easier refinement of EMR methods (Takeshita et al. 1993). The 
technique requires a specialized transparent plastic cap that is fitted to the tip of the 
endoscope. Different-sized caps are available, according to the diameter of the endoscope 
(MH-594 MAJ-290 etc. Olympus, Japan). In addition, a soft 18-mm diameter cap designed 
for en bloc resection of larger lesions is available (D-206, Olympus, Japan). Matsuzaki et al. 
(2003) used this soft cap for resection of gastric lesions 1.4-times larger than specimens that 
could be removed by the conventional cap. 
 
EMR and ESD for Gastrointestinal Neoplasms 
 
23 
After marking the periphery of the lesion, submucosal solution (saline, glucose, Glyceol®, 
etc.) is injected into the submucosa. The crescent-shaped snare (SD-221L-25 or SD-7P-1; 
Olympus, Japan) is then prelooped into the groove of the rim of the cap. The endoscopist 
performs this prelooping by lightly pressing against and suctioning normal mucosa to seal 
the cap outlet. The snare is opened and forced to rest along the inside groove of the rim of 
the cap to form the loop. Suction is released and the cap is then used to suck the lesion with 
medium to high vacuum into the cap. After the endoscopist strangulates the lesion by 
closing the snare, the suction is again released. After the lesion looks similar to a snared 
polypoid lesion, blend electrosurgical current is typically used to resect the lesion. 
3.3.2 EMRC-UI (EMRC under irrigation) 
One problem with the EMRC method is that the lesion cannot always be kept in the center 
of the cap, because the procedure is performed in a blind manner after aspiration. The 
usefulness of a novel end-hood that facilitates endoscopic hemostatic procedures while 
simultaneously allowing irrigation of the bleeding site was improved by the author (Kume 
et al. 2003, 2004, 2005), resulting in a soft, prelooped cap with attached irrigation tube (Kume 
et al. 2004). 
The aspiration method of EMRC-UI method is similar to EMRC. Aspiration is applied 
repeatedly until the lesion is stabilized in the center of the hood. If the field of view is 
compromised because of the presence of mucus and/or blood, the site is irrigated. After 
strangulating the lesion by closing the snare, the negative aspiration pressure is released.  
EMR-UI was performed in 15 patients. Mean diameter of specimens was 24.5 mm 
(interquartile range, 15-35 mm). The proportion of en bloc-resected lesions was 86.7% 
(13/15). The median time required for EMR-UI was 19 min. 
3.3.3 Grasping forceps-assisted EMRC using a 2-channel prelooped cap 
Next, the author improved the EMRC-UI cap. Two side holes were fabricated by drilling in 
the hood portion of a conventional soft prelooped cap, and then the irrigation tube and the 
accessory channel tube were glued to the exterior surface of the holes. The author developed 
a 2-channel prelooped cap that facilitates EMRC while simultaneously allowing both grip of 
the centeral position of the lesion and irrigation of the aspiration site (Kume et al. 2006). 
The aspiration method of grasping forceps-assisted EMRC using a 2-channel prelooped cap 
method is similar to EMRC. The endoscopist releases the negative aspiration pressure while 
slowly pulling the regular biopsy forceps gripping the center of the lesion. Until the lesion is 
stabilized in the center of the hood, the endoscopist repeatedly performs grasp and 
aspiration of the lesion. If the field of view at the aspiration site is poor as a result of 
contamination by mucus and blood, the endoscopist repeatedly performs irrigation of the 
site. After strangulating the lesion by closing the snare, the endoscopist again releases the 
aspiration.  
Grasping forceps-assisted EMRC using a 2-channel prelooped cap was performed in 12 
patients. Mean diameter of specimens was 22.3 mm (interquartile range, 15-31 mm). The rate 
of en bloc resection was 91.7% (11/12). Median time required for the procedure was 19 min. 
3.3.4 EMRC using IRS (internally retained snare) cap 
In EMRC, the crescent-shaped snare needs to be prelooped into the groove of the rim of the 
cap during the procedure itself. As this prelooping can be initially difficult, the author has 
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avoided this step by developing a new type of prelooped cap, the “internally retained 
snare” (IRS) cap that makes prelooping unnecessary (Kume et al. 2008). 
After adapting the IRS cap to the tip of the endoscope, EMRC using the IRS cap method is 
similar to EMRC. The endoscopist releases the negative aspiration pressure and the cap is 
then placed to aspirate the lesion with medium to high vacuum into the hood. The 
endoscopist again releases the aspiration, after strangulating the lesion by closing the 
snare. 
EMRC using an IRS cap was performed in 27 patients. Mean diameter of specimens was 27.6 
mm (interquartile range, 15-38 mm). The rate of en bloc resection was 88.9% (24/27). 
Median time required for EMRC using IRS cap was 16 min.  
3.3.5 EMRC-C (EMRC and closure) 
This device has not yet been used in human patients. 
Delayed bleeding may occur from a gastric ulcer after EMRC. Solving this problem may 
allow surgery on an outpatient basis. The author therefore developed a novel EMRC and 
closure (EMRC-C) cap that facilitates the EAM procedure, simultaneously allowing 
endoscopic closure (Kume et al. 2007). The EMRC-C hood was produced by attaching an 
additional hood of short length and another accessory channel to the top of the 2-channel 
prelooped cap. Two types of snares are then set. The crescent-shaped snare (SD-221L-25; 
Olympus) is inserted through the accessory channel tube of the first part of the hood, and 
prelooped into the groove of the rim of the hood. The detained snare (HX-20L-1; Olympus) 
is passed through and tightened around the outer circumference of the second part of the 
hood.  
The endoscopist places the EMRC-C hood at the tip of the endoscope. Aspiration is released 
and the hood is then used to aspirate the lesion by high-power vacuum into the hood. The 
endoscopist confirms aspiration of the lesion with the outside CCD camera, then snares the 
lesion using the detained and crescent-shaped snares. The endoscopist uses the former to 
tightly strangle the lesion, and resects the lesion using blend electrosurgical current closing 
the latter snare. 
3.4 EAM 
EAM has methods using a standard device and my original device. 
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Fig. 5. EAM device: (a) Conventional EAM hood, (b) EAM-V device placed at the top of the 
scope. 
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3.4.1 EAM (standard) 
The EAM hood uses a conventional hood (Create Medic, Yokohama, Japan, and TOP, 
Tokyo, Japan). In this device, a snare is passed through an outside channel and tightened 
around the outer circumference of the hood (Katayama et al. 2006, Torii et al. 1995). 
Prelooping during the EAM procedure is thus unnecessary. 
As a method to adapt EAM with a snare on the tip of the endoscope, the EAM hood method 
is similar to EMRC. The endoscopist releases the negative aspiration pressure and the hood 
is then placed to aspirate the lesion with medium to high vacuum into the hood. The snare is 
pushed over the tumor while the lesion is aspirated. In addition, the loop is pushed tightly 
around the specimen. The endoscopist again releases the aspiration, after strangulating the 
lesion by closing the snare. 
3.4.2 EAM-V (EAM with vibration) 
This device has not yet been used in patients. 
EAM carries a risk of aspirating and perforating the full thickness of the gastric wall. A 
novel vibration hood to reduce such risks was thus developed (Kume et al. 2009). A novel 
vibration hood enables strangulation and resection of only the mucosal and submucosal 
layers by vibrating the snare during strangulation to shake off the muscle layer and serous 
membrane. 
Investigations were conducted separately with and without vibration at 10,000 rpm applied 
at the time of strangulation and resection. Perforation rates were lower in the vibration 
group (0/9: 0%) than in the group without vibration (2/9: 22.2%).  
3.5 EEMR (Endoscopic esophageal mucosal resection) 
With EEMR tube (Create Medic, Yokohama, Japan) method, the largest enbloc resection tha 
can be carried out is when the esophageal lesion is less than 3 cm in diameter (Makuuchi et 
al. 2004). EEMR tube method is similar to EAM. 
 
 
Fig. 6. EEMR tube 
3.6 EMR-L (EMR with ligation) 
The technique of EMR with ligation (EMR-L) uses a standard endoscopic variceal ligation 
device fitted to a single-channel endoscope (Suzuki et al. 1999). The maximum lesion size for 
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en bloc resection is 1.5 cm. Larger lesions may require piecemeal resection. This technique 
has been reported with or without prior submucosal injection. The lesion is snared by 
standard snare polypectomy after it has been ligated at its base with an endoscopic variceal 
ligation device. 
3.7 Multi-camera system using a novel 1-channel camera-hood 
This device has not yet been used in patients. 
Precise snaring during EMR is important to achieve en bloc resection. However, this can 
be difficult to achieve in practice, because snaring cannot be performed under complete 
observation. Although we can easily observe the proximal side of the lifting lesion, the 
distal side is hard to see after injection of saline solution into the submucosa. The author 
therefore developed a novel 1-channel camera-hood that allows observation of the distal 
side of the lesion during snaring in the EMR procedure (Kume et al. 2007). The 1-channel 
camera-hood was fabricated by cutting the partial hood in a “U-shape” in the cap portion 
of the hood and then attaching a machined camera for dental use that consisted of a 
charge-coupled device (CCD) camera and 4 light-emitting diodes (LEDs) (“Miharu-kun”; 
RF System Lab, Japan) through two tubes. The length of the two tubes is variable and one 
is an accessory channel. 
EMR using the 1-channel camera-hood was performed as follows. After injection of saline 
solution into the submucosa, the endoscope was removed and the 1-channel camera-hood 
was placed on the tip and fixed with tape. A snare was passed through the accessory 
channel of the hood, and grasping forceps were passed through the accessory channel of the 
endoscope. We made the grasping forceps catch hold of the snare. The lesion was then 
strangulated by precisely closing the snare under adequate observation by both CCD 
cameras of the 1-channel camera-hood and the endoscope. Blend electrosurgical current was 
used to resect the lesion. 
 
 
Fig. 7. Multi-camera system using a novel 1-channel camera-hood placed at the top of the 
scope. 
4. ESD 
The technique of ESD was introduced to resect large specimens of early gastric cancer in a 
single piece. ESD can provide precise histological diagnosis and can also reduce the 
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recurrence rate (Muto et al. 2005). The drawback of ESD lies in the technical difficulty, and 
this technique is therefore associated with a high rate of complications, the need for 
advanced endoscopic techniques, and a lengthy procedure time (Oka et al. 2006, Ono et al. 
2001). 
4.1 Stadard ESD 
Standard ESD requires special cutting knives, such as a needle knife (Hirano et al. 1988), an 
insulation-tipped electrosurgical (IT) knife (Ono et al. 2001, Ohkuwa et al. 2001, Miyamoto et 
al. 2002, Rösch et al. 2004, Gotoda et al. 2005), a hook knife (Oyama et al. 2002, 2005), a flex 
knife (Yahagi et al. 2004), a flush knife (Toyonaga et al. 2007), a triangle-tip (TT) knife (Inoue 
et al. 2004) and a mucosectome (Kawahara et al. 2007).  
Standard ESD is performed with a standard single accessory-channel endoscope. Typical 
sequences are the following: marking; incision; and submucosal dissection with 
simultaneous hemostasis. After making several marking dots outside the lesion, various 
submucosal solutions are injected, including the normal saline solution and epinephrine 
mixture, glycerol mixture, and hyaluronic acid. A circumferential incision into the mucosa is 
made using one of the special cutting knives. Direct dissection of the submucosal layer is 
performed with one of the specified knives until complete removal is achieved. During ESD, 
the endoscopist performs endoscopic hemostasis with either the knife itself or hemostatic 
forceps whenever active bleeding is noticed. After ESD, the endoscopist performs 
preventive endoscopic hemostasis for any oozing or exposed vessels. High-frequency 
generators (Erbotom ICC200 or VIO 300D; ERBE, Tübingen, Germany) were used for 





Fig. 8. Technique of standard ESD method: (a) Several marking dots outside the lesion are 
made, (b) Submucosal solutions are injected. (c) A circumferential incision into the mucosa 
is made using one of the special cutting knives. (d) Direct dissection of the submucosal layer 
is performed with one of the specified knives until complete removal is achieved. (e) The 
specimen is removed. 
4.2 Supecial cutting knives 
4.2.1 IT knife 
The IT knife consists of a small ceramic ball attached to the tip of a high-frequency needle 
knife (Ono et al. 2001, Ohkuwa et al. 2001, Miyamoto et al. 2002, Rösch et al. 2004, Gotoda et 
al. 2005). The ceramic ball functions as an insulator for the tip of the needle knife, so that 
incision and dissection of the mucosa and submucosa can be performed safely. The insulator 
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helps to prevent perforation due to accidental cutting of the muscularis propria. A 
specialized feature of the IT knife is that the portion between the insulator tip and sheath is 
used for incision, sweeping off the tissue with the blade portion of the knife instead of the 
tip. This feature makes a pull-cut, whereas the direction of incision is limited, and straight-
forward incision is difficult while looking directly at the incision line or submucosa.  
4.2.2 Hook knife 
The top of the hook-type knife is right-angled, 1 mm in size (Oyama et al. 2002, 2005). 
Compared to the use of a needle knife, safety is improved because the submucosal tissue is 
hooked and pulled before incision. This knife has a rotating function so that the operator can 
select the optimal direction of the hook. 
4.2.3 Flex knife 
The point of the flex knife is rounded with a twisted wire, like a snare (Yahagi et al. 2004). 
The sheath is soft and flexible. This knife is less likely to cause perforation when reaching 
the muscular layer, as the tip is round and the entire knife is soft and flexible. As the tip of 
the sheath is thick and functions as a stopper, operators can easily control the depth of 
incision very. 
4.2.4 Flash knife (Water jet short needle knife) 
The Flush knife is a characteristic knife with a needle 0.4 mm in a diameter and five 
projecting parts of 1, 1.5, 2, 2.5, and 3 mm in length (Toyonaga et al. 2007). A knife clamp at 
the tip of the sheath is ceramic for heat insulation. The outer sheath is 2.6 mm in diameter 
and water emission is possible through the lumen of the sheath by connecting a water 
pump. The water jet is swiftly activated by pressing a foot pedal on the conduction pump. 
The conductor of the sheath lumen is insulated to prevent electric current dispersion. 
4.2.5 TT knife 
The TT knife evolved from the process of ESD, which began with the IT knife (Inoue et al. 
2004). The triangular tip of the knife can be used for either cutting or coagulating, and has 
been designed to operate in any direction. 
4.2.6 Mucosectome 
The mucosectome is composed of a flexible plastic shaft and cutting wire (Kawahara et al. 
2007). By handle operation, the top of this device turns freely, which assists the cutting wire 
to face the proper direction. The plastic shaft moves the muscular layer aside. Cutting wire 
moves the mucosal layer aside from the submucosa during ESD, and then the procedure 
itself can be performed safely. 
4.2.7 Grasping type scissor forceps (GSF) 
Each step of ESD (circumferential incision, submucosal excision, hemostatic treatment) can 
be achieved by the following three operations: (1) grasping the targeted tissue (fixation), (2) 
lifting up the grasped tissue (separation of the grasped tissue from the underlying proper 
muscle layer) and (3) cutting the grasped tissue (or coagulating the blood vessel) using an 
electrosurgical current. These operations are simple and as easy as a bite biopsy technique 
(Akahoshi et al. 2007, 2010). 
 





         
        
Fig. 9. Special cutting knives for ESD: (a) IT knife, (b) IT knife 2, (c) Hook knife, (d) Flex 
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4.3 Transparent hood 
A transparent hood is helpful for better visualization of the operating field. In particular, 
good visualization of the submucosal tissue with the aid of a small-caliber-tip transparent 
(ST) hood makes the cutting procedures easy and safe (Yamamoto et al. 2003) (Fujifilm. 
Tokyo, Japan). ESD using ST hood is a peeling-off method using a needle-knife for mucosal 
and submucosal incisions. 
 
 
Fig. 10. Small-caliber-tip transparent (ST) hood. 
4.4 Tip hood 
4.4.1 Cap knife 
The author developed a novel one-third partial transparent hood that facilitates 
endoscopic hemostatic procedures while simultaneously allowing the irrigation of 
bleeding (Kume et al. 2004). The one-third partial hood is easily placed on the tip of the 
endoscope, although the hood has to be fitted to the right side of the endoscope. The 
hood-knife was fabricated by drilling another side hole in addition to the hole of the 
irrigation tube at the cap portion of a transparent end hood (Kume et al. 2005). A snare 
forceps was glued to the exterior surface over the hole and attached using short tubes at 
the inside of the cap. Based on this prototype, the irrigation cap-knife (cap-knife 
attachment (Type KUME) with a fixed snare) was developed as shown in Figure 10b 
(Create Medic, Yokohama, Japan) (Kume et al. 2007). 
The ESD procedure using the cap-knife is performed as follows. After the tumor is 
separated from surrounding normal mucosa by complete incision around the lesion using 
the IT knife, the endoscope is then removed, and the cap-knife is placed on the tip and fixed 
with tape. Grasping forceps are passed through accessory channel and push the lesion away 
from the muscle layer. Submucosal exfoliation was that the cap-knife was only slid with 
coagulation current on the muscle layer. 
4.4.2 Wiper-knife 
This device has not yet been used in patients. 
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The wiper-knife was fabricated by installing a needle-knife in exchange for a snare forceps 
(Kume et al. 2007). The needle-knife lets a handling wire intersect and fixes it. The handling 
wire is put through a hole opening at both ends of the hood. A novel wiper-knife was 
fabricated such that ESD could be performed by moving like a windshield wiper. 
ESD using the wiper-knife was performed as follows. A grasping forceps was passed 
through accessory channel and pushed the lesion away from the muscle layer. The wiper-
knife moved like a windshield wiper with coagulation current on the muscle layer to 
separate submucosal exfoliation from the muscle layer.  
4.4.3 B-cap 
B-cap is a device in which the snare of the cap knife has been replaced with a bipolar knife 
(Miyamoto et al. 2007). The direction for use of the B-knife is the same as the cap knife. 
 
   
                       (a)                                              (b)                                              (c) 
Fig. 11. Tip hoods: (a) Irrigation hood knife, (b) Cap-knife attachment (Type KUME) with a 
fixed snare placed on the tip of the endoscope through grasping forceps, (c) Wiper knife. 
4.5 Therapeutic endoscope 
4.5.1 Multibending scope 
Some tumor locations are difficult to carry out EMR using a conventional scope, including 
the lesser curvature or posterior wall of the gastric body, and the cardia. To facilitate EMR of 
tumors at these locations, a two-channel scope with two independently curving segments, 
that is, a multibending scope (the ‘M-scope’) was developed (Ishi et al. 2004). The M-scope 
consists of a distal flexible segment that can bend in any of the four major directions and a 
proximal flexible segment that can bend in two directions. Combined operation of the 
segments allows the operator to obtain a variety of visual fields, to randomly approach or 
recede from the lesions, and to obtain an en face view. 
4.5.2 Multibending double-channel therapeutic endoscope 
The multibending double-channel therapeutic endoscope (the ‘R-scope’) has been designed 
for lifting lesions and for improved dissection with the incorporation of two movable 
channels (Yonezawa et al. 2006, Neuhaus, et al. 2006). The R-scope has two movable 
instrument channels: one moves vertically; and the other swings horizontally. The two 
instruments can be manipulated during the operation with knob and a lever that surrounds 
the angulation control knobs of the R-scope. 
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4.4.2 Wiper-knife 
This device has not yet been used in patients. 
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The wiper-knife was fabricated by installing a needle-knife in exchange for a snare forceps 
(Kume et al. 2007). The needle-knife lets a handling wire intersect and fixes it. The handling 
wire is put through a hole opening at both ends of the hood. A novel wiper-knife was 
fabricated such that ESD could be performed by moving like a windshield wiper. 
ESD using the wiper-knife was performed as follows. A grasping forceps was passed 
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knife moved like a windshield wiper with coagulation current on the muscle layer to 
separate submucosal exfoliation from the muscle layer.  
4.4.3 B-cap 
B-cap is a device in which the snare of the cap knife has been replaced with a bipolar knife 
(Miyamoto et al. 2007). The direction for use of the B-knife is the same as the cap knife. 
 
   
                       (a)                                              (b)                                              (c) 
Fig. 11. Tip hoods: (a) Irrigation hood knife, (b) Cap-knife attachment (Type KUME) with a 
fixed snare placed on the tip of the endoscope through grasping forceps, (c) Wiper knife. 
4.5 Therapeutic endoscope 
4.5.1 Multibending scope 
Some tumor locations are difficult to carry out EMR using a conventional scope, including 
the lesser curvature or posterior wall of the gastric body, and the cardia. To facilitate EMR of 
tumors at these locations, a two-channel scope with two independently curving segments, 
that is, a multibending scope (the ‘M-scope’) was developed (Ishi et al. 2004). The M-scope 
consists of a distal flexible segment that can bend in any of the four major directions and a 
proximal flexible segment that can bend in two directions. Combined operation of the 
segments allows the operator to obtain a variety of visual fields, to randomly approach or 
recede from the lesions, and to obtain an en face view. 
4.5.2 Multibending double-channel therapeutic endoscope 
The multibending double-channel therapeutic endoscope (the ‘R-scope’) has been designed 
for lifting lesions and for improved dissection with the incorporation of two movable 
channels (Yonezawa et al. 2006, Neuhaus, et al. 2006). The R-scope has two movable 
instrument channels: one moves vertically; and the other swings horizontally. The two 
instruments can be manipulated during the operation with knob and a lever that surrounds 
the angulation control knobs of the R-scope. 
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4.5.3 Vibration endoscopy 
This device has not yet been used in patients. 
The author attempted to increase the efficiency of endoscopic treatment techniques by 
vibrating the endoscope scope itself. The vibration used must be at a frequency that ensures 
safety when applied to the body. Examples of inventions that are made effective by adding 
safe vibration to the body are vibrating oral care devices developed to clean between the 
teeth and manual multiple-blade shavers with vibration added to increase cutting efficiency. 
The latter is a commercial product in which vibration successfully raised cutting efficiency 
without harming the skin, even though the blades cut whiskers in direct contact with the 
face (M3 Power; Gillette, Japan). An endoscope with an incorporated eccentric motor was 
therefore developed and used in conducting ESD. The vibration endoscope comprised a 
modified commercial endoscope (GIF-Q200; Olympus). First, the covering plastic of the tip 
and the metal mesh were stripped off. After exposing the interior, a vibration motor (J71; 
Shicoh, Japan) fitted within a cylinder was attached and this section was covered using heat-
shrinkable tubing (Kume. 2010).  
Among circumferential incisions, submucosal dissection and a total of both, mean 
procedure durations with vibration at 10,000 rpm were significantly shorter than those 
without vibration. When performing peripheral incisions and submucosal dissection with a 
knife in ESD, the time for the procedure can be reduced by adding vibration. 
 
   
                                                     (a)                                                 (b) 
Fig. 12. Therapeutic endoscopes: (a) Multibending double-channel therapeutic endoscope, 
(b) Vibration endoscope. 
4.6 Traction methods 
4.6.1 Magnetic anchor system 
The magnetic anchor (Pentax, Tokyo, Japan) consists of 3 parts: a hand-made magnetic weight, 
made of magnetic stainless steel; microforceps; and a connecting thread. A weight is designed 
to facilitate gastric ESD by use of an extracorporeal hands-free electromagnet, whereby 
magnetic forces allow a suitable counter-traction for submucosal dissection (Gotoda et al. 2009).  
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4.6.2 Percutaneous traction 
A small snare is introduced into the gastric lumen through a percutaneous gastric port (2-
mm diameter) to grasp and pull the lesion away from the muscularis propria to facilitate 
resection (Kondo et al. 2004). 
4.6.3 External grasping forceps 
In ESD using an external grasping forceps, oral traction applied with the external forceps 
can elevate the lesion and make the submucosal layer on the aboral side wider and more 
visible, thereby facilitating submucosal dissection under direct vision (Imada et al. 2006). 
4.6.4 EndoLifter 
In ESD using an external grasping forceps through EndoLifter (LA-201, 202. Olympus, 
Tokyo, Japan), traction applied with the external forceps can elevate the lesion and make the 




Fig. 13. EndoLifter. 
4.7 Water jet 
4.7.1 Water jet endoscope 
By washing the bleeding field with the water jet, the bleeding source can be immediately 
identified and coagulated, although in a small number of cases of erupting venous bleeding, 
identifying the bleeding source can be difficult. 
4.7.2 Irrigation hood 
The author developed an end hood that facilitates endoscopic hemostatic procedures while 
simultaneously allowing irrigation of the hemorrhage site. The end hood piece was 
fabricated by drilling a side hole in the cap portion of a conventional transparent hood, then 
the irrigation tube was glued to the exterior surface of the hole (Kume et al. 2003, 2004). The 
fabricated transparent hood was placed at the tip of the endoscope. Based on this prototype, 
the irrigation hood (irrigation cap; Type KUME) was developed as shown in Figure 13b 
(Create Medic, Yokohama, Japan). 
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                                           (a)                                                               (b) 
Fig. 14. Water jet: (a) Water jet endoscope, (b) Irrigation hood. 
4.8 Hemostatic device 
4.8.1 Coagula-irrigation hood (CI hood) 
The author developed a new type of hood, the "coagula-irrigation hood” (CI hood), which 
could simultaneously perform both coagulation and irrigation (Kume et al. 2006). The CI hood 
was fabricated by installing a machined papillotomy knife in exchange for an irrigation tube of 
irrigation hood. The tip of papillotomy knife was cut off and the tip of a wire was bent into a 
hoop. A CI hood was fabricated such that ESD and enodoscopic hemostasis could be 
performed while simultaneously applying adequate coagulation and irrigation. 
 
 
Fig. 15. CI hood. 
4.9 Fan devices 
This device has not yet been used in patients. 
During resection, incision, and detachment using an endoscope, smoke is produced due to 
electrocautery. Accumulation of this smoke in the gastrointestinal (GI) tract impairs the visual 
field and makes continuation of the procedure difficult. The author therefore developed two 
types of new fan device that improve the visual field by circulating air without changing the 
air volume (Kume. 2009). Both devices were created using a super-micro fan motor (Shiko, 
Japan). The first works by blowing air, while the second uses ventilation. 
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                                   (a)                                                                     (b) 
Fig. 16. Endoscopic fan device. (a) Blowing type, (b) Ventilation type. 
4.10 Injection solutions 
4.10.1 Injection solutions for elevation 
Two types of solution are used for submucosal injection: isotonic solution (normal saline, 
hyaluronic acid); and hypertonic solution (hypertonic saline, glucose, Glyceol®)(Yamamoto et 
al. 2003, 1999, Fujishiro et al. 2006, Uraoka et al. 2005, Akahosh et al. 2006). The advantages of 
hypertonic solution are better mucosal elevation and better hemostatic effect than normal 
saline. However, hypertonic solution is more likely to damage tissue in a resection sample, 
post-resection ulcer, or surrounding mucosa compared with isotonic solution. 
Hyaluronic acid solution makes a better long-lasting submucosal cushion without tissue 
damage than other available solutions (Yamamto et al. 2003, 1999). 
4.10.2 Injection solution for submucosal dissection 
The author reported a new method of ESD by submucosal injection of jelly, which obviates 
the need for submucosal incision with a knife (Yamasaki et al. 2005). As jelly is thick and 
viscous, the mucosal layer can be dissected from the muscular layer when injected into the 
submucosal layer. 
Sodium carboxymethylcellulose (SCMC) is a water-soluble polymer derived from cellulose. 
When dissolved in water, it becomes very viscous, like jelly. We used SCMC for ESD in 
porcine stomachs (Yamasaki et al. 2006). The mucosal layer was dissected from the muscular 
layer with submucosal injection of 2.5% SCMC. 
5. Discussion: EMR vs ESD  
In a Japanese multicentre collaborative prospective study of endoscopic treatment for early 
gastric cancer, if the diagnosis of intramucosal cancer (<20 mm, UL(-)) from the specimen 
resected at initial EMR was histologically correct, then local cure could be achieved with 
EMR, including cases of recurrence, with appropriate follow-up and use of concomitant 
techniques such as piecemeal resection and coagulation therapy (Ida et al. 2004). Therefore, 
intramucosal gastric cancer less than 20 mm in size and with no ulceration is considered 
appropriate for EMR. 
ESD, which first developed in the stomach, is a new endoluminal therapeutic technique 
involving the use of cutting devices to permit a larger resection of the tissue over the 
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muscularis propria. The technique has also spread to other organs in the gastrointestinal 
tract (Kakushima et al. 2008). In comparison with EMR, ESD needs very experienced hands 
because of its far more complex procedural sequence. However, the obtained outcomes 
seem to be more advantageous especially for early-stage neoplasms with a large size or 
submucosal fibrosis, although long-term data are still lacking. Additionally, by using ESD 
technique, the resected area can be precisely controlled by the operators, which may not 
only lead to complete removal of even large lesions, but also to the least non-neoplastic 
mucosal resection. 
ESD time is increased in cases with ulceration, scarring, a large lesion, or location in the 
upper portion of the stomach (Chung HK et al. 2009). The large upper portion of the 
stomach region has a large vascular network, resulting in technical difficulty in the 
approach to dissection or control of bleeding, all of which increases the procedure time. In 
cases of recurrent lesion or a lesion with an accompanying scar, the endoscopist needs to 
dissect very carefully, as a thin submucosal cushion and hard fibrotic tissue both make 
dissection difficult to perform without perforation. 
In the colon ESD has some advantages, such as better control of the shape and size of the 
resected specimen, and the possibility to perform en bloc and R0 resections even for large 
tumors or tumors that lift poorly due to fibrosis. But ESD does carry some disadvantages too: 
it is a time consuming procedure, and it carries a higher risk of bleeding and a slightly higher 
probability of perforation (Fujishiro et al. 2007). Although ESD seems to be a promising 
technique that is applicable to colorectal epithelial neoplasm, when determining whether 
colorectal ESD is indicated, it is important to weigh the potential benefits against the risks. This 
may be different for each endoscopist and for each lesion. Currently, it may be better to resect 
some large flat colorectal epithelial neoplasms using a method such as picemeal EMR or 
colorectal resection when expertise with ESD is still limited (Deprez et al. 2010). 
In the esophagus various data with ESD are still lacking, such as the technical difficulty and 
the risk of complications. 
Due to the high level of expertise needed to perform the technique safty, ESD should be 
performed in a step-up approach after prior experience with conventional EMR, starting 
with lesions presenting in the distal stomach, then inthe proximal stomach, rectum, colon, 
and finally in the esophagus. 
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1. Introduction 
The recent advances in pancreatic imaging lead to higher detection of pancreatic cysts [1]. It 
has become very common for general practitioners as well as gastroenterologists to face the 
dilemma of further management of a large number of incidentally found pancreatic cysts. In 
this chapter, we will discuss the epidemiology, pathogenesis and the role of EUS in 
managing pancreatic cysts. 
2. Epidemiology 
The prevalence of pancreatic cysts is much higher than previously estimated. Earlier reports 
suggested that the prevalence of pancreatic cysts in adult populations to be around 2.5% [2] . 
Recent studies using Magnetic Resonance Imaging (MRI) showed a higher prevalence of 
pancreatic cysts in the general population up to 13%  [3]. This prevalence increases with age 
and for an unknown reason it is extremely high (more than 50%) in liver transplanted 
patients [4].  
3. Pathology 
Pancreatic cysts can be classified according to their malignant potential or according to their 
morphological features. Initially, pancreatic cyst could be classified as pseudocyst which 
indicates the lack of the epithelial lining of the cyst wall, true cyst with epithelial lining or 
cystic degeneration or necrosis of solid pancreatic masses [5]. Pseudocyst are common after 
acute or chronic pancreatitis as a result of extravasation of pancreatic fluid from the 
disrupted pancreatic duct [6]. Pseudocyst complicating acute pancreatitis has no malignant 
potential and the majority of them will resolve spontaneously [7]. The management of 
pseudocyst is beyond the scope of this review.  
True pancreatic cysts can be further divided into cysts lined with mucinous epithelium 
(mucinous cystic neoplasms and Intraductal Papillary Mucinous Neoplasm [IPMN]), cysts 
lined with clear cell (serous cystic tumors) or cysts lined with acinar cells. In addition, cystic 
degeneration of solid tumor can occur such as cystic neuroendocrine tumors and 
pseudopapillary tumors [8]. 
The hallmark of mucinous cystic neoplasms (mucinous cystadenoma) of the pancreas is the 
presence of ovarian stroma [9]. More than 90% of patients with mucinous cystic neoplasms 
are females and more than 90% of these lesions are within the body - tail region of the 
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managing pancreatic cysts. 
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Recent studies using Magnetic Resonance Imaging (MRI) showed a higher prevalence of 
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patients [4].  
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indicates the lack of the epithelial lining of the cyst wall, true cyst with epithelial lining or 
cystic degeneration or necrosis of solid pancreatic masses [5]. Pseudocyst are common after 
acute or chronic pancreatitis as a result of extravasation of pancreatic fluid from the 
disrupted pancreatic duct [6]. Pseudocyst complicating acute pancreatitis has no malignant 
potential and the majority of them will resolve spontaneously [7]. The management of 
pseudocyst is beyond the scope of this review.  
True pancreatic cysts can be further divided into cysts lined with mucinous epithelium 
(mucinous cystic neoplasms and Intraductal Papillary Mucinous Neoplasm [IPMN]), cysts 
lined with clear cell (serous cystic tumors) or cysts lined with acinar cells. In addition, cystic 
degeneration of solid tumor can occur such as cystic neuroendocrine tumors and 
pseudopapillary tumors [8]. 
The hallmark of mucinous cystic neoplasms (mucinous cystadenoma) of the pancreas is the 
presence of ovarian stroma [9]. More than 90% of patients with mucinous cystic neoplasms 
are females and more than 90% of these lesions are within the body - tail region of the 
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pancreas [10]. Macroscopically, mucinous cysts are large and multilocular with thick wall. 
Mucinous cystic neoplasms usually do not communicate with the pancreatic duct. Ten to 
15% of the discovered mucinous cystic neoplasms were found to have invasive carcinoma or 
at least carcinoma in situ [11, 12].  
Unlike mucinous cystic neoplasms, IPMN arises within the pancreatic duct and it is 
characterized by papillary projections containing neoplastic mucin producing cells [13]. 
Macroscopically, IPMN appears as cystic dilations of the pancreatic duct. Cysts are varying 
in size and they are filled with mucin. Occasionally mucin could be seen extruding from the 
ampulla which is virtually pathognomonic for IPMN. IPMN can be divided according to its 
anatomical location as main duct - branch duct- and mixed-IPMN. The histological 
classification divides IPMN into four main categories: gastric, intestinal, pancreatobiliary 
and oncocytic type [14]. Both classifications are very important in determining the 
malignant potential of the disease. For example, the malignant potential of main duct - and 
of intestinal type of IPMN is much higher than branch duct IPMN and gastric type IPMN 
[15]. IPMNs are equally distributed between males and females and their incidence 
increases with age [16]. In a retrospective trial of  208 patients who underwent pancreatic 
resection of IPMN, 64 % of main duct IPMN were malignant while only 18 % of branch duct 
IPMN were harboring malignant cell on pathological examination [17]. 
Serous cystic tumors of the pancreas are lined by glycogen rich cell secreting serous fluid 
[18]. Macroscopically, it has sponge appearance with large number of minute cysts with 
occasional central scar. Usually serous cysts are large in size with a diameter of several 
centimeters. Serous cystic tumors are more common in females over 60 years old [19] with 
rare malignant potential (~3%) [20, 21]. 
The cystic form of acinar cell tumor is rare [22]. It could be present in a benign form as 
acinar cell cystadenoma, in addition to the malignant form known as acinar cell 
cystadenocarcinoma [23, 24]. This rare tumor entity should not be confused with solid 
pseudopapillary tumor of the pancreas in which the cystic component is rather a 
degenerative process than true cyst as in the cystic form of acinar cell tumors [25]. Both 
tumors, however, occur in young patients and should be included in the differential 
diagnosis in cystic tumor of the pancreas in pediatric and young adults. The cystic form of 
neuroendocrine tumor is another example of cystic degeneration within solid tumor. There 
are few case reports describing cystic glucagonoma and cystic insulinoma in the literature 
[26, 27]. The cyst is usually filled with clear fluid secreted by the neuroendocrine cells and 
not necrotic materials as in the case of solid pseudopapillary tumor[5]. It is also worth 
mentioning that cystic degeneration can occur in any solid tumor of the pancreas including 
ductal adenocarcinoma. 
4. Role of imaging in diagnosing pancreatic cystic lesions 
Although the advances in diagnostic imaging allowed more discovery of incidental 
pancreatic cyst, CT scan has only 50 to 60% accuracy in differentiating between different 
types of pancreatic cysts [28]. The new generation multi-slice helical CT scan has higher 
accuracy in differentiating between serous and mucinous cysts with a diagnostic accuracy of 
70 to 80% [29]. The accuracy of a CT scan is not that impressive either in differentiating 
benign from malignant cysts. In a study of 47 patients with IPMN who underwent surgical 
resection, the diagnostic accuracy of a CT scan in differentiating invasive from non-invasive 
cyst was 76% [30]. Magnetic Resonance Imaging (MRI) of the pancreas could have better 
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diagnostic performance in differentiating mucinous from non-mucinous cysts  in 
comparison with the CT scan[31]. In addition, MRI enables more characterization of cyst 
features suggestive of malignancy such as mural nodule, thick septae, solid component or 
main pancreatic duct dilation [32, 33]. However, studies comparing the relative accuracy of 
MRI and CT scan in differentiating benign from malignant cysts did not show any 
difference between the two modalities. In a retrospective study of 58 pancreatic cystic 
lesions irrespective of the cyst size, the relative accuracy of CT and MRI was similar  [34]. In 
another well-designed retrospective trial by Sainani et al, 38 small (less than 3 cm) 
pancreatic cysts were included. All patients had a CT scan, MRI and histopathological 
diagnosis. CT and MRI had overall similar performance. The accuracy of CT scan and MRI 
in differentiating mucinous from non-mucinous cyst was 71% and 84% respectively, while 
the accuracy of CT vs MRI in differentiating benign from malignant cyst was 75-78% vs 78-
86% (not statistically significant) [35]. Recently, 3D MRCP was shown to improve the image 
quality of pancreatic cysts [36]. However, 3D MRCP had similar diagnostic performance to 
2D MRCP in differentiating benign from malignant cysts [37]. 
5. Role of Endoscopic Ultrasonography (EUS) 
5.1 Cyst morphology 
EUS has emerged as an important tool in the diagnosis of pancreatic cysts. EUS allows close 
inspection of pancreatic cysts and delineates the characteristic features of the cyst that might 
not be apparent on CT or MRI. For example, serous cystadenoma (SCA) has a typical 
honeycomb appearance with multiple microcysts separated with thin septae and 
occasionally central scar [38]. Mucinous cystadenoma (MCA) is usually present in the body 
and tail of the pancreas as a well-circumscribed, rounded, anechoic cyst without any 
communication with the pancreatic duct. Branch duct IPMN has a similar appearance to 
MCA but it is not rounded, occasionally multicystic with communication with the 
pancreatic duct [39]. In some occasions, MCA cannot be differentiated from branch duct 
IPMN if the communication with the pancreatic duct is not clear.  Main duct IPMN appears 
as a cystic dilation of the main pancreatic duct and it could be either segmental or diffuse in 
nature. EUS can also identify features that are worrisome for malignancy such as solid 
component, thick septae or lymphadenopathy [40, 41]. However, EUS alone cannot 
differentiate benign from malignant cysts [42]. In a retrospective study of 47 patients who 
underwent EUS examination prior to surgical resection of the pancreatic cyst, the diagnostic 
accuracy of EUS to differentiate benign from malignant cyst was 76% [30]. Furthermore, 
interobserver agreement among endosonographers to differentiate mucinous from non 
mucinous cysts was evaluated by Ahmad et al. by using videotapes of 31 pancreatic cystic 
lesions. The interobserver agreement among the eight endosonographers included in the 
study was shown to be only fair (kappa =0.24). Accuracy rates of EUS to differentiate benign 
from malignant lesions ranged from 40 to 93% which highlights the variability among 
endosonographers [43]. The result of this study should be taken with a grain of salt since the 
endosonographers were evaluating video tapes which are different than performing the 
actual procedure and interpreting the findings. 
5.2 Cytological evaluation 
In addition to cyst characterization, EUS allows fine needle aspiration (FNA) of the cyst 
for cytology and measurement of molecular markers. FNA of pancreatic cyst is safe with 
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complication rate of 0.5 to 2% as acute pancreatitis, bleeding or infection [44-47]. Although 
cytology of pancreatic cyst has high specificity, its sensitivity is very low in differentiating 
mucinous from non-mucinous cysts. Sedlack et al in a retrospective study of 111 patients 
at Mayo Clinic found that cytology had 100% specificity and 27% sensitivity for mucinous 
cysts. This translates into 55% diagnostic accuracy [40]. Similar results were confirmed by 
Attasaranya et al from Indiana University in a retrospective study of 48 patients with 
pancreatic cysts. The specificity of cytology to differentiate mucinous from non-mucinous 
cyst was 90% with sensitivity of 12.5% [48]. What can explain such high specificity and 
low sensitivity for cytology is that the presence of sticky fluid on aspiration or mucin in 
cytology is highly diagnostic for mucinous cysts. However, aspirate can be acellular or 
with minimal cellularity in up to 72% of aspirated cysts [49, 50].  FNA is not useful in SCA 
with diagnostic accuracy of only 17% [51]. Giving the innumerable microcystic structure 
of SCA, FNA is often non diagnostic due to the lack of fluid aspirate. However, the 
presence of glycogen rich cells is highly specific for SCA [51, 52]. In terms of 
differentiating benign from malignant cyst, cytology has an accuracy of 50% in most of the 
trials reported in the literature [53-56]. The presence of tight epithelial cell clusters with 
hyperchromic cell nuclei and high nuclei to cytoplasm ratio is suggestive of malignant 
cysts [50, 57]. Giving the higher risk of bacteremia in FNA of cystic lesions of GI tract in 
comparison with solid lesions, the American Society of Gastrointestinal Endoscopy 
(ASGE) recommends antibiotics administration prior to FNA of cystic lesions of the 
pancreas [58]. 
Recently, a new through the needle cytology brush system (Echobrush, Cook Endoscopy, 
Winston-Salem, NC) was developed in order to improve the diagnostic accuracy of the 
FNA. This system was initially evaluated at Mayo Clinic Florida in a pilot study of 10 
patients with pancreatic cysts who prospectively underwent standard FNA followed by 
FNA with Echobrush. Echobrush was superior to the standard FNA in 7 of the 10 patients. 
However, two of the 10 patients (who stopped anticoagulation 5 days prior to the 
procedure) had bleeding complication after the procedure; in one patient the bleeding 
stopped on its own, while angiographic embolization was required to stop the bleeding in 
the 2nd patient [59]. Similar findings were replicated by Bruno et al in cases series of 39 
patients with 12 pancreatic cysts. Six of 12 patients with pancreatic cysts had an adequate 
cellularity sample with only 1 Echobrush pass [60].  In a larger study by the same group at 
Mayo Clinic Florida, Echobrush was more likely to detect intracellular mucin on cytology 
specimen compared to EUS-FNA in 39 pancreatic cysts larger than 2 cm. However, two 
patients developed acute pancreatitis and one patients developed post brushing acute 
bleeding [61].   
Sendino et al from Spain reported an increased accuracy of Echobrush compared to 
conventional FNA in a group of 22 patients with pancreatic cystic neoplasms (cellular 
diagnosis in 91%). However, the authors witnessed complications of this procedure in 3 
patients (10%) which included a subacute retroperitoneal haemorrhage in a patient on 
anticoagulation who died one month after the procedure [62]. The most recent study by 
Thomas et al from United Kingdom did not show any difference in the cytology yield 
between Echobrush and the standard FNA in prospective study of 51 patients [63]. In 
conclusion, more studies are needed to evaluate the efficacy and the safety of the new 
Echobrush system prior to recommending it for routine clinical practice. To date, Echobrush 
should be avoided in patients with pancreatic cystic neoplasms who are in need for 
anticoagulation.  
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5.3 Molecular markers 
The measurement of intracystic markers and in particular of Carcinoembryonic Antigen 
(CEA) has emerged as an additional tool in evaluating pancreatic cysts. In a landmark 
prospective study published in 2004 by the cooperative pancreatic cyst study, 341 patients 
with pancreatic cysts underwent FNA. The utility of CEA, CA 72-4, CA 125, CA 19-9, and 
CA 15-3 in differentiating mucinous from non-mucinous cyst was evaluated. Only CEA was 
proven to be valuable in differentiating mucinous from non-mucinous cyst. The study 
suggests that an intracystic CEA level higher than 192 ng/ml can predict the presence of 
mucinous cyst with diagnostic accuracy of 79% which was higher compared to EUS 
morphology alone (accuracy 51%)  and cytology (accuracy 59%)  (p:<0.05) [64]. In a 
retrospective study of 126 patients with proven pathological diagnosis of pancreatic cyst, 
CEA level of 200 ng/ml had a sensitivity of 60%, specificity of 93% and diagnostic accuracy 
of 72% in differentiating mucinous from non-mucinous cyst [65]. Although CEA was proven 
useful in differentiating mucinous from non-mucinous pancreatic cysts, the CEA utility in 
differentiating benign from malignant cysts is questionable. A pooled analysis of 12 trials 
proposed that a CEA level of 800 ng/ml can differentiate benign from malignant cyst (48% 
sensitive and 98% specificity) [53]. Another trial suggested that a CEA level of 6000 ng/ml 
can differentiate benign from malignant cyst [66]. However, many trials did not find CEA 
useful in differentiating benign from malignant cysts [65]. In a retrospective long-term 
follow-up study (median follow up period is 21 months) of 267 patients with pancreatic 
cysts, Nagula et al found that intracystic CEA level had no correlation with malignant 
changes of the cyst or with the cyst progression in size [67]. The above mentioned data 
indicate that intracystic CEA level should be limited to differentiation between mucinous 
and non-mucinous cyst.  
Cyst amylase level is usually elevated in pseudocyst and IPMN, given the communication of 
these cysts with the pancreatic duct [66]. Interestingly, malignant IPMN cyst was found to 
have a higher amylase level compared to benign IPMN cysts [65]. 
Identifying DNA mutations in the cysts by genetic markers is considered the new frontier in 
differentiating benign from malignant pancreatic cysts. Several mutations were found to be 
associated with progression of pancreatic cysts from non-dysplastic to dysplastic cysts such 
as k-ras, p-16 and p53 mutations [68-70]. Currently, it is commercially available to measure 
k-ras point mutations and loss of heterozygosity (LOH) analysis of tumor suppressor gene 
[71]. The PANDA study, which is a landmark study in the area of the utility of DNA 
markers in evaluating pancreatic cyst, prospectively enrolled 113 patients with pancreatic 
cysts and proven pathology. Elevated cyst DNA content and k-ras mutation were associated 
with malignant cyst. The presence of k-ras mutation in this study had high specificity of 
96%, but low sensitivity of 37% in diagnosing malignant cysts [72]. k-ras mutation correlated 
with atypical cytology and a high CEA level in a study of 60 patients with pancreatic cysts 
measuring less than 3 cm in size and without mural nodule or pancreatic duct dilation [73]. 
The above results are dissimilar with another trial of 27 patients who underwent EUS with 
FNA and measurement of CEA level, k-ras mutation and LOH mutation. In this trial, 
correlation between histology, CEA level, k-ras mutation and LOH mutation occurred in 
35% of cases, all of which were benign cases. In addition, the sensitivity of k-ras and LOH 
mutation to detect malignant cysts was significantly low compared to CEA (33% and 50% vs 
66%, respectively). Given the high specificity of k-ras mutation to detect malignant cyst 
(92%), the authors of the study recommended ordering DNA mutation analysis only in 
patients with equivocal results or when malignancy is suspected [74].  
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6. Role of EUS in pancreatic cyst ablation 
EUS has emerged from being a merely diagnostic utility to be an effective therapeutic utility 
in various gastrointestinal disorders. Management of pancreatic cyst is an example of this 
transformation. In addition to the important role of EUS in diagnosing pancreatic cysts, new 
studies are currently evaluating the role of EUS in pancreatic cyst ablation with the use of 
different agents. Ethanol lavage of the pancreatic cyst was successful in ablating 35% of 
included cysts in a small study of 25 patients [75]. A randomized controlled trial of 58 
patients compared ethanol lavage to saline lavage for cyst ablation found that ethanol 
lavage was more effective in decreasing cyst diameter compared to saline lavage. Thirty-
three patients from both arms of the study underwent a second ethanol lavage with 
complete cyst resolution in 12 patients (33.3%). Ethanol lavage was generally safe with a 5% 
rate of acute pancreatitis. Twenty-two per cent of patients who underwent ethanol lavage 
complained of mild abdominal pain after the procedure [76]. In a long-term follow-up study 
of the same 12 patients who had complete cyst resolution, follow-up CT scan was available 
in 9 patients. No cyst recurrence was seen in the mean follow-up period of 26 months [77]. A 
combination of ethanol and Paclitaxel was used in a recent prospective trial of 52 patients. 
Paclitaxel is a chemotherapeutic agent which can prevent cyst growth in the long-term 
without leakage from the cystic space. 62% of patients enrolled in this trial had complete 
cyst resolution. The procedure was generally safe with 1 case of mild pancreatitis and 1 case 
of splenic vein obliteration reported [78].  Critiques of this study include the questionable 
injection of chemotherapeutic agent in a cyst most likely benign in nature.  
More studies are needed to evaluate the long-term efficacy of these new technique and to 
define which types of cysts are more responsive to cyst ablation. It is also worth mentioning 
that the majority of cysts included in these studies are either mucinous or serous cysts. Cyst 
with communication with the pancreatic duct such as IPMN cannot be ablated because of 
the risk of inducing stricturing of the pancreatic duct. 
7. Role of EUS in surveillance of pancreatic cysts 
In addition to the role of EUS in establishing the diagnosis of pancreatic cyst , EUS is a 
useful tool in surveillance of  patients with cysts of unclear malignant potential. This role is 
particularly important in side branch IPMN in which disease progression could vary from 
patient to another. There is abundant evidence now that smaller side branch IPMN cysts are 
usually benign and that malignant potential of these cysts is correlating with its size [79]. 
Three cm in size was proposed as a cut off value in differentiating benign from potentially 
malignant branch duct IPMN. Branched ducts IPMN less than 3 cm in size and without any 
mural nodule are usually benign [80]. Surveillance EUS can monitor those patients with 
branch duct IPMN for size progression or for development of worrisome features such as 
mural nodule or mass component and accurately refer them to surgery. It is also worth 
mentioning that symptomatic side branch IPMN should be referred to surgery regardless of 
its size [81]. Guidelines also advocate referring all patients with MCA and main duct IPMN 
to surgery, if they are surgically fit. [82, 83] 
8. Integrating EUS in clinical practice 
EUS should be used in the context of the clinical data and its result should not be interpreted 
in isolation of other finding. For example, an isolated cyst in the tail of the pancreas in a 
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middle age female is most likely mucinous cystadenoma rather than branch duct IPMN. The 
same principle applies to interpreting FNA and cytology results.  FNA has low yield in a 
cyst smaller than 1 cm without any worrisome features. Also, if the patient is not a surgical 
candidate either because of multiple comorbidities or advanced age, FNA cannot be justified 
[84]. For this reason the decision for FNA should be taken on case by case basis. Negative or 
non diagnostic cytology of suspicious pancreatic cyst should not deter the clinician from 
considering surgery of the cystic lesion especially if the cyst has features of malignancy. In 
29 patients with pancreatic cystic lesions who underwent EUS FNA prior to surgical 
resection, more than 2/3 of cysts with negative cytology and 90% of cysts with non 
diagnostic cytology were harboring malignant or premalignant tissue on surgical specimens 
[85].  
9. Conclusions 
The role of EUS in the management of pancreatic cyst is crucial. However, EUS results 
should be incorporated in the overall clinical assessment of the patients. 
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the risk of inducing stricturing of the pancreatic duct. 
7. Role of EUS in surveillance of pancreatic cysts 
In addition to the role of EUS in establishing the diagnosis of pancreatic cyst , EUS is a 
useful tool in surveillance of  patients with cysts of unclear malignant potential. This role is 
particularly important in side branch IPMN in which disease progression could vary from 
patient to another. There is abundant evidence now that smaller side branch IPMN cysts are 
usually benign and that malignant potential of these cysts is correlating with its size [79]. 
Three cm in size was proposed as a cut off value in differentiating benign from potentially 
malignant branch duct IPMN. Branched ducts IPMN less than 3 cm in size and without any 
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mural nodule or mass component and accurately refer them to surgery. It is also worth 
mentioning that symptomatic side branch IPMN should be referred to surgery regardless of 
its size [81]. Guidelines also advocate referring all patients with MCA and main duct IPMN 
to surgery, if they are surgically fit. [82, 83] 
8. Integrating EUS in clinical practice 
EUS should be used in the context of the clinical data and its result should not be interpreted 
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cyst smaller than 1 cm without any worrisome features. Also, if the patient is not a surgical 
candidate either because of multiple comorbidities or advanced age, FNA cannot be justified 
[84]. For this reason the decision for FNA should be taken on case by case basis. Negative or 
non diagnostic cytology of suspicious pancreatic cyst should not deter the clinician from 
considering surgery of the cystic lesion especially if the cyst has features of malignancy. In 
29 patients with pancreatic cystic lesions who underwent EUS FNA prior to surgical 
resection, more than 2/3 of cysts with negative cytology and 90% of cysts with non 
diagnostic cytology were harboring malignant or premalignant tissue on surgical specimens 
[85].  
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Endorectal Ultrasound Scan 
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Dept. of Surgery, Royal University Hospital, Saskatoon,  
Canada 
1. Introduction 
1.1 Endoscopic ultrasound anatomy of rectum 
Assessment of the rectum with endoscopic ultrasound [EUS] has evolved as an excellent 
tool in the management of   malignant as well as benign diseases of the rectum and anus. 
The endoluminal ultrasound provides accurate evaluation of rectal, perirectal and perianal 
pathology.  Initially, the standard radial endoscopic ultrasound scan was used in the 
assessment of the rectum as people were familiar with its usage in the management of upper 
gastrointestinal tract problems. The rigid endoscopic ultrasound scan has been used since 
the early 80’s. Improvements in the instrument as well as high resolution of the ultrasonic 
waves have resulted in very significantly improved image quality and accurate 
interpretation of this particular examination. Color Doppler as well as 3D imaging has also 
added some benefits to this modality. The EUS has now become an excellent tool in the 
preoperative staging of low rectal cancer compared to CT scan and/or MRI. The rigid probe 
is 20cm in length, has the rotating transducer at the tip covered by a balloon filled with 
water. There are different types of linear as well as radial scanning devices available in the 
market and the frequencies vary from 3.5 MHz to 15MHz. EUS is portable, cost effective and 
can be completed in a short time with minimal discomfort to the patient. Most of the 
patients can have it done without any sedation and the recovery time is very short. 
1.2 Examination technique 
Patients are often given full bowel prep or Fleet enemas to clean the rectum. This is quite 
important as fecal material can interfere with the interpretation of the test. Sedation is 
optional. The examination is often preceded by a digital rectal exam to evaluate the size, 
fixation, location and morphology of the rectal lesion. In most instances a large bore 
proctoscope is used as it allows visual examination of the rectum and facilitates suctioning 
any residual stools or enema fluid that can interfere with the ultrasound acoustic waves 
leading to distorted images. Patients are usually placed on left lateral position and then the 
rigid scope is passed up to 20cm. 
The probe with lower frequency gives better details of the depth of the tumour whereas the 
probe with the higher frequency gives better details of the bowel wall. One may choose the 
appropriate probe depending on the clinical situation. The balloon is then inflated with 
water and the normal anatomy is identified.  The probe is then withdrawn slowly looking 
for perirectal lymph nodes as well as the lesion. Detailed examination of the lesion is carried 
out by placing the probe on top of the lesion. If the probe cannot be passed beyond the 
lesion in the rectum, the examination can be quite difficult. 
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1.3 EUS anatomy of the rectum 
The rectal wall appears as concentric layers of rings on the endoscopic ultrasound images. 
Some adjustment has to be made to the ultrasound scan unit to provide optimal imaging. 
Vary rarely one can perfectly show all the 5 layers of the rectum circumferentially. Usually, 
only a portion of the bowel wall is displayed clearly. However, in the newer machines 
changing the zoom facilities enables one to have a global view of the entire rectal wall.  This 
is usually accompanied by images with much less clarity; yet when one zooms it to one 
portion of the rectal wall, the clarity becomes much more apparent. This is however then 
limited to partial visualization of the rectal wall. 
The rectal wall appears as concentric rings of echo-dense followed by echo-poor layers. The 
first three layers correspond to the mucosa and submucosa, the fourth layer corresponds to 
the muscularis propria and the fifth layer corresponds to the perirectal fat. 
The inner white line represents the interface between the balloon and the mucosa. The inner 
dark or high poor echo ring signifies the mucosa and muscularis mucosa. The submucosa is 
represented by the middle white layer. The outer black ring is muscularis propria and the 
outer white line represents the interface between the perirectal fat. [Figure1a,1b]. 
Interpretation of changes in these layers is clinically significant. For example in the 
evaluation of rectal neoplasms, the relationship of the tumour to each layer is an important 
determinant in the staging of rectal cancer. 
 
 
Fig. 1. (A) The normal rectal anatomy is visualized as dark hyperechoic and light 
hypoechoic regions  
The perirectal tissue shows different echogenicity. The blood vessels show up as circular 
echo-poor areas which may be difficult to differentiate from the lymph nodes. However, the 
blood vessels have a tendency to run either longitudinally or circumferentially which is a 
helpful hint to differentiate between the lymph nodes and the blood vessels. The hypoechoic 
areas also branch and elongate in longitudinal fashion confirming the presence of a blood 
vessel rather than a node.  Normal size lymph nodes are generally not visualized on routine 
ultrasound scan examination. There are established guidelines to identify lymph nodes in 
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the perirectal tissue. In a male patient, the prostate and the seminal vesicles are easily 
detectable on ultrasound scan examination. 
 
 
Fig. 1. (B) Endorectal ultrasonograhic images of the normal rectal anatomy  
The normal anal canal is nicely demonstrated by endo anal ultrasonography. The internal 
anal sphincter and external anal sphincters are better defined in the mid-low anal canal. In 
the distal anal canal, the internal sphincter is not visualized and the external sphincter is 
seen as a mixed echogenic structure on ultrasound scanning.  
2. Indications for using EUS in the rectum 
The most common use of EUS is for staging of rectal cancer. This will help in deciding 
whether a patient should undergo preoperative chemoradiation or whether surgery alone 
would be sufficient to treat an early cancer. The use of EUS to determine very early invasion 
in a villous polyp has limited usage. In this context, EUS can assess suitability for transanal 
excision. Retrorectal masses though rare can also be visualized and assessed.  EUS can also 
be used in the diagnosis and management of submucosal lesions such as submucosal 
lipoma, carcinoid tumour and occasionally in gastro intestinal tumours [GIST] as well. For 
this purpose a 12 MHz probe is more useful than the 7.5 MHz probe. The higher frequency 
allows a more detailed examination of the bowel wall where as the lower frequency allows 
us to examine more in depth then the high frequency. However, for the detection of lymph 
node metastases, a 7.5MHz might serve better than a 12.5 MHz probe. It is also a necessity to 
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have a fluid interspace between the transducer and the bowel wall to get accurate pictures. 
For cancer staging the relationship of the tumor to the 4th echo-poor layer has particular 
significance as this would determine whether a lesion is UT2] or UT3 [Ultrasound T stage 
which in turn will determine the sequence of therapy for the patient. 
3. Preoperative staging for rectal carcinoma 
The depth of invasion, T [Tumour] stage of the rectal cancer can be assessed by EUS with 90-
95% accuracy. However, the N [Node] staging is more difficult and the specificity and 
sensitively of EUS staging of lymph nodes is only up to 65-70%. 
UT1 tumour specifies a tumour mass invading the first 3 innermost layers shown 
previously. 
UT2 carcinoma extends into the muscularis propria which is the 4th layer which is echo-
poor. However, this does not breach this layer and extend beyond this. 
UT3 carcinoma corresponds to the infiltration into the pericolic fat or the perirectal tissue 
with an irregular outer margin. 
UT4 lesion involves the adjacent structures such as uterus, vagina, seminal vesicles, prostate 
and/or bladder. 
In practice, a tumour tends to get overstaged on endoscopic ultrasound scan rather than 
under staged. This is partially because of peri-tumor inflammation which may mimic 
invasion on ultrasonographic examination.  
EUS has limitations in rectal carcinoma staging. Limitations that preclude optimal imaging 
include faeces in the rectum, stenotic lesion and an extremely mobile lesion that moves with 
the ultrasound probe and deters adequate examination.  
Lymph node metastasis is an independent prognostic variable in colorectal cancer. 
Metastatic lymph nodes can also be visualized on EUS. Detection of lymph nodes is much 
more difficult. Lymph nodes have to be separated from blood vessels. During the active 
scanning it is relatively easy to separate a blood vessel from a lymph node usually. Detailed 
examination of the lymph node is also a necessity to determine the likely hood of its 
involvement with cancer. A lymph node that is more than 2cm with irregular margins and 
no hilar fat is much more likely to be involved with a tumour deposit then smaller lymph 
nodes. A size criterion is most commonly accepted determinant in the evaluation of lymph 
nodes. The shape of the lymph node, demarcation and echogenicity are soft criteria and 
somewhat less well defined. The difference between a metastatic and an inflammatory 
lymph node can be extremely difficult especially when the lymph nodes are small. In 
summary, there is no agreed consensus to the EUS guidelines that should be used in 
determining whether a lymph node is involved with carcinoma or not. In this context, 
though targeted Ultrasound guided transrectal biopsy of these lymph nodes have been 
described; it has not gained popularity for widespread clinical use. 
Preoperative EUS therefore helps to direct choice of therapy for rectal cancer such as 
planning for neo adjuvant therapies in combination with less extensive surgeries. It thereby 
improves the quality control of the various treatment modalities available.  
EUS for restaging following neo adjuvant chemotherapy has not gained popularity due to 
its relative inaccuracy reflected by the poor concordance with pathological staging. This is 
largely attributed to the post radiation induced oedema and fibrosis that distort ultrasonic 
images.   
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4. Post-operative follow-up of rectal cancer 
One of the major problems of rectal cancer surgery is the local recurrence. Even though 
endoscopic evaluation is used as the main method for early detection of asymptomatic 
recurrences at the anastomotic site it is important to recall that the majority of recurrences 
commonly occur in an extra luminal area which is closely correlated to suboptimal total 
mesorectal excision [TME] techniques at the time of primary surgery. In summary, though 
EUS is a useful tool in the evaluation of early anastomotic recurrences it is of limited use in 
the evaluation of extra luminal recurrences.  
5. The use of EUS in anal canal  
The use of endoluminal ultrasonograhic probes in the anal canal is limited in comparison to 
its widespread usage in rectal lesions. The procedure is similar to that employed for imaging 
the rectum. However, a plastic cap is used instead of the balloon to cover the probe. 
The anal ultrasonic image differs from the rectal image in having only four layers.  
1. Hyper echoic inner ring   
2. Hypo echoic –internal anal sphincter 
3. Hyper echoic-/ hypoechoic outer ring longitudinal muscle/external anal sphincter and  
4. Mixed pattern- ischiorectal fat.  
The T staging for anal cancers refers to the size of the tumour as opposed to the depth of 
infiltration in rectal cancers. Therefore endoanal imaging has limited value in the 
preoperative staging as the anus is easily accessible for determining the size of the lesion.    
EUS can be used for sphincter assessment. EUS complements manometric testing in this 
regard. EUS can define the precise locations, thickness of the internal and external 
sphincters and to detect muscular defects especially in the investigations of patients with 
fecal incontinence or in women with anal problems following childbirth. . 
EUS is helpful in the evaluation and treatment of select perianal inflammatory conditions.  
The use of EUS is however not widespread in the management of uncomplicated perianal 
sepsis or perianal fistula. However, in the case of complex fistulas, EUS has been used to 
evaluate the extent of the fistulous tract, the location of the internal opening, as well as any 
residual undrained fluid collections and assess the state of the sphincters.  Many of these 
patients have often had multiple previous surgeries, resulting in quite distorted anatomy; 
therefore accurate assessment of the sphincter mechanism can be quite difficult. In 
comparison, detection of undrained fluid collections or abscess locations is identified on 
EUS relatively easily as hypoechoic areas. Additionally image enhancing techniques to 
improve the detection of fistulous tract as well as visualization of the internal opening 
include injecting the tract with hydrogen peroxide. In summary endoanal ultrasound has 
limited clinical value in anal tumours yet is easy to use and remains a safe, inexpensive 
means to assess the anus in inflammatory disease.  
6. Conclusion 
In conclusion endoluminal ultrasonography is easily performed and is an extremely useful 
modality of investigation for evaluation and staging of anorectal lesions. It is a simple 
inexpensive outpatient procedure that can be accomplished with minimal sedation. EUS 
offers good staging accuracy in rectal tumours with T [tumour depth] and N [nodal] staging. 
This directs management pathways by facilitating the selection of stage-dependent 
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treatment options including preoperative chemo radiation therapy. Such preoperative 
staging of malignancies can help to decrease extensive colorectal surgery thereby improving 
the quality of life without any sacrifice to the oncological principles of disease management 
and control. In current practice EUS is an established valuable staging method for rectal 
cancers that is superior to digital examination and CT scan with impact on treatment 
selection for radical extirpation or trans anal local excision. In contrast, the role of EUS in 
restaging anorectal malignancies post chemo radiation therapy is less clear as accuracy is 
impaired due to therapy related oedema, inflammation and fibrosis. Similar problems are 
encountered in restaging extramural recurrences or recurrent lymphadenopathy. However, 
if a definite mass or recurrent lymphadenopathy is identified complementary testing with a 
Fine Needle Aspiration Biopsy may improve accuracy of the assessment of disease 
recurrence. 
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Video capsule endoscopy (VCE) introduced a new era in the study of small bowel 
disease(Iddan et al., 2000).  Prior to VCE, visualization of the small intestine required 
radiographic or endoscopic methods that had significant disadvantages in terms of radiation 
hazard, patient discomfort as well as had low diagnostic sensitivity and specificity.(Foutch 
et al., 1990; Rabe et al., 1981).  In contrast, VCE allowed for evaluation of the entire small 
bowel mucosa without radiation, sedation or discomfort to the patient(Appleyard et al., 
2000; Ell et al., 2002; Hahne et al., 2002; Lewis & Swain, 2002). The videocapsule is a 11×26 
mm disposable device that weighs 3.7 g. and is covered with a biocompatible plastic 
containing a metal oxide silicon chip camera, lens, light source, battery, and radio-telemetry 
transmitter(Davis et al., 2005; Iddan et al., 2000).  Images are transmitted to an antenna array 
worn on the abdomen and stored externally in a portable data recorder. VCE records stream 
images at rate of 2 per second over a 7 to 8 hours image acquisition period, yielding a total 
of approximately 50,000 image per examination. The image covers 140 degrees with 8-fold 
magnification and a depth of view of 1 to 30 mm(Swain, 2003). VCE has been available for 
clinical use since 2001(Meron, 2000; Nakamura & Terano, 2008; Seidman, 2002). The primary 
indications for VCE include evaluation of patients with occult or overt obscure 
gastrointestinal bleeding, suspected Crohn’s disease, non-steroidal anti-inflammatory drug-
induced small bowel injury, celiac disease, and chronic diarrhea(Rondonotti et al., 2007; 
Scapa et al., 2002). VCE examination is now the accepted standard for examination of the 
small bowel worldwide. A variety of VCE devices are currently in development with the 
goal of extending the technology to different areas and capabilities.(Aihara et al., 2011; 
Fireman, 2010; Moglia et al., 2009). VCE provides high resolution images that differ from 
those obtained by fiberoptic video endoscopy.  VCE is passive and what is seen depends on 
small bowel motility.  Current versins do not have an ability to insufflate air and distend 
bowel or to go back to an area of interest in order and review the site from different angles 
and degrees of illumination. As such, the visualization is not complete and important 
lesions may be missed(Selby & Prakoso, 2011) . Interpretation of VCE small bowel images is 
both subjective and time consuming(Cave, 2004) with a significant potential for inter-
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observer variation in the interpretation of the VCE results(Chen et al., 2006; Lai et al., 2006; 
Pezzoli et al., 2011).  Industry has responded by continuing to develop software programs to 
assist in interpretation of the captured images (see below)(Gan et al., 2008; Spada et al., 
2007). The relatively long time required to properly interpret a VCE examination has results 
in use of non-physicians being trained in interpretation of VCE examinations.(Levinthal et 
al., 2003; Sidhu et al., 2007).  
This chapter discusses current issues regarding VCE reading and interpretation and 
highlights clinical aspects of inter-observer variation. 
2. Reading a capsule endoscopy 
2.1 General introduction 
The technical issues regarding reliably obtaining a sufficient number of good images of the 
small intestine have a major focus of the software and hardware manufactures of VCE 
equipment. However, from the patient’s and clinician’s standpoint, the keys to a successful 
examination encompass the ability to capture the appropriate images and the ability to find 
and correctly interpret those images using the VCE reader software.  VCE reading requires 
an extended period of focused concentration(Fleischer, 2002) and the first step to a successful 
result is to perform the reading in a comfortable environment with low background 
noise(Becker et al., 1995), ((Palinkas, 2001).  The reader should be rested, physically 
comfortable, and alert(Lieberman et al., 2002) ((Lane & Phillips-Bute, 1998).  Depending on 
the speed of the rapid scan, average time of interpretation may range from 30 to 90 
minutes(Lewis, 2004; Melmed & Lo, 2005),  It has been shown that for best results sustained 
concentration in reading a VED for 50 minutes should be followed by a rest period of 
approximately 10 minutes in order to sustain appropriate concentration(Cave, 2004; Lewis, 
2004; Westerhof et al., 2009). The quality and accuracy of the reading can also be improved 
by providing the reader with clues regarding the condition or conditions that prompted the 




Table 1. Items for an appropriate VCE reading room 
2.2 Order of reading  
The first step is to identify whether the examination was complete, (i.e., did the capsule pass 
into the colon during the time the images were being collected) or was the capsule still in the 
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stomach or small bowel when the battery died.  To aid in reading one should mark the 
images (ie, time) when the capsule entered and left the stomach and when it reached the 
colon. This also provides a measure of the transit times through these organs. If the 
indication is evaluation of a patient with gastrointestinal bleeding, one can screen the 
examination using the Suspect Blood Indicator program (SBI). However, this useful 
software program has low sensitivity and does not obviate the need to do a proper full 
reading of the examination(D'Halluin et al., 2005). Experience has shown that many lesions 
responsible for the VCE examination are present in the proximal small intestine.  The 
capsule also tends to move more quickly through the proximal than the distal small bowel 
such that the reader should keep a finger on the jog wheel so as to stop the image stream to 
take a closer look at suspected lesions. We recommend that one should also to take a short 
break in reading approximately every 30 minutes and that a thumbnail be captured at that 
time. Reading time can be reduced by using dual image playback rather than the original 
single-viewing mode. Importantly using the multi-image modality has not been shown to 
result in a lower detection rate of abnormal findings, at least among experienced 
readers(Melmed & Lo, 2005). Standard viewing speeds range from 15 to 21 frames/second.  
Faster viewing speeds do not necessarily shorten overall reading times because viewers are 
more likely to need to stop and review suspicious findings. In 2002 a consensus panel 
suggested that the optimal review rate was 15 images/second, which requires 64 minutes to 
read an 8-hour procedure(Lewis, 2004).The capsule records the mucosal images and thus 
one can generally identify whether the capsule is in the esophagus, stomach, or small bowel.  
Clearly, when one identifies an abnormality, one of the first questions is “where is it?” as 
this information is needed to plan what options are best to deal with the finding(Lewis & 
Goldfarb, 2003; Li et al., 2009). A computer program shows the approximate location of the 
capsule in terms of one of the 4 quadrants of the abdomen(Fig.1.).This information coupled 
with the time it elapsed after entering the small bowel before reaching the location of 
interest, and the time from the lesion to the ileocecal valve allows one to failly reliably 
identify where the lesion is likely located. The relation to thumbsnaill markings made of the 
esophagus, stomach, duodenum, small intestine, ileum, organs and anatomical landmarks 
such as the Z-line, pyloric, ampulla and ileocecal valve are especially helpful in this regard.   
 
 
Fig. 1. Localization on capsule endoscope: A computer program shows the approximate 
location of the capsule in 4 quadrants of the abdomen. 
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Fig. 1. Localization on capsule endoscope: A computer program shows the approximate 
location of the capsule in 4 quadrants of the abdomen. 
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Most divide the small bowel into 3 parts, proximal, middle and distal based on the time 
from the first image of the duodenum to first image of appendix according to elapsed 
time(Bocker et al., 2010; Goldstein et al., 2007). This method ignores the speed of the capsule 
and possible areas of delay in capsule transit. In general the small intestine transit time is 4 
hours and 30 minutes.  Proximal lesions (ie, those located in the left abdomen) can generally 
be reached by push enteroscopy(Fischer et al., 2004). If single or double balloon endscopy is 
used to follow up lesions, those in the proximal half of the small bowel are often generally 
approached orally and those in the distal half trans rectally.  
2.3 Video capsule reading software 
The most widely available software for reading VCE is the software “RAPID” developed by 
Given Imaging.  This chapter will describe capsule endoscopy reading using RAPID 
software. The software for reading VCE is propriotary to each company, however most are 
very similar. The current version of RAPID software is RAPID 6however, new versions 
appear regularly each with slight to modest improvements(Glukhovsky & Jacob, 2004). The 
first step in reading is to determine which software and which version you have.  In RAPID 
1 and subsequent versions the small bowel images are down loaded from Data Recorder.  
The speed of the streaming images can be controlled using a speed control button.  A 
localization function presents the position of capsule in gastrointestinal tract based on 
positioning of images on a sketch of the small intestine.  RAPID 2 introduced a software 
program called Suspected Blood Indicator in which suspected bleeding points are expressed 
as red line on a tissue color bar.  This software saves a video of 100 frames (for 20 seconds) 
which includes 50 frames before and after the thumbnail.  RAPID 2 also introduced 
MultiView which enables one to see two continuous images at the same time.  This is said to 
reduce reading time by 30-50%. RAPID 3 can also read images from the esophageal capsule 
and introduced QuadView with presents 4 images at the same time (Fig.2.). It also allows 
readers to store or delete term for the video capsule report using the My GI Dictionary 
program. Terms stored in the dictionary move automatically to the comment after a double-
click or pressing the enter key.  RAPID 4 introduced an Automatic Viewing Mode which 
automatically retarded the video playing times during rapid transit and quickens the 
viewing when there is slow transit. This stabilized rate the small bowel image changed and 
made for a smoother reading experience.  The images can also be compared with those 
stored in an atlas (ie, the RAPID4 Atlas) allowing one to make direct side by side 
comparisons.  The RAPID4-Circumference scale program allows one to assess the extent of 
esophageal varices or small bowel ulcerations: this is activated in reporter editor, click 
circumference scale botton, can measure % of affected area. RAPID 5 supports the reading of 
PillCam SB2, PillCam ESO 2, PillCam colon, and includes a function callled colon 
localization track.  The Quick view function has been improved with improved image 
quality control.  The addition of applications such as the (Lewis score, Rapid atlas, colon 
localization track, circumstance scale) also improved the efficiency of reading and reporting. 
This version enhance workflow can forward multiple exams simultaneously and  RAPID 5 
Access software has been shown to improve diagnostic yield while reducing reading time 
(Shiotani et al., 2011). RAPID 6 supports the PillCam Sensor Belt, a “patient-friendly” 
alternative to the sensorArray and its stick-on adhesive sleeves. The Image Adjustment 
program enables Flexible spectral Imaging Color Enhancement( FICE) which is a spectral 
image processing technology for high contrast display that may enhance viewing of subtle 
structural and color changes (Fig.3).  The software includes Mosaic View which displays 
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multiple, consecutives images simultaneously for a convenient overview of 18 or 24 RAPID 
images at a time (Fig.4).   
 
 
         
 
 
Fig. 2. View Mode of RAPID software. Single View(upper left), Double View(upper right) 




Fig. 3. FICE image display in RAPID 6. The FICE image is a spectral image processing 
technology for high contrast display that may enhance viewing of subtle structural and 
color changes. 
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multiple, consecutives images simultaneously for a convenient overview of 18 or 24 RAPID 
images at a time (Fig.4).   
 
 
         
 
 
Fig. 2. View Mode of RAPID software. Single View(upper left), Double View(upper right) 




Fig. 3. FICE image display in RAPID 6. The FICE image is a spectral image processing 
technology for high contrast display that may enhance viewing of subtle structural and 
color changes. 
 





Fig. 4. Mosaic view in RAPID 6 version. This View mode which displays multiple, consecutives 
images simultaneously for a convenient overview of 18 or 24 RAPID images at a time. 
2.4 Normal finding 
Because the VCE images are not real time continuous but are individual images taken at 2 per 
second, the appearance differs from that of conventional endoscopy(Appleyard et al., 2001) 
and those experienced in video endoscopy may misinterpret normal findings as an abnormal 
condition. However, the learning curve is short once one becomes familiar with the variability 
of normal findings. Here, we will discuss the normal small bowel structure observed by VCE.  
The capsule takes 2 pictures in a second starting from outside the body through the oral cavity, 
oropharynx, esophagus, stomach, small bowel, and colon.  Oropharynx: The pharynx is 
located between posterior nasopalatine and 6th cervical spine and only 1 or 2 images are 
obtained as the capsule transits rapidly.  The mean esophagal transit time is 6 second such that 
approximately 10 pictures can be taken. The Z-line is often visible because the lower 
esophageal sphincter delays the transit time at the level of esophago-gastric junction (Fig.5.). 
Capsule endoscopy designed for observing the esophagus has been developed and takes 
pictures at 14 flames/second from both ends of the capsule(Eliakim et al., 2004).  The mean 
gastric transit time of the capsule through the stomach is about 1 hour but with a wide 
variation(Dai et al., 2005; Faigel & Fennerty, 2002).  Because the antrum is not distended, the 
pylorus appears folded. The most common and characteristic findings in capsule endoscopy of 
the stomach is seeing the same image of large rugae as the capsule remains in one location. 
However, often a clear image of gastric mucosa along with peristalsis of antrum and pylorus 
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can be observed (Fig.6.). The length of small bowel is about 6 meters. The small bowel transit 
time is defined as the time elapsed from passing through the pyloric ring to the ileocecal valve. 
When the capsule enters the duodenum, one notices a color change as the image becomes 
brighter and bile can be seen.  Bile flowing from the distal duodenum to the proximal part can 
sometimes be seen.  The duodenal bulb is covered with villi and vessels are not seen.  When 
the capsule passes the bulb, it enters to 2nd portion of the duodenum where the villi become 
more prominent. The ampulla of Vater can often be seen at the medial wall 3 to 6 cm from the 
edge of bulb. The minor papilla is located 2 to 4 cm from the ampulla, however, it is not often 
observed because it is hiden by a Kerckring fold.  In the 2nd portion of the duodenum the 
Kerckring folds are often prominent and run perpendicular to the long axis of the duodenum 
(Fig.7.). There is often a moderated amount of fluid and because there is no luminal distension 
capability in capsule endoscopy, the villi appear more prominent than in conventional 
endoscopy.  The capsule enters the jejunum after passing the ligament of Treitz. This can not 
be seen visually and entry into the jejunum is identified by the presence of the capsule being 
on the left side of the abdomen.  The ileum is located at right lower quadrant in the pelvis and 
has a more narrow lumen than the jejunum.  The small intestinal mucosa has many plicae 
circularis, Kerckring folds from the distal duodenum to the jejunum (Fig.8.). Lymphoid 
follicles may be seen at any site in the small bowel but are most frequently seen in the distal 
ileum. Small bowel villi are 0.5 to 1.5 mm “fingers” protruded into the lumen and appear 
longer in the distal duodenum and proximal jejunum than more distally.  Vascular structures 
of the small intestine are often seen clearly after the capsule reaches distal jejunum and 
sometimes thick veins along with an artery can be seen (Fig.9.).  Bile becomes increasingly 
concentrated as the capsule moves distally such that villi can often not be seen in the ileum 
(Fig.10). It is not possible to clearly discriminate the jejunum from the ileum so as noted above, 
it is traditional to divide the small bowel into proximal, mid and distal portions according the 
small bowel transit time and the location of capsule in the tract image.  The movement of the 
capsule from the terminal ileum to the cecum can generally be easily recognized seeing the 
more wide lumen and darker sometimes find fecal material.  Passage of the capsule if often 
delayed in the distal ileum due to a closed ileocecal valve.  After passing the ileocecal valve, 
the prominent vascular distribution of colon mucosa appears.  
 
 
Fig. 5. Capsule endoscopy findings of normal esophagogastric junction. The Z-line is often 
visible because the lower esophageal sphincter delays the transit time at the level of 
esophago-gastric junction. 
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Fig. 5. Capsule endoscopy findings of normal esophagogastric junction. The Z-line is often 
visible because the lower esophageal sphincter delays the transit time at the level of 
esophago-gastric junction. 
 




Fig. 6. Capsule endoscopy findings of normal antrum & pylorus. It shows gastric mucosa 
and normal rugal fold along with peristalsis of antrum and pylorus can be observed. 
 
 
Fig. 7. Capsule endoscopy findings of duodenum:  Kerckring folder and vili can be seen in 
2nd portion of duodenum. 
 
 
Fig. 8. Capsule endoscopy findings of normal jejunum: The small intestinal mucosa has 
many plicae circularis, Kerckring folds from the distal duodenum to the jejunum 
 




Fig. 9. Capsule endoscopy findings of normal distal jejunum: Vascular structures of the 
small intestine are seen clearly after the capsule reaches distal jejunum and sometimes thick 
veins along with an artery can be seen.  
 
 
Fig. 10. Capsule endoscopy findings of normal ileum: Bile is more concentrated and the 
height of villi is lower than jejunum in ileum. 
3. Capsule endoscopy in disease 
3.1 Obscure gastrointestinal bleeding 
The most frequent indication for VCE is evaluation of obscure gastrointestinal bleeding 
(OGIB) defined as bleeding in which no diagnosis has been reached after upper endoscopy 
and colonoscopy have performed.  OGIB represents approximately 5% of all gastrointestinal 
bleeding.  The goal of VCE is to identify whether the site of bleeding is from the small bowel 
and if so what is the cause.  Active bleeding will be associated with blood in the lumen 
which is often readily visible because of its red color with fresh red material on the villi.  
However, all that is red is not blood.  For example, close contact of dome of VCE to the 
mucosa will cause normal mucosa to appear red and simulate a telangiectasia(Regula et al., 
2008). As with any finding it is critical to be able to distinguish true from false positive 
lesions such as caused by food, feces, closeness to the mucosa, bile, etc.. The distinction 
between blood and bile may be difficult as the image may appear dark and it becomes 
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between blood and bile may be difficult as the image may appear dark and it becomes 
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difficult to see the details of the surrounding mucosa.  The greatest difficulty are when only 
one image of the lesion is seen, when the lesion appears to be submucosal, and when the 
lumen contains dark-colored blood or bile.   
There are many potential causes of small bowel bleeding (Table 2.)(Concha et al., 2007) which 
can be broadly classified into vascular diseases (eg, arteriovenous diseases), inflammatory 
diseases (eg, Crohn’s disease)(van Tuyl et al., 2007), systemic diseases (eg, amyloidosis), 
infectious diseases (eg, tuberculosis), tumors, and chemical/radiation injuries(Christodoulou 
et al., 2007; Maieron et al., 2004; Polese et al., 2008).  Most of these conditions can be detected 
with VCE.  The most common cause of bleeding from the small intestine are vascular ectasis 
(ie, angioectasia) which are especially likely in the elderly where they account for 30% to 40% 
of bleeding.  In contrast tumors are a prominent cause in patients 30 to 50 years of age. 
Telangiectasia often clearly shows bright red border(Polese et al., 2008).  Small bowel ulcer also 
cause bleeding.  Both nonsteroidal anti-inflammatory drug use and Crohn’s disease cause 
ulcers, erosions, and strictures, and should always be considered in the differential diagnosis 
of OGIB(Graham et al., 2005; Leighton et al., 2006; Shiotani et al., 2010; van Tuyl et al., 2003).  
Small bowel ulcers may also be simulated by material floating on normal mucosa.  A Meckel’s 
diverticulum with gastric metaplasia in the diverticulum can occasionally be seen but is a less 
common cause of OGIB(Sokol et al., 2009). Much more rarely bleeding may originate from a 
small bowel enteropathy or varices due to portal hypertension.  
Occasionally the bleeding may originate from the stomach or colon which was missed during 
the pre-VCE endoscopic evaluation. If the initial VCE for OGIB is negative, there may be a role 
for repeating the VCE study in patients with recurrent gastrointestinal bleeding and those with 
limited visualization on their initial examination or with incomplete small-bowel visualization 
due to the capsule not reaching the colon. Repeat VCE in these settings can result in new 
findings that lead to changes in patient management(Min et al.).  We believe that patients with 
recurrent obscure bleeding and prior negative VCE should have VCE done as soon as possible 
to the repeated episode as this likely increases the yield. 
3.2 Small bowel tumors 
Small intestinal bleeding might be the most frequently encountered presentation(Bailey et 
al., 2006).  Small bowel tumors account for approximately 6% of obscure gastrointestinal 
bleeding.  The second most common indication for VCE was unexplained abdominal pain, 
followed by unexplained weight loss, diarrhea(Liao et al., 2010).  This is consistent with 
previously reported data suggesting that abdominal pain and weight loss are reliable factors 
for predicting small bowel tumors. 
The terminology used for possible small intestinal tumors seen at VCE is primarily descriptive 
with findings described as “tumor”, “tumor mass”, “polypoid mass”, “a bleeding polypoid 
mass”, “ulcerated mass lesion”, “thickened folds”, and “irregular ulcer”(Trifan et al., 2010).  
Structured terminology for capsule endoscopy has been proposed(Korman, 2004; Korman et 
al., 2005) in which tumor-like lesions are divided into nodules, polyps, tumors and venous 
structure.  A nodular lesion is defined as a 2 to 3 mm  luminal protruding lesion without clear 
margins surrounded by normal mucosa.  The differential diagnosis includes lymphoid follicle 
hyperplasia, lymphangiectsia and lymphoma.  A polypoid lesion is defined as an intraluminal 
protrusion and can be sessile, pedunculated or unknown in terms of pedicle(Korman et al., 
2005). The common differential diagnosis for such lesions includes lymphoid follicle 
hyperplasia, a peudopolyp, inflammatory polyp, adenomatous polyp or hamartoma. Because 
the image by capsule endoscope is different from conventional image, it is important to 
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distinguish true lesion and normal image. The lymphoid follicle should not be interpreted as 
polyposis and the concentrated bile is sometimes confused with gastrointestinal bleeding. The 
mucus on the mucosa can be misdiagnosed as inflamed villi or lymphangiectasia. A tumor 
was defined as a either a subepithelial mass covered with normal mucosa, a fungating mass, or 
a frond-like/villous mass.  VCE does not allow measurement of exact sizes and lesions are 
defined as being small, medium, or large with medium size being defined as  occupying one-
half of the bowel lumen upon close view. In general, benign tumors are not ulcerated and have 
regular and symmetric features. Malignant lesions tend to be large, ulcerated masses with an 
irregular and asymmetric appearance. We previously characterized(Cheung et al., 2010), small 
bowel tumors found at VCE as polyps, epithelial mases with fungation or ulceration, 
subepithelial tumor with/without bleeding, and vascular masses. Most of these tumors 
(59.6%) presented as subepithelial tumors. With VCE, it is not easy to distinguish between a 
subepithelial tumor and normal peristalsis. Subepithelial mucosal lesion are sometimes 
difficult to distinguish from intestinal loops and peristalsis.  For suspected tumors it is 
important to examine the character of surface and whether there is an associated ulcer or 
bleeding which are suggestive of small bowel tumors.  We found active bleeding in 
approximately 10.5% of suspected tumors. Approximately one third of the lesions in our series 
were either fungating or ulcerative masses.  Such mucosa changes point to the mass being a 
true lesion.  Four patients presented with polyps, and one patient presented with a vascular 
mass.  When in doubt, single or double ballon endsscopy, CT enterography, or surgical 
resection may be needed to resolve the problem.   
Lipomas appear as subepithelial masses with intact covering mucosa and yellowish hue 
generally be diagnosed with confidence. Subepithelial lesions with round or oval 
protruding contour are suggestive a leiomyomas or Gastrointestinal Stromal Tumor.  The 
histologic findings of small bowel tumors found at VCE are described in Table 3 
(Rondonotti et al., 2008).  
 
 
Table 2. Common cause of Occult Gastrointestinal bleed 
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distinguish true lesion and normal image. The lymphoid follicle should not be interpreted as 
polyposis and the concentrated bile is sometimes confused with gastrointestinal bleeding. The 
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subepithelial tumor with/without bleeding, and vascular masses. Most of these tumors 
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subepithelial tumor and normal peristalsis. Subepithelial mucosal lesion are sometimes 
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bleeding which are suggestive of small bowel tumors.  We found active bleeding in 
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were either fungating or ulcerative masses.  Such mucosa changes point to the mass being a 
true lesion.  Four patients presented with polyps, and one patient presented with a vascular 
mass.  When in doubt, single or double ballon endsscopy, CT enterography, or surgical 
resection may be needed to resolve the problem.   
Lipomas appear as subepithelial masses with intact covering mucosa and yellowish hue 
generally be diagnosed with confidence. Subepithelial lesions with round or oval 
protruding contour are suggestive a leiomyomas or Gastrointestinal Stromal Tumor.  The 
histologic findings of small bowel tumors found at VCE are described in Table 3 
(Rondonotti et al., 2008).  
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VCE, capsule endoscopy; GIST, gastrointestinal stromal tumor, D, duodenum, J, jejenum, I, ileum. 
Table 3. Histological diagnoses of small bowel tumors found by VCE 
3.3 Inflammatory bowel disease 
There are no pathognomic findings of capsule findings in inflammatory bowel disease 
(IBD).  Rather, the findings are those of an inflammatory condition and consist of mucosal 
redness, erosions, aphtous ulcers, linear and irregular shape ulcers, strictures and a 
cobblestone-like appearance(Arguelles-Arias et al., 2004; Fireman et al., 2003; Herrerias et 
al., 2003). VCE is considered useful to evaluate patients with suspected inflammatory bowel 
disease and possibly to examine those after surgical resection to identify early 
relapse(Fireman et al., 2003; Ge et al., 2004; Kornbluth et al., 2004; Leighton et al., 2007).  The 
diagnosis of is IBD is a clinical one that integrates the history and physical examination with 
the radiological, endoscopic, and pathologic findings.  VCE is superior to barium contrast 
small examinations which have a poor sensitivity for Crohn’s disease(Table 4.). The 
characteristic VCE finding in Crohn’s disease are mucosal ulcerations. Characteristics to be 
evaluated include whether the ulcer is longitudinal or transverse, the status of the 
surrounding mucosa, whether it is single or multiple, the size and the anatomical location.  
In small bowel Crohn’s disease one typically sees longitudinal ulcer with a cobblestone 
appearance of the mucosa(Legnani & Kornbluth, 2005) of the distal small bowel.  Eliakim 
and Adler (Eliakim & Adler, 2004) studied 20 patients with Crohn’s disease suspected on 
the basis of abdominal pain, diarrhea, and weight loss.  16 of 20 patients had abnormalities 
including ulcers and erosions in 36%, erythema in 22%, aphthae in 17%, absent or blunted 
villi in 14%, and nodular lymphoid hyperplasia in 5.6%.  Clearly, erythema, nodular 
lymphoid hyperplasia, absent or blunted villi, are not specific findings for IBD and small 
bowel ulcerations are seen in asymptomatic individuals, and especially those taking aspirins 
or non-aspirin nonsteroidal anti-inflammatory drugs. Thus, while capsule endoscopy clearly 
has a role to play in assisting in the diagnosis of Crohn’s disease, it is only one part of the 
evaluation and would should hesitate before a patients is labeled with this life-long disease 
based solely on VCE findings. VCE may provide helpful data in the evaluation of patients 
with indeterminate inflammatory bowel disease(Flamant et al., 2009).  Mow et al(Mow et al., 
2004) used VCE to examine 22 patients with either ulcerative colitis (UC) or indeterminate 
colitis (IC) and 9 (40%) were given a diagnosis of definite Crohn’s disease CD (40%) based 
on findings of linear erosions and multiple ulcerations. Five of the 9 patients had subsequent 
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histologic findings in agreement the clinical diagnosis of Crohn’s disease. There are several 
potential indications for performing VCE in patients with IBD: Suspected Crohn’s disease 
with negative findings on upper GI endoscopy and colonoscopy, evaluation of OGIB in 
patients with Crohn's disease, evaluation of disease extent in patients with Crohn's disease, 
if such information is likely to alter patient management, evaluation of postoperative 
recurrence, evaluation of patients with indeterminate colitis, evaluation of response to anti-
inflammatory therapy, if clinically indicated(Di Nardo et al., 2011; Swaminath et al., 2010).  
However, contraindications for patients to have VCE include having a known or suspected 
gastrointestinal tract obstruction and/or known small bowel strictures , because of the 
increased risk of capsule retention in patients with Crohn’s disease. Retention rates specific 
to IBD populations are in the range of 1.4% to 6.7%, even among those in hwom the VCE 
was proceeded by a small bowel series that did not demonstrate the presence of a 
stricture(Buchman et al., 2004; Herrerias et al., 2003; Mow et al., 2004). The Agile Patency 
Capsule (Given Imaging Inc.) has been used in Europe and was recently FDA approved in 
the United States for use in patients with suspected small bowel obstruction or known 
stricture(Delvaux et al., 2005; Herrerias et al., 2003). The goal of this capsule is to avoid 
capsule retention and the resultant requirement for endoscopic or surgical intervention.  The 
patency capsule is identical in size to the regular imaging capsule but is composed of lactose 
with barium, a radiofrequency identification (RFID) tag, and 2 side timer plugs with 
exposed windows.  The capsule remains intact for a minimum of 30 hours and then begins 
to disintegrate.  The system comes with an RFID patency scanner that can detect the RFID 
tag.  If the patient witnesses excretion of the patency capsule intact or the scanner does not 
detect the RFID tag at or before 30 hours, it is considered safe to proceed with VCE . 
Although we await confirmation from other studies on the patency capsule data to date 
support its use in identifying patients who may be at risk of obstruction from VCE(Leighton 
et al., 2007).  
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3.4 Finding of other diseases and indications 
3.4.1 Small bowel intestinal tuberculosis 
Small bowel intestinal tuberculosis on VCE shows multiple transverse and serpiginous 
ulcers, scattered small ulcers and multiple aphthous ulcer(Pulimood et al., 2011).  Similar 
finding are also found in small bowel Crohn’s disease and NSAID enteropathy(Reddy et al., 
2003). Although intestinal tuberculosis may involved the entire gastrointestinal tract, is most 
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often involves the terminal ileum and ascending colon and thus is frequently confused with 
Crohn’s disease.  Tuberculosis should especially be considered in areas where the disease is 
endemic and in patients from those areas.  Tuberculosis is best confirmed by histology and 
staining for acid fast bacilli, along with culture or polymerase chain reaction identification of 
the organism.  
3.4.2 Drug induced small bowel damage 
Capsule findings of NSAID small bowel injury consists of ulcers, erosions, aphthous ulcers, 
small mucosal breaks, and nucosal redness. NSAID-induced small bowel injury is common 
and at least one half of patients on long term NSAIDs can be expected to have small bowel 
abnormalities seen at VCE(Goldstein et al., 2005; Graham et al., 2005).  
3.4.3 Polyposis syndromes 
VCE has been used for surveillance of polyposis syndromes (familial adenomatous 
polyposis and Peutz–Jegher’s syndrome)(Schulmann et al., 2005).  VCE is more accurate in 
detection of polyps than small bowel follow through and compared to MRI can detect 
smaller polyps. Whether there is a clinical benefit from the routine use of VCE in patients 
with polyposis syndromes is unknown and currently it is not advocated for surveillance.  
4. Development of capsule endoscopy  
VCE has changed the approach to diagnosis of small bowel disease making it a much less 
invasive, more complete, and more accurate examination. There are however competing 
technologies such as single and double-balloon endoscopy which offer the advantage of 
allowing biopsy and other endoscopic procedures. The more traditional endoscopic 
techniques are invasive, time consuming and uncomfortable procedures such that these 
technologies are best thought of as complementary with VCE being the initial diagnostic 
modality of choice in most instances.  VCE is a mature but not yet ideal technology as 
problems remain in relation to image quality especially in the presence of bile or blood, 
the relatively short battery life which limits the examination, no ability to distend the 
bowel, and dependence on normal gut peristalsis for transit. VCE was initially made 
possible by miniaturization of digital chip camera technology, especially CMOS or CCD 
technology along with extensive software development. Both CMOS and CCD technology 
have their own advantages and disadvantages in terms of image quality and power 
consumption.  Between the two, CCD technology produces a greater level of signal and 
the least amount of signal noise (ie, a higher signal to noise ratio). CMOS imagers require 
a more uniform illumination than CCD technology to get good images but require less 
power and are capable of having all of their electronic circuitry o a single 
microchip(Gerber et al., 2007).  Newer ASIC imager chips, together with special power 
management algorithms, should enable CMOS-based capsules to produce higher frame 
rates, have a longer duration, and employ multiple head capsules(Swain, 2008). Clinically 
both technologies provide excellent images of the GI tract.  Capsules designed for 
different locations employ different frame rates, 2 per second (fps) for the small bowel 
capsules, 14 fps for Given Imaging’s esophagus capsule, and up to 4 fps for the colon 
capsule(Fireman & Kopelman, 2007). These frame rates are designed to optimize the data 
collection while maximizing the diagnostic yield(Fireman et al., 2004).  Future VCE 
systems are expected to offer wireless power supplies, capsule guidance systems, drug 
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delivery systems, body fluid sampling technology, self-propelled capsules, and even an 
ultrasound capsule. Olympus using CCD technology has released their small bowel 
capsule system in Europe and the USA.  One anticipates that continued development of 
both the hardware and software will provide more convenient and accurate capsule 
reading, interpretation of finding, with higher quality images.  
5. Pitfalls in interpretation and inter-observer variation 
Interpretation of VCE images is labor intensive and requires a different skill set than 
traditional endoscopy.  The potential for inter-observer variation is high with regard to 
the interpretation of the VCE results.  Inter-observer variation between 
gastroenterologists and endoscopy nurses with 12 years of experience was evaluated by 
Leviathan et al.(Levinthal et al., 2003). The nurses reviewed five training procedures 
provided by the capsule manufacturer prior to VCE evaluations. The sensitivity of the 
VCE readings was similar between the nurses and gastroenterologists (93% vs. 89%). The 
lesions most often missed by both groups were small angioectasias and subtle small 
bowel erosions. The difference in findings did not influence the management of the 
patients. Clearly, with training observers other than physicians can learn to read VCE 
examinations.  A study of inter-observer variability between gastroenterologists and 
fourth year therapeutic endoscopy students(Adler et al., 2004), suggested that more than 
15 cases of VCE reading were sufficient for competency in reading VCEs.  Liv et al.(Niv & 
Niv, 2005) evaluated the ability of an experienced gastroenterology nurse in reading the 
VCEs of 50 patients.  The nurse had 20 years of experience as a gastroenterology nurse 
and was trained to read the VCE videos on 15 procedures. The VCE findings of the 
physician were used as the gold standard. The lesions were classified as either significant 
(such as angiodysplasia, tumor, ulcer, flat mucosa, or capsule retention) or minor (such as 
redness or small isolated erosion). Complete agreement for normal findings between the 
gastroenterologist and nurse was achieved. For the other findings, there was agreement 
for 93 out of the 96 lesions defined as significant by the physician (96.9%). The three 
significant lesions missed by the nurse were a suspected short Barrett’s esophagus in 1 
case and flat mucosa in the duodenum in 2 cases. The four significant lesions missed by 
the physician were a clot in the gastric mucosa, a suspected short Barrett’s esophagus, an 
ileal aphthous lesion, and an ileal polyp. The results suggested that training nurse 
practitioners for the first-pass interpretation of VCE results was cost effective and 
improved the accuracy of the evaluation. Petrofina et al.(Petroniene et al., 2005) studied 
agreement of VCE results in patients with celiac disease. The VCE reading by 
investigators with pre-study experience with VCE for celiac disease had greater 
agreement than novice readers. Therefore, experience with VCE reading appears to be 
important for reduction of the inter-observer variation. Lai et al.(Lai et al., 2006) reported 
on the inter-observer variation between two gastroenterology residents in their first year 
of specialty training in gastroenterology and gastroenterologists with seven years of 
experience in gastrointestinal endoscopy. Prior to interpreting the findings of 58 VCE 
examinations, they had training for VCE evaluation and had read at least 10 VCEs.  The 
accuracy of the evaluations for gastric emptying time, small bowel transit time, and the 
small bowel diagnoses were significantly lower for the two residents than the experienced 
specialists.  The characteristics of the lesions influenced the diagnostic accuracy. The 
diagnostic accuracy for Crohn’s disease and active small bowel bleeding with no 
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identifiable source was high; however, the accuracy for angiodysplasia and small bowel 
tumors was only about 33%.  The mean kappa value for the three reviewers was 0.56.  
The results of this study were consistent with prior studies showing that more prominent 
intraluminal lesions as well as prior experience with conventional endoscopy improved 
the diagnostic accuracy of reading VCEs and reduced variation in the interpretation of  
the findings. Therefore, increase in the level of training for VCEs would likely improve 
the accuracy of reading the findings of VCEs.  Another report demonstrated that multiple 
novice readers are an alternative method to improve the accuracy of VCE reading (Chen 
et al., 2006). In addition, endoscopic nurse, gastroenterology students or medical residents 
abilities to detect abnormalities on VCE before physician begin to screen capsule 
endoscopy in clinical practice(Levinthal et al., 2003; Postgate et al., 2009; Sidhu et al., 
2008). 
Jang et al.(Jang et al., 2010) in a systematic study evaluated the inter-observer variation 
associated with capsule endoscopy interpretation by experts compared to trainees. The goal 
of this study was to evaluate the inter-observer agreement between these two groups and 
determine the factors associated with missing a lesion. The findings showed that the inter-
observer differences were greatest for subtle lesions which were more often missed by 
trainees. The inter-observer variation in the expert group (the mean kappa value, 0.61, 
substantial agreement) was lower than in the trainee group (the mean kappa value, 0.46, 
moderate agreement). These findings underscore the importance of experience with 
conventional endoscopy in the review of VCE findings. We needed to better understand the 
learning curve for VCE and the education necessary to become proficient in reading VCEs. 
There are two aspects of reading: finding the lesions and interpretation of the findings.  
Training to find lesions and thumbnailing them is likely to be easier than learning how to 
interpret many findings.  The use of improved software and the use of non-physician 
prereaders to focus the reading experience on interpretation should go a long way toward 
improving the usefulness of the technique in ordinary practice.  The inclusion of an atlas as 
part of the reading software is also helpful. 
6. Conclusions 
The introduction of VCE resulted in a revolution in evaluation of the small bowel as it 
allows the mucosa of the entire small bowel to be visualized without pain. VCE is now 
available world wide and has greatly simplified the approach to evaluating and diagnosing 
small bowel diseases. Interpretation of the VCE small bowel images is both subjective and 
time consuming. Improved hardware and software with high speed reading techniques, 
multi-image viewing with dual image play back, and the computer-aided screening 
diagnosis should improve the experience and reduce interobserver variation.  Continued 
software improvements coupled with higher quality images, dual head VCE, controlled 
high frame capture techniques, radio-control capsule movement, and lumen distending 
devices all should improve both the diagnostic accuracy and interpretation of VCE.  
Nonetheless, the best results will probably continue to rely on a good strategy in terms of 
the order of reading and interpretation strategy.  
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1. Introduction 
Until a few years ago, the small bowel was an organ which was very difficult to explore 
with the available endoscopic, radiological and nuclear medicine techniques due to 
anatomical (i.e. distance from external orifices, length) and physiological (i.e. active 
peristalsis) reasons. In routine practice, only the last few centimeters of the ileum was 
accessible to retrograde visualization by ileo-colonoscopy. Exploration from the proximal 
side by push, sonde or intra-operative enteroscopy were invasive procedures that did not 
always allow us to visualize the lesions in the small bowel (Galmi che et al.,2008). Sonde 
enteroscopy had been abandoned in the 90’s because it was a tedious technique (long 
duration of the procedure) and it had several technical limitations. Push enteroscopy is 
limited by the depth of insertion of the scope and is poorly tolerated. Intra-operative 
enteroscopy is the most effective of these techniques, but it is the most invasive with a 
significant percentage of adverse side effects (Rondonotti  et al., 2007). 
The concept for small bowel capsule was developed independently by two groups. Dr. Paul 
Swain, a British gastroenterologist demonstrated the first live transmissions in 1996 with the 
broadcast of a pig's stomach. In 1997, he collaborated with Dr. Gavriel  Iddan, a mechanical 
engineer working with the Israel Ministry of Defense(Appleyard et al.,2001;Meron,2000;Swain 
et al.,1996). Successful animal trials were conducted and first published in 2000. (Swain et 
al.,1996) Human studies followed and the use of capsule endoscopy (CE) in clinical trials was 
first published in 2001. (Kornbluth et al.,2004)  Since the emergence of CE, more than 1000000 
capsules have been swallowed worldwide and nearly 1000 peer reviewed publications have 
appeared in the literature. This article reviews the fundamental of wireless capsule endoscopy. 
Special attention is paid to the indications, benefits and drawbacks of the technique, as well as 
to the strengths and limitations of clinical data available to the date. 
2. Technical features of the capsule 
The M2A capsule (figure-1) initially, and Pillcam SB2 (Small Bowel) later, from GIVEN 
(Gastro Intestinal Video Endoscopy, Given Imaging Limited, Yoqneam, Israel), and endo 
capsule from Olympus are the capsules that have been approved for use in the clinical 
setting, approved in Europe by the European Medicines Agency and in the United States by 
the Food and Drug Administration in 2001 (Pannazio, 2006). The capsule which measures 
only 11 mm × 26 mm and weighs 3.7 g, holds a metal oxide semiconductor imaging chip 
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video camera, 6 white light-emitting diode illumination sources, 2 silver-oxide batteries and 
a radio telemetry transmitter. The image filed is 140 degrees, magnification is × 8 and the 
depth of view is 1 to 30 mm (Iddan et al.,2000;Davis et al.,2005).  
 
 
Fig. 1. M2A Capsule 
Once swallowed, the capsule moves thorough the intestine via peristalsis and is excreted in 
the stool. The camera takes two images per second as it sweeps the intestine and transmits 
these to eight lead sensor arrays, arranged in a specific manner and taped to the anterior 
abdominal wall, connected to a recording device in the belt for the duration of the battery 
life, which is 6-8 h. Once the study is completed, the recording device and sensor arrays are 
removed and the images (50000-60000 images total) are downloaded to a computer with 
reporting and processing of images and data (Rapid, Given Imaging) software that displays 
the video images on a computer monitor. This software includes a localizing system, blood 
detector and some features to assist the interpreter. The suspected blood indicator is quite 
good at detecting active bleeding, but is not so useful at detecting other lesions and does not 
replace careful examination of the CE. It is recommended that patients avoid magnetic fields 
such as magnetic resonance imaging (MRI), and metal detectors until the capsule is excreted 
in the stool, which usually occurs in 24-48 h. Small bowel preparation is still a controversial 
issue. Some groups used fasting or clear liquids for 10 to 12 h (or even for 24 h) before the 
study, although some studies suggest that bowel preparation (with 2 or 4 liters of 
polyethylene glycol based electrolyte solution or oral sodium phosphate preparation) 
improves the visualization of the small intestine(Dai et al.,2005;de Franchis et al.,2005).A 
recent Spanish prospective multicenter trial published in abstract form, has shown that all 
three strategies have similar results(Pons et al.,2006). After ingestion of the capsule, patients 
were allowed to drink clear liquids after 2 h and eat a light meal after 4 h and were observed 
for 8 h at the study site. 
 




Capsule endoscopy is mainly indicated (Table-1) for the evaluation of Small Bowel (SB) 
diseases, particularly for the diagnosis of Obscure Gastro Intestinal Bleeding (OGIB). CE can 
be used in a variety of conditions including Crohn’s disease (CD), mal-absorption, chronic 
diarrhea, evaluation of refractory iron   deficiency anemia,    abdominal   pain,   polyposis 
syndromes, celiac disease, and detection of SB tumors. 
 
Small Bowel 
 Obscure gastrointestinal bleeding 
 Occult (positive FOBT) 
 Evaluation of iron deficiency anemia 
 Crohn’s disease 
 Suspected crohn’s disease 
 Indeterminate colitis 
 Assessment of mucosal healing 
 Abdominal pain 
 Craft-versus-host disease 
 Surveillance of polyposis syndromes 
 Celiac disease 
 Suspected small bowel tumors 
 Follow up of small intestine Transplantation 
 Evaluation of abnormal SB Imaging 
 Evaluation of drug induced injury 
Esophagus 
 Barrett’s esophagus 
 Esophagitis 
 Variceal evaluation 
Table 1. Indication 
Graft versus host disease (GVHD) and follow up of small intestine transplantation are rare 
indications. In later years, breakthrough developments in CE technology have enabled the 
direct visualization of the upper (de Franchis et al.,2008;Fernandez et al.,2007)and lower 
segments (Deviere et al.,2008;Schoof et al.,2006)of the gut using specifically designed capsules. 
CE with high frame rate (PillCam Eso, Given Imaging)  can be used  for esophageal disorders, 
such as non-invasive   evaluation   of   esophageal varices, esophagitis and Barrett’s esophagus 
(Galmiche et al.,2008). Colon capsule endoscopy is an emerging form of colon imaging that 
may be useful to improve compliance with colorectal cancer screening. 
3.1 Obscure GI bleeding 
Obscure GI bleeding (OGIB) is the most common indication for CE examination. CE has a 
high diagnostic yield in OGIB, facilitates effective decision-making regarding subsequent 
investigations and treatments (Eliakim et al., 2008).Diagnostic yield of CE for OGIB varied 
between 31% and 91% (Adler et al.,2004;Costamagna et al.,2004;Ell et al.,2002;Ersoy et 
al.,2006;Ge et al.,2004;Golder et al.,2006;Hartmann et al 2003,2005;Lewis & Swain,2002;Mata 
et al.,2004;Panazio et al.,2004;Scapa et al.,2002;Saurin et al.,2003;Saperas et al.,2007;Van 
gossum et al.,2003;Voderholzer et al.,2003). The published studies of CE for OGIB were 
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reviewed and reported that sensitivity ranged from 79% to 95% and specificity from 75% to 
100%(Varela Lema & Ruano-Ravina, 2008 ). The positive predictive value (PPV) varied from 
94% to 100% and the negative predictive value (NPV) from 80% to 100%.   
 
   
 
    
Fig. 2. VCE images of lesions found in patients with obscure-overt GI bleeding. A: Multiple 
angiodysplasias in the jejunum; B: A jejunal mass with active bleeding; C: An ileal ulcer in a 
patient with newly diagnosed Crohn’s disease. D: Benign lymphoid hyperplasia located 
diffusely through the GI tract in a patient with CVID; E: A jejunal polyp in a patient with 
peutz-jeghers disease; F: Multiple small polyps in the ileum. 
Capsule endoscopy led to a change in therapeutic management in 9%-77% of patients. A 
recent study (Albert et al., 2008) reported that CE detected the bleeding source in 76.8% of 
patients. The diagnostic yield of CE in OGIB depends on the type of bleeding. Highest yield 
of CE was 92.3% in patients with active bleeding (Pannazio et al., 2004) compared to those 
with obscure occult bleeding (44.2%). Researchers observed a reverse relationship between 
findings and time after last bleeding episode. The longer the time from last bleed, the lower 
the diagnostic yield. Do the lesions discovered by CE have any bleeding potential or clinical 
importance in terms of management change? Saurin et al., 2003 showed that CE detects 
more lesions, but only half of them have true bleeding potential. CE is superior to other 
techniques in diagnosing the source of bleeding. The yield for CE is 63% and 67% compared 
with 28% for push enteroscopy (PE) and 8% for barium study(Lewis,2008). 
3.2 Crohn’s disease 
Crohn’s disease (CD) is a chronic inflammatory disease that can involve any part of the 
Gastro-intestinal (GI) system, and disease is confined to the SB in about one-third of the 
patients. There is no single test to diagnose CD completely, so CD diagnosis can be established 
with a combination of clinical, endoscopic and histological findings. Most imaging studies lack 
sensitivity to identify early changes, and endoscopy does not allow total examination of the 
bowel. CE is able to identify mucosal changes before other technologies. It has a valuable role 
in the evaluation of the SB in patients with suspected or known CD. The use of CE in the 
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diagnosis of small bowel CD(Papadakis et al.,2005) has been examined in several studies and 
found to be superior to small bowel follow-through(Fireman et al .,2003;Herrerias et al., 
2003;Mow et al.,2004), enteroclysis (chong et al.,2005;Liangpunsakul et al.,2003), push 
enteroscopy(chong et al.,2005) and CT enteroclysis (Voderholzer et al.,2005) for identifying 
small intestinal disease. the Diagnostic yield of CE was  compared with other modalities in 
patients with suspected small bowel CD, yield of CE was 63% compared with 23% for barium 
radiography. When compared with ileo-colonoscopy, CE had a higher yield (61% vs 46%). 
Compared with PE, CE had a 38% higher yield, and when compared with CT enterography, 
the yield of CE was 69% vs 30%. Due to its high diagnostic yield, CE will have a very 
important place in the diagnostic workup of patients with CD, but more studies are needed to 
make such suggestions since there was no statistical significance in the incremental yield 
between CE and other diagnostic modalities in patients suspected of having CD in an meta 
analysis (Triester et al., 2006). However, there was a significant difference in yield of CE over 
alternative methods in patients with known CD, who were being evaluated for SB recurrence 
(Triester et al., 2006) Yield of CE is low when performed in patients with abdominal pain 
alone; when other criteria are added, this yield is increased (Lewis, 2008).Capsule endoscopy 
can be used for the assessment of mucosal healing after treatment.  
The only limitation of CE is its inability to offer biopsy for histological examination.  
A scoring system has been proposed to evaluate CD on the basis of CE findings of villous 
structure, ulceration and stenosis. Each variable is assessed by size and extent of the change 
(Grelnek et al., 2008). However, further studies are needed to clarify the helpfulness of this 
system. The score provides a common language to quantify mucosal changes associated 
with any inflammatory process. The index does not diagnose or measure a disease, it 
measures mucosal change. In addition, this scoring index does not have the discriminatory 
ability to differentiate between illnesses. This index could be helpful in determining mucosal 
healing after therapy in CD (Lewis, 2008). Mucosal breaks and aphthous ulcers or erosions 
are also seen in asymptomatic healthy volunteers. Since non-steroidal anti-inflammatory 
drugs (NSAIDs) may cause ulcerations resembling those of CD, patients should be advised 
to stop such drugs at least one month before the CE examination (Mergener et al., 2007). It is 
difficult to differentiate these findings with the presence of CD.  
3.3 Celiac disease 
Celiac disease is an immune-mediated disease characterized by chronic SB inflammation that 
may result in mucosal atrophy, mal-absorption and related clinical manifestations. Diagnosis 
is based on the combination of serologic, endoscopic and typical histological changes of the SB 
biopsy in clinically suspected patients. Its prevalence is around 1% in the United States. There 
are four endoscopic changes suggestive of villous atrophy: loss of mucosal folds, mosaic 
mucosal pattern, scalloping of the duodenal folds and nodularity of the mucosa (Spada et al., 
2008). It is no surprise that CE provides high resolution images that contain such changes. 
Fourty three patients with signs or symptoms suggestive of celiac disease and positive 
serological markers were evaluated (Rondonotti et al., 2007). Patients underwent both CE and 
upper GI endoscopy. Characteristic histological changes were observed in 32 patients. Using 
this as a gold standard, 87.5% of patients were diagnosed by CE. Mucosal changes beyond the 
duodenum were detected in 18 (66.6%) patients and in 3 (11.1%) patients the whole SB was 
affected. Another newly published study, (Muhammad & Pitchumoni,2008) searching for 
celiac disease in older adults, also showed that duodenal mucosa was normal in appearance 
on CE in 71% of patients, but classic abnormalities of celiac disease were present distally. 
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Overall, CE can detect endoscopic markers of celiac disease. In addition, CE seems to be able to 
recognize the extent of disease and may be a tool for follow-up. CE has a high sensitivity 
(range, 70%-95.2%), specificity (range, 63.6%-100%) and high PPV and NPV (96.5%-100% and 
71.4%-88.9%, respectively)(Biagi et al.,2006;Hopper et al., 2007; Muhammad & Pitchumoni 
2008; Petroniene et al., 2005; Rondonotti et al 2007a. 2007b). When an atrophic pattern is 
detected by CE, the patient has a high probability of having celiac disease (Spada et al., 2008). 
CE has also been reported to be able to demonstrate diseases such as adeno-carcinoma, 
lymphoma or ulcerative jejuno-ileitis, which may complicate the course of celiac disease. A 
limitation is that CE is able to detect Marsh III lesions, which are associated with clear mucosal 
abnormalities, but may not distinguish between Marsh I and II lesions (Spada et al., 2008). At 
present, CE is an alternative to endoscopy with biopsy in patients with suspected celiac 
disease who do not consent to the conventional methods. 
3.4 Small bowel tumors and polyps 
Capsule endoscopy is a major advance in the diagnosis of SB tumors. Before the introduction 
of CE, malignant neoplasms of the SB were often diagnosed at a later stage of the disease, 
mostly during the work-up of obstructive symptoms. Diagnosis is delayed because 
conventional imaging techniques fail to detect small neoplasm’s in almost half of the patients. 
SB tumors are a rare disease, accounting for 1%-3% of all primary GI tumors. SB mass lesions 
are responsible for OGIB in up to 10% of patients. (Ciresi & Scholten, 1995; DiSario et al., 1994; 
Lewis, 1994; Lewis et al., 2005; Kariv & Arber 2003). Early clinical studies of CE have reported 
a frequency of SB tumors ranging between 6% and 9% (Bailey et al.,2006; Cobrin et al.,2006; de 
Franchis et al.,2004; Estevez et al.,2007; Schwartz &Barkin,2007; Urbain et al.,2006). This has led 
to an idea that CE doubled the rate of diagnosing SB tumors. However, a recent multicenter 
European study showed that the frequency of SB tumors was 2.4% and the most common 
indication for CE was OGIB (Pennazio et al., 2008; Rondonotti et al., 2008). SB tumors appear 
as masses or polyps in most patients and ulcer or stenoses in a minority of patients. It is not 
possible to distinguish the type of tumor based only on CE pictures. Most of the tumors reside 
in the mid SB (Rondonotti et al., 2008).Capsule endoscopy is also useful for the surveillance of 
polyps in patients with inherited GI polyposis syndromes (Familial adenomatous polyposis 
and Peutz- Jeghers syndrome), who are at increased risk of developing polyps in the SB. 
Several studies comparing the yield of CE to other imaging modalities in patients with 
polyposis syndromes have shown that CE is accurate in the detection of polyps. The same 
studies also emphasized that the duodenum is a potential blind point of CE because the 
capsule passes quickly with tumble and results in inadequate examination. CE underestimated 
the total number of polyps and did not reliably detect larger polyps in that portion (Wong et 
al., 2006). Nevertheless, more prospective studies with longer follow-up are required, to define 
the role of capsule endoscopy findings in the outcome of patients with gastrointestinal 
polyposis syndrome. 
3.5 Other indications 
Abdominal pain is one of the most common symptoms of patients referred to the 
gastroenterologist. Use of CE for the evaluation of abdominal pain is debated. Although 
some serious causes are identified in such patients, CE is mostly unyielding. If patients with 
other signs and symptoms of inflammation were selected, than the diagnostic yield was 
considerably higher (El-Matary, 2008). Capsule endoscopy may be helpful in the diagnosis 
of the following diseases: surveillance for NSAID side effects, Henoch Schönlein purpura, 
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indeterminate colitis, protein losing enteropathy, intestinal lymphangiectasia,  Meckel’s 
diverticulum, follow-up of SB transplantation, GVHD, and bowel changes in refractory 
pouchitis (El-Matary,2008). 
4. Contra-indication and safety issue of capsule endoscopy 
Capsule endoscopy is a safe and contraindications (Table-2) include the presence of 
intestinal obstruction, fistulas and strictures. Swallowing abnormalities, esophageal 
stricture, pseudo-obstruction, severe motility disorder are other contraindications for the 
procedure. Relative contraindications are pregnancy, numerous diverticuli, Zenker’s 
diverticulum, gastroparesis, and previous pelvic/abdominal surgery.  
 
Absolute
 Bowel obstruction 
 Extensive and active Crohn’s 
 Disease ± strictures 
 Intestinal pseudo-obstruction 
 Young children (<10 years) 
 
Relative 
 Cardiac pacemakers 
 Implanted electro-medical Devices 
 Dysphagia 
 Previous abdominal surgery 
 Pregnancy 
Diverticulosis
Table 2. Contra Indication 
Other former contraindications such as implanted cardiac pacemakers or other electro-
medical devices and patients with swallowing disorders have been excluded since some 
studies showed no interference between capsule endoscopy and pacemaker or implantable 
defibrillators functioning (Leighton et al.,2004,2005) and endoscopic placement of the 
capsule into the gut (Leung & Sung,2004). The retention of the device is the main 
complication  of the procedure and is defined when CE remains in the digestive tract for a 
minimum of 2 wk (Cave et al.,2005).The frequency of this problem varies, depending mostly 
on the clinical indication for CE, and ranges from 0% in  healthy subjects, to 1.5% in patients 
with obscure gastrointestinal bleeding, to 5% in patients with suspected Crohn’s disease 
(Mata et al.,2008) and to 21% in patients with intestinal obstruction(Pennazio,2006).How to 
prevent capsule retention has yet to be defined since neither radiologic studies nor the 
“patency capsule” has shown conclusive results so far. The clinical setting of each patient, as 
well as some features related to intestinal strictures (previous small bowel surgery, NSAIDs, 
suspected small bowel Crohn’s disease), have to be analyzed prior to the study. Patients 
should be informed about the possibility of capsule retention and further treatment. 
5. Technical limitations 
It cannot be used to obtain biopsy specimens or for endoscopic treatment and it cannot be 
controlled remotely (Pennazio,2006). CE has also some clinical limitations which are 
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problems in sizing and locating small bowel lesions(Rondonotti et al.,2008), a possible false-
negative CE result, global miss rate is about 11%, ranging from 0.5% for ulcerative lesions to 
18.9% for neoplastic disease and almost 20% of procedures the capsule does not reach the 
cecum while it is active (Waterman & Eliakim,2009). 
6. Esophageal capsule – PillCam ESO 
The esophageal capsule (PillCamTM ESO) which was approved by the FDA in November 
2004, has a double head with the potential of 14 frames per second. The new-generation 
capsule endoscopy SB2 takes 18 frames per second. The battery life is only  20 minutes. The 
capsule has two cameras, each taking seven frames per second in the first 10 minutes, then 
four frames in the remaining 10 minutes. The patient does not need sedation, there is no 
recovery time, and no intubation or insufflations is used. The two FDA-approved 
indications for the esophageal capsule are screening and follow-up of esophageal varices 
and screening for Barrett’s esophagus in gastro-esophageal reflux patients.  
 
  
Fig. 3. A: PillCam™ ESO image of erosive esophagitis; B: endoscopy image of distal 
esophagus in the same patient. 
 
  
Fig. 4. A: PillCam ESO™ image showing esophageal varices; B: Upper endoscopy image of 
distal esophagus in the same patient. 
According to the guidelines of the American Society of Gastrointestinal Endoscopy, 
established cirrhosis and cholestatic liver disease with a low platelets count are clear 
indications for esophago-gastro-duodenoscopy(EGD)(Qureshi et al.,2005).Large varices 
dictate treatment with propranolol or ligation. Capsule endoscopy may replace EGD for 
diagnosis of varices. Grading of varices according to the capsule endoscopy study is simpler 
than that of EGD.  Three grades were evaluated: C0 = no varices, C1 =small and non-
tortuous varices<25% of the circumference of the frame, and C2 =large varices>25% of the 
frame circumference. A recent multicenter international study with PillCam ESO prior to 
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hours by endoscopists blinded to the results of capsule endoscopy, while the PillCam ESO 
study was read by a blinded second investigator.Complete agreement was demonstrated in 
84 of the 97 patients. The sensitivity and specificity of the capsule endoscopy for esophageal 
varices were 86.6% and 86.7%, respectively. A recent study (Galmiche et al.,2008) 
demonstrated 79% sensitivity and 94% specificity of capsule endoscopy for Barrett’s 
esophagus in 77 patients. However, these results could not be demonstrated in another 
recent paper and there was a significant variation between observers. 
7. Colonic capsule – PillCam colon 
The colonic capsule was ready for research in 2006 and had been studied by Israeli, 
American and European groups of investigators  (Eliakim et al.,2006; Fireman & Kopelman, 
2007). The capsule had great potential for colorectal cancer screening since the procedure is 
not invasive. The first generation of the colonic capsule had two cameras on both heads, 
taking four frames per second. It is 5 mm longer than the small bowel capsule. The main 
limitation of this examination is the colonic preparation before the procedure as the colon 
must be perfectly clean without any remnants of stool. Sedation is not needed, and 
radiation, intubation and insufflation are not involved. The capsule procedure may become 
the first-line examination of the colon. It can be performed instead of colonoscopy when there 
is a contraindication to colonoscopy, is suitable for people unwilling to undergo colonoscopy 
or complete failed colonoscopy, and it can be used for screening colitis patients. It is believed 
that compliance for capsule endoscopy as a screening tool will be higher than for colonoscopy.  
 
   
   
Fig. 5. Images captured by the Pillcam™ Colon and conventional colonoscopy. A and B: 
Pedunculated polyp in the sigmoid colon; C and D: Ulcerated tumor in the transverse colon; 
E and F: Flat adenoma in the ascending colon. 
In a recently published European multicenter study of 328 patients (Von Gossum et 
al.,2009), the sensitivity and specificity of capsule endoscopy for detecting polyps ≤ 6 mm in 
size were 64% (95% confidence interval 59–72) and 84% (95% CI 81–87), respectively, and for 
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(95% CI 77–81) respectively of 19 cancers detected by colonoscopy, 14 were detected by 
capsule endoscopy (sensitivity 74%, 95% CI 52–88). For all lesions, the sensitivity of capsule 
endoscopy was higher in patients with good or excellent colon cleanliness compared to 
those with fair or poor colon cleanliness. 
8. Next generation capsule endoscopy 
What, would be the ideal capsule of the gastroenterologist’s Wildest imagination? Would 
we prefer a single capsule that, in one ‘‘shot’’, can give us the entire view from the oral 
cavity to the anal canal, or are we hoping that someday there will be an “intelligent” capsule 
that specializes in each section of the GI tract? Unfortunately, the anatomical and 
physiological differences in the GI tract make it impossible to use the same capsule for both 
purposes. Small bowel, esophageal and colonoscopy capsules are now commercially 
available. The latter two are equipped with miniature cameras on both ends of two video 
cameras. How we would love to be able to pinpoint drug deliveries in specific diseases such 
as Crohn’s disease! The problem is that it would have to be done daily over a long period 
and this would be time consuming and costly. A pre-programmed non-viewing (i.e. no 
camera) capsule for drug delivery would be much cheaper and one can imagine a 
combination of viewing and non-viewing capsules that can be used to make this treatment 
efficient and cost effective. For clinicians, the capsule’s motility feature in the small bowel 
would open a window to study the patho-physiology of relatively elusive medical entities 
such as irritable bowel syndrome. Malagelada et al., 2008 were the first to publish their 
findings on CE motility in the clinical setting and they found that CE was useful in 
diagnosing patients with irritable bowel syndrome. Next in our dream of CE are zooming or 
magnification capabilities. Why not? Think of chromo-endoscopy, narrow band imaging, 
ultrasound imaging and the delivering of therapy including tissue coagulation and 
immunologically or chemically targeted optical recognition of malignancy as it exists in 
endoscopy, capable of spraying fluid (methylene blue, Lugol solution, etc.) in specific areas 
of the small bowel. At present, the capsule cannot obtain biopsies, aspirate fluid or brush 
lesions for cytology. These techniques require real-time viewing as well as radio-controlled 
triggering and remote controlled capsule manipulation if they are to be used with precision. 
However, optical biopsy seems feasible (DaCosta et al.,2005).We can easily visualize our 
capsule eventually becoming  a complete miniature laboratory with the functions of bio-
sensing luminal contents and biopsy (probably by optical technologies) as well. 
The quality of current CE images is inferior to that of conventional endoscopes and the 
solution awaits advances in microelectronics that will lead to image sensors with a smaller 
pixel size that enable higher resolution. In addition, current CE systems use image data 
compression which causes blurring at the edges of objects and leads to lower image quality, a 
major limitation of CE. In particular, depletion of the two silver oxide batteries used in current 
devices may prevent complete imaging of the small intestine if the pill remains in the stomach 
for too long. The problem becomes most apparent by the inability to view the cecum (the 
marker of a complete examination) in 10%-15% of CE examinations of the small bowel(Neu et 
al.,2005;Triester et al.,2006).This will eventually be overcome by using power transfer methods 
from outside the body. In the short term, this problem can partly be solved by using more 
efficient power management algorithms that enable an 11 h recording time. There have been 
important “breakthroughs” in battery design with the advent of carbon nanotubes 
(Buckytubes) which have the intrinsic characteristics desired in the material used as electrodes 
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in batteries and capacitors. Other methods that are under consideration for development for 
solving imaging issues include control units that vary the frame rate. One example is the 
OMOM capsule, developed at Chongqing Jinshan Science and Technology Group (Chongqing, 
China), which can switch from 0.5 frames per second (fps) inside the stomach to 2 fps after 
entering the pylorus (DaCosta et al.,2005).In a well-conducted randomized prospective study 
of 50 patients in China, the cecum was visualized in the 25 subjects who ingested the capsule 
in the switching frame rate mode compared with 18 of 25 in whom the pill functioned at a 
steady frame rate of 2 fps (Moglia et al.,2008). The benefit from size reduction and power 
efficiency is best exemplified by MiroCam by Intromedic (Seoul, South Korea). This is the first 
endoscopic capsule that uses the human body instead of radiofrequency to transmit data, 
reducing power consumption. In the first clinical trial on 45 patients in South Korea, MiroCam 
captured images from the whole small intestine as far as the cecum in all the subjects. Because 
the device does not use image compression, the bowel mucosa was viewed without blurring 
or distortion in over 90% of patients(de Franchis et al.,2005)This system also uses fewer 
components for remote transmission, thus saving space for the possible addition of modules 
for biopsy or locomotive guidance (Liao et al.,2009). 
We eagerly look forward to the day that we will be able to ‘‘control and steer’’ the CE as 
endoscopists are able to do in standard endoscopy. Two research projects supported by the 
European Union are currently pursuing this goal. One is VECTOR (Versatile Endoscopic 
Capsule for gastrointestinal Tumor Recognition and therapy) and the other is NEMO (Nano-
based capsule-Endoscopy with Molecular Imaging and Optical biopsy). The former aims to 
develop a self-propelled miniaturized robotic pill for advanced diagnostics and treatment in 
the digestive tract. Over the last few months, the topic of the feasibility and effectiveness of the 
combined use of external static magnetic fields to achieve wirelessly controllable and precise 
camera steering has been published(Gao et al.,2010;Swain et al.,2010;Valdastri et al.,2010)The 
second study is looking into the detection of surface and deep seated pathology by photonic 
technologies that enable optical biopsies. This would eliminate the need to take biopsy 
specimens and perform histological examination (Swain, 2008). 
9. Conclusion  
Capsule endoscopy is the latest evolution in gastrointestinal endoscopy and the first to 
enable complete investigation of the small bowel. It is a simple and well-tolerated 
procedure. Capsule retention is the major complication. Care must be taken in patients with 
symptoms suggesting partial obstruction and CD. SB series and computerized tomography 
enteroclysis before CE may reveal stenosis. The newly developed patency capsule may be an 
alternative for detection of stenoses. The value of CE in patients with OGIB appears to be 
high and is supported by high yields in the literature. CD and celiac disease appear to be 
areas where use of CE would be helpful. There may also be an indication for CE in CD 
surveillance and follow-up. The diagnostic role of CE extends beyond the SB. Recent new 
developments in the field of capsule endoscopy include the esophageal capsule (PillCam 
ESO™) and the colonic capsule (PillCam Colon™). More research is needed to explore the 
feasibility of CE in these contexts. Blind spots of CE such as the duodenum should be 
examined by a second look endoscopy before the CE procedure, especially in patients with 
OGIB. After negative endoscopic examinations, CE should be recommended as a first-line 
investigation over balloon assisted enteroscopies in view of its noninvasiveness, higher 
probability of visualizing the entire small intestine and the similar diagnostic yield of both 
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important “breakthroughs” in battery design with the advent of carbon nanotubes 
(Buckytubes) which have the intrinsic characteristics desired in the material used as electrodes 
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in batteries and capacitors. Other methods that are under consideration for development for 
solving imaging issues include control units that vary the frame rate. One example is the 
OMOM capsule, developed at Chongqing Jinshan Science and Technology Group (Chongqing, 
China), which can switch from 0.5 frames per second (fps) inside the stomach to 2 fps after 
entering the pylorus (DaCosta et al.,2005).In a well-conducted randomized prospective study 
of 50 patients in China, the cecum was visualized in the 25 subjects who ingested the capsule 
in the switching frame rate mode compared with 18 of 25 in whom the pill functioned at a 
steady frame rate of 2 fps (Moglia et al.,2008). The benefit from size reduction and power 
efficiency is best exemplified by MiroCam by Intromedic (Seoul, South Korea). This is the first 
endoscopic capsule that uses the human body instead of radiofrequency to transmit data, 
reducing power consumption. In the first clinical trial on 45 patients in South Korea, MiroCam 
captured images from the whole small intestine as far as the cecum in all the subjects. Because 
the device does not use image compression, the bowel mucosa was viewed without blurring 
or distortion in over 90% of patients(de Franchis et al.,2005)This system also uses fewer 
components for remote transmission, thus saving space for the possible addition of modules 
for biopsy or locomotive guidance (Liao et al.,2009). 
We eagerly look forward to the day that we will be able to ‘‘control and steer’’ the CE as 
endoscopists are able to do in standard endoscopy. Two research projects supported by the 
European Union are currently pursuing this goal. One is VECTOR (Versatile Endoscopic 
Capsule for gastrointestinal Tumor Recognition and therapy) and the other is NEMO (Nano-
based capsule-Endoscopy with Molecular Imaging and Optical biopsy). The former aims to 
develop a self-propelled miniaturized robotic pill for advanced diagnostics and treatment in 
the digestive tract. Over the last few months, the topic of the feasibility and effectiveness of the 
combined use of external static magnetic fields to achieve wirelessly controllable and precise 
camera steering has been published(Gao et al.,2010;Swain et al.,2010;Valdastri et al.,2010)The 
second study is looking into the detection of surface and deep seated pathology by photonic 
technologies that enable optical biopsies. This would eliminate the need to take biopsy 
specimens and perform histological examination (Swain, 2008). 
9. Conclusion  
Capsule endoscopy is the latest evolution in gastrointestinal endoscopy and the first to 
enable complete investigation of the small bowel. It is a simple and well-tolerated 
procedure. Capsule retention is the major complication. Care must be taken in patients with 
symptoms suggesting partial obstruction and CD. SB series and computerized tomography 
enteroclysis before CE may reveal stenosis. The newly developed patency capsule may be an 
alternative for detection of stenoses. The value of CE in patients with OGIB appears to be 
high and is supported by high yields in the literature. CD and celiac disease appear to be 
areas where use of CE would be helpful. There may also be an indication for CE in CD 
surveillance and follow-up. The diagnostic role of CE extends beyond the SB. Recent new 
developments in the field of capsule endoscopy include the esophageal capsule (PillCam 
ESO™) and the colonic capsule (PillCam Colon™). More research is needed to explore the 
feasibility of CE in these contexts. Blind spots of CE such as the duodenum should be 
examined by a second look endoscopy before the CE procedure, especially in patients with 
OGIB. After negative endoscopic examinations, CE should be recommended as a first-line 
investigation over balloon assisted enteroscopies in view of its noninvasiveness, higher 
probability of visualizing the entire small intestine and the similar diagnostic yield of both 
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investigations. Such an approach may decrease the time between diagnosis and 
intervention. A second look CE may reveal more findings in up to 35% of patients who had 
prior non diagnostic CE. 
The ideal next generation CE of the gastroenterologist’s imagination should be capable of 
performing an ordinary biopsy as well as carry out an online analysis (an “optical” biopsy) 
and ‘‘stop’’ bleeding by an adrenaline injection, a heat probe, argon plasma coagulation, etc. 
The ultimate capsule would include special detectors for white blood cells and be capable of 
checking oncological markers (e.g. CEA, CA 19-9), perform serology tests (e.g. anti-
endomysial, IgE) and measure various cytokines, pH, temperature and pressure, in addition 
to delivering drugs. The capsule’s motility feature in the small bowel may open a window to 
study the patho-physiology of relatively elusive medical entities such as irritable bowel 
syndrome (Fireman & Kopelman, 2007; Fireman et al, 2004; Nakamura & Terano, 2008; 
Kochman & Swain, 2007; Swain, 2008). Finally, the optimal capsule needs to contain a 
computerized system for automatic detection of pathologies such as the design of a holter 
electrocardiographic recording in order to overcome the drawback of time-consuming 
viewing the video. Future gastroenterologists will have a number of types of capsules from 
which to choose according to whether the purpose of the evaluation is diagnostic and/or 
therapeutic. 
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1. Introduction
Wireless Capsule Endoscopy (WCE) is a recent and exciting technology, which involves
recording images of the entire Gastrointestinal (GI) tract including the parts of the human
body never before seen outside operative surgery. The development of the capsule was
first announced in Nature in 2000 by Iddan et al. (2000). Since then a number of different
capsules have been launched by different vendors which varied slightly in their purpose, but
retained the principle of wireless non-invasive investigation of the GI tract. It is particularly
suited for computer-assisted diagnosis, as it records a large quantity of data (mostly, but
not exclusively images) from the human gut, which consequently requires a time-consuming
visual assessment that can be carried out only by an experienced clinician. The duration of this
assessment, which involves the scrutiny of a video comprising approximately 50, 000 frames,
varies between one to two hours. Thus, it can be seen that in terms of time requirement, the
WCE is a very costly medical imaging procedure. This opens a door for computers to aid the
analysis of the WCE footage, by reducing the time required to reach the diagnosis and thus
the cost of the procedure, making it a more affordable technique. This view is supported by
the leading endoscopists in the United Kingdom:
"The cumbersome analysis of WCE images has been the major faction in preventing the spread
of WCE to become a routine service in every DGH." Dr Jonathan Green, Secretary of the
Endoscopy Committee of the British Society of Gastroenterologists.
"The key constraint for uptake of WCE is the time taken to read and report the examination.
Increased automation of reading of WCE will have a dramatic effect on the uptake of this
important endoscopic technique, and to the costs of providing the service." Dr Roland Valori,
National Endoscopy Lead.
Another aim of computer-assisted WCE video analysis can be considered in terms of
improvement of the clinicians diagnosis. Here, the computer assumes the role of an expert
system able to give a second opinion on the state of the patient.
This chapter reviews the problems of Wireless Capsule Endoscopy video analysis from an
image processing and pattern recognition perspective. As it has been ten years since the first
capsule was launched we consider there is a need for a review of the work to date which
would sum up the current state-of-the-art and draw certain conclusions about the future
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directions of the research. Moreveor, we review in detail the technologies of the capsule as
they were developing.
The paper is organised in the following manner. In Section 2, WCE technology and its
clinical use are described. In Section 3, a review of the different types of the computer vision
algorithms is given. Finally, Section 4, contains the conclusions.
2. Technology and its clinical use
The first wireless capsule endoscope was launched in 2001 by Given Imaging Ltd, and
reported in an article in "Nature" Iddan et al. (2000). Since the device received FDA (American
Food & Drug Administration) clearance in August 2001, over 1,000,000 examinations have
been conducted globally. The 11mm x 26mm M2A capsule (later rebranded PillCam SB
(SB stands for small bowel)) (see Figures 1 and 2) is propelled passively, hence having
been swallowed, it is propelled through the food tract by normal peristaltic movement of
the human gastrointestinal (GI) system, usually reaching the colon, before being expelled
naturally from the body. One end of the capsule contains an optical dome with six white
Light Emitting Diodes (LEDs) and a CMOS camera that captures 2 images (circular shape from
a square of 256 × 256 pixels) a second. These images are compressed using JPEG and relayed
via a transmitter using a radio frequency signal to an array of aerials, which are attached to
the patient’s body, from where they are transferred over the wires to a data-recorder worn by
the patient on a belt. The sensor array allows for continues triangulation of the position of
the capsule inside the body of the patient so that the trajectory of the capsule passage can be
later displayed on the workstation monitor. The accuracy of the capsule location provided
by this method was reported to be ±3 cm by Ravens & Swain (2002). After 8 hours (the
capsule two silver-oxide batteries lifetime), the data-recorder is removed and the image data
uploaded to a workstation for viewing and analysis. The upload process originally took two
to three hours using early versions of the Given Imaging Rapid Reader (RR) software, but a
more recent version of this application has reduced this to around 30 minutes. The stored
data consists of ∼ 50, 000 images, and is viewed as a video sequence using software provided
by the manufacturers (RR) (see Figure 3)).
In 2007 PillCam SB 2 was cleared for marketing in the US. According to the manufacturers, it
offers advanced optics and a wider field of view. PillCam SB 2 also captures nearly twice the
mucosal area per image. It also provides Automatic Light Control for optimal illumination of
each image.
Fig. 1. M2A capsule
The clinical procedure is a simple and painless process, which is one of the factors why the
patients prefer WCE to conventional endoscopy methods Melmed & Lo (2005). Before the
procedure begins, patients must fast overnight. Moreover, some studies suggest that results
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Fig. 2. The inside of the M2A capsule - 1) Optical dome, 2) Lens holder, 3) Lens, 4) LEDs, 5)
CMOS imager, 6) Battery, 7) RF transmitter, 8) Antenna.
Fig. 3. Rapid Reader ver.4 software - A part of the Given Imaging diagnostic system. Note, the
quad view - four images blended on the edges and displayed at the same time
may be improved by bowel preparation i.e. ingesting a drug that shortens food and capsule
transit times through the GI track Dai et al. (2005). The exam begins by the attachment of the
antennas to the patient’s chest, which are then connected to the data-recorder worn on a belt.
The capsule starts acquiring images and transmitting them immediately after it is removed
from its magnetic holder. After a brief capsule test by the physician (less than one minute),
it should be immediately ingested by the patient. Water and food intake can begin after 2
and 4 hours respectively. Patients are asked to monitor a blinking diode on the belt pack,
which indicates the quality of the signal reception. The patient should not exercise during the
procedure, and avoid any powerful electromagnetic field source.
In October 2005, Olympus launched a competitor system called EndoCapsule (see Figure 4)
in Europe. Their device, acquires images at the same rate and at the same resolution as the
Given Imaging PillCam. The difference lies in the use of a different imaging technology -
CCD, which the manufacturers claim is of higher quality Fuyono (2005). Another feature of
the EndoCapsule is the Automatic Brightness Control (ABC), which was applied from the
traditional endoscope technology. ABC provides an automatic illumination adjustment as
the conditions in the GI track vary. EndoCapsule also features a real-time viewing device (see
Figure 5), which allows the physician to watch the capsule examination in real time. Moreover,
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directions of the research. Moreveor, we review in detail the technologies of the capsule as
they were developing.
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the capsule inside the body of the patient so that the trajectory of the capsule passage can be
later displayed on the workstation monitor. The accuracy of the capsule location provided
by this method was reported to be ±3 cm by Ravens & Swain (2002). After 8 hours (the
capsule two silver-oxide batteries lifetime), the data-recorder is removed and the image data
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Fig. 1. M2A capsule
The clinical procedure is a simple and painless process, which is one of the factors why the
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Fig. 2. The inside of the M2A capsule - 1) Optical dome, 2) Lens holder, 3) Lens, 4) LEDs, 5)
CMOS imager, 6) Battery, 7) RF transmitter, 8) Antenna.
Fig. 3. Rapid Reader ver.4 software - A part of the Given Imaging diagnostic system. Note, the
quad view - four images blended on the edges and displayed at the same time
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which indicates the quality of the signal reception. The patient should not exercise during the
procedure, and avoid any powerful electromagnetic field source.
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in Europe. Their device, acquires images at the same rate and at the same resolution as the
Given Imaging PillCam. The difference lies in the use of a different imaging technology -
CCD, which the manufacturers claim is of higher quality Fuyono (2005). Another feature of
the EndoCapsule is the Automatic Brightness Control (ABC), which was applied from the
traditional endoscope technology. ABC provides an automatic illumination adjustment as
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the EndoView software also features image pre-processing capabilities, which result in a high
image quality.
Fig. 4. Olympus EndoCapsule
Fig. 5. Olympus Real-time viewer (taken from Olympus website)
Fig. 6. Olympus EndoView video viewing software
In December 2004, FDA approved a second type of capsule developed by Given Imaging -
the PillCam ESO, which allows the evaluation of oesophageal disease. The motivation for
developing this capsule lay in the rapid capsule transit through the oesophagus. Here the
frame rate of only two frames per second (of the original PillCam SB) did not provide enough
data for a thorough examination of this GI region to be undertaken. This opinion was also
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Fig. 7. Olympus EndoCapsule sensor array and data recorder (taken from Olympus website)
reported in Neu et al. (2003), where the authors concluded that esophageal capsule endoscopy
could not be achieved without further technical developments. The response to this demand
materialised in the development of the PillCam ESO which has the higher frame rate and
CMOS cameras positioned at both ends of the capsule. This capsule acquires and transmits
seven frames per second from each camera, giving a total of 14 frames per second Mishkin
et al. (2006). Due to the increased frame rate, the capsule battery life is only 20 minutes, which
is ample time for the capsule to visualise the entire oesophagus.
In October 2006, Given Imaging received the CE Mark to market a third capsule - the PillCam
COLON throughout the European Union. This device was developed as a diagnostic test
to visualize the colon. The capsule measures 11 mm by 31 mm - slightly larger than the
previous two capsules. Similar to PillCam ESO, the capsule has cameras at both ends. These
capture 4 images a second for up to 10 hours. A new feature in Given Imaging capsules is
an automatic lighting control. Since the lumen of the colon is wider than the small bowel
and also highly compartmentalised, the PillCam COLON capsule optics captures more than
twice the coverage area and depth of field of the PillCam SB capsule. After switching on the
capsule and within a few minutes of image transmission, the device enters a delay mode.
This lasts approximately 2 hours, after which it "wakes" up to resume the image transmission.
This saves the battery power during the transit of the capsule through the earlier parts of
the gut, allowing longer transmission from the relevant GI region - the colon. In 2009, the
second-generation capsule, PillCam COLON 2, was cleared by the European Union. PillCam
COLON 2 offers additional features such as: intelligent functionality, superior imaging and
a convenient workflow. The capsule has the ability to adjust the frame rate in real time to
maximize colon tissue coverage. The imaging devices on either end of the capsule provide a
near 360 °view of the colon. The manufacturers claim that with this capsule the patient study
process has been simplified and hence it allows for more efficient utilisation of staff time and
resources.
Another competitor capsule was launched by the IntroMedic IntroMedic (n.d.). Their capsule
known as MicroCam received the CE Mark in 2007. The dimensions of the capsule are
11 × 24 mm and the 150°field of view. During the 11h battery life time, the capsule is
capable of capturing around 120,000 images with a frame rate of 3 images per second and
a resolution of 320 × 320 pixels. The manufacturers also supply a real-viewing device. The
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This lasts approximately 2 hours, after which it "wakes" up to resume the image transmission.
This saves the battery power during the transit of the capsule through the earlier parts of
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COLON 2 offers additional features such as: intelligent functionality, superior imaging and
a convenient workflow. The capsule has the ability to adjust the frame rate in real time to
maximize colon tissue coverage. The imaging devices on either end of the capsule provide a
near 360 °view of the colon. The manufacturers claim that with this capsule the patient study
process has been simplified and hence it allows for more efficient utilisation of staff time and
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Another competitor capsule was launched by the IntroMedic IntroMedic (n.d.). Their capsule
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MiroView software contains features such as: Capsule Positioning, Suspected GI Bleeding,
Image Enhancement, Multi-Display Viewing and the Quick View Mode.
Yet another capsule has been developed in China. The OMOM capsule Liao et al. (2008) has
been also FDA approved and received the CE Mark. The novel features offered by OMOM
include the first two-way transmission allowing the image capture rate and the light level
adjustment; and the vest jacket containing the RF sensors.
2.1 Future development directions
All active endoscopes (those whose movement can be controlled) produced so far are wired
ie. they transmit the images from the camera to the display over a wire. The capsules
described in this chapter are all passive, which means they are propelled by peristalsis and
their movement cannot be controlled. An active propulsion system would offer obvious
benefits. It is not surprising, therefore, that it is the focus of intensive research. Two main
approaches in this field have been proposed: internal, where the locomotion results from the
mechanisms contained in the capsule and external, which utilises forces transmitted from the
outside, usually by the means of the magnetic field Toennies et al. (2010). Below, we will
describe a few developments in these fields that were reported in the literature.
In Sendoh et al. (2003), the authors propose an external type of propelling the capsule using
a magnetic accurator. The device uses a permanent magnet in the capsule and an external
rotational magnetic field to control the capsule movement. The authors report a preliminary
experiment in which they used a dummy capsule without any endoscopic functions. Kosa
et al. (2008) propose a miniature swimming mechanism that uses MRI’s magnetic fields for
powering the capsule. Their method uses both the static and radio frequency (RF) magnetic
fields available in MRI to generate propulsion force and deliver wireless energy. Another
magnetic propulsion mechanisms have been proposed by Gao et al. (2010).
Olympus has been also working on the development of a new generation capsule endoscope,
which features magnetic propulsion Olympus News Release (2004) (see Figure 8). Apart from
the novel propulsion and guidance system, the capsule designers aim to provide provide a
drug delivery system, which would administer drugs directly to an affected area; a body fluid
sampling system, taking body fluid extracts for diagnosis and analysis; and also an ultrasound
scan capability.
RF System Lab Company RF Systems (n.d.) has also announced the intention of producing a
Norika capsule with a magnetic field based propulsion (see Figure 9). In December 2005, they
also announced the design of the new Sayaka capsule, which would have a lens on the lateral
surface of the capsule instead of the front as in the capsules of the competitors (see Figure 10).
The inventors claim that such a design would obtain clear-cut images of the gastrointestinal
wall while the capsule spins in the GI tract with the stepping angle of 7.5°. Sayaka acquires
images at a rate of 30 frames per second, which generates ∼ 870, 000 over an eight hour period
of operation. The images are later combined together in a process called mosaicing, which
produces an image (map) of the GI tract walls.
Further applications of magnetic fields are presented by Lenaerts & Puers (2006), where
the authors propose to use an inductive link to power a wireless capsule endoscope. The
capsule, known as the Intracorporeal Videoprobe (IVP2, see Figure 11) Arena et al. (2005)
is induction-powered and equipped with a tilting image sensor on a motorised plate (see
Figure 12) and a telemetric datalink. In Turgis & Puers (2004), the authors describe the video
compression method of this system. According to Innovative imaging probes for endoscopy (2005)
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, the capsule is still a long way from becoming a commercial product. Moreover, the author
could not find any publication on this capsule in the last four years.
Fig. 8. Conceptual diagram of the future Olympus capsule guidance principle (taken from
Olympus New Release)
Fig. 9. Norika capsule design (taken from RF System website)
Fig. 10. Sayaka capsule (taken from RF System website)
Fig. 11. IVP2 capsule (taken from IVP project website)
An internal approach to capsule locomotion has been proposed by Quirini et al. (2007). The
authors presented the design of the locomotion for a 12-legged, swallowable (11mm diameter
by 25mm long), endoscopic capsule to be utilised in the lower GI tract (large bowel). The
capsule utilises a slot-follower mechanism driven via lead-screw generating 2/3 N of force at
each leg tip.
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Olympus has been also working on the development of a new generation capsule endoscope,
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surface of the capsule instead of the front as in the capsules of the competitors (see Figure 10).
The inventors claim that such a design would obtain clear-cut images of the gastrointestinal
wall while the capsule spins in the GI tract with the stepping angle of 7.5°. Sayaka acquires
images at a rate of 30 frames per second, which generates ∼ 870, 000 over an eight hour period
of operation. The images are later combined together in a process called mosaicing, which
produces an image (map) of the GI tract walls.
Further applications of magnetic fields are presented by Lenaerts & Puers (2006), where
the authors propose to use an inductive link to power a wireless capsule endoscope. The
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Fig. 12. IVP2 capsule steering system (taken from IVP project website)
2.2 WCE clinical importance
The gastrointestinal (GI) tract consists of the oesophagus, stomach and duodenum (upper GI
tract), the jejunum, ileum (small bowel), colon and rectum.
Fibre optic gastrointestinal endoscopy, introduced in the early 1970s enabled effective
diagnosis and biopsy of disease in the lumen of the stomach and duodenum
(gastroduodenoscopy OGD) and shortly afterwards the colon and rectum (colonoscopy). In
the 1980s, videoendoscopy using microchip cameras improved image resolution and the ease
of use of the equipment.
These innovations enabled clinicians to diagnose a large number of GI pathologies which
occur mostly in the stomach, duodenum and colon. Examination of the remainder of the small
intestine using a conventional endoscopy (the jejunum and ileum) was until very recently
limited only to the first few centimeters of jejunum and last few centimeters of the terminal
ileum. However, this part of the GI tract can be the site of "obscure" bleeding, inflammation
and a rare location for tumours. There exist non-standard endoscopy methods to investigate
this part of the small bowel. However, they use a flexible tube to propel the endoscope along
the bowel, which given the length of the investigated gut (up to 4.5 m) and its shape with
many loops, rendered the procedure very difficult and uncomfortable to patients. Other
means of imaging the small bowel, such as computerised tomography (CT) or magnetic
resonance (MR) axial imaging cannot provide a direct view of the tissue. Hence, there was
a clinical need to provide a tool which would enable clinicians to diagnose the jejunum and
the ileum more efficiently.
The wireless capsule endoscope (WCE) developed by Given Imaging Ltd was an answer to
this demand, which for the first time allowed an endoscope to record the high-resolution
images of its full passage through the GI tract including the parts of the human body never
before seen outside operative surgery.
Following many clinical studies Gay et al. (2004); Leighton et al. (2006); Selby (2004); Viazis
et al. (2005) into the efficacy of WCE in clinical practice, the superior imaging capabilities
of WCE above contrast imaging and CT imaging became clear. These studies concentrated
on patients with "obscure" GI bleeding; those who had lost blood into the lumen with no
cause found at OGD or colonoscopy. Consequently, WCE is now established as the first
line diagnostic test for patients with this condition, and received approval as such from the
National Institute for Clinical Excellence (NICE) in the UK in 2004.
WCE also received attention with regard to the diagnosis and assessment of patients with
suspected or known Crohn’s disease (CD) Bona et al. (2006); Dubcenco et al. (2005); Pennazio
(2004a;b); Swain (2005), a chronic inflammatory disease affecting any part of the GI tract,
but most often localised in the terminal ileum. This disease is of increasing prevalence in
the developed world Bernstein (2006), and causes significant morbidity to patients. It is
difficult to diagnose, partly due in the lack of sensitivity of contrast radiology to minor
mucosal pathologies. WCE offers significant improvements to the diagnosis of CD due to
its greater sensitivity, and also allows follow-up examinations without exposing the patient to
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the hazards of ionising radiation. The capsule has also been found useful in the diagnosis of
another form of small bowel inflammation - Celiac disease Culliford et al. (2005).
Cancer of the small bowel is rare but often has a high mortality rate since it tends to be
diagnosed late. A number of clinical studies Cobrin et al. (2006); Urbain et al. (2006); van
Tuyl et al. (2006) have found WCE as a sensitive tool in detecting cancerous conditions.
Therefore, if employed with this group of patients, capsule endoscopy is expected to offer a
clinical benefit in terms of cancer survival rate. Peutz-Jegher disease is a hereditary condition
that involves the formation of small bowel polyps with a potential to become malignant,
especially when they reach a large size. In Brown et al. (2006), the authors suggest that wireless
capsule endoscopy should become the investigation of choice in those undergoing follow-up
in interval surveillance for this condition.
Patients with obscure diarrhoea abdominal pain and possible functional bowel disease have
also been examined in series of studies to assess potential diagnostic benefits of WCE,
but in this heterogeneous group no clear benefit has been demonstrated to date Fry et al.
(2006). The capsule has also proven useful in studies concerning the impact of drugs on the
gastrointestinal tract Qureshi (2004). Moreover, children can benefit from the device as well
as adults Argüellas-Arias et al. (2004).
The development of PillCam ESO with a faster frame acquisition rate has allowed the
non-invasive imaging of oesophageal conditions in selected groups of patients. This safe
and acceptable-to-patients form of WCE may represent an alternative to conventional upper
endoscopy, and give a clinical benefit in the assessment of endoscopic signs of esophageal
varices and portal hypertension Caunedo-Alvarez & Herrerias-Gutierrez (2006); Eisen et al.
(2006); Eliakim et al. (2004). Early studies from the PillCam COLON Eliakim et al. (2006);
Schoofs et al. (2006) launched for clinical use by Given Imaging in 2006 show promising
accuracy compared with colonoscopy and suggest further clinical trials to establish the
efficacy and appropriate role for this application of capsule endoscopy.
It is believed by some researchers Iddan et al. (2000) that WCE approximates ’physiological
endoscopy’ as it is more closely aligned with human physiology than conventional endoscopy,
where sedation and air insufflation are required to provide a clear passage for the conventional
wired scope. These factors result in the distortion of the natural appearance of the viewed area
in traditional endoscopy and colonoscopy.
3. Computer vision tools in WCE video analysis
In this section, we give a detailed review of the computer vision tools that were either
developed by the manufacturers or reported in the scientific literature. This section was
divided into the main areas of research, namely: topographic video segmentation (Section
3.1), bleeding detection (Section 3.2), abnormality detection (Section 3.3), capsule retention
detection (Section 3.4),adaptive viewing speed adjustment(Section 3.5), non-informative
frame filtering (Section 3.6) and intestinal contraction detection (Section 3.7).
3.1 Topographic video segmentation
The GI tract consists of the mouth, oesophagus, stomach, small intestine and large intestine
(colon). Once switched on, the capsule endoscope is usually outside the body of the patient for
no more than a few seconds, before it is placed in the mouth, where it usually stays for a few
seconds, before it is swallowed. After which, it is pushed by peristalsis along the oesophagus,
in which it stays for around two seconds. Hence, usually we can see only around 3-5 images
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Fig. 12. IVP2 capsule steering system (taken from IVP project website)
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that involves the formation of small bowel polyps with a potential to become malignant,
especially when they reach a large size. In Brown et al. (2006), the authors suggest that wireless
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in interval surveillance for this condition.
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3.1 Topographic video segmentation
The GI tract consists of the mouth, oesophagus, stomach, small intestine and large intestine
(colon). Once switched on, the capsule endoscope is usually outside the body of the patient for
no more than a few seconds, before it is placed in the mouth, where it usually stays for a few
seconds, before it is swallowed. After which, it is pushed by peristalsis along the oesophagus,
in which it stays for around two seconds. Hence, usually we can see only around 3-5 images
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taken inside the oesophagus (the capsule transmits two images per second), before the capsule
reaches the esogastric junction (EJ) separating the oesophagus from the stomach. Typically, the
time spent in the stomach (GTT) is around 15 minutes. However, this time can be significantly
longer, and it is possible for a capsule to stay in the stomach for several hours before it passes
through the pylorus (the valve between the stomach and the intestine). The small intestine is
the longest part of the GI tract, and the capsule usually spends around four hours in transit
through this region. It ends with the ileocaecal valve (IV), which marks the beginning of the
colon.
Finding the pylorus in the video can be difficult and time-consuming, even for an experienced
viewer, as visually the stomach tissue in the pyloric region and the tissue at the beginning
of the intestine appear very similar. Annotating the place in the video where the capsule
enters the IV is even more difficult, since intestine and colon tissues are very similar and are
often contaminated with faecal material that occludes the camera view. Annotating the EJ is
relatively the easiest of these three tasks, as the physical features inside the mouth, oesophagus
and stomach are visually quite unique and, thus significantly different.
The possibility of classifying different organs was first indicated in 2004 by Berens et al.
(2004) who reported building a Stomach/Intestine classifier which could be used to predict
the pylorus. Later, Berens, Mackiewicz & Bell (2005) propose an extended discriminator
that could also determine the Ileocecal Valve (IV). In that paper, they also compare the
performance of two classifiers used to build the discriminators: k-nearest neighbour (kNN)
and Support Vector Classifier (SVC). Next, Berens, Mackiewicz, Fisher & Bell (2005) present
a further discriminator for the Mouth/Oesophagus&Stomach regions and then combine all
the discriminators to provide an estimate of the time taken for the capsule to pass through
the stomach ( known as the Gastric Transit Time (GTT)) and the intestine (known as the
Intestinal Transit Time (ITT)). These are used by clinicians as important indicators of the
health of the digestive system. The discriminators utilise hue saturation histograms which
are compressed using a hybrid transform, incorporating both the Discrete Cosine Transform
(DCT) and Principal Component Analysis. More recently, Mackiewicz, Berens & Fisher (2008)
expand their previous work on capsule tissue discrimination and present yet another WCE
video segmentation algorithm based on a Hidden Markov Model (HMM). They compare
the performance of two classifiers Multivariate Gaussian and SVC, which were built within
the framework of HMM. They also show that adding texture and motion features in the
classifiers improves the results. Moreover, they note that WCE images often contain artifacts
and shadows that can obscure the underlying tissue images. To address these problems, they
develop a technique for extracting only those image regions that contain clearly visible tissue.
They show that combining features for these regions with features derived from the entire
image provides more accurate discrimination between the GI body parts.
An extensive work on the same topic was also carried out by another research group in
Portugal starting with Coimbra et al. (2005), where they present an attempt to segment a
WCE video into meaningful parts. They divide the video into four zones: Entrance (Z1)
- consisting of image frames acquired from the mouth and oesophagus as well as those
acquired before the capsule is swallowed; Stomach (Z2) - whose limits are determined by
the oesogastric junction and the pylorus; small intestine (Z3) - delimited by the pylorus and
IV; Colon (Z4) - from IV to the end of the footage. MPEG-7 descriptors (Scalable Colour and
Homogeneous Texture) are used as low-level image features. The classification is performed
using a Bayesian classifier, which assigns a topographic location label to each frame in the
video. Iteration is used to minimise the segmentation error, resulting in three parameters that
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show the positions of transitions between the four previously defined zones. Later Coimbra,
Campos & Cunha (2006b) show that using a Support Vector Classifier instead of the Bayesian
approach significantly improves the results, which can be used to estimate the capsule Gastric
and Intestinal Transit Times. The authors have later shown that combining content with
context features may give an additional boost to WCE video segmentation Coimbra, Kustra,
Cunha & Campos (2006). Contextual features may include spatial location of the capsule
inside the body of the patient and capsule displacement velocity. The authors conclude that
such an approach mimics more closely additional expert knowledge that the clinician draws
on in order to perform the annotation more accurately.
More recently, Duda, Zielinski, Fraczek, Bulat & Duplaga (2007) report the results of a study
in which they attempt to classify the images from the upper part of the GI tract into a larger
number of distinctive regions than it was done before. They choose six anatomical regions:
A) oesophagus, B) cardia, C) fundus, D) corpus of the stomach, E) pylorus and F) duodenal
cap, whereas the previous studies looked only at oesophagus, stomach and small intestine.
As in their other work Duda, Zielinski, Duplaga, Grega & Leszczuk (2007),they use MPEG-7
features together with Vector Quantisation and Principal Component Analysis to produce
the feature vectors; and Neural Networks as the classifiers. The study is small size and it
utilises only two video sequences. The authors report only the classification results and do
not attempt to segment the actual videos.
Lee et al. (2007) present yet another method for detecting GI organ boundaries. In their
work, they try to segment the CE video into 5 regions: oesophagus; stomach; duodenum
and jejunum; ileum; and colon using frequency domain functions derived from the variations
of the intensity signal across the video. The idea for their algorithm is based on the fact that
each digestive organ has different patterns of intestinal contractions. These patterns have been
earlier used in the analysis of biogenic signals e.g. Electrogastrogram, which is a non-invasive
recording of the stomach electrical activity. The analysis of the aforementioned frequency
functions leads to the event boundaries which indicate either entrance to the consecutive
organ or unusual events in the same organ, such as intestinal juices, bleeding, ulceration,
and unusual capsule movements. These events are then further classified and merged into
higher level events that represent digestive organs which leads to a tree-like representation of
the CE events. The authors report that the proposed scheme can detect the most of stomach
and duodenum correctly, but the performance on ileum and cecum is worse. Similar findings
regarding difficulties in locating the IV were reported in the other studies that looked only at
colour and texture features Coimbra, Campos & Cunha (2006b); Mackiewicz, Berens & Fisher
(2008).
3.2 Bleeding detection
Rapid reader - the Given proprietary software provided with the PillCam capsule, has an
automatic image analysis tool called Suspected Blood Indicator (SBI). This tool however, was
reported to have a very low specificity and sensitivity Signorelli et al. (2005) and as authors
suggest, it can be used only as a complementary rapid screening tool, which cannot replace the
complete view of the recordings by the specialist. Moreover, it is not obvious how SBI exactly
detects red areas since Given Imaging has not revealed this. Similarly, we do not know how
Olympus EndoCapsule red spot detector works. In Signorelli et al. (2005), the authors state
that in their observations the ability of SBI to detect red lesions was related neither to their
size nor to the length of the lesion event (number of frames). It is believed that as the new
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versions of the Rapid Reader software are released, the SBI algorithm is improved, however
the author of this chapter has no knowledge of how significant if any these improvements are.
Hwang et al. (2006) propose an algorithm that as they claim can detect bleeding areas in the
capsule videos. The algorithm uses Expectation Maximization (EM) clustering and Bayesian
Information Criterion (BIC). The authors manually segmented around 200 images into blood
and non-blood regions. Then, they selected 16,000 bleeding and 45,000 non-bleeding pixels
and modelled the colour distribution of these regions using Gaussian mixtures in RGB colour
space. Bayesian Information Criterion was used to decide the number of clusters. In the first
step of the algorithm, dark pixels are removed. In the second step, the algorithm chooses
those pixels x to be bleeding candidates for which conditional probability p(x|bleeding)
of a pixel x given by bleeding pixels is significantly larger than conditional probability
p(x|non − bleeding) of a pixel x given by non-bleeding pixels; and also it is larger than a
certain predefined threshold. In the final step of the algorithm, the areas of bleeding regions
are calculated and all segmented regions containing less than 1,000 pixels are rejected. To
test the results of bleeding detection, the authors selected 15,222 capsule images of which
1,731 contained blood from three different videos. On this test set, a reported specificity and
sensitivity were 98.10% and 92.55% respectively. Unfortunately, this algorithm was not tested
on full-length video sequences, which makes it difficult to state whether it performs better
than SBI.
Contrary to Hwang et al. (2006), where the authors use parametric bleeding colour
distribution modelling, Mackiewicz, Fisher & Jamieson (2008) choose a histogram based
method. They claim that this was motivated by the need of fast model adaptation,
which is easier in the non-parametric method. Their method uses in its first stage
Hue-Saturation-Intensity colour histograms to track a moving background and bleeding
colour distributions over time. Such an approach addresses the problem caused by drastic
changes in blood colour distribution that occur when it is altered by gastrointestinal fluids
and allow detection of other red lesions, which although are usually "less red" than fresh
bleeding, they can still be detected when the difference between their colour distributions
and the background is large enough. In the second stage of their method, their algorithm
analyses all candidate blood frames, by extracting colour (HSI) and texture (LBP) features
from the suspicious image regions (obtained in the first stage) and their neighbourhoods and
classifying them using Support Vector Classifier into Bleeding, Lesion and Normal classes.
They show that their algorithm compares favourably with the SBI on the test set of 84 full
length videos.
Recently, Li & Meng (2009) propose a method of bleeding and ulceration detection by means
of chromaticity moments constructed from the Tchebichef polynomials. The authors divide
the circular CE image into a grid of 36 non-overlapping blocks (30 × 30 pixels)(similar grid
was also used for feature extraction by Mackiewicz, Berens & Fisher (2008)), from which
they calculate six chromaticity moments. Next, they performed an experiment in which
5400 (1800 normal, 1800 bleeding and 1800 ulceration) image blocks were selected from
300 non-consecutive CE images extracted from 10 patient video sequences. The blocks
were randomised and classified using an MLP Neural Network with 4-fold cross-validation.
Finally, the authors reported sensitivity and specificity figures obtained from the block
classifications. This study should be considered as preliminary as it was not performed on
the full length videos. Moreover, one can note that the training and the test sets were allowed
to contain the blocks from the same patient sequence as the 4 folds of the dataset were chosen
after the blocks extracted from the 10 video sequences were randomised.
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3.3 Abnormal tissue detection
One of the first image processing studies in capsule endoscopy was conducted by
Boulougoura et al. (2004) who describe an intelligent system, which they claim is capable
of discriminating between normal and abnormal tissue in M2A WCE images. They use
54 feature vector elements, which are nine measures (standard deviation, variance, skew,
kurtosis, entropy, energy, inverse different moment, contrast and covariance), calculated from
histograms (1st order statistics) of six channels (R,G,B,H,S,V). The images are classified using
an advanced neural network scheme containing the fusion of multiple classifiers dedicated to
specific feature parameters. The authors report a detection accuracy of 100%. However, this
result was evaluated using only 73 capsule images (33 abnormal and 38 normal), which were
split into the training set (23 abnormal,25 abnormal) and the test set. The size of data used
in this study is insufficient to draw conclusions whether the system can be used in a working
application. The authors intended to test their algorithm on the images acquired from the IVP
capsule Arena et al. (2005), which was under development at that point in time.
More recently Szczypinski & Klepaczko (2009) proposed a method of feature selection which
selects relevant features by searching for a subspace that would encapsulate all vectors from
one chosen pathology type by a convex hull and hence they call their algorithm Vector
Supported Convex Hull (VSCH). The authors work with a high dimensional dataset extracted
using MaZda software consisting of several hundred colour and texture features. The
motivation for this approach was to minimise the rate of false negative errors. Apart from
identifying significant features, the method also determines a classification rule based on the
mathematical definition of the optimal convex hull. The authors compare their method to the
Radial Basis Function network and conclude that it compares favourably with the RBF and
that it ensures the desired behaviour of low false negative ratio without any explicit weighting
of error types. The study should be considered as preliminary as it was carried out on a dataset
extracted from only 50 images which came from 3 video sequences.
Bejakovic et al. (2009) present a method that uses color, texture and edge features to analyse
the Crohn’s disease lesion in CE images. They used 3 MPEG-7 visual descriptors (dominant
color (DCD), homogeneous texture (HTD) and edge histogram (EHD)); and Haralick texture
features calculated from 1 pixel co-occurrence matrices. They used Support Vector Machines
to classify CE images into 3 classes: lesion, normal tissue, and extraneous matter (food, bile,
stool, air bubbles, etc). The database used to evaluate their method contained a number of 100
frame video sequences extracted from 10 patients which were pre-annotated by the clinicians.
Ten-fold patient specific cross validation was performed. The results are given as Accuracy
and Recall rates for the three earlier defined classes and one of the earlier defined descriptors.
Authors conclude that it is the colour which carries the most useful information with regard
to the CE image classification, which confirms earlier findings by Coimbra, Campos & Cunha
(2006a).
Recently, Li et al. (2011) presented a study with an aim to develop a computer aided system
to diagnose small bowel tumours. They propose a textural feature that is built on wavelet
and local binary pattern. With regard to the classifier, they employ a classifier ensemble
consisting of k-nearest-neighbor, multilayer perceptron neural network and support vector
machine. Results obtained from the analyses of 1200 (600 normal and 600 abnormal) capsule
images showed the promising performance for small bowel tumour detection.
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3.4 Capsule retention detection
Szczypinski et al. (2004) attempt to localise the areas in the GI tract that might be affected by
Crohn’s Disease (CD). In their work a Model of Deformable Rings (MDR) is used to locate the
areas where the capsule moves more slowly or stops. This, according to some researchers
(Tang et al., 2003) may signify the appearance of CD. The model aims to determine the
movement of a tube-like surface (GI tract) by comparing adjacent video frames with regard to
the displacement of its distinctive portions. MDR calculates a 2D map of the internal surface
and provides an estimate of the capsule velocity. The map can be used as a quick reference,
supporting identification of the segments of the GI tract and according to the authors claim,
may be useful in identification of large scale pathologies.
3.5 Adaptive viewing speed adjustment
The main motivation for applying computer vision techniques to WCE video analysis is the
potential improvement gained by reducing the overall time needed to review the data, by
alerting the expert to clinically significant video frames. This may be achieved not only by
automatic detection of events or segmenting the video into some meaningful parts, but also
by adjusting the replay speed (number of frames displayed per second). Hai et al. (2006)
propose such a method of handling the frame rate in a capsule image sequence. In their
solution, instead of letting the clinician adjust the frame rate manually, video speed is adjusted
by an algorithm, which plays the video at high speed in stable regions and at slower speed
where significant changes between frames occur, signifying the possibility of pathologies.
The authors divide each frame into 64 blocks and measure the similarity of colours between
respective blocks in consecutive frames. RGB histograms quantised to 163 bins are used to
describe each image block. The distance between local histograms is computed using the
L1 norm, which is later used to calculate the similarity between two frames. Moreover, the
maximum and minimum of distances between blocks are collected. In addition to these
colour features, the algorithm estimates motion displacement by extracting features using
the KLT algorithm and tracking them using Newton-Raphson iterations. Then, these motion
and similarity features are used to classify each frame by the decision tree into four states: 1)
capsule and small intestine are stationary; 2) movement of the small intestine is small; 3) the
small intestine has larger movements and finally 4) the small intestine has abrupt changes.
From the sequence of states, the delay time between consecutive frames is calculated using
parametric functions, which take into account: the state to which the frame belongs, motion
and similarity features, the skill of the clinician and the hardware limitations. The authors
conclude that using their method the viewing time may be reduced from 2h to around 30
minutes without loss of information.
The software supplied by both Given Imaging (Rapid Reader) and Olympus (EndoView) also
include play speed control. Unfortunately, the details of these algorithms remain unknown.
Moreover, in the more recent versions of Given’s Rapid Reader, the clinician is given an option
of watching a video in either "Normal Mode" or in the "Quick View Mode". Although the
"Quick View" mechanism is not precisely explained in the documentation, we noticed that
it uses an approach similar to that described above to reduce the viewing time of the video.
It must be added though, that the "Quick View" mode skips some frames, displaying only
the most suspicious (at least to the algorithm that is used by Given Imaging), which makes
it different to the algorithms described above and puts it closer to the category of algorithms
aiming to detect abnormalities, as described in Section 3.3.
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The obvious conclusion regarding these methods must be that they are highly subjective. All
research on this topic has to include particularly extensive clinical evaluations.
3.6 Non-informative frame filtering
Another idea for aiding capsule endoscopy video review involves removing non-informative
frames from the video sequence. It was proposed by Vilarino et al. (2006) who presented an
algorithm which detects areas in the WCE video comprising images completely obscured by
intestinal fluids. Early detection of such regions is highly beneficial since they can be removed
from the sequence, before it is presented to the clinician, resulting in a shortening of the
reviewing time. Intestinal fluids appear as yellowish to brownish semi-opaque turbid liquids
often containing air-bubbles as well as other artifacts. The authors point out that the most
relevant feature of the intestinal fluids is the presence of small bubbles of different sizes and
quasi-circular shapes. The algorithm is based on texture analysis performed using Gabor filter
banks. In order to construct a filter bank, the authors used four different directions oriented
at 0o, 45o, 90o, 135o, arranged of four gaussian scales (sigma values of 1,2,4 and 8), resulting in
16 filters in the bank. Frames that contained bubbles detected in more than 50% of the useful
visualisation area were considered not valid for clinician analysis. The authors tested their
algorithm on ten WCE videos in which the reduction in number of frames varied from 12 to
46% (mean 23%). They plan to expand this work to consider postprandial cases, where the
texture patterns are more irregular.
Bashar et al. (2009) propose a cascade method for none-informative frame filtering, which uses
local color histogram to isolate highly contaminated non-bubbled frames (HCN), and Gauss
Laguerre Transform based multiresolution norm-1 energy feature to filter out significantly
bubbled (SB) frames. Their algorithm comprises of two steps: 1) HCN frames are isolated by
means of Support Vector Machine classifier and 2) SB frames are filtered out using automatic
bubble segmentation followed by threshold operation, which leaves us with the remaining
informative frames. In an experiment with 20,558 frames from the three CE videos they
compare the performance of their new method with Gabor and discrete wavelet feature
methods concluding that the former significantly outperforms the latter two.
3.7 Intestinal contraction detection
Intestinal contractions, which are of some relevance to clinicians constitute only around 1%
of the WCE video. Vilarinao et al. (2005) propose using ROC curves with ensembles of
classifiers to detect these contractions based on 34 low-level image features from 9 consecutive
frames including: mean intensity; hole size; global contrast; correlations between three
previous sequences; and the corresponding sequences averaged across the objects for the
class "contractions" and the variance of intensity. Spyridonos et al. (2005) introduce a two
stage contraction detection algorithm based on a Support Vector Classifier. Patterns of
intestinal motility are encoded using a number of textural and morphological features, that
include: 1st order statistics (mean, standard deviation, skew, kurtosis estimated from the
image histogram); 2nd order statistics (energy, entropy, inertia, local homogeneity, cluster
shade and cluster prominence); Local Binary Pattern histograms (radius = 2, number of points
= 16); and morphological features of the intestinal lumen (blob area, blob shape (solidity),
blob sharpness and blob deepness). The authors report 73.5% sensitivity, 98.8% specificity
and a false alarm ratio of 60%. The above figures were calculated from the test set comprising
of 6 capsule videos. Detection of intestinal contractions is further pursued by Igual et al.
(2007) who propose Eigenmotion-based Contraction Detection algorithm. First, the algorithm
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From the sequence of states, the delay time between consecutive frames is calculated using
parametric functions, which take into account: the state to which the frame belongs, motion
and similarity features, the skill of the clinician and the hardware limitations. The authors
conclude that using their method the viewing time may be reduced from 2h to around 30
minutes without loss of information.
The software supplied by both Given Imaging (Rapid Reader) and Olympus (EndoView) also
include play speed control. Unfortunately, the details of these algorithms remain unknown.
Moreover, in the more recent versions of Given’s Rapid Reader, the clinician is given an option
of watching a video in either "Normal Mode" or in the "Quick View Mode". Although the
"Quick View" mechanism is not precisely explained in the documentation, we noticed that
it uses an approach similar to that described above to reduce the viewing time of the video.
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extracts the motion information of a set of contraction sequences in form of optical flow
fields. Next, these motion data are transformed into the space of eigenmotions using Principal
Component Analysis. Then, a subset of the eigenmotions is used to characterise the high
dimensional optical flow information. Finally, this contraction representation is fed into the
Relevance Vector Machine for classification. The authors show the results which suggest that
motion information improves the contraction detection task. Moreover, they claim that the
scheme they propose may speed up the analysis time.
4. Conclusions
In this chapter, a number of computer image analysis algorithms developed over the period
of ten years and presented in the literature was described. The picture that emerges from
this description is very positive as far as the future of this field is concerned. The number of
papers published in the field increases fast and there is still plenty of valuable research to be
conducted.
Of all the different areas described, arguably the most thoroughly studied was the area of
topographic segmentation. The algorithms involved here were tested on full length videos,
proved to perform well and were shown to reduce the video analysis time. Many of these
algorithms could be used in their current form in some real viewing software applications.
Regarding future research in this field, the main areas of focused research will involve finding
new features, which would allow better discrimination between different tissue types. In
particular interesting new prospects might be opened by the use of context features such
as capsule location in 3-D, pH factor, temperature etc. Moreover, the bowel preparation
procedure (emptying the colon), which may become the standard procedure prior capsule
ingestion, may have the influence on tissue classification. On the one hand, it will uncover
more colon and terminal ileum surface, but on the other hand, there will be less digestive
remains in the colon, which are used in the colour and texture description. It remains to be
seen, whether this will have a significant influence on intestine/colon classification.
Another major area of capsule research is bleeding detection. Here, a large number of clinical
studies have been published, assessing the performance of Given Suspected Blood Indicator.
The authors report different sensitivity and specificity figures, although, they generally agree
that the current performance of SBI is insufficient, does not reduce the video viewing time
and must be improved. Bleeding detection algorithms described in this chapter are very
promising. There was at least one study, which contained a comprehensive comparison of
the algorithm performance with the SBI carried out using the large set of full length videos.
Moreover, the work described here demonstrated that it is possible to detect a large number
of other abnormalities using this method and in this respect it may constitute a prelude to the
solution for detection of much wider range of GI tract abnormalities.
As to detection of other pathological events, the computer vision research is still in its infancy.
Neither Given nor Olympus offer any automatic tools capable of detecting abnormalities. The
studies presented in Section 3.3 claim achieving different often very high accuracy figures
on detection of certain abnormalities. However, the sizes of training and test sets used in
these studies are insufficient to draw conclusions as to whether such systems can be used
in a working application. None of the studies described in that section was tested on the
full length videos and discussed the implications arising from the large number of false
positive detections. According to the author, this is the most challenging field of research
in capsule endoscopy image processing since detecting pathologies is the ultimate goal of
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reliable automatic tools. From the work presented in (Coimbra, Campos & Cunha, 2006a), we
can see that this task is very difficult since so far the features (in this particular study MPEG-7
visual descriptors) have not the sufficient discriminant power.
Another successful field of computer vision research is adapting the video play rate to
the local video contents. Given Imaging Rapid Reader provides the first automatic tool
- Quick View capable of shortening the viewing time. Given the previously mentioned
difficulties regarding detection of single pathologies, this seems to be a reasonable way
forward. Moreover, the authors of the publication presented in Section 3.5 claim their Quick
View-like algorithm achieves reduction of video assessment time to 30 minutes, which is an
impressive achievement.
Other algorithms presented in Section 3.6 and 3.7 attempt to detect either relevant frames,
which should be kept for future viewing by the clinician or irrelevant frames, which may be
discarded. Detecting both types could reduce video viewing time - in a particular algorithm,
attempting to detect intestinal fluids, the authors report the mean reduction in a number of
frames to be viewed by 23%. Again, this is a very promising result and given what was
said in the previous paragraphs about the difficulties of detecting single image pathologies,
we strongly anticipate the growth of the number of algorithms, building on the same idea
- instead of detecting particular pathologies, we would rather detect and discard irrelevant
parts of the video (e.g. intestinal fluids) and again detect and focus attention of the clinician
on particularly important frames (e.g. intestinal contractions).
There are still "unchartered territories" in the WCE image processing. All WCE computer
vision research so far was focused on the early capsules designated for investigation of the
small intestine. The more recent technologies enabling more detailed investigation of the
oesophagus and the colon were not investigated in this context. In particular, the latter is
expected to attract the significant interest from the image processing community.
There are a number of difficulties that WCE computer vision researchers face. The first
problem results from the nature of the capsule video data and is particularly troublesome
as far as event detection such as bleeding or abnormality is concerned. The problem is that
although each video exam consists of around 50, 000 images, these images include very few
relevant abnormal events. Thus, it is difficult to build sufficiently general models from the
large, one might think, set of say around 100 exams. The more specific the abnormality is the
more serious this problem becomes. The author of this chapter has come across this problem
when building blood colour distributions for bleeding detection. It is anticipated, however,
that this problem will be even more difficult with regard to describing other pathologies since
they are even rarer in the capsule videos than blood and take significantly larger number of
forms. Having said that, it is not difficult to explain why abnormality detection, which is the
ultimate goal of computer vision in WCE image analysis, have not achieved excellent results
in the first ten years of capsule video research. This is even more apparent when we look at
other areas of WCE computer vision research (such as topographic segmentation, intestinal
fluid and contraction detection), where thanks to abundance of relevant data in each video,
building general models was possible and consequently resulted in the significant progress in
these areas.
The second problem, which will become more apparent in the forthcoming future is the lack
of public databases of annotated WCE videos, which could be used for testing and comparing
the performance of different algorithms as the number of systems addressing similar problems
will increase. Building such a database is not an easy task, since the amount of clinicians
work annotating hundreds of videos with respect to many types of events (not necessarily
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extracts the motion information of a set of contraction sequences in form of optical flow
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dimensional optical flow information. Finally, this contraction representation is fed into the
Relevance Vector Machine for classification. The authors show the results which suggest that
motion information improves the contraction detection task. Moreover, they claim that the
scheme they propose may speed up the analysis time.
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In this chapter, a number of computer image analysis algorithms developed over the period
of ten years and presented in the literature was described. The picture that emerges from
this description is very positive as far as the future of this field is concerned. The number of
papers published in the field increases fast and there is still plenty of valuable research to be
conducted.
Of all the different areas described, arguably the most thoroughly studied was the area of
topographic segmentation. The algorithms involved here were tested on full length videos,
proved to perform well and were shown to reduce the video analysis time. Many of these
algorithms could be used in their current form in some real viewing software applications.
Regarding future research in this field, the main areas of focused research will involve finding
new features, which would allow better discrimination between different tissue types. In
particular interesting new prospects might be opened by the use of context features such
as capsule location in 3-D, pH factor, temperature etc. Moreover, the bowel preparation
procedure (emptying the colon), which may become the standard procedure prior capsule
ingestion, may have the influence on tissue classification. On the one hand, it will uncover
more colon and terminal ileum surface, but on the other hand, there will be less digestive
remains in the colon, which are used in the colour and texture description. It remains to be
seen, whether this will have a significant influence on intestine/colon classification.
Another major area of capsule research is bleeding detection. Here, a large number of clinical
studies have been published, assessing the performance of Given Suspected Blood Indicator.
The authors report different sensitivity and specificity figures, although, they generally agree
that the current performance of SBI is insufficient, does not reduce the video viewing time
and must be improved. Bleeding detection algorithms described in this chapter are very
promising. There was at least one study, which contained a comprehensive comparison of
the algorithm performance with the SBI carried out using the large set of full length videos.
Moreover, the work described here demonstrated that it is possible to detect a large number
of other abnormalities using this method and in this respect it may constitute a prelude to the
solution for detection of much wider range of GI tract abnormalities.
As to detection of other pathological events, the computer vision research is still in its infancy.
Neither Given nor Olympus offer any automatic tools capable of detecting abnormalities. The
studies presented in Section 3.3 claim achieving different often very high accuracy figures
on detection of certain abnormalities. However, the sizes of training and test sets used in
these studies are insufficient to draw conclusions as to whether such systems can be used
in a working application. None of the studies described in that section was tested on the
full length videos and discussed the implications arising from the large number of false
positive detections. According to the author, this is the most challenging field of research
in capsule endoscopy image processing since detecting pathologies is the ultimate goal of
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- Quick View capable of shortening the viewing time. Given the previously mentioned
difficulties regarding detection of single pathologies, this seems to be a reasonable way
forward. Moreover, the authors of the publication presented in Section 3.5 claim their Quick
View-like algorithm achieves reduction of video assessment time to 30 minutes, which is an
impressive achievement.
Other algorithms presented in Section 3.6 and 3.7 attempt to detect either relevant frames,
which should be kept for future viewing by the clinician or irrelevant frames, which may be
discarded. Detecting both types could reduce video viewing time - in a particular algorithm,
attempting to detect intestinal fluids, the authors report the mean reduction in a number of
frames to be viewed by 23%. Again, this is a very promising result and given what was
said in the previous paragraphs about the difficulties of detecting single image pathologies,
we strongly anticipate the growth of the number of algorithms, building on the same idea
- instead of detecting particular pathologies, we would rather detect and discard irrelevant
parts of the video (e.g. intestinal fluids) and again detect and focus attention of the clinician
on particularly important frames (e.g. intestinal contractions).
There are still "unchartered territories" in the WCE image processing. All WCE computer
vision research so far was focused on the early capsules designated for investigation of the
small intestine. The more recent technologies enabling more detailed investigation of the
oesophagus and the colon were not investigated in this context. In particular, the latter is
expected to attract the significant interest from the image processing community.
There are a number of difficulties that WCE computer vision researchers face. The first
problem results from the nature of the capsule video data and is particularly troublesome
as far as event detection such as bleeding or abnormality is concerned. The problem is that
although each video exam consists of around 50, 000 images, these images include very few
relevant abnormal events. Thus, it is difficult to build sufficiently general models from the
large, one might think, set of say around 100 exams. The more specific the abnormality is the
more serious this problem becomes. The author of this chapter has come across this problem
when building blood colour distributions for bleeding detection. It is anticipated, however,
that this problem will be even more difficult with regard to describing other pathologies since
they are even rarer in the capsule videos than blood and take significantly larger number of
forms. Having said that, it is not difficult to explain why abnormality detection, which is the
ultimate goal of computer vision in WCE image analysis, have not achieved excellent results
in the first ten years of capsule video research. This is even more apparent when we look at
other areas of WCE computer vision research (such as topographic segmentation, intestinal
fluid and contraction detection), where thanks to abundance of relevant data in each video,
building general models was possible and consequently resulted in the significant progress in
these areas.
The second problem, which will become more apparent in the forthcoming future is the lack
of public databases of annotated WCE videos, which could be used for testing and comparing
the performance of different algorithms as the number of systems addressing similar problems
will increase. Building such a database is not an easy task, since the amount of clinicians
work annotating hundreds of videos with respect to many types of events (not necessarily
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relevant to clinicians! e.g. intestinal fluids) is enormous, not to mention the size of the data
and resulting server requirements. Moreover, the problem might become even more difficult
when the amount of data significantly increases due to unavoidable increases in capsule image
acquisition rate and image resolution.
Having said all that, there is no doubt that the computer vision research on WCE videos will
become an important field of medical image processing and will gain much wider interest of
the researchers in the coming years. With this field clearly maturing and the steady increase
in the clinical usage of WCE, it is predicted a very bright future for clinical and computer
research in this topic.
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relevant to clinicians! e.g. intestinal fluids) is enormous, not to mention the size of the data
and resulting server requirements. Moreover, the problem might become even more difficult
when the amount of data significantly increases due to unavoidable increases in capsule image
acquisition rate and image resolution.
Having said all that, there is no doubt that the computer vision research on WCE videos will
become an important field of medical image processing and will gain much wider interest of
the researchers in the coming years. With this field clearly maturing and the steady increase
in the clinical usage of WCE, it is predicted a very bright future for clinical and computer
research in this topic.
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1. Introduction  
The most difficult to examine segment of the digestive tract is the small bowel. However, 
examining the distal portions that follow the duodeno-jejunal junction is vital when trying 
to diagnose an important number of pathologies, most of them with vital implications for 
the patient. 
Until recently, standard diagnostic techniques were limited to radiological barium-enhanced 
investigations, “push-enteroscopy” and intraoperatory enteroscopy, selective arteriography, 
scintigraphy or computer tomography. All these methods were either too intrusive, such as 
the case with intraoperatory enteroscopy, or did not provide sufficient data for an accurate 
diagnostic.  
Technological progresses in recent years allowed for the rapid development of novel, more 
patient-friendly and diagnostically competent investigation techniques dedicated to this 
particular GI segment. 
Videocapsule endoscopies (VCE), along with balloon (single or double) enteroscopy are 
currently considered the two most valuable tools available to the gastroenterologist. (Iddan 
et al, 2000; Swain P, 2003) 
The VCE system is currently the most widespread investigation technique for the small 
bowel, due to its convenience of use and slightly better affordability. It has been tested in a 
large number of studies, being compared to all other investigatory techniques, currently a 
large number of high-impact papers existing on the subject. It is estimated that over one 
million such devices have been swallowed over the course of almost ten years since its first 
introduction on a global scale.  
2. Historical background  
A miniaturized device, small enough for a human to swallow, that could reach all segments 
of the digestive tracts was imagined thirty years ago, in 1981, by Gavriel Iddan (considered 
the inventor of capsule endoscopy). He was the first to conceive a miniature wireless 
camera-enabled device that could reach the difficult segments of the digestive tract, 
otherwise accessible at that time only by means of small-bowel follow-through (SBFT). The 
technology of that time did not however permit for such miniaturized devices which could 
complete this task; hence, production was stopped for nearly 20 years. In 1994, he filled a 
patent for such a small wireless device equipped with a videocamera and capable of 
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1. Introduction  
The most difficult to examine segment of the digestive tract is the small bowel. However, 
examining the distal portions that follow the duodeno-jejunal junction is vital when trying 
to diagnose an important number of pathologies, most of them with vital implications for 
the patient. 
Until recently, standard diagnostic techniques were limited to radiological barium-enhanced 
investigations, “push-enteroscopy” and intraoperatory enteroscopy, selective arteriography, 
scintigraphy or computer tomography. All these methods were either too intrusive, such as 
the case with intraoperatory enteroscopy, or did not provide sufficient data for an accurate 
diagnostic.  
Technological progresses in recent years allowed for the rapid development of novel, more 
patient-friendly and diagnostically competent investigation techniques dedicated to this 
particular GI segment. 
Videocapsule endoscopies (VCE), along with balloon (single or double) enteroscopy are 
currently considered the two most valuable tools available to the gastroenterologist. (Iddan 
et al, 2000; Swain P, 2003) 
The VCE system is currently the most widespread investigation technique for the small 
bowel, due to its convenience of use and slightly better affordability. It has been tested in a 
large number of studies, being compared to all other investigatory techniques, currently a 
large number of high-impact papers existing on the subject. It is estimated that over one 
million such devices have been swallowed over the course of almost ten years since its first 
introduction on a global scale.  
2. Historical background  
A miniaturized device, small enough for a human to swallow, that could reach all segments 
of the digestive tracts was imagined thirty years ago, in 1981, by Gavriel Iddan (considered 
the inventor of capsule endoscopy). He was the first to conceive a miniature wireless 
camera-enabled device that could reach the difficult segments of the digestive tract, 
otherwise accessible at that time only by means of small-bowel follow-through (SBFT). The 
technology of that time did not however permit for such miniaturized devices which could 
complete this task; hence, production was stopped for nearly 20 years. In 1994, he filled a 
patent for such a small wireless device equipped with a videocamera and capable of 
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transiting the gastrointestinal tract, while similar results being reported by Gong and Swain 
in the same year (Gong Fet al, 1994) and in 1996 (Swain C et al, 1996). 
The initial blueprint of the system remained mostly unchanged since conception, and 
consists of three main elements: a small, swallowable device equipped with a lens system, a 
recording sensor, an integrated circuit and a wireless antenna; a recording device equipped 
with skin-mounted sensors that receives and stores the video data, and a computer interface 
equipped with a specialized software application, necessary for later interpretation of these 
recordings. (Jeremy G et al, 2007; Koulaouzidis A et al, 2009) 
The technology progressed rapidly over the following years, and after almost 20 years since 
the first time that the idea emerged, the first prototype was produced by Given Imaging of 
Yokneam, Israel, in 1999. The device received FDA (U.S. Food and Drug Administration) 
approval in 2001, being the first such device to receive official accreditation for human use. 
This was the birth of the first videocapsule endoscopy system (VCE for short), and was 
entitled Pillcam® M2A. A series of more specialized devices for different anatomical regions 
were later introduces, such as the Pillcam® ESO (for the esophagus) and Pillcam® COLON, 
which is currently used in Europe and Israel. A specialized capsule for investigating the 
small bowel (entitled Pillcam® SB) followed the more general-use device M2A, and the ESO 
and Colon devices already received a generation update.  
Other VCE platforms became available, such as the one produced by Olympus Medical 
Systems Corp, Japan, the Chinese company Chongqing Jinshan Science and Technology, 
and the Korean company IntroMedic.  
Currently, the main differences between these platforms consist in different sensor types 
used for video recording, battery operating time and the complexity and features of the 
interpretation software. 
3. Technical characteristics 
As we noted earlier, technical constrains delayed the production of VCE systems. 
Complementary metal oxide semiconductor (CMOS) imaging sensors, small and affordable in 
price, became available in the late 1990s, the introduction of application-specific integrated 
circuits (ASIC) chips allowed for rapid data integration. Light emitting diode (LED) light 
sources became widespread, and all these components made good use of a small enough 
battery that could be integrated in the pill-shaped concept a videocapsule required. Recording 
devices could be smaller and lighter, larger capacity magnetic hard drives allowed for 
extensive storage space necessary for the several hours of recording time, and personal 
computing sufficiently evolved, allowing the production of software capable of displaying and 
analyzing the video files resulting from VCE recordings. (Vere CC et al, 2008) 
The videocapsule itself is basically an ingestible cylindrical device measuring 26x11 mm and 
weighting 3.7 grams. The on-board CMOS sensor captures two images per second. The 
device also contains an optical system, a LED light source, an ASIC control chip, a RFID 
antenna system, all these circuits being powered by a battery pack with a median lifespan of 
approximately 8 hours, which is considered to be the average duration of a full GI transit. 
The resulting video contains well over 50 000 images for one test. Recent generations 
improved the lightning capabilities of the LED system, with advanced light controls, as well 
as a wider lens system, offering 156° viewing angles (versus only 140° in the old systems. 
The improved optics also provides 1:8 magnifications and an estimated 1-30 mm depth of 
view. 
 





Fig. 1. (a) – Videocapsule. The transparent optical dome hosts the camera lens system  
and the six LEDs used for illumination. The battery pack, circuit board and 
communication antenna are protected inside the body. (b) – Videocapsule in its original 
plastic container. Once removed, the capsule activates and starts sending images to the 
recording device. 
The Olympus version, the EndoCapsule for the small bowel, is equipped with a CCD 
(Charge Coupled Device) sensor for image acquisition. Its dimensions are basically the same 
(26x11 mm), weighting 3.8 grams and having a field of view of 145°, while providing a 
similar battery life of 8 hours. The EndoCapsule received clinical approval in the United 
States, parts of Europe and Japan. 
MiroCam®, the device produced by the Korean company Intromedic, records three frames 
per second (compared to only two frames on other devices), using a high resolution 
(320x320 pixels) CCD  image sensor, and has an improved battery pack capable of 
sustaining 11 hours of recording. The battery life is also improved by the different 
transmission method, which uses the human body as a conductive medium for sending data 
to the attached electrodes. The higher battery life, as well as different transmission method, 
may allow for a type of „second-look” enteroscopy to be performed by consecutively 
ingesting the two VCE systems. A recent pilot study however did not provide statistically 
significant data in this respect. (Kim HM et al, 2010) 
This system is not widely spread and clinical data is scarce on the actual upgrades in terms 
of patient management, although the extended recording time might make it more suitable 
for localizing distal lesions, which might be missed by other VCE systems due to incomplete 
examinations caused by lower battery life or patient-related factors such as higher transit 
times or longer GI tracts. 
 
New Techniques in Gastrointestinal Endoscopy 
 
126 
transiting the gastrointestinal tract, while similar results being reported by Gong and Swain 
in the same year (Gong Fet al, 1994) and in 1996 (Swain C et al, 1996). 
The initial blueprint of the system remained mostly unchanged since conception, and 
consists of three main elements: a small, swallowable device equipped with a lens system, a 
recording sensor, an integrated circuit and a wireless antenna; a recording device equipped 
with skin-mounted sensors that receives and stores the video data, and a computer interface 
equipped with a specialized software application, necessary for later interpretation of these 
recordings. (Jeremy G et al, 2007; Koulaouzidis A et al, 2009) 
The technology progressed rapidly over the following years, and after almost 20 years since 
the first time that the idea emerged, the first prototype was produced by Given Imaging of 
Yokneam, Israel, in 1999. The device received FDA (U.S. Food and Drug Administration) 
approval in 2001, being the first such device to receive official accreditation for human use. 
This was the birth of the first videocapsule endoscopy system (VCE for short), and was 
entitled Pillcam® M2A. A series of more specialized devices for different anatomical regions 
were later introduces, such as the Pillcam® ESO (for the esophagus) and Pillcam® COLON, 
which is currently used in Europe and Israel. A specialized capsule for investigating the 
small bowel (entitled Pillcam® SB) followed the more general-use device M2A, and the ESO 
and Colon devices already received a generation update.  
Other VCE platforms became available, such as the one produced by Olympus Medical 
Systems Corp, Japan, the Chinese company Chongqing Jinshan Science and Technology, 
and the Korean company IntroMedic.  
Currently, the main differences between these platforms consist in different sensor types 
used for video recording, battery operating time and the complexity and features of the 
interpretation software. 
3. Technical characteristics 
As we noted earlier, technical constrains delayed the production of VCE systems. 
Complementary metal oxide semiconductor (CMOS) imaging sensors, small and affordable in 
price, became available in the late 1990s, the introduction of application-specific integrated 
circuits (ASIC) chips allowed for rapid data integration. Light emitting diode (LED) light 
sources became widespread, and all these components made good use of a small enough 
battery that could be integrated in the pill-shaped concept a videocapsule required. Recording 
devices could be smaller and lighter, larger capacity magnetic hard drives allowed for 
extensive storage space necessary for the several hours of recording time, and personal 
computing sufficiently evolved, allowing the production of software capable of displaying and 
analyzing the video files resulting from VCE recordings. (Vere CC et al, 2008) 
The videocapsule itself is basically an ingestible cylindrical device measuring 26x11 mm and 
weighting 3.7 grams. The on-board CMOS sensor captures two images per second. The 
device also contains an optical system, a LED light source, an ASIC control chip, a RFID 
antenna system, all these circuits being powered by a battery pack with a median lifespan of 
approximately 8 hours, which is considered to be the average duration of a full GI transit. 
The resulting video contains well over 50 000 images for one test. Recent generations 
improved the lightning capabilities of the LED system, with advanced light controls, as well 
as a wider lens system, offering 156° viewing angles (versus only 140° in the old systems. 
The improved optics also provides 1:8 magnifications and an estimated 1-30 mm depth of 
view. 
 





Fig. 1. (a) – Videocapsule. The transparent optical dome hosts the camera lens system  
and the six LEDs used for illumination. The battery pack, circuit board and 
communication antenna are protected inside the body. (b) – Videocapsule in its original 
plastic container. Once removed, the capsule activates and starts sending images to the 
recording device. 
The Olympus version, the EndoCapsule for the small bowel, is equipped with a CCD 
(Charge Coupled Device) sensor for image acquisition. Its dimensions are basically the same 
(26x11 mm), weighting 3.8 grams and having a field of view of 145°, while providing a 
similar battery life of 8 hours. The EndoCapsule received clinical approval in the United 
States, parts of Europe and Japan. 
MiroCam®, the device produced by the Korean company Intromedic, records three frames 
per second (compared to only two frames on other devices), using a high resolution 
(320x320 pixels) CCD  image sensor, and has an improved battery pack capable of 
sustaining 11 hours of recording. The battery life is also improved by the different 
transmission method, which uses the human body as a conductive medium for sending data 
to the attached electrodes. The higher battery life, as well as different transmission method, 
may allow for a type of „second-look” enteroscopy to be performed by consecutively 
ingesting the two VCE systems. A recent pilot study however did not provide statistically 
significant data in this respect. (Kim HM et al, 2010) 
This system is not widely spread and clinical data is scarce on the actual upgrades in terms 
of patient management, although the extended recording time might make it more suitable 
for localizing distal lesions, which might be missed by other VCE systems due to incomplete 
examinations caused by lower battery life or patient-related factors such as higher transit 
times or longer GI tracts. 
 




Fig. 2. The videocapsule in detail. 
Both the CMOS and the CCD imaging sensor offer excellent picture quality of the GI tract. 
While the CCD does produce the highest level of signal with the least amount of signal 
noise, the CMOS images get more uniform illumination at theoretical higher frame rates, 
due to the decreased size and dedicated ASIC imager chips enabled with power 
management algorithms and dynamic light and exposure adjustments. 
The second part of the wireless endoscopic capsule platform is represented by the lightweight 
data recorder unit, attached to the patients’ body by a belt, designed not only to support it, but 
also to attenuate radio signal loss. This receiver is equipped with a set of eight external 
adhesive electrodes that are placed on the lower chest and abdomen in precise locations. These 
serve as receivers for the radio frequency communication coming from the wireless capsule, 
while the recording unit itself, equipped with a magnetic disk drive and an appropriate 
hardware interface receives the signals, processes and stores them as image clips. The recorder 
has a rechargeable battery pack that ensures eight to ten hours of continuous functioning.  
 
 
Fig. 3. Recording unit with the receiving electrodes. The videocapsule itself, as well as the 
initial cradle are pictured above. 
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It is possible to review the live recording coming from the wireless videocapsule using an 
USB-connected viewing device equipped with a small LCD screen. It is also possible to 
approximate the capsule location by using a triangulation method that takes into account 
the receiving electrode, knowing that the capsule itself should be in the immediate vicinity 
of the active pad. This is extremely important, as prokinetics can be administered to ensure 
faster passage of the videocapsule through the pylorus, thus reducing the possibility of an 
incomplete enteroscopies due to gastric retention. (Qureshi Wa et al, 2005; Souquet JC et al, 
2005) 
It is notable that the MiroCam system developed in Korea uses a different system to 
transmit data, which, as noted above, improves battery performance of the video capsule, as 
well as making the use of both systems in parallel possible. (Delvaux M et al, 2008) 
Initially, protocols for capsule endoscopy excluded its use in patients with cardiac 
pacemakers, implantable defibrillators or other vital medical equipment, due to possible 
interference between the wireless capsule and these devices. As a large number of cardiac 
pacemakers and implantable defibrillators are available on the market today, it is practically 
impossible to test every single one, hence caution is always advised when dealing with this 
type of patients. Even though the majority of hospital protocols still enforce this regulation, 
several recent trials provided conclusive evidence that no significant interference actually 
occurs. Several reports cite blank periods when the receiving electrode was the one near the 
location of the patient’s pacemaker, lasting from 20 to 30 minutes.  This problem was 
resolved by adjusting the position of the electrode in relation to the pacemaking unit. 
(Gravina AG et al, 2010) No malfunctioning of the pacemaking units were recorded in the 
case report presented by Gravina et al, as well as several other studies.  (Gravina A.G et al 
2010; Guyomar Y. et al, 2004; Leighton J. A. et al, 2004; Payeras G et al, 2005;  Dirks M. H. et 
al, 2008; Bandorski D. et al, 2008; Daas AY et al, 2008) 
The reader station consists of a base unit that is connected to a workstation computer, 
equipped with specialized software that can receive and display in a specific user interface 
the recordings. The software installed on this computer receives each image recorded by CE 
and assembles a movie, in a proprietary format specific to each manufacturer that can only 
be read by its designed software equipment. Each recording device uses different 
compression algorithms; however the end result is a series of uncompressed images that can 
be fully exploited by the analyzer. The workstation software also applies various algorithms 
for image enhancement and land marking, later used by the examiner in reviewing a 
recording. Movies are usually stored on Data Versatile Disks (DVDs) or even high capacity 
universal-serial bus (USB) magnetic drives. Flash memory keys are usually used to transfer 
the data between the workstation and any computer or laptop which has the viewing 
software installed. 
The viewing software is one of the most updated components of the WCE platform, 
suffering continuous upgrades that come to help the physician in interpreting the CE 
recordings and reducing viewing time.  (Jeremy et al, 2007) 
It is possible to scroll faster or choose the exact moment from which to begin viewing, as 
with any recorded video material. The visual time bar also contains a color-grading 
component which can be used by the reviewer to distinguish between each type of mucosa, 
pertinent to one particular GI segment. All software programs also have the ability to extract 
single images from a video, or cut and edit video segments. The viewing speed may vary 
from 5-40 to up to 80 frames per second, depending on the viewed segment and the 
physician’s experience with CE recordings. Usual reviewing frame rates are between 12 and 
24 frames per second for small bowel investigations. (Gay G et al, 2006) 
 




Fig. 2. The videocapsule in detail. 
Both the CMOS and the CCD imaging sensor offer excellent picture quality of the GI tract. 
While the CCD does produce the highest level of signal with the least amount of signal 
noise, the CMOS images get more uniform illumination at theoretical higher frame rates, 
due to the decreased size and dedicated ASIC imager chips enabled with power 
management algorithms and dynamic light and exposure adjustments. 
The second part of the wireless endoscopic capsule platform is represented by the lightweight 
data recorder unit, attached to the patients’ body by a belt, designed not only to support it, but 
also to attenuate radio signal loss. This receiver is equipped with a set of eight external 
adhesive electrodes that are placed on the lower chest and abdomen in precise locations. These 
serve as receivers for the radio frequency communication coming from the wireless capsule, 
while the recording unit itself, equipped with a magnetic disk drive and an appropriate 
hardware interface receives the signals, processes and stores them as image clips. The recorder 
has a rechargeable battery pack that ensures eight to ten hours of continuous functioning.  
 
 
Fig. 3. Recording unit with the receiving electrodes. The videocapsule itself, as well as the 
initial cradle are pictured above. 
 
Videocapsule Endoscopy of the Small Bowel 
 
129 
It is possible to review the live recording coming from the wireless videocapsule using an 
USB-connected viewing device equipped with a small LCD screen. It is also possible to 
approximate the capsule location by using a triangulation method that takes into account 
the receiving electrode, knowing that the capsule itself should be in the immediate vicinity 
of the active pad. This is extremely important, as prokinetics can be administered to ensure 
faster passage of the videocapsule through the pylorus, thus reducing the possibility of an 
incomplete enteroscopies due to gastric retention. (Qureshi Wa et al, 2005; Souquet JC et al, 
2005) 
It is notable that the MiroCam system developed in Korea uses a different system to 
transmit data, which, as noted above, improves battery performance of the video capsule, as 
well as making the use of both systems in parallel possible. (Delvaux M et al, 2008) 
Initially, protocols for capsule endoscopy excluded its use in patients with cardiac 
pacemakers, implantable defibrillators or other vital medical equipment, due to possible 
interference between the wireless capsule and these devices. As a large number of cardiac 
pacemakers and implantable defibrillators are available on the market today, it is practically 
impossible to test every single one, hence caution is always advised when dealing with this 
type of patients. Even though the majority of hospital protocols still enforce this regulation, 
several recent trials provided conclusive evidence that no significant interference actually 
occurs. Several reports cite blank periods when the receiving electrode was the one near the 
location of the patient’s pacemaker, lasting from 20 to 30 minutes.  This problem was 
resolved by adjusting the position of the electrode in relation to the pacemaking unit. 
(Gravina AG et al, 2010) No malfunctioning of the pacemaking units were recorded in the 
case report presented by Gravina et al, as well as several other studies.  (Gravina A.G et al 
2010; Guyomar Y. et al, 2004; Leighton J. A. et al, 2004; Payeras G et al, 2005;  Dirks M. H. et 
al, 2008; Bandorski D. et al, 2008; Daas AY et al, 2008) 
The reader station consists of a base unit that is connected to a workstation computer, 
equipped with specialized software that can receive and display in a specific user interface 
the recordings. The software installed on this computer receives each image recorded by CE 
and assembles a movie, in a proprietary format specific to each manufacturer that can only 
be read by its designed software equipment. Each recording device uses different 
compression algorithms; however the end result is a series of uncompressed images that can 
be fully exploited by the analyzer. The workstation software also applies various algorithms 
for image enhancement and land marking, later used by the examiner in reviewing a 
recording. Movies are usually stored on Data Versatile Disks (DVDs) or even high capacity 
universal-serial bus (USB) magnetic drives. Flash memory keys are usually used to transfer 
the data between the workstation and any computer or laptop which has the viewing 
software installed. 
The viewing software is one of the most updated components of the WCE platform, 
suffering continuous upgrades that come to help the physician in interpreting the CE 
recordings and reducing viewing time.  (Jeremy et al, 2007) 
It is possible to scroll faster or choose the exact moment from which to begin viewing, as 
with any recorded video material. The visual time bar also contains a color-grading 
component which can be used by the reviewer to distinguish between each type of mucosa, 
pertinent to one particular GI segment. All software programs also have the ability to extract 
single images from a video, or cut and edit video segments. The viewing speed may vary 
from 5-40 to up to 80 frames per second, depending on the viewed segment and the 
physician’s experience with CE recordings. Usual reviewing frame rates are between 12 and 
24 frames per second for small bowel investigations. (Gay G et al, 2006) 
 




Fig. 4. Videocapsule software interface. 
It is also possible to view thumbnail previews of interest areas of the GI tract, giving the 
examining physician an overview, while cutting down on viewing time. Features such as the 
QuickView function, provided by both the Given and the Olympus software, or similar 
tools, are designed to reduce reading time, however are associated with greater diagnostic 
bias, hence being recommended only when Inflammatory bowel disease (IBD) is suspected, 
or prior to a full examination, for previewing purposes. (Westerhof J et al, 2009)  
Other useful additions to the viewing software are represented by the inclusion of the Fiji 
intelligent color enhancement (FICE) system, an inflammation (Lewis) scoring system, as 
well as a reference atlas to come to the aid of the interpreter.(Eliakim R et al, 2010)   
As a whole recording may take up to eight hours hence all software provided by companies 
producing CE systems offer a wide variety of specialized tools that help eliminating human 
error, as well as making the interest areas easier to spot. One such tool is the red color 
detection component, which highlights the images containing traces of red color, thus 
pinpointing the location of possible OGIBs, telangiectasia etc. According to some studies this 
function gives a high rate of false positives; however it remains extremely useful in 
detecting intestinal bleedings. (Signorelli C et al, 2005; D’Halluin PN et al, 2005) 
The time spent analyzing the video recordings varies from one to three-four hours, 
depending on the experience of the clinician, as well as the suspected pathology. Generally, 
viewing time for the small bowel varies between one and two hours. Many factors related to 
the existing conditions in the examining room may influence the interpretation of these 
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results, such as viewers’ distance from the computer screen, position and number of light 
sources, as well as factors linked to the examiner, such as reading speed, attention level and 
level of specialized training. Several studies compared reading abilities of specialized 
gastroenterologists versus trained physicians as well as gastroenterology nurses. (Reena S et 
al, 2007; Hoeroldt B.S. et al, 2008) The general consensus was that interpretation of these 
recordings does not pose extreme difficulties to any examiner, however, specialized training 
should be considered for all individuals performing this task. (Cave DR, 2004) 
Internet-based reading services currently exist, where several institutes provide on-line help 
with the analysis of the recordings, through a web-based interface. Specialized teams of 
physicians offer their experience, thus reducing the risk of overviewing essential diagnostic 
signs in an investigation. 
4. Examining technique 
4.1 Patient consent 
Even though it is a minimal invasive procedure, CE requires prior informed consent given 
by the patient. The performing physician has to fully explain the procedure, all risks 
deriving from it, as well as stating all potential complications, such as capsule retention, 
inconclusive findings or capsule aspiration. It should be noted that magnetic resonance 
imaging (MRI) is an absolute contraindication until the capsule passed the GI tract and its 
exit is confirmed. (Rondonotti E et al, 2005; Koulaouzidis A et al, 2009) The existence of 
cardiac pacemakers or implanted defibrillators may represent contraindications for capsule 
use, however, as noted earlier, recent consensus policies and a number of studies, confirm 
that the functioning of these devices is not influenced by CE. Caution is however advised, as 
a high number of different devices exist and not all have been tested. 
4.2 Bowel preparation 
According to existing literature, there is no standard bowel preparation for CE examining. 
(Melmed Gy et al, 2005) All patients are required to fast 10-12 hours prior to the 
investigation, and specific medication, such as iron tablets, opiates, and antimony drugs 
should be stopped two-three days prior to the investigation. 
Some studies recommend the use of prokinetic solutions which should accelerate intestinal 
transit, while claiming to improve image clarity and diagnostic accuracy. (Viazis N et al, 2004; 
Mylonaki M et al, 2003) when compared to clear liquids alone. (Niv Y et al, 2004; Cave D et al, 
2004; Ning D et al, 2005) However, a number of recent studies and meta-analyses concluded 
that bowel preparation is not necessary, as it does not improve the image quality or diagnostic 
rate of CE investigations. This conclusion is also supported by the latest consensus reports (de 
Franchis R et al, 2005) as well as by official recommendations given by several major capsule-
producing companies. The polyethylene glycol (PEG) electrolyte purgative solution is widely 
used for bowel preparation, as it was proven to improve the rate of complete procedures, 
(Triantafyllou K et al, 2010; Rokkas T et al, 2009) along with prokinetics (metoclopramid, 
domperidone or tegaserod), while not significantly influencing the quality of the results in 
small bowel investigations. The majority of UK clinics do not use prokinetics in daily practice. 
(Lapalus MG et al, 2008; Ben-Soussan E et al, 2005; Postgate A et al, 2009) 
4.3 Steps of the procedure 
Electrodes are placed with the patient in supine position on a bed or a bench, except obese 
patients on which they can be placed while standing. The recording device should have the 
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4.3 Steps of the procedure 
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patients on which they can be placed while standing. The recording device should have the 
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battery fully charged and all necessary connections with the sensor array properly 
established; afterwards the device is attached using the belt. 
The capsule is activated automatically once it is removed from its containing blister, after 
making sure that the expiration date is not overdue. The patient swallows the camera pill 
and the receiver starts recording as soon as it receives the first signal from the capsule.  
In cases when swallowing difficulties may interfere with the procedure, or when the device 
has failed to enter the small bowel despite prokinetic preparations, an endoscope equipped 
with a Roth® net or a special delivery device such as the AdvanCE® may be used. 
Once the capsule reached the small intestine, patients are free to move around, or in some 
cases even leave the hospital for a few hours. 
4.4 Capsule retention and the patency capsule 
One major concern when using CE is capsule retention at any level of the gastrointestinal 
(GI) tract. Besides the major cause of retention, obstruction, which also constitutes a major 
contraindication of this procedure, these situations can occur in stricturing Crohn’s disease 
patients, or in some obscure/occult GI bleedings (OGIBs).  
This problem can be prevented by using standard radiology and/or a special patency 
capsule, such as the Agile® patency capsule developed by Given Imaging. The patency 
system received a recent update. The second generation device now used consists of a 
central 13 x 3 mm radiofrequency identifiable tag (RFID), an antenna system and a magnet. 
A battery is not necessary for operating the device. It can receive electromagnetic waves at a 
frequency of 128 KHz, while emitting at 64 KHz. It also contains a small barium pellet which 
makes it trackable under a fluoroscopic screen. The device is placed in a lactose shell which 
completely dissolves once inside the GI tract and a plastic coating protects the device from 
digestive fluids. Excretion can be confirmed by X-ray examination or through the portable 
scanner which detects the electromagnetic signal it emits. If the patency capsule is excreted 
in under 30 hours of ingestion, the patient is viable for CE investigation. 
5. Indications and contraindications for Capsule Endoscopy 
The current list of indications for the VCE include a number of different pathologies, being 
somewhat limited by concomitant conditions which may be found in particular patients. 
As such, possible indications include, but are not restricted to: 
 Obscure, occult or manifest gastrointestinal bleedings with negative 
endoscopy/colonoscopy results; 
 Feriprive anemia of unknown cause; 
 Suspected small bowel Crohn’s disease; 
 Early evaluation of small bowel Crohn’s disease recurrence after surgical treatment; 
 Differential diagnosis of undetermined colitis; 
 Refractory or recurrent celiac disease despite treatment; Selected cases of intestinal 
malabosrbition with inconclusive conventional test results; 
 Complications of non-steroidal anti-inflammatory drug treatment; 
 Screening and surveillance of polyps in familial polyposis syndromes;  
 Suspected tumors of the small bowel;  
 Gastrointestinal „graft versus host” symptoms with GI interest; 
 Small bowel transplant; 
Several contraindications are cited in literature, some of them being relative while other 
clearly excluding the use of the device. 
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 Swallowing disorders (relative contraindication, as the capsule can be inserted with 
devices cited above); 
 Patients with implanted defibrillators/cardiac pacemakers, or who are to be subjected 
to RMI investigations before capsule passage completion (relative contraindication, as 
noted above); 
 Pregnant patients (tolerance insufficiencies); 
 Altered peristalsis (diabetic gastro paresis); 
 Gastrointestinal fistula; 
 Previous major surgical interventions in the abdominal/pelvic areas; 
 Suspicion of stenosis which could lead to capsule retention. 
6. Diagnostic yield, comparison with other investigations, and impact on 
clinical outcome 
A large number of studies exist on the diagnostic capabilities of this technology. The 
diagnostic yield of capsule endoscopy varies depending on the number of patients included 
in these studies, and several meta-analyses deal with the impact it has on disease 
progression and outcome. (Pennazio M et al, 2004; Appleyard MN et al, 2006; Gupta R et al, 
2006; Ersoy O et al, 2006; Lewis BS et al, 2002; Appleyard M et al, 2001; Rastogi A et al, 2004) 
The indications for CE investigations are somewhat limited, and insufficient evidence 






VCE may be used as the first investigation for OGIB after 
negative endoscopies (upper and lower) 2b B 
Recommended in patients with unexplained iron-deficiency 
anemia 2b B 
Crohn’s disease 
Most indicated procedure for evaluation of small-bowel mucosal 
lesions specific to Crohn’s disease 3a B 
Small bowel imaging or patency capsules should be used to 
eliminate the risk of capsule retention in Crohn’s Disease 2b B 
NSAIDs treatment should be stopped two months prior to CE 2a B 
Celiac disease 
High diagnostic yield in Celiac disease patients 2b B 
Refractory or complicated celiac disease patients should receive 
CE 2b B 
Small bowel tumors / Polyposis
Should be considered as first line of screening in patients with 
Peutz-Jeghers syndrome 2b B 
CE indicated in familial adenomatous polyps patients with 
duodenal polyps 2b B 
Influenced the therapeutic work-up of small-bowel tumors 3b B 
Table 1. The 2009 European Society of Gastrointestinal Endoscopy (ESGE) updated 
information on the indications for video capsule endoscopy  (adapted from Ladas SD et al, 
2009) 
 
New Techniques in Gastrointestinal Endoscopy 
 
132 
battery fully charged and all necessary connections with the sensor array properly 
established; afterwards the device is attached using the belt. 
The capsule is activated automatically once it is removed from its containing blister, after 
making sure that the expiration date is not overdue. The patient swallows the camera pill 
and the receiver starts recording as soon as it receives the first signal from the capsule.  
In cases when swallowing difficulties may interfere with the procedure, or when the device 
has failed to enter the small bowel despite prokinetic preparations, an endoscope equipped 
with a Roth® net or a special delivery device such as the AdvanCE® may be used. 
Once the capsule reached the small intestine, patients are free to move around, or in some 
cases even leave the hospital for a few hours. 
4.4 Capsule retention and the patency capsule 
One major concern when using CE is capsule retention at any level of the gastrointestinal 
(GI) tract. Besides the major cause of retention, obstruction, which also constitutes a major 
contraindication of this procedure, these situations can occur in stricturing Crohn’s disease 
patients, or in some obscure/occult GI bleedings (OGIBs).  
This problem can be prevented by using standard radiology and/or a special patency 
capsule, such as the Agile® patency capsule developed by Given Imaging. The patency 
system received a recent update. The second generation device now used consists of a 
central 13 x 3 mm radiofrequency identifiable tag (RFID), an antenna system and a magnet. 
A battery is not necessary for operating the device. It can receive electromagnetic waves at a 
frequency of 128 KHz, while emitting at 64 KHz. It also contains a small barium pellet which 
makes it trackable under a fluoroscopic screen. The device is placed in a lactose shell which 
completely dissolves once inside the GI tract and a plastic coating protects the device from 
digestive fluids. Excretion can be confirmed by X-ray examination or through the portable 
scanner which detects the electromagnetic signal it emits. If the patency capsule is excreted 
in under 30 hours of ingestion, the patient is viable for CE investigation. 
5. Indications and contraindications for Capsule Endoscopy 
The current list of indications for the VCE include a number of different pathologies, being 
somewhat limited by concomitant conditions which may be found in particular patients. 
As such, possible indications include, but are not restricted to: 
 Obscure, occult or manifest gastrointestinal bleedings with negative 
endoscopy/colonoscopy results; 
 Feriprive anemia of unknown cause; 
 Suspected small bowel Crohn’s disease; 
 Early evaluation of small bowel Crohn’s disease recurrence after surgical treatment; 
 Differential diagnosis of undetermined colitis; 
 Refractory or recurrent celiac disease despite treatment; Selected cases of intestinal 
malabosrbition with inconclusive conventional test results; 
 Complications of non-steroidal anti-inflammatory drug treatment; 
 Screening and surveillance of polyps in familial polyposis syndromes;  
 Suspected tumors of the small bowel;  
 Gastrointestinal „graft versus host” symptoms with GI interest; 
 Small bowel transplant; 
Several contraindications are cited in literature, some of them being relative while other 
clearly excluding the use of the device. 
 
Videocapsule Endoscopy of the Small Bowel 
 
133 
 Swallowing disorders (relative contraindication, as the capsule can be inserted with 
devices cited above); 
 Patients with implanted defibrillators/cardiac pacemakers, or who are to be subjected 
to RMI investigations before capsule passage completion (relative contraindication, as 
noted above); 
 Pregnant patients (tolerance insufficiencies); 
 Altered peristalsis (diabetic gastro paresis); 
 Gastrointestinal fistula; 
 Previous major surgical interventions in the abdominal/pelvic areas; 
 Suspicion of stenosis which could lead to capsule retention. 
6. Diagnostic yield, comparison with other investigations, and impact on 
clinical outcome 
A large number of studies exist on the diagnostic capabilities of this technology. The 
diagnostic yield of capsule endoscopy varies depending on the number of patients included 
in these studies, and several meta-analyses deal with the impact it has on disease 
progression and outcome. (Pennazio M et al, 2004; Appleyard MN et al, 2006; Gupta R et al, 
2006; Ersoy O et al, 2006; Lewis BS et al, 2002; Appleyard M et al, 2001; Rastogi A et al, 2004) 
The indications for CE investigations are somewhat limited, and insufficient evidence 






VCE may be used as the first investigation for OGIB after 
negative endoscopies (upper and lower) 2b B 
Recommended in patients with unexplained iron-deficiency 
anemia 2b B 
Crohn’s disease 
Most indicated procedure for evaluation of small-bowel mucosal 
lesions specific to Crohn’s disease 3a B 
Small bowel imaging or patency capsules should be used to 
eliminate the risk of capsule retention in Crohn’s Disease 2b B 
NSAIDs treatment should be stopped two months prior to CE 2a B 
Celiac disease 
High diagnostic yield in Celiac disease patients 2b B 
Refractory or complicated celiac disease patients should receive 
CE 2b B 
Small bowel tumors / Polyposis
Should be considered as first line of screening in patients with 
Peutz-Jeghers syndrome 2b B 
CE indicated in familial adenomatous polyps patients with 
duodenal polyps 2b B 
Influenced the therapeutic work-up of small-bowel tumors 3b B 
Table 1. The 2009 European Society of Gastrointestinal Endoscopy (ESGE) updated 
information on the indications for video capsule endoscopy  (adapted from Ladas SD et al, 
2009) 
 
New Techniques in Gastrointestinal Endoscopy 
 
134 
6.1 Capsule endoscopy in obscure gastrointestinal bleedings 
Subgroup analysis showed that if patients suffer from ongoing GI bleedings, the diagnostic 
yield reaches as high as 92.3%, however it sharply descends to 44.2% in obscure occult 
bleedings. (Gupta R & Reddy DN, 2007) 
The International Consensus on Capsule endoscopy (2005 and 2006) recommend that the 
procedure should be performed within the first two weeks following patient admission 
(Pennazio M et al, 2005), as it has been proven that early use dramatically increases the 
chances of discovery of OGIBs. (Bresci G et al, 2005) Figure XX presents the suggested 
diagnostic algorithm for OGIBs, which recommends early use of CE after negative upper 
and lower endoscopy findings. 
 
 
Fig. 5. Proposed algorithm for the diagnosis and management of OGIBs. ICCE Consensus 
for obscure gastrointestinal bleedings, 2005 
The large majority of studies discuss the changes in patient management after capsule 
investigation, however failing to provide accurate information on the clinical outcome. In 
the case of OGIBs, a positive outcome is represented by successfully identifying the cause of 
bleeding and efficiently stopping it while preventing recurrences. Compean et al (2007) 
referred to 40 patient patients with chronic OGIB investigated by CE between 2003 and 2005. 
They assessed the impact of therapeutic interventions on the recurrence of OGIBs, following 
positive CE findings. The study found a positive correlation between the success rate of CE 
and favorable clinical outcome, recurrent bleedings being less likely in these patients. 
Pennazio et al (2004) followed a group of 56 patients over the course of 18 months, 
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determining that 85.9% of the patients with ongoing overt GI bleedings had complete 
resolution, compared with only 69.2% of the patients with current OGIBs and 41.4% of 
patients with prior episodes of OGIBs. Its conclusion was that a direct correlation between 
the time when CE is performed and the status of the GI bleeding exists, and is extremely 
important when assessing clinical outcome. 
A series of large multicentric studies reported changes in the management of OGIB patients 
after capsule endoscopy. Albert et al (2005) reported that 66% of a total of 247 included 
patients were recommended a certain procedure or followed a specific treatment after 
positive diagnostic by using CE. Other studies report that nearly 70% of all positively-
identified patients received adequate treatment. Contradictory results were reported 
however by Rastogi et al (2004), with positive clinical outcome in only 16% of all patients 
considered in their study. Positive and negative predictive values (PPV and NPV) of CE 
were reported to be extremely high in various studies. Delvaux and his team (2004) after a 
one-year follow-up of 44 patients, found a 94.% PPV and 100% NPV in CE patients. In his 
study of 100 consecutive cases, Pennazio et al (2004) reported a PPV of 97%, and 82.6% NPV. 
A large retrospective study performed in the Mayo Clinic proved that there was a 
significant decrease in hospitalization time for all OGIB patients after CE was performed. 
Also, it was noted that less investigations were performed, and that transfusional needs 
were reduced after positive CE investigations. 
Each study included variable population groups and lacked standardized management 
specific to different medical centers. This accounts for the relatively variable outcome and 
different diagnostic yields reported. (Lai LH et al, 2006; Carey EJ et al, 2007) More meta-
analyses and large populational studies are needed in order to give a final verdict on the 
efficacy of this method; however it is clear that both clinical outcome and disease 
management is influenced by CE in a positive manner. 
High diagnostic yield and ease of use make it a prime candidate in early diagnosis and 
screening programs for OGIBs. 
Since its introduction in 2000, the main concern with capsule endoscopy was to determine 
the advantages it provides over other more invasive existing techniques. 
The vast majority of published literature compared CE to PE, DBE and barium follow-
through. Wireless capsule performed better than radiation techniques and surpassed PE in 
diagnostic capabilities. Costamagna (Costamagna G et al, 2002) and Eliakim (Eliakim R et al, 
2003) reported more than 100% increase in positive findings when using CE after classical 
radiology. One meta-analysis (Leighton JA et al, 2006) totalizing 88 patients found a 59% 
increase in positive findings (67% positive CE versus only 8% barium investigations). 
Comparison with PE favors the use of CE, as the vast majority of studies indicate more than 
double diagnostic rates for capsule investigations (Saurin JC et al, 2003; Lewis BS et al, 2002; 
Ell C et al, 2002; Mylonaki M et al, 2003; Adler DG et al, 2004; Mata A et al, 2004; Hartmann 
D et al, 2003; Van Gossum A et al, 2003; Ge ZZ et al, 2004), especially when studies deal with 
occult OGIBs (Neu B et al, 2005) An analysis of these reports prompt a 63% yield for CE 
versus only 24% yield for PE. Another meta-analysis including 14 different studies 
(Leighton JA et al, 2006) and 396 patients revealed similar results, 63% positive results for 
CE and only 28% for PE. Small population groups, eligibility criteria and biases in the 
selection criteria were the main issues which could influence these statistics. 
In a study published in 2007, Saperas E et al showed that CE diagnostic yield was  
72%, compared with CT angiography (24%) or standard angiography (56%), also giving 
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Fig. 6. Telangiectasies. Still images from different patients investigated with CE.  (from the 
Research Center of Gastroenterology and Hepatology of Craiova Videocapsule Endoscopy 
Image Archive). 
Recent studies focused on balloon enteroscopy, mainly the double balloon version, as it 
became increasingly popular over the world. CE has a higher detection rate of potential 
bleeding sources in a number of studies, mainly due to more complete investigations when 
compared with DBE. (Mehdizadeh S et al, 2006; Hadithi M et al, 2006) Hatidi et al (2006) 
performed both procedures on a lot of 35 patients, concluding that CE is more likely to 
detect the presence of bleedings; however the two procedures should be regarded as 
complementary rather than competitive.  
General consensus today is that early diagnosis by CE can be followed by DBE findings, 
combined with interventional enteroscopy by the same method. (Kameda N et al, 2008; 
Marmo R et al, 2007) 
6.2 Capsule endoscopy in Crohn’s disease 
In Crohn’s disease, patients often experience pain, diarrhea and weight loss, non-specific 
symptoms that do not correlate with the negative results from usual imaging investigations. 
(Kornbluth A et al, 2005) A consensus panel suggested that further investigation by CE is 
useful when patients display at least two of these symptoms. (Kornbluth A et al, 2005) 
 




Fig. 7. Proposed algorithm for the diagnosis and management of Crohn’s disease by using 
CE and DBE. Adapted from Sidhu R et al, 2008. 
Capsule endoscopy has been shown to have a rather high diagnostic yield in non-stricturing 
Crohn’s disease. CE might prove useful in both diagnosing early the disease, as well as in 
establishing disease prognostic, activity or mucosal response to treatment. Triester et al 
(2006) concluded in their meta-analysis that CE does not differ in diagnostic yield from 
other investigations when an initial suspicion of Crohn’s disease existed. A statistically 
significant difference, favoring CE, existed however when analyzing subgroups of patients 
with established disease and suspected small-bowel recurrence. A small prospective study 
on only 27 patients having a suspected diagnosis of Crohn’s disease shown a sensitivity of 
93% and specificity of 84% for CE, also demonstrating significant changes in their 
management and subsequent outcome. (Girelli CM et al, 2007) A recent study shown that 
CE is useful in patients displaying atypical clinical symptoms, especially when surgery was 
performed at some point. (Mehdizadeh S et al, 2008) However, not all studies published so 
far rate CE as the most effective method of investigating Crohn’s disease. A retention rate as 
high as 5 to 13 percent in Crohn’s disease patients (Cheifetz AS et al, 2006) encourage the 
use of small-bowel follow-through, CT or a patency capsule examination prior to capsule 
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ingestion. This was shown to limit the use as a first-intent test in a small prospective study. 
(Solem CA et al, 2008) When investigating disease recurrence after surgery, CE proved to be 
more useful than colonoscopy and ileal intubation. Recurrence was demonstrated in 15 out 
of 24 patients after CE, compared to only 6 after colonoscopy (62% versus 25%).  (Pons B et 
al, 2007) 
A diagnostic index with a scoring system designed for grading disease activity in the small 
bowel, destined for clinical needs and research, was recently developed, as nonsteroidal 
anti-inflammatory drug intake, lymphomas, vasculitis or infectious disease may resemble 
the lesions found in Crohn’s disease patients. (Gal E et al, 2008) 
A meta-analysis of multiple studies, totaling 115 patients, showed a diagnostic yield of 61% 
for CE, compared to only 46% for ileo-colonoscopy. (Kornbluth A et al, 2005).  Comparisons 
with push enteroscopy also favored the videocapsule, as this method allows deeper small 
bowel mucosa visualization. (Chong AK et al, 2005; Herrerias JM et al, 2003) Ileo-
colonoscopy has a higher yield in the detection of disease recurrence compared to CE in 
patients who underwent ileo-colonic resection (Sidhu et al, 2008); however, one study 
showed that even at lower sensitivity, CE positively identified lesions outside the reach of 
the ileo-colonoscope. (Bourreille A et al, 2006) 
Comparison with small bowel barium imaging showed superior diagnostic yield for CE, 
when dealing with suspected or recurrent Crohn’s disease. (Chong AK et al, 2005; Dubcenco 
E et al, 2005; Triester et al, 2005; Marmo R et al, 2005) Higher diagnostic yield of CE when 
compared with CT enteroclysis were reported, and comparisons between CE and MR 
enteroclysis showed comparable or better yield for CE. Capsule retention remains a risk in 
patients with Crohn’s disease, hence the majority of studies comparing radiological imaging 
techniques with CE clearly underline that the presence of strictures identified by said 
methods precluded further use of the videocapsule. A recent meta-analysis showed superior 
diagnostic yield to both barium follow-through and ileo-colonoscopy in non-stricturing 
Crohn’s disease patients. (Triester et al, 2006) 
Double balloon enteroscopy is considered the golden standard when assessing the 
diagnostic yield of CE, however studies with a longer follow-up period are required. The 
general consensus, as with most other indications, is that both procedures are beneficial and 
are not exclusive to each other.  
6.3 Capsule endoscopy in celiac disease 
Being a non-invasive investigation with a deep visualization of the intestine, CE may prove 
useful in the diagnosis of celiac disease. The mucosal “mosaic” pattern specific to celiac 
disease is recognized on the CE recording, and the usual aspects such as scalloping, loss of 
mucosal folds and mucosal atrophy are easily spotted. Also, positive correlation between 
aspects seen in endoscopy and those observed after CE evaluation, coupled with the greater 
reach of the latter, point to it as a useful tool for “virtual histology”, giving the possibility of 
a correct macroscopic interpretation of the mucosal lesions. 
In suspected celiac disease, when using duodenal histology as a gold standard, three studies 
shown good sensitivity (80%, 87.5% and 92%, respectively), as well as excellent specificity 
(100%, 90.9% and 100%, respectively) of the CE for a positive diagnosis.  (Hopper AD et al, 
2007; Rondonotti E et al, 2007; Murray JA et al, 2008) At present, however, more evidence is 
needed for CE to be used as a routine investigation in celiac disease, and duodenal biopsy 
remains the gold standard. (Sidhu R et al, 2008) 
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Patients with known celiac disease would also benefit from CE, as an evaluation of 
refractory or complicated forms is often needed. CE was shown to have a high diagnostic 
yield in identifying abnormalities of the mucosa and exclusion of adenocarcinomas. A study 
reported a yield of 60% in detection of complications relating to celiac disease, including 
ulcerated mucosa, malignancy and strictures (Culliford A et al, 2005)  
 
 
Fig. 8. Celiac disease. Still images from different patients investigated with CE. (from the 
Research Center of Gastroenterology and Hepatology of Craiova Videocapsule Endoscopy 
Image Archive) 
6.4 Capsule endoscopy in hereditary polyposis syndromes 
A number of studies indicate that CE has a superior diagnostic capability in identifying 
polyposis syndromes (both familial polyposis, and Peutz-Jeghers syndrome) when 
compared with small bowel barium follow-through and MRI. (Mata A et al, 2005) 
Detection rate was however influenced by the polyp size, as detection rate was equal for 
polyps larger than 15 mm, and greatly improved when sizes decreased, being visible only 
through CE when they were below 5 mm. However, CE provided incomplete data 
regarding large polyps, while MRI provided a better estimation of their site and size. 
(Caspari R et al, 2004) 
Recent data suggests that CE may be used as a replacement for enteroclysis for surveillance 
of Peutz-Heghers syndrome patients; however this is not accurate in all cases, as it has low 
sensitivity for identifying the major papilla, also being inaccurate in distinguishing between 
periampullar and ampullary regions. (Ladas et al, 2009) 
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Fig. 9. Intestinal polyps. Still images from different patients investigated with CE. (from the 
Research Center of Gastroenterology and Hepatology of Craiova Videocapsule Endoscopy 
Image Archive) 
6.5 Capsule endoscopy in diagnosing small-bowel tumors 
Older literature showed a discrepancy between the number of diagnosed small bowel 
tumors during the course of life, and post-mortem autopsy findings. This was mostly due to 
the lack of investigatory techniques for this portion of the intestinal tract. As such, after the 
introduction of CE in routine clinical practice, the reported incidence for small-bowel 
tumors raised from 2% to as high as 9.6% (Corbin et al, 2006; Urbain D et al, 2006; 
Rondonotti E et al, 2008) 
Capsule endoscopy is useful in diagnosing a full range of malignancies, the majority of 
findings being adenocarcinomas. Gastrointestinal stromal tumors are the most frequent 
benign tumoral finding, with more than 32% incidence (Rondonotti E et al, 2008) A complete 
list of usual tumors identified by CE can be found in table 2. 
The majority of tumors are found in the jejunum (approximately 60%), followed by ileum 
(25-40%) and the duodenum (15-20%).  
CE investigation is frequently delayed by multiple negative standard techniques, which do 
not provide sufficient data regarding the small bowel. It was shown that a good estimation 
of tumor location compared with surgical findings exists, thus dramatically influencing the 
course of the treatment and disease outcome. Accurate information regarding the location, 
dimensions and appearance is also available after CE. (Sidhu R et al, 2009) 
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Table 2. Usual tumoral findings following Capsule Endoscopy. 
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7. Capsule endoscopy: Cost effectiveness 
Capsule endoscopy represents a viable diagnostic tool in the early detection of OGIBs. One 
of the primary advantages being the ease of use, when accounting for its similar or greater 
diagnostic yields, it becomes evident that the method may be cost-effective for both 
screening and for patient diagnostic. Oradei et al (2005) estimated the costs of CE treatment 
on a population of 76 OGIB patients by studying synthetic indicators of different diagnostic 
tests. The main conclusion was that CE is indicated when diagnosing small bowel 
pathology, especially when an active bleeding is present. Similar findings were reported by 
Dyer et al (2004) in an Australian hospital, this study also proving the superiority of this 
procedure when compared with series radiography (58% versus only 4%).  
As patients need no further diagnostic tests after a positive CE finding, do not necessarily 
require hospitalization, and there is no imperative need for bowel preparation, the 
procedure may be cost-effective when dealing with OGIB suspected subjects. (Marmo R et 
al, 2007; Oradei et al, 2005) 
DBE and CE are considered complementary, initial DBE proved to be more cost effective; 
however CE followed by DBE was more cost-effective if DBE showed a probability below 
59% of angiectasia. (Dyer S et al, 2004; Kamal A et al, 2006) 
8. Conclusion 
The videocapsule represents one of the most useful technologies for exploring an otherwise 
difficult segment of the digestive tracts. Its use on a larger scale in a clinical environment 
will help provide physicians take correct, informed decisions regarding a wide range of 
pathologies. A number of studies demonstrated multiple uses in screening, diagnostic or 
stadialization of different diseases. 
Future protocols will probably include the technology in even more therapeutic strategies, 
confirming its usefulness and unique abilities. Hospitalization costs will be reduced as 
technology advances, as patients will not require extensive care before and after the 
completion of the procedure. 
Despite the limitations and lack of treatment abilities, CE established itself as an accurate 
tool in the arsenal of endoscopic procedures available to an increasing number of clinicians 
around the globe. Different products offer a wide choice of features, even enabling 
concomitant use of two different devices to perhaps improve diagnostic accuracy, under 
special conditions.  
Different improvements are expected in the following years, most notably in the image 
capturing field, where new compact High-Definition image sensors are expected to 
drastically improve the level of detail in captured movies. The software used for analysis is 
under continuous development, new features aiding the clinicians in their task to detect 
abnormalities. Improved battery life-span and perhaps basic maneuverability inside the 
digestive tract should be available in future generations of the device, thus dramatically 
improving diagnostic accuracy and specificity. Drug-delivery mechanisms, small surgical 
tools and enhanced imagistic equipment are just some of the multiple future add-ons which 
are planned for future iterations, further expanding the list of uses for the device. 
In conclusion, Capsule Endoscopy currently provides a convenient alternative to more 
conventional or novel, but invasive techniques for exploring the small intestine. Future 
improvements of the platform, and virtually endless possibilities to improve upon the concept, 
will continue to offer even more benefits for the patients, at increasingly lower costs. 
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1. Introduction 
Small bowel tumors (SBTs) are rare, accounting for 3-6% of all digestive neoplasms (Gay  
Delvaux, 2008) which is strikingly low when one considers that the small bowel represents 
75% of the length and 90% of the mucosal surface area of the alimentary tract. However, the 
accuracy of this estimate is uncertain because traditional small bowel examining 
methodologies have proved inadequate. 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchimal tumors of the 
gastrointestinal tract (Nowain et al., 2005). Recognized as a distinctive entity in early 1980s 
(Mazur  Clark, 1983), GISTs have been a very active area over the last decade with 
remarkable progress in diagnostic modalities, pathophysiologic understanding, and new 
treatments.  
Until a decade ago, most of the small bowel was out of the range of endoscopic examination. 
The advent of capsule endoscopy (CE) was a major breakthrough for endoscopic diagnosis 
of small bowel diseases (Pennazio, 2005). CE is a safe, painless and sensitive endoscopic 
imaging of the entire small bowel, and several studies have revealed its diagnostic 
superiority over other methods such as push enteroscopy (Mylonaki et al., 2003), small 
bowel follow-through (Costamagna et al., 2002), angiography (Saperas et al., 2007), 
erythrocyte scintigraphy, CT–enterography and magnetic resonance-enterography (Eliakim 
et al., 2004; Golder et al., 2006; Jensen et al., 2011). Several published studies (Arakawa et al., 
2009; Fukumoto et al., 2009; Pasha et al., 2008) showed that CE and double-balloon 
enteroscopy (DBE) are nearly equal in their ability to detect lesions when the entire small 
bowel is examined.  
Following the introduction of CE in clinical practice it was shown that the frequency of SBTs 
is higher than previously published (Cobrin et al., 2006; Estevez et al., 2007), and GISTs are 
the most frequent tumors identified by CE (Rondonotti et al., 2008). Nevertheless, CE lacks 
the ability to obtain biopsy specimens and performed therapeutic procedures, and therefore 
the role of CE in the diagnostic work-up of SBTs, including GISTs is still debated.  
The rising incidence and importance of GISTs represent an interesting challenge for CE 
considering the particular characteristics of these neoplasms. This review will discuss the 
main features of GISTs –one of the most advancing fields of gastrointestinal oncology- with 
particular emphasize on the role of capsule endoscopy in their management. 
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Gastrointestinal stromal tumors (GISTs) are defined as specific  mesenchymal tumors of 
the gastrointestinal tract arising from the gastrointestinal wall, omentum, mesentery or 
retroperitoneum, that express the KIT (CD117, stem cell factor receptor) protein,  a cell 
membrane receptor with tyrosine kinase activity (Miettinen  Lasota, 2001). Previously, 
GISTs were described as smooth muscle tumors and gastrointestinal autonomic nerve 
tumors (GANTs). The above definition excludes gastrointestinal true smooth muscle 
tumors (leiomyomas, leiomyosarcomas, leiomyoblastomas), neurofibromas and 
schwannomas.  
3. Etiology 
The etiology of GISTs is not known.  Familial GISTs with inheritable KIT or PDGFRA 
(platelet-derived growth factor receptor alpha ) mutations have been identified (Nishida et 
al., 1998). GISTs can also be a component of Carney triad (gastric stromal sarcoma, extra-
adrenal paraganglioma, pulmonary chondroma) (Carney, 1999). A relationship between 
neurofibromatosis 1 and GISTs typically occurring in the small bowel has also been 
postulated (Miettinen et al., 2002). 
4. Epidemiology 
GISTs are the most common mesenchymal tumors of the gastrointestinal tract, with an 
estimated incidence of 10-20 cases per million per year (Nilsson et al., 2005). However, the 
true epidemiology of GISTs has been difficult to determine. GISTs typically occur in older 
adults (age 55 to 65 years), with a mild male predominance in some series (Tran et al., 2005). 
Nevertheless, GISTs have been reported in all ages, including children. GISTs may occur in 
the entire length of the gastrointestinal tract, the most frequent location being the stomach 
(60-70%), followed by small bowel (20-30%), colon and rectum (5%) and esophagus (1%) 
(Miettinen et al., 2006). Within the small bowel, half of the stromal tumors are located in the 
jejunum, 25% in the duodenum and 25% in the ileum. GISTs are the most frequent 
histological type of primary small bowel tumors (Miettinen  Lasota, 2006a).  Occasional, 
GISTs primary in the mesentery and omentum have also been reported (Miettinen et al, 
1999). 
5. Pathogenesis 
The current theory is that an oncogenic  mutation (acquired as a result of unidentified 
factors) on the KIT gene plays the central role in GISTs tumorigenesis. In the 
gastrointestinal tract, KIT (originally also called CD117) is normally expressed by the 
interstitial cells of Cajal, and therefore it has been proposed that GISTs originate from 
these cells (Blay et al., 2005). In the normal cell, the KIT receptor ligand is stem cell factor 
and, when bound, it leads to activation of the receptor and subsequent controlled 
downstream cellular cascades including several of cellular proliferative mechanisms and 
antiapoptotic pathways. In GISTs cells, mutations in the KIT genes lead to activation of 
tyrosine kinase receptor  independent of the receptor ligand. These gain-of-function 
mutations allow uncontrolled cell proliferation and inhibition of normal apoptosis - well-
known steps in carcinogenesis.  
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Mutations of the KIT genes occur in approximately 90% of GISTs. Less than 5% gain-of-
function mutation occur in PDGFRA gene (Heinrich et al., 2003). Nearly 10% of GISTs do 
not have detectable mutation in either KIT or PDGFRA genes.  
6. Pathology 
Small bowel GISTs occur most commonly as a single tumor varying greatly in size from few 
millimeters to several centimeters, and being histologic more often spindled than epitheloid 
type (Figure 1).  
 
 
         
Fig. 1. Small bowel stromal tumor: A) histological picture showing the tumor localized in 
the jejunal submucosa, comprised predominantly of spindle cells (HE stain, 4X); B) 
immunohistochemical staining for KIT (CD 117): strong KIT - positivity in tumor cells 
(images courtesy of M. Danciu, MD) 
Histopathologic appearances of GISTs can be divided into three main categories: 1) spindle 
cell type, containing oval-shaped spindle cells with pale eosinophilic cytoplasm and 
uniform ovoid nuclei; 2) epitheloid cell type, consisting of round cells with variable 
eosinophilic to clear cytoplasm; 3) mixed spindle cells - epitheloid cells type (Corless et al., 
2004). Spindle cell type is the most common (70%), followed by epithelioid  cell (20%), and 
mixed spindle cell-epithelioid pattern (10%). Small bowel GISTs often (40%) contain 
distinctive extracellular collagen fibers (skeinoid fibers) (Min, 1992). 
Macroscopically, GISTs are gray or white tumors, well-circumscribed with a pseudocapsule, 
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Fig. 2. Gastrointestinal stromal tumor at surgery: ulcerated jejunal tumor 
Several pathological and molecular factors have been evaluated to predict biological 
behavior of GISTs. At present, GISTs are classified according to their risks of malignancy 
rather than simply as benign or malignant. A risk assessment scale (Table 1) for the 
malignant potential of GISTs is available after 2001 NIH (National Institute of Health) 
consensus conference (Fletcher et al., 2002), and it is based on two criteria: tumor size and 
mitotic index on histology (number of mitotic figures seen in 50 high-power fields). 
According to this histologic classification, GISTs have a spectrum of malignant behavior 
ranging from “very low risk” (but not zero) to “high risk” (but not certainly malignant). The 
frequency of malignant behavior of GISTs also varies according to site, being higher for 
small bowel tumors (40%) than for gastric ones (20%) (Miettinen  Lasota, 2006b). Survival 
outcomes, tumor-specific deaths, tumor recurrence and metastases are strongly correlated 
with tumor size and mitotic index (Crosby et al., 2001). 
 
Risk level                                              Tumor size (cm)                                           Mitotic count per          
                                                                                                                                          50 HPF*    
Very low                                                       <2                                                                  <5 
Low                                                               2-5                                                                 <5 
Intermediate                                                <5                                                                   6-10 
                                                                       5-10                                                               <5 
High                                                              >5                                                                   >5 
                                                                       >10                                                                any  
                                                                       any                                                                >10 
* HPF: high-power field 
Table 1. NIH criteria for malignant risk in gastrointestinal stromal tumors  
(Fletcher et al., 2002) 
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7. Clinical presentation 
Usually, small bowel GISTs grow slowly and remain asymptomatic for many years. The 
symptoms and signs are not disease-specific. Typically, they are discovered incidentally 
during radiologic or endoscopic investigations and at surgery for other conditions. When 
symptomatic, the most common presenting symptom is gastrointestinal bleeding (melena), 
followed by bowel obstruction. Usually the bleeding is occult, resulting in long-standing 
anemia and associated symptoms before a small bowel GIST is diagnosed. Other presenting 
symptoms are abdominal pain or discomfort, altered bowel function, and abdominal 
fullness. On physical examination, findings based on the tumor size may include a palpable 
abdominal mass. Approximately half of small bowel GISTs have a metastatic component 
(liver, peritoneum) at the time of diagnosis.  
8. Diagnostic procedures 
8.1 Immunohistochemistry 
The final diagnosis of small bowel GISTs depends on histological and immunochemistry 
examinations. The hallmark of small bowel GISTs is their positivity for KIT (CD117), 
confirmed by immunohistochemical staining usually using purified polyclonal antibodies. 
The antibodies against CD34 (hematopoietic progenitor cell antigen) is expressed in about 
50% of small bowel GISTs, and can be used as an adjunct marker for diagnosis. Protein 
kinase C theta are used as secondary immunohistochemical markers  in KIT negative GISTs 
(less than 3%) and for differential diagnosis.  
8.2 Imaging studies 
The diagnosis imaging procedures for small bowel GISTs are similar to those used for other 
small intestinal tumors. Several imaging methods (small bowel follow-through, angiography, 
computed tomography / magnetic resonance – enterography etc) have been used for the 
diagnosis of small bowel GISTs, often with inconclusive results. When diagnostic, at small 
bowel follow-through and computed tomography (CT) enterography, the stromal tumor 
appears as a smooth-lined filling defect in the lumen with well-demarcated borders, 
sometimes with focal area of ulceration (Figure 3). Magnetic resonance (MR) enterography 
does not offer additional information in comparison to CT-enterography. 
The imaging method of choice is contrast-enhanced CT of the abdomen and pelvis 
(Sandrasegaran et al., 2005). As GISTs involve the muscularis propria of the bowel wall, the 
tumor typically appear  as well-circumscribed mass, predominantly extra-luminal. Contrast 
enhancement is usually homogenous within the tumor, though large tumors are 
heterogeneous, with necrotic centers or a cystic component. Less frequently, small bowel 
GISTs occur on CT as intramural masses or intra-luminal polypoid lesions with regular 
contours.  
MR-imaging is helpful in large GISTs that have hemorrhagic and necrotic components at 
contrast enhanced-CT. Solid portions of the tumor show low signal intensity on T1-
weighted images and high signal intensity on T2-weighted images, and enhance of the mass 
after intravenous gadolinium administration. Signal intensity of hemorrhagic areas within 
the tumors can vary from high to low, depending on the age of hemorrhage (Sandrasegaran 
et al., 2005). 
Positron emission tomography (PET scanning) may be helpful in the initial staging or 
evaluation of response to imatinib therapy for GISTs . 
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Fig. 3. CT findings of small bowel stromal tumor: a 43/28/28 mm well-defined  mass with 
central necrosis in the proximal jejunum (image courtesy of D. Negru, MD) 
Endoscopic ultrasonography is helpful in other sites (esophagus, stomach, duodenum, 
rectum), although the method with special probes has been used during single - or double 
balloon - enteroscopy in small bowel GISTs (Matsui et al., 2008).  
Angiography may be the initial radiologic procedure in a patient with significant bleeding; 
angiographically, small bowel GISTs are characterized by irregular or ball-like vessels with 
neovascularity (Fang et al., 2004).  
Double-balloon enteroscopy (DBE) or single balloon enteroscopy have proved effective for 
the diagnosis of small bowel stromal tumors (Lin et al., 2008); typically, they appear as a 
submucosal mass (Figure 4) with normal lining mucosa and may be dimpled or ulcerated. 
Biopsies rarely yield diagnostic material; moreover, biopsy entails the risk of bleeding and 
seeding (National Comprehensive Cancer Network, 2008).  
 
            
Fig. 4. Small bowel stromal tumor: enteroscopy shows submucosal mass with normal 
overlying mucosa, located in distal duodenum (A) and proximal jejunum (B) 
A B 
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GISTs encountered in duodenum and the last centimeters of ileum are diagnosed during 
upper gastrointestinal endoscopy and, respectively, colonoscopy, having the same features 
described at enteroscopy. 
9. Capsule endoscopy  
Traditionally, small bowel stromal tumors have been difficult to diagnose due to their 
nonspecific clinical symptoms, combined with inadequate methodologies for examining the 
small bowel. The advent of CE has revolutionized the investigation of patients with 
suspected SBTs, including GISTs. 
Conventional methods of investigating the small bowel (upper gastrointestinal endoscopy, 
colonoscopy, small bowel follow-through, CT- or MR- enterography) have a low diagnostic 
yield for GISTs. Small bowel is the second most frequent site for GISTs (20-30%), which are 
the most frequent tumor type identified by CE (Rondonotti, 2008). Within the small bowel, 
50% of the stromal tumors are located in the jejunum, 25% in duodenum, and 25% in ileum. 
Usually, all patients with small bowel GISTs undergo several investigations prior to CE 
without a definitive diagnosis being made. The average work-up prior to capsule endoscopy 
is reported to range between 3 and 5 previous negative procedures per patient (Spada et al., 
2008). Thus, the diagnosis of small bowel GISTs is often delayed with the use of traditional 
diagnostic modalities and, consequently, such tumors often are discovered late, 
approximately half having already metastasized at the moment of diagnosis. In this context, 
the sooner we use capsule endoscopy in the investigation of symptomatic patients the 
earlier we can establish a diagnosis, with a positive impact on patient management and 
improved outcome. 
The CE findings of SBTs, and particularly of small bowel GISTs are seldom described in 
details in the published papers probably due to the absence of universally accepted 
terminology, the terms usually being “tumor”, “polypoid mass”, “submucosal mass”, 
“tumor mass”, “bleeding polypoid mass”, “ulcerated mass lesion” and  “irregular ulcer”. 
We have found that a polypoid lesion with normal appearance of overlying mucosa or, 
sometimes, with central ulceration is strongly suggestive of small bowel GIST (Figure 5).    
Nevertheless, any elevated lesion with normal overlying mucosa or a bleeding mucosa 
without a clear identified lesion should to be suspected to hide a GIST. A second CE 
examination may be necessary, or a balloon assisted enteroscopy should be performed when 
the first CE did not reveal a diagnosis and a clinical suspicion persists. During CE reading, 
an inexperienced physician might miss a lesion with no clear-cut features or could 
misinterpret a bleeding lesion as a NSAID ulcer or angiodysplasia. A second reading at a 
slower speed (frame to frame) is mandatory in any lesions, even in those without features of 
tumor. Even an endoscopist with a long experience in traditional endoscopy could also be 
mislead by images provided by CE. A special kind of training requiring patience and visual 
skills rather than manual skills is needed for this time consuming procedure.  
It should be emphasized that CE findings are of uncertain significance in the most of small 
bowel GISTs, and the final diagnosis is established by further diagnostic/therapeutic 
procedures (balloon assisted enteroscopy, surgery) after CE. Moreover, CE cannot reliably 
distinguished between benign and malignant tumors as CE is unable to provide histological 
confirmation to the diagnosis. However, it should be stressed that in case of suspected 
GISTs biopsy entails the risk of bleeding and seeding. Most authors consider that biopsy 
should be avoided in patients with resectable small bowel GISTs (Casali et al., 2006). 
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Fig. 5. Capsule endoscopy findings of small bowel stromal tumors: A) submucosal mass in 
distal duodenum; B) ulcerated jejunal polipoid lesion; C, D) jejunal submucosal mass with 
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In all published series about CE in the diagnosis of SBTs, obscure gastrointestinal bleeding was 
the leading indication for capsule endoscopy (Rondonotti  et al., 2008; Soufleris et al., 2008). 
CE is also important to establish the location of small bowel tumors, including GISTs. Most 
frequently, they are located in the jejunum, and it has been agreed that in 90% of cases the 
location as assessed by CE coincides with that found by further diagnostic and/or 
therapeutic work-up (Rondonotti et al., 2008). 
As reported in the literature, the most frequent small bowel tumors types identified by CE 
was small bowel gastrointestinal stromal tumors (Rondonotti et al., 2008). In the largest 
database published so far on SBTs detected by CE, Rondonotti et al (Rondonotti et al., 2008) 
found that GISTs accounted for 32% of all cases. Schwartz and Barkin (Schwartz  Barkin, 
2007) found that small bowel GISTs were the most common benign tumors and CE was the 
diagnostic procedure of choice in patients with suspected small bowel tumors. In our series 
SBTs were detected in 4.9% of patients undergoing CE and the main tumor type was GIST 
(Trifan et al., 2010). Recently, Sidhu and McAlindon (Sidhu  McAlindon, 2011) reported 
that CE is an important modality in the diagnostic work-up of patients with small bowel 
tumors and it has a positive impact on patient management. Similar, Riccioni et al. (Riccioni 
et al., 2010) found CE an effective and sensitive diagnostic modality in GISTs in comparison 
to traditional radiology, having an important role in the algorithm for diagnostic work-up in 
suspected small bowel tumors.  
Capsule endoscopy has some limitations and risks. The first is inability to provide 
histological confirmation of the diagnosis. However, in case of suspected GISTs, biopsy is 
unnecessary as it may cause bleeding and seeding. Another is that CE cannot be 
maneuvered, and it has no means to allow prolonged examination or reexamination of 
questionable or poorly seen areas. Moreover, CE is not a therapeutic tool. Capsule retention 
remains the most significant complication and a major concern to both physicians and 
patients as it has the potential to cause small bowel obstruction which can lead to surgical 
intervention (Lin et al., 2007; Repici et al., 2008). The incidence of capsule retention varies 
widely depending on the indications for the examination. Absence or low rate (1-2%) of 
capsule retention was documented in studies with very strict exclusions criteria (Li et al., 
2008), while high rates (5-21%) occurred in patients with suspected partial small bowel 
obstruction (Cheifetz  Lewis, 2006). Among the main causes of capsule retention are small 
bowel tumors (Toy et al., 2008). So far, there is no safe method of avoiding capsule retention. 
Radiological examination and even the newer imaging techniques entero-CT/MR have a 
low diagnostic yield and tend to underestimate small bowel strictures. Therefore, a patency 
capsule was developed to assess whether patients with suspected small bowel strictures 
could undergo CE. The patency capsule is a self-dissolving capsule, with the same size as 
the conventional capsule. The limitations of the first-generation patency capsule have been 
overcome by the second-generation (the Agile patency capsule), although its role in 
predicting retention needs to be further documented (Herrerias et al., 2008).  Once the 
capsule has been retained only endoscopic (including double-balloon enteroscopy) and 
surgical intervention have been shown to be effective in removing the capsule (Baichi et al., 
2006; Van Weyenberg et al., 2010). Currently, there are different view points regarding 
capsule retentions, some authors considering it as a feared complication of CE (Karagiannis 
et al., 2009), while others have suggested clear benefits from retentions by identifying and 
treating the underlying disease (Mason et al., 2008; Yang et al., 2009). Particularly, capsule 
retention in a patient with small bowel tumor is not a major clinical problem  since the 
tumor will require surgical treatment and the capsule can be retrieved at the time of surgery.  
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Prognosis of GISTs is variable, determined by the malignant potential of the tumor. The best 
documented prognostic markers are tumor size and mitotic activity (Table 1). Tumors that 
show low mitotic frequency (< 5 mitosis per 50 HPF) usually have a benign behavior; 
however, a low mitotic index does not rule out a malignant behavior (Franquemont, 1995). 
A combination of low mitotic rate and small size (< 5 cm) is a more accurate predictor of a 
benign behavior. The small bowel GISTs have a markedly worse prognosis than gastric 
GISTs; thus, small bowel GISTs >10 cm but with a low mitotic rate have 52% metastatic rate, 
whereas gastric GISTs with similar parameters metastasize in 12% of cases (Miettinen  
Lasota, 2006a).  The 5-year survival of all patients with curative resection range from 20% to 
80%. Tumor recurrence after surgical resection is frequent within 2-5 years. The median 
survival after palliative resection is about 10 months (DeMatteo et al., 2000). 
11. Treatment  
11.1 Localized resectable disease 
Surgery is the main type of treatment in patients with localized and potentially resectable 
disease (Ho  Blanke, 2011). The surgeon must avoid intraoperative tumor rupture, which is 
associated with high risk of peritoneal seeding. Small bowel GISTs often require segmental 
resection. Neoadjuvant therapy for patients with resectable disease is not recommended. 
However, preoperative imatinib may be considered for patients with potentially resectable 
disease but with a risk of significant morbidity (Eisenberg  Judson, 2004). The recurrence 
rate remains high after resection of a small bowel GIST, and some questions remain 
regarding post-operative or adjuvant therapy. Imatinib was approved by US Food and Drug 
Administration for patients with resected  GISTs > 3cm in size (Cohen et al., 2010).  
11.2 Unresectable or metastatic disease 
Management of inoperable GISTs has changed radically with discovery and introduction in 
practice of molecularly targeted agents. Imatinib mesylate (Gleevec, Novartis 
Pharmaceuticals, Basel, Switzerland) is the first effective drug in patients with unresectable 
or metastatic GISTs (Cohen et al., 2009). Imatinib is a selective competitive inhibitor of 
protein tyrosine kinases including ABL (Abelson proto-oncogene), KIT and PDGFR. By 
competing with ATP for the kinase-binding site, imatinib inhibits the receptor activation 
and disables downstream cascades (Heinrich et al., 2000). Currently, for patients with 
marginally resectable, metastatic, progressive or recurrent disease, the recommended first-
line therapy is imatinib.  The use of imatinib can be guided by genotyping of KIT mutations: 
KIT exon 11 mutants respond well to imatinib, while KIT exon 9 mutants, which occur 
predominantly in small bowel GISTs are less sensitive to imatinib.  Therefore, in these 
patients  the starting dose of imatinib is 400 mg once daily and then is increased to 800 mg 
daily,  if tolerated, over one month. The present recommendations are for life-long treatment 
with imatinib for patients with metastatic GISTs. The most frequent side effects of imatinib 
include leg edema, nausea, diarrhea, myalgias, fatigue and skin rash. Several clinical trials 
have demonstrated tumor regression and improved survival in patients treated with 
imatinib (Le Cesne et al., 2009).  
Sunitinib malate, a multitargeted tyrosine kinase inhibitor, is considered the standard 
second-line therapy for advanced GISTs (Demetri et al., 2006). It has been used in patients 
who did not respond to imatinib or who could not tolerate imatinib.  
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Several drugs with potential activity against GISTs have been developed and tested in 
recent years. Second-generation tyrosine-kinase inhibitors (nilotinib, dasatinib), sorafenib 
(Nexavar) and other similar drugs (AZD 2171, XL-820) are in clinical testing (Dewaele et al., 
2009; Montemurro et al., 2009). 
12. Conclusion 
Gastrointestinal stromal tumors have been an active area of gastrointestinal oncology over 
the last decade with remarkable progress in diagnostic modalities and new treatments. 
Small bowel is the second most frequent site for GISTs, and their diagnosis is often delayed 
with the use of traditional diagnostic methods. Usually, all patients with small bowel GISTs  
undergo several investigations prior to CE, without a final diagnosis being made. The 
advent of CE has revolutionized the investigation of patients with suspected small bowel 
tumors, including GISTs which are the most frequent tumor type identified by CE.  Despite 
its limitations, CE may be the most reasonable initial diagnostic strategy to evaluate patients 
with suspected  small bowel stromal tumors. In addition, CE has the potential of shortening 
the diagnostic work-up of small bowel stromal tumors. Furthermore, it may be expected 
that CE could identify such tumors at an early stage and thus the prognosis of the patients 
would be improved. Even more, CE could be used to assess  patients after surgery or the 
efficacy of medical therapy.  
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1. Introduction 
Capsule endoscopy (CE), which was invented to visualize the entire small intestine in a 
noninvasive manner was first described in 2000 (Iddan, 2000), was approved for adult patients 
in 2001 by Food and Drug Administration (FDA). More than 600,000 PillCam SB capsules, 
which is the first model for CE in the world, have been used worldwide since 2001 
(Nakamura, 2009). In pediatric patients, Seidman et al has first described the diagnostic value 
of CE (Seidman, 2002), and in 2003, FDA approved CE for pediatric patients ages 10 years and 
older. Emerging number of CE studies in children indicate the great demand for this 
population ( Tokuhara, 2010; de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; 
Guilhon de Araujo Sant'Anna, 2005; Thomson, 2010; Ge, 2007; Postgate, 2009; Pinho, 2008; 
Shamir, 2007; Stiffler, 2003; Argüelles-Arias, 2004; Cohen, 2008 ), but performed number is 
relatively small (approximately 600, at the time of 2010) compared to adult cases (> 600,000), 
therefore, informations about indications, obtained results and risk of complications are not 
fully understood in pediatric patients. In pediatric patients, as well as in adults, CE is a first-
line of examination to evaluate the entire small intestine and provides evidence for the 
diagnosis to the suspected small bowel disease especially in obscure gastrointestinal bleeding 
(OGIB) and suspected inflammatory bowel disease (IBD), on the other hand, accumulated 
studies are extending the indication of CE to protein loss, growth failure, abdominal pain, 
suspected polyp or graft-versus-host disease (GVHD) and regular follow-up for the known 
small bowel diseases. In this review, we summarize and discuss the capsule endoscopy 
system, indication, limitation, and future perspective of CE in pediatric patients. 
2. General features of CE 
2.1 Capsule endoscopy system 
Capsule endoscopy system in children is almost same as that of adults. It is available to use 
a pediatric accessory kit with a recorder belt and sensor array, which are more appropriately 
sized for children (Fritscher-Ravens, 2009), on the other hand, CE, a PillCam SB capsule 
itself is the same type used by adults. The PillCam SB system has three components: a 
capsule endoscopy body, an external receiving antenna (consisting of eight sensor arrays) 
with attached portable hard disc drive (data recorder), and a customized PC workstation 
(RAPID: reading and processing images and data) with dedicated software for review and 
interpretation of images (Cave, 2004). CE is 26-mm long, 11-mm wide, weighs 3.4 g, records 
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images at a rate of 2 frames per second (fps), and has a battery life of about 8 hours. Image 
features include a 1400C field of view, 1:8 magnification, 1- to 30-mm depth of view, and a 
minimum size of detection of about 0.1mm. There is no capability of biopsy. After the 
patients ingest capsule, they can resume normal activities immediately, and are permitted to 
consume clear liquids and food at 2 h and 4 h thereafter (Tokuhara, 2010). 
2.2 Abnormalities assessed by CE 
CE visualizes various mucosal abnormalities such as ulcer, erosion, stricture, vascular 
anomaly, and mucosal protuberance such as polyp and tumor in pediatric patients as well 







White villi Intestinal contents (ex. parasitic worm) 
Mass 
Diagnosed or suggested diseases
Crohn’s disease Celiac disease
Angiodysplasia Hemangioma
Lymphangiectasia
Meckel’s diverticula Lymphonodular hyperplasia
Peutz-Jeghers syndrome GVHD
Blue rubber bleb Parasitic worm
Table 1. Findings and diagnosed or suggested diseases by CE 
 
 
Fig. 1. CE findings. (a) Normal jejunum. (b) Longitudinal ulcer (black arrow). (c) Stricture 
with redness and ulcer (arrows). (d) Active bleeding. (e) White villi. (f) Stenosis with ulcer. 
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parasitic worm can be seen (Table 1). Those abnormalities are highly detectable in the entire 
small intestine, to some extent, CE provide supportive information for the presence of 
abnormalities in the esophagus, stomach and colon. Transit time of CE and analyzed 
pathway by the software will help to assess the localization of detected abnormality in the 
small intestine. In pediatric patients with suspected small intestinal disease, CE detect 
abnormal findings in 55% (286/523) of cases (Tokuhara, 2010; de'Angelis, 2007; Atay, 2009; 
Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo Sant'Anna, 2005; Thomson, 2010; Ge, 
2007; Argüelles-Arias, 2004; Pinho, 2008; Stiffler, 2003). Based on the detected abnormalities 
by CE in addition to the clinical and/or other laboratory informations, various small 
intestinal diseases are diagnosed or suggested, or further elucidated of their involvements of 
small intestinal lesions in known diseases (Table 1). 
2.3 Comparison with other modalities 
A previous study demonstrated that CE is superior to small-bowel radiography, computed 
tomography enterography (CTE), and colonoscopy with ileoscopy in the evaluation of adult 
patients with suspected CD (Dionisio, 2010). As well as adult patients, CE is more sensitive 
than radiological and standard endoscopic modalities in the detection of small bowel CD 
distribution, OGIB source, and presence of polyps in children (Thomson, 2007; Guilhon de 
Araujo Sant'Anna, 2005). In addition, because of its non-invasive approach, even if initial 
study is non-diagnostic, repeat CE may increase diagnostic yield (Tokuhara, 2010). Further, 
even if initial CE study is technically inadequate (poor visualization and/or not reaching 
colon), it is possible to repeat examination compared to the invasive conventional 
examination.   Almost at the same time with CE, double balloon enteroscopy (DBE), which 
is relatively a novel technique compared to the conventional examination, was developed to 
investigate the entire small intestine (Yamamoto, 2001). DBE can evaluate the small intestine 
as well as CE, but can gather biopsy specimens, and can carry out therapeutic procedures 
which are impossible by CE. In order to evaluate the entire small intestine, it is necessary to 
perform DBE 2 times with anterograde and retrograde routes. On the other hand, DBE often 
cannot visualize the entire small intestine. In regard to the application of DBE in children, 
previous studies reported the feasibility and usefulness of DBE in pediatric patients 
(Nishimura, 2010; Thomson, 2010; Leung, 2007). Another study described the successful use 
of DBE in 3 years old children with OGIB (Kramer, 2009). In regard to the differences in 
diagnostic accuracy and other advantages between CE and DBE, most of studies have 
concluded that CE was superior to the initial diagnosis but DBE was superior to treatment 
or histopathological diagnosis in adult patients with OGIB (Hadithi, 2006; Nakamura, 2006). 
In addition, lack of experience and expertise for smaller children are to be solved for the 
future extensive use of DBE in children (Leung, 2007). Thus it is expected that DBE is used 
in pediatric patient, but it is prefer that DBE is performed based on the screening by CE.  
2.4 Preparations for CE 
Generally, overnight fasting is used as a standard preparation for CE in pediatric patients 
(Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Atay, 2009). Diagnostic yield of 
capsule endoscopy depends on the quality of visualization of the small bowel wall and 
complete passage through the small bowel. Some abnormalities such as angiodysplasias are 
sometimes hampered by residual intestinal contents. Thus, a bowel preparation is studied 
previously, and sodium phosphate (Niv, 2005) or polyethylene glycol (PEG) (Viazis, 2004; 
Dai, 2005) has been described to offer improved visualization of the small intestine in adults. 
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In pediatric patients, colonoscopic bowel preparation was reported to offer the most 
favorable preparation. On the other hand, evaluation of entire small intestine is sometimes 
not completed because of prolonged gastric emptying and limited battery life (< 8h). In 
pediatric patients, completion rate of CE in the entire small intestine varies from 69 – 89 % 
(Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Atay, 2009; de'Angelis, 2007; Ge, 2007; 
Moy, 2009; Postgate, 2009). In order to improve the completion rate, mosapride citrate or 
laxatives are one of candidate to increase the ability to observe the entire small intestine, but 
there is no systematic study in regard to the use of mosapride or laxatives as a preparation 
drug for CE study in pediatric patients. In adults, a previous study (Wei, 2007) reported oral 
10mg mosapride citrate 1h before CE examination could accelerate the gastric emptying 
(13.5 min vs 34 min) and completion rate of small bowel examination ( 93.3 % vs 66.7 % ). In 
regard to the laxatives, a previous study (Franke, 2008) reported that a combination of 
bisacodyl and sodium phosphate significantly accelerated small bowel transit time (262 min 
±55min vs 287 min ± 97min) but had no effect on the visibility of CE. Taken together, in 
order to increase the completion rate of small intestine and carefully examine the mucosal 
abnormality such as angiodysplasias, mosapride or laxatives might be effective preparation 
drug for CE in addition to the overnight fasting as the standard method. 
3. Ages and indications for CE 
3.1 Age 
Accumulated studies confirmed that CE is safe and useful to children over 10 years of age 
(Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Argüelles-Arias, 2004), and 
application to this age group is considered as appropriate as well as adult. On the other 
hand, it is still controversial to use CE for the children under 10 years of age. Several studies 
described that CE has high diagnostic yield to those patients under 10 years of age 
(de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Ge, 2007), and their small body size 
don’t relate to the risk of capsule retention, which is the most serious complication in this 
modality as described in the latter paragraph. In addition, there was no difference in the 
gastric and small intestinal passage time between adult and pediatric patients (Ge, 2007). In 
young children (1.5-8 yr), a previous study reported CE detected small intestinal pathology 
in 45% (37 of 83 patients) in whom their indications are gastrointestinal bleeding, suspected 
Crohn’s disease, abnormal pain, protein loss and malabsorption (Fritscher-Ravens, 2009). 
Because of no incidence of retention among those aged patients (1.5-7.9yr), CE is considered 
as feasible and safe down to the age of 1.5 yr. As another important aspect, swallowing of 
CE is unavoidable problem in small children. Based on the previous studies, most of 
pediatric patients (>10yr) can ingest CE (Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 
2005). In regard to children > 4yr, 32% of children could ingest CE (Fritscher-Ravens, 2009). 
In case those young children cannot ingest capsule, endoscopic placement of the capsule 
into the duodenum is used (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). In the 
endoscopic placement, CE is released at the third part of the duodenum in order to prevent 
migration of CE back to the stomach (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). 
Some of devices are developed and reported (Orendain, 2010), on the other hand, mucosal 
injury by passage of device should be taken into consideration as a complication (Barth, 
2004; Fritscher-Ravens, 2009). As another potential risk regarding the age, complication 
associated with deep intravenous sedation and general anesthesia for the endoscopic 
placement should be taken into consideration. 
 




The indications for CE in pediatric patients are similar to that of adult patients; OGIB and 
suspected IBD are the major indications and suspected or known polyps such as Peutz-
Jeghers syndrome are the following well-studied indication (Table 2). Known CD is also 
well-studied indication, but needs attention before the use of CE because of a relative high 
risk of capsule retention as described later. Malabsorption, protein loss, recurrent abdominal 
pain, and growth failure are the other minor indications, but sometimes important rather 
than adult population because of importance of mental and physical growth in children. 
Celiac disease is one of major indication in adult of Western countries such as USA and 
Europe, but it is rarely included as indication in children. On the other hand, because of 
non-invasive method, CE can be used repeatedly thus has been applied to get information to 
evaluate the treatment of known small bowel disease. Further, CE can provide supportive 
information about further examination, for example, when a physician determine the route 























Age 8~21 1.5~7.9 1.5~18 ND 10~18 9.4~15.9 3~18 10~18 
n 509 207 83 87 46 30 28 16 12 
Indications 
IBD 285 (56) 172 (83) 20 (24) 32 (37) 19 (41) 20 (67) 16 (57) 0 (0) 6 (50) 
(Suspected IBD) 138 (27) 73 (35) 20 (24) 10 (11) 0 (0) 20 (67) 10 (36) 0 (0) 5 (42) 
(Known IBD) 147 (29) 99 (48) 0 (0) 22 (25) 19 (41) 0 (0) 6 (21) 0 (0) 1 (8) 
OGIB 94 (18) 15 (7) 30 (36) 21 (24) 7 (15) 4 (13) 6 (21) 9 (56) 2 (17) 
Polyps 55 (11) 2 (1) 0 (0) 33 (38) 11 (24) 6 (20) 3 (11) 0 (0) 0 (0) 
Abdominal pain 22 (4) 0 (0) 12 (14) 0 (0) 1 (2) 0 (0) 1 (4) 3 (19) 4 (33) 
Protein loss 13 (3) 1 (1) 9 (11) 0 (0) 1(2) 0 (0) 2 (7) 0 (0) 0 (0) 
Malabsorption 13 (3) 0 12 (14) 1 (1) 0 0 0 0 0 
Growth failure 5 (1) 0 0 0 5(10) 0 0 0 0 
Diarrhea 4 (1) 4 (2) 0 0 0 0 0 0 0 
Table 2. Indications for CE in pediatric patients. 
Indications were summarized based on the previous CE studies for pediatric patients, which 
included at least 10 CE examinations for suspected small intestinal diseases (Tokuhara, 2010; 
de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo 
Sant'Anna, 2005; Thomson, 2010; Ge, 2007). We excluded the studies with limited 
indications (ex. abdominal pain alone). (   ), percentage. ND, not described. 
3.2.1 Chron’s disease or inflammatory bowel disease 
CE provides supportive evidence to diagnose or exclude small bowel CD. Thus, CE can be 
used in order to evaluate suspected CD or IBD, small bowel involvement of known CD, or 
follow-up of known small bowel CD. In adults, OGIB is the major indication rather than 
suspected IBD, however in children, suspected CD or IBD became the major indication (Table 
2). Although indication rate of suspected CD or IBD depends on the physicians’ protocol and 
criteria, in regard to the papers in which all of small intestinal disease are included as 
indication, indication rate for suspected IBD varies from 0%-67% and total indication rate is 
27%(138/509). If known CD or IBD are included, indication rate increase up to 56% (285/509) 
(Table 2). On the other hand, a previous study showed the indication rate of suspected CD as 
7.8% in adult patients (Rondonotti, 2010). Because a known CD increases a risk of capsule 
retention possibly caused by an intestinal stricture (Cheifetz, 2006; Moy, 2009; Atay, 2009), it is 
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pediatric patients, completion rate of CE in the entire small intestine varies from 69 – 89 % 
(Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Atay, 2009; de'Angelis, 2007; Ge, 2007; 
Moy, 2009; Postgate, 2009). In order to improve the completion rate, mosapride citrate or 
laxatives are one of candidate to increase the ability to observe the entire small intestine, but 
there is no systematic study in regard to the use of mosapride or laxatives as a preparation 
drug for CE study in pediatric patients. In adults, a previous study (Wei, 2007) reported oral 
10mg mosapride citrate 1h before CE examination could accelerate the gastric emptying 
(13.5 min vs 34 min) and completion rate of small bowel examination ( 93.3 % vs 66.7 % ). In 
regard to the laxatives, a previous study (Franke, 2008) reported that a combination of 
bisacodyl and sodium phosphate significantly accelerated small bowel transit time (262 min 
±55min vs 287 min ± 97min) but had no effect on the visibility of CE. Taken together, in 
order to increase the completion rate of small intestine and carefully examine the mucosal 
abnormality such as angiodysplasias, mosapride or laxatives might be effective preparation 
drug for CE in addition to the overnight fasting as the standard method. 
3. Ages and indications for CE 
3.1 Age 
Accumulated studies confirmed that CE is safe and useful to children over 10 years of age 
(Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 2005; Argüelles-Arias, 2004), and 
application to this age group is considered as appropriate as well as adult. On the other 
hand, it is still controversial to use CE for the children under 10 years of age. Several studies 
described that CE has high diagnostic yield to those patients under 10 years of age 
(de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Ge, 2007), and their small body size 
don’t relate to the risk of capsule retention, which is the most serious complication in this 
modality as described in the latter paragraph. In addition, there was no difference in the 
gastric and small intestinal passage time between adult and pediatric patients (Ge, 2007). In 
young children (1.5-8 yr), a previous study reported CE detected small intestinal pathology 
in 45% (37 of 83 patients) in whom their indications are gastrointestinal bleeding, suspected 
Crohn’s disease, abnormal pain, protein loss and malabsorption (Fritscher-Ravens, 2009). 
Because of no incidence of retention among those aged patients (1.5-7.9yr), CE is considered 
as feasible and safe down to the age of 1.5 yr. As another important aspect, swallowing of 
CE is unavoidable problem in small children. Based on the previous studies, most of 
pediatric patients (>10yr) can ingest CE (Tokuhara, 2010; Guilhon de Araujo Sant'Anna, 
2005). In regard to children > 4yr, 32% of children could ingest CE (Fritscher-Ravens, 2009). 
In case those young children cannot ingest capsule, endoscopic placement of the capsule 
into the duodenum is used (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). In the 
endoscopic placement, CE is released at the third part of the duodenum in order to prevent 
migration of CE back to the stomach (Bizzarri , 2005; Barth, 2004; Fritscher-Ravens, 2009). 
Some of devices are developed and reported (Orendain, 2010), on the other hand, mucosal 
injury by passage of device should be taken into consideration as a complication (Barth, 
2004; Fritscher-Ravens, 2009). As another potential risk regarding the age, complication 
associated with deep intravenous sedation and general anesthesia for the endoscopic 
placement should be taken into consideration. 
 




The indications for CE in pediatric patients are similar to that of adult patients; OGIB and 
suspected IBD are the major indications and suspected or known polyps such as Peutz-
Jeghers syndrome are the following well-studied indication (Table 2). Known CD is also 
well-studied indication, but needs attention before the use of CE because of a relative high 
risk of capsule retention as described later. Malabsorption, protein loss, recurrent abdominal 
pain, and growth failure are the other minor indications, but sometimes important rather 
than adult population because of importance of mental and physical growth in children. 
Celiac disease is one of major indication in adult of Western countries such as USA and 
Europe, but it is rarely included as indication in children. On the other hand, because of 
non-invasive method, CE can be used repeatedly thus has been applied to get information to 
evaluate the treatment of known small bowel disease. Further, CE can provide supportive 
information about further examination, for example, when a physician determine the route 























Age 8~21 1.5~7.9 1.5~18 ND 10~18 9.4~15.9 3~18 10~18 
n 509 207 83 87 46 30 28 16 12 
Indications 
IBD 285 (56) 172 (83) 20 (24) 32 (37) 19 (41) 20 (67) 16 (57) 0 (0) 6 (50) 
(Suspected IBD) 138 (27) 73 (35) 20 (24) 10 (11) 0 (0) 20 (67) 10 (36) 0 (0) 5 (42) 
(Known IBD) 147 (29) 99 (48) 0 (0) 22 (25) 19 (41) 0 (0) 6 (21) 0 (0) 1 (8) 
OGIB 94 (18) 15 (7) 30 (36) 21 (24) 7 (15) 4 (13) 6 (21) 9 (56) 2 (17) 
Polyps 55 (11) 2 (1) 0 (0) 33 (38) 11 (24) 6 (20) 3 (11) 0 (0) 0 (0) 
Abdominal pain 22 (4) 0 (0) 12 (14) 0 (0) 1 (2) 0 (0) 1 (4) 3 (19) 4 (33) 
Protein loss 13 (3) 1 (1) 9 (11) 0 (0) 1(2) 0 (0) 2 (7) 0 (0) 0 (0) 
Malabsorption 13 (3) 0 12 (14) 1 (1) 0 0 0 0 0 
Growth failure 5 (1) 0 0 0 5(10) 0 0 0 0 
Diarrhea 4 (1) 4 (2) 0 0 0 0 0 0 0 
Table 2. Indications for CE in pediatric patients. 
Indications were summarized based on the previous CE studies for pediatric patients, which 
included at least 10 CE examinations for suspected small intestinal diseases (Tokuhara, 2010; 
de'Angelis, 2007; Atay, 2009; Fritscher-Ravens, 2009; Moy, 2009; Guilhon de Araujo 
Sant'Anna, 2005; Thomson, 2010; Ge, 2007). We excluded the studies with limited 
indications (ex. abdominal pain alone). (   ), percentage. ND, not described. 
3.2.1 Chron’s disease or inflammatory bowel disease 
CE provides supportive evidence to diagnose or exclude small bowel CD. Thus, CE can be 
used in order to evaluate suspected CD or IBD, small bowel involvement of known CD, or 
follow-up of known small bowel CD. In adults, OGIB is the major indication rather than 
suspected IBD, however in children, suspected CD or IBD became the major indication (Table 
2). Although indication rate of suspected CD or IBD depends on the physicians’ protocol and 
criteria, in regard to the papers in which all of small intestinal disease are included as 
indication, indication rate for suspected IBD varies from 0%-67% and total indication rate is 
27%(138/509). If known CD or IBD are included, indication rate increase up to 56% (285/509) 
(Table 2). On the other hand, a previous study showed the indication rate of suspected CD as 
7.8% in adult patients (Rondonotti, 2010). Because a known CD increases a risk of capsule 
retention possibly caused by an intestinal stricture (Cheifetz, 2006; Moy, 2009; Atay, 2009), it is 
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recommended to avoid the use of CE for the evaluation of known CD in both adult and 
children. In regard to the diagnostic accuracy, the previous pediatric study elucidated that CE 
was a more effective diagnostic tool in established CD patients compared with small-bowel 
radiography, CTE, and push enteroscopy (Thomson, 2007). Further, CE provides evidence not 
only to diagnose a patient having CD but also exclude CD and discriminate CD from 
indeterminate colitis. The rate of diagnosis of CD in patients with suspected CD depends on 
the study, which was 12.5-70.6% in adult (Cheifetz, 2006; De Bona, 2006; Fireman, 2003), and 
50-55% in children (de'Angelis, 2007; Fritscher-Ravens, 2009; Guilhon de Araujo Sant'Anna, 
2005), thus criteria of suspected CD will be an important issue of concern.  
3.2.2 OGIB and chronic anemia 
Obscure gastrointestinal bleeding (OGIB) including chronic anemia is one of the major 
indication of CE in children as well as in adults (Table 2). In adults, a previous study 
showed the indication rate of OGIB as 43.4% (Rondonotti, 2010). Another study identified 
those patients of having significant findings; small bowel CD, angiodysplasia, Meckel's 
diverticulum, and rarely parasitic infection such as hookworm (Sriram, 2004). In regard to 
the previous studies in which all of small intestinal disease are included as indication, 
indication rate of OGIB in pediatric CE varies from 7.2%-56.2%, and a total indication rate is 
18.4% (94/509) (Table 2). In regard to the outcome of CE for the evaluation of source of 
OGIB, CD, polyp or polyposis and angiodysplasia are the most frequently detected source 
of OGIB in children (Table 3). Hemangioma, ulcerative jejunitis and Meckel’s diverticulum 
are also sometimes found in pediatric patients with OGIB.  In regard to the source of venous 
malformations, Turner syndrome, which caused by loss of part or all of an X chromosome, is 
important in the field of pediatrics. In Turner syndrome, an intestinal telangiectasia is 
described as an association with an estimated incidence of 7% (Eroglu, 2002) and cause 
obscure GI bleeding. A previous report described that CE well detected multiple 
angiectasias and 2 large telangiectasia in the small intestine of a Turner syndrome with 
OGIB (Nudell, 2006). CE can determine the size, the location, and the number of 
telangiectasias, therefore contribute to select medical, surgical, or endoscopic therapy. 
 
Findings  Rate (%) 
Total abnormal findings 69.3 
CD  9.3 
Polyp or polyposis 9.3 
Angiodysplasia  9.3 
Hemangioma*  6.7 
Ulcerative jejunitis 5.3 
Meckel’s diverticulum 4 
Non-specific bleeding lesions 4 
Multiple venous malformations 2.6 
Giant ileal lymphoid nodular hyperplasia 2.6 
Hemorrhagic gastroduodenopathy 2.6 
Asmotic ulcer, Cobble stone appearance, Reduplication of the intestine, NSAID-
induced mucosal lesions, Erosive gastroenteropathy, Ileal bleeding ulcer,  
Multiple small intestinal varices, Ileal stenosis, TAM 
1.3 
* includes Blue rubber bleb syndrome 
Table 3. Outcome of CE in 75 patients with OGIB. 
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As another option, CE provides helpful information in the diagnosis of OGIB in patients 
who was suffered from malignant diseases such as leukemia and received chemotherapy 
and cord-blood transplantation or bone marrow transplantation . Our recent study 
described that CE provided a real-time imaging without patient’s stress and played a 
significant role in the management of OGIB in the malignant disease (Tokuhara, 2010). 
Chronic malignant diseases, such as leukemia, sometimes require repeated evaluation of 
gastrointestinal bleeding, but repeated conventional endoscopy is stressful and invasive, 
especially for seriously ill patients. Thus, repeated CE evaluation was acceptable to these 
patients and did not cause undue physical or mental stress. CE increases patient compliance 
and can therefore provide real-time informations about changes in gastrointestinal mucosal 
lesions without invasive bowel preparation.  
3.2.3 Polyp or tumor 
Although polyps and tumors are commonly detected in adult patients, it is rare to detect 
malignant tumor in pediatric patients thus polyp is a main indication in children. Following 
the 2 major indications (suspected IBD and OGIB), polyp or polyposis are well-performed 
indication (Table 2). In regard to the papers in which all of small intestinal disease are 
included as indication, indication rate of polyps in pediatric CE was 11% (55/509) (0-38%) 
(Table 2). The purpose of CE for the patients with suspected polyposis is diagnosis, follow-
up, selection of route of endoscopy to resect polyp, or determine the necessity of 
laparotomy. Polyp is sometimes found in a patient with OGIB as an indication (Ge, 2007). 
As a known polyposis, Peutz-Jeghers syndrome (PJS), familial adenomatous polyposis 
(FAP), juvenile polyp, and Bannayan-Riley-Ruvalcaba syndrome have been reported. CE 
provided high diagnostic yield (100%, 5/5) to those pediatric patients with suspected 
polyposis (deAngelis, 2007). Another study  examined 6 pediatric patients with known 
polyposis (3 PJS, 2 multiple juvenile polyposis, and 1 familial polyposis) and demonstrated 
that CE had 100% concordance with previously performed imaging modalities, but CE had 
a higher sensitivity revealing 50% more polyps than observed with the traditional imaging 
studies (Guilhon de Araujo Sant'Anna, 2005). Among polyposis, hereditary polyposis 
syndromes including PJS and FAP are known to develop benign small bowel pathology and 
cancer, thus the follow-up for PJS and FAP is especially important.  
In regard to PJS, which is a rare autosomal dominant disorder characterized by 
mucocutaneous pigmentation and the hamartous polyps throughout the gastrointestinal 
tract, diagnosis is made by genetic analysis of STK11 gene mutation or 2 of the 3 clinical 
criteria: family history of PJS, hamarmatous polyps, and mucocutaneous pigmentation 
(Giardillelo, 2006). Intestinal polyps sometimes cause bleeding, anemia, and 
intussusceptions. Further, the patients with PJS have risk of malignancy including intestinal, 
breast, lung cancer in which average age of development of malignancy is the fourth decade 
of life (van Lier, 2010). Their first episode of manifestation also tend to occur during the first 
decade of life. Previous study revealed that 68% of children had undergone a laparotomy for 
bowel obstruction by the age of 18 years and many of these proceeded to a second 
laparotomy within 5 years (Hinds, 2004). Further, PJS sometimes need endoscopic removal 
of polyps or surgical treatment for bowel obstruction. Based on the accumulated studies, it 
has been recommended that endoscopic evaluation of the upper and lower gastrointestinal 
tract and imaging of the small bowel should be performed from the age of 8 years of earlier 
if symptoms are present (Hinds, 2004; Hyer, 2000). Therefore it is important to detect 
malignancies in an early phase and to remove polyps that may be premalignant and may 
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recommended to avoid the use of CE for the evaluation of known CD in both adult and 
children. In regard to the diagnostic accuracy, the previous pediatric study elucidated that CE 
was a more effective diagnostic tool in established CD patients compared with small-bowel 
radiography, CTE, and push enteroscopy (Thomson, 2007). Further, CE provides evidence not 
only to diagnose a patient having CD but also exclude CD and discriminate CD from 
indeterminate colitis. The rate of diagnosis of CD in patients with suspected CD depends on 
the study, which was 12.5-70.6% in adult (Cheifetz, 2006; De Bona, 2006; Fireman, 2003), and 
50-55% in children (de'Angelis, 2007; Fritscher-Ravens, 2009; Guilhon de Araujo Sant'Anna, 
2005), thus criteria of suspected CD will be an important issue of concern.  
3.2.2 OGIB and chronic anemia 
Obscure gastrointestinal bleeding (OGIB) including chronic anemia is one of the major 
indication of CE in children as well as in adults (Table 2). In adults, a previous study 
showed the indication rate of OGIB as 43.4% (Rondonotti, 2010). Another study identified 
those patients of having significant findings; small bowel CD, angiodysplasia, Meckel's 
diverticulum, and rarely parasitic infection such as hookworm (Sriram, 2004). In regard to 
the previous studies in which all of small intestinal disease are included as indication, 
indication rate of OGIB in pediatric CE varies from 7.2%-56.2%, and a total indication rate is 
18.4% (94/509) (Table 2). In regard to the outcome of CE for the evaluation of source of 
OGIB, CD, polyp or polyposis and angiodysplasia are the most frequently detected source 
of OGIB in children (Table 3). Hemangioma, ulcerative jejunitis and Meckel’s diverticulum 
are also sometimes found in pediatric patients with OGIB.  In regard to the source of venous 
malformations, Turner syndrome, which caused by loss of part or all of an X chromosome, is 
important in the field of pediatrics. In Turner syndrome, an intestinal telangiectasia is 
described as an association with an estimated incidence of 7% (Eroglu, 2002) and cause 
obscure GI bleeding. A previous report described that CE well detected multiple 
angiectasias and 2 large telangiectasia in the small intestine of a Turner syndrome with 
OGIB (Nudell, 2006). CE can determine the size, the location, and the number of 
telangiectasias, therefore contribute to select medical, surgical, or endoscopic therapy. 
 
Findings  Rate (%) 
Total abnormal findings 69.3 
CD  9.3 
Polyp or polyposis 9.3 
Angiodysplasia  9.3 
Hemangioma*  6.7 
Ulcerative jejunitis 5.3 
Meckel’s diverticulum 4 
Non-specific bleeding lesions 4 
Multiple venous malformations 2.6 
Giant ileal lymphoid nodular hyperplasia 2.6 
Hemorrhagic gastroduodenopathy 2.6 
Asmotic ulcer, Cobble stone appearance, Reduplication of the intestine, NSAID-
induced mucosal lesions, Erosive gastroenteropathy, Ileal bleeding ulcer,  
Multiple small intestinal varices, Ileal stenosis, TAM 
1.3 
* includes Blue rubber bleb syndrome 
Table 3. Outcome of CE in 75 patients with OGIB. 
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As another option, CE provides helpful information in the diagnosis of OGIB in patients 
who was suffered from malignant diseases such as leukemia and received chemotherapy 
and cord-blood transplantation or bone marrow transplantation . Our recent study 
described that CE provided a real-time imaging without patient’s stress and played a 
significant role in the management of OGIB in the malignant disease (Tokuhara, 2010). 
Chronic malignant diseases, such as leukemia, sometimes require repeated evaluation of 
gastrointestinal bleeding, but repeated conventional endoscopy is stressful and invasive, 
especially for seriously ill patients. Thus, repeated CE evaluation was acceptable to these 
patients and did not cause undue physical or mental stress. CE increases patient compliance 
and can therefore provide real-time informations about changes in gastrointestinal mucosal 
lesions without invasive bowel preparation.  
3.2.3 Polyp or tumor 
Although polyps and tumors are commonly detected in adult patients, it is rare to detect 
malignant tumor in pediatric patients thus polyp is a main indication in children. Following 
the 2 major indications (suspected IBD and OGIB), polyp or polyposis are well-performed 
indication (Table 2). In regard to the papers in which all of small intestinal disease are 
included as indication, indication rate of polyps in pediatric CE was 11% (55/509) (0-38%) 
(Table 2). The purpose of CE for the patients with suspected polyposis is diagnosis, follow-
up, selection of route of endoscopy to resect polyp, or determine the necessity of 
laparotomy. Polyp is sometimes found in a patient with OGIB as an indication (Ge, 2007). 
As a known polyposis, Peutz-Jeghers syndrome (PJS), familial adenomatous polyposis 
(FAP), juvenile polyp, and Bannayan-Riley-Ruvalcaba syndrome have been reported. CE 
provided high diagnostic yield (100%, 5/5) to those pediatric patients with suspected 
polyposis (deAngelis, 2007). Another study  examined 6 pediatric patients with known 
polyposis (3 PJS, 2 multiple juvenile polyposis, and 1 familial polyposis) and demonstrated 
that CE had 100% concordance with previously performed imaging modalities, but CE had 
a higher sensitivity revealing 50% more polyps than observed with the traditional imaging 
studies (Guilhon de Araujo Sant'Anna, 2005). Among polyposis, hereditary polyposis 
syndromes including PJS and FAP are known to develop benign small bowel pathology and 
cancer, thus the follow-up for PJS and FAP is especially important.  
In regard to PJS, which is a rare autosomal dominant disorder characterized by 
mucocutaneous pigmentation and the hamartous polyps throughout the gastrointestinal 
tract, diagnosis is made by genetic analysis of STK11 gene mutation or 2 of the 3 clinical 
criteria: family history of PJS, hamarmatous polyps, and mucocutaneous pigmentation 
(Giardillelo, 2006). Intestinal polyps sometimes cause bleeding, anemia, and 
intussusceptions. Further, the patients with PJS have risk of malignancy including intestinal, 
breast, lung cancer in which average age of development of malignancy is the fourth decade 
of life (van Lier, 2010). Their first episode of manifestation also tend to occur during the first 
decade of life. Previous study revealed that 68% of children had undergone a laparotomy for 
bowel obstruction by the age of 18 years and many of these proceeded to a second 
laparotomy within 5 years (Hinds, 2004). Further, PJS sometimes need endoscopic removal 
of polyps or surgical treatment for bowel obstruction. Based on the accumulated studies, it 
has been recommended that endoscopic evaluation of the upper and lower gastrointestinal 
tract and imaging of the small bowel should be performed from the age of 8 years of earlier 
if symptoms are present (Hinds, 2004; Hyer, 2000). Therefore it is important to detect 
malignancies in an early phase and to remove polyps that may be premalignant and may 
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cause complications. In this regard, it is necessary to understand the size and localization of 
polyps in PJS. CE can evaluate the entire small intestine and contribute to select whether 
polyps should be observed or removed by upper endoscopy, colonoscopy, or double 
balloon enteroscopy. In comparison to conventional technique, a previous study 
demonstrated that CE detected significantly higher numbers of small-bowel polyps (at least 
1cm in diameter) than barium follow-through in adult PJS patients (Brown, 2006). In 
pediatric patients with PJS, CE significantly detected small polyps (<10mm), and was 
assessed as a feasible, safe, and sensitive tool for small bowel screening in patients with PJS 
(Postgate, 2009). Therefore, CE can be used as a first-line surveillance approach in PJS. 
In regar to FAP, which is an autosomal dominant condition with a defect in the APC gene on 
chromosome 5q21, if the patient was left untreated, there is a nearly 100% progression to 
colorectal cancer  by the age of 35–40 yr (Hyer, 2000). The diagnosis is confirmed by finding 
adenomas during flexible sigmoidoscopy, or more than four pigmented ocular fundus 
lesions based on indirect ophthalmoscopy carries a 100% positive predictive value. In FAP-
affected families with a known gene mutation, direct DNA genotypic analysis can 
determine whether a family member has the condition. In children with FAP, 
hepatoblastoma is important as complication rather than intestinal polyps (Aretz, 2006). 
Typical FAP is characterized by the occurrence of hundreds to thousands of colorectal 
adenomas. Adenomas usually appear within the second decade, and become symptomatic 
during the third decade of life. In the patients with FAP, they have high risk to develop 
duodenal adenoma and cancer, thus the duodenum and particularly the periampullary 
region is recognized as a major cause of morbidity and mortality. A previous CE study in 
adult patients with FAP reported that 76% of the patients with FAP with duodenal 
adenomas had additional adenomas in the proximal jejunum in addition to polyps in the 
distal jejunum or ileum, in contrast, in FAP patients without duodenal polyps, jejunal or 
ileal polyps occurred rarely (12%) (Schulmann, 2005). Thus, CE may be useful in selected 
patients with FAP. In children, the feasibility and usefulness of CE is not remarkable in FAP 
compared to PJS. It is necessary to accumulate further studies for FAP in children to 
evaluate the feasibility and usefulness of CE. 
3.2.4 Abdominal pain 
Several CE studies evaluated pediatric patients with abdominal pain. Based on the 
previous studies in which all of small intestinal diseases are included as indication, 
indication rate of abdominal pain in pediatric CE was 4% (20/509), varies from 0.0 % to 
33.0% depends on the studies (Table 2). As for usefulness of CE, it is controversial that 
abdominal pain can be an appropriate indication for CE. In adult patients, a previous 
study described 20 patients with chronic abdominal pain who were negative for extensive 
diagnostic workup, but no patients had clinically significant CE findings (Bardan, 2003). 
On the other hand, another study for adult patients demonstrated that abdominal pain 
with additional symptoms such as weight loss (>10% of body weight), inflammation 
shown by laboratory tests, chronic anemia, and suspected OGIB was associated with high 
diagnostic yield (May, 2007). In addition, another study applied to 16 patients with 
chronic abdominal pain without criteria for other gastrointestinal disorders and detected 
abnormal findings in 3 patients but in which only 1 patient, with additional symptom of 
weight loss, had relevant findings to abdominal pain in which ileal erosions and 
inflammation with a stricture which undetected by radiology (Spada, 2006). Based on 
previous studies in adult population, CE doesn’t provide diagnostic value against 
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abdominal pain itself, and strict patient selection on the basis of additional symptoms of 
signs is the key to increasing the field to capsule endoscopy in patients with chronic 
abdominal pain. In regard to children, a previous study reported that CE detected small 
bowel involvement in 1/10 patients with functional abdominal pain and most of patients 
don’t have the related organic etiology (Shamir, 2007). Another pediatric study described 
that 6/12 patients with abdominal pain had abnormal findings in which 3 with small 
bowel CD, 2 lymph nodular hyperplasia, and 1 blue rubber bleb syndrome, however it is 
undescribed whether those patients had additional symptoms or signs (Fritscher-Ravens, 
2009). CE evaluation for a patient with recurrent abdominal pain reported a self-resolving 
ileojejunal intussusceptions in the mid-small bowel (Thomson, 2007). Taken together, as 
well as adult patients, it is indicated that CE doesn’t provide diagnostic value against 
abdominal pain in children, but additional symptoms or signs may increase the demand 
of CE. On the other hand, in treating children with FAP, it is important to give the family 
the reassurance that no serious disease in present according to physical examination and 
laboratory examination. In this regard, CE provides supportive informations to exclude 
the significant small bowel involvement. In adults, celiac disease might be suggested by 
CE in patients with abdominal pain (Culliford, 2005), but there is no report in pediatric 
population. 
3.2.5 Protein loss 
Protein loss might be included as indication for CE. A previous study evaluated 9 patients 
as having protein loss as a main indication, and revealed, in spite of normal duodenal 
biopsies, 6/9 had abnormal findings in which 4 had lymphangiectasia and 2 had lymph 
nodular hyperplasia (Fritscher-Ravens, 2009). Protein loss originated from the gut is often 
found in children with protein-losing gastropathy such as Menetrier disease (Tokuhara, 
2007). In case of protein loss as an indication, lymphangiectasia is one of the most suspected 
and obtained result by CE. Several reports (Alkhouri, 2009; Tokuhara, 2010;Thomson, 2007) 
described 4 cases of protein loss were identified of having intestinal lymphangiextasia in 
pediatric patients. 
3.2.6 Others 
Malabsorption and growth failure are not main indication for CE, but CE sometimes 
contribute to evaluate those patients. A previous study (MoyL, 2009) reported that CE 
identified 4/7 pediatric patients with unexplained growth failure and normal small bowel 
series as having small bowel CD. In their study, 5/7 patients had positive anti-Saccharomyces 
cerevisiae antibodies (ASCA), a diagnostic serological marker for CD. In addition, 3 patients 
had growth failure with abdominal pain, 2 patients had growth failure with diarrhea and 
apthous ulcers, and 1 patient had a family history of CD. Thus, Growth failure with 
additional symptom might be included as an indication for CE. 
As an optional application, CE can be applied to evaluate the management of 
gastrointestinal diseases such as Henoch-Schonlein purpura (HSP) (Preud’Homme DL, 
2006) and GVHD (Silbermintz, 2006; Yakoub-Agha I, 2004). In HSP, sastrointestinal bleeding 
occurs in ~50% of children, and massive bleeding may occur (Katz, 1991). A previous report 
demonstrated that CE contributed to identify the extent of the small intestinal involvement 
of HSP and confirmed the efficacy of cyclophosphamide therapy in improving the 
gastrointestinal lesions (Preud’Homme DL, 2006). In regard to GVHD, a previous study 
reported that in an 8-yr old child following allogeneic hematopoietic cell transplantation 
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cause complications. In this regard, it is necessary to understand the size and localization of 
polyps in PJS. CE can evaluate the entire small intestine and contribute to select whether 
polyps should be observed or removed by upper endoscopy, colonoscopy, or double 
balloon enteroscopy. In comparison to conventional technique, a previous study 
demonstrated that CE detected significantly higher numbers of small-bowel polyps (at least 
1cm in diameter) than barium follow-through in adult PJS patients (Brown, 2006). In 
pediatric patients with PJS, CE significantly detected small polyps (<10mm), and was 
assessed as a feasible, safe, and sensitive tool for small bowel screening in patients with PJS 
(Postgate, 2009). Therefore, CE can be used as a first-line surveillance approach in PJS. 
In regar to FAP, which is an autosomal dominant condition with a defect in the APC gene on 
chromosome 5q21, if the patient was left untreated, there is a nearly 100% progression to 
colorectal cancer  by the age of 35–40 yr (Hyer, 2000). The diagnosis is confirmed by finding 
adenomas during flexible sigmoidoscopy, or more than four pigmented ocular fundus 
lesions based on indirect ophthalmoscopy carries a 100% positive predictive value. In FAP-
affected families with a known gene mutation, direct DNA genotypic analysis can 
determine whether a family member has the condition. In children with FAP, 
hepatoblastoma is important as complication rather than intestinal polyps (Aretz, 2006). 
Typical FAP is characterized by the occurrence of hundreds to thousands of colorectal 
adenomas. Adenomas usually appear within the second decade, and become symptomatic 
during the third decade of life. In the patients with FAP, they have high risk to develop 
duodenal adenoma and cancer, thus the duodenum and particularly the periampullary 
region is recognized as a major cause of morbidity and mortality. A previous CE study in 
adult patients with FAP reported that 76% of the patients with FAP with duodenal 
adenomas had additional adenomas in the proximal jejunum in addition to polyps in the 
distal jejunum or ileum, in contrast, in FAP patients without duodenal polyps, jejunal or 
ileal polyps occurred rarely (12%) (Schulmann, 2005). Thus, CE may be useful in selected 
patients with FAP. In children, the feasibility and usefulness of CE is not remarkable in FAP 
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abdominal pain itself, and strict patient selection on the basis of additional symptoms of 
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the reassurance that no serious disease in present according to physical examination and 
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As an optional application, CE can be applied to evaluate the management of 
gastrointestinal diseases such as Henoch-Schonlein purpura (HSP) (Preud’Homme DL, 
2006) and GVHD (Silbermintz, 2006; Yakoub-Agha I, 2004). In HSP, sastrointestinal bleeding 
occurs in ~50% of children, and massive bleeding may occur (Katz, 1991). A previous report 
demonstrated that CE contributed to identify the extent of the small intestinal involvement 
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gastrointestinal lesions (Preud’Homme DL, 2006). In regard to GVHD, a previous study 
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who developed large volume bloody diarrhea requiring multiple blood transfusions that 
was resistant to aggressive therapy for GVHD, CE provided significant information not 
provided by upper endoscopy and colonoscopy that allowed for successful treatment 
changes (Silbermintz, 2006). Another study (Yakoub-Agha I, 2004) in adults demonstrated 
that CE provided more significant findings than upper endoscopy in the diagnosis of 
intestinal GVHD. The diagnosis of intestinal GVHD is based upon histological findings in 
endoscopic mucosal biopsy specimens. Therefore, it is sometimes required to use 
colonoscopy and upper endoscopy in order to diagnose and evaluate the extent of GVHD, 
but these tools cannot provide the entire small bowel information. In this regard, CE can 
provide supportive information about small bowel involvement of GVHD and the unknown 
source of OGIB and the effect of treatment. While DBE might be superior approach to CE in 
certain cases, it is an inappropriate option for exhausted children undergoing 
chemotherapy. In this regard, CE evaluation is acceptable to these patients and does not 
cause undue physical or mental stress, thus repeated CE examination is available. 
4. Complications and contraindications 
4.1 Complications 
The most significant complication in the CE examination is capsule retention (Fig.2). 
Capsule retention is defined as having a capsule endoscope remain in the digestive tract for 
a minimum of 2 weeks (Cave, 2005). A preceding normal small-bowel series does not 
preclude subsequent CE retention. The reported capsule retention rate in a study of 900 
adult patients was approximately 0.7% (Barkin, 2002). It should be noted that there are 
potential risks of retention in CD, especially known CD. A previous study in adults 
(Cheifetz, 2006) revealed that CD is an potential risk of having the retention which is caused 
by unsuspected strictures, and retention was occurred in 13% (5 of 38) of patients with 
known CD , whereas in 1.6% (1 of 64) with suspected CD. When we reviewed previous CE 
studies of pediatric patients, which included at least 10 CE examinations for each patient, 
and found that 13 capsules had been retained in a total of 345 CE examinations giving an 
average frequency of capsule retention of 3.7% (range, 0–20%) (Table 4).  
 
 
Fig. 2. Capsule retention.  
Small bowel series showing a capsule retention at ileal stenoses in a 10-year-old girl with 
OGIB. After 2 months of retention, stenoses were surgically resected and a capsule was 
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removed. The patient was finally diagnosed as having non-specific multiple ulcers of small 
intestine (Tokuhara, 2010). 
As well as adult cases, in also pediatric patients, a previous study retrospectively 
demonstrated that the risk of retention was significantly high (37.5% ; 3/8) in known CD, 
whereas none of patients with other indications showed the retention(Atay, 2009) . When 
capsule retention happened, a risk of endoscopic or surgical removal might arise, although 
some reports described successful excretion of capsule after the corticosteroid therapy 
against gastrointestinal disease such as eosinophillic gastroenteropathy(Guilhon de Araujo 
Sant'Anna, 2005). As another severe insults related to capsule retention, a previous study 
described that adult patient with Crohn’s disease had a perforation after capsule endoscopy 
(Parikh, 2009). To decrease the risk of capsule retention and the following perforation, care 
should be taken in obtaining a history of problems with delayed gastric emptying, small 
bowel obstruction secondary to previous surgical changes, pyloric stenosis, Crohn disease, 
or Meckel diverticulum. 
 




Tokuhara, 2010 10y, F OGIB 2 months None Surgical ileal resection (stricture) ** 
de’Angelis , 2007 
F CD 3 months None Spontaneousexcretion CD 




22y, M Known CD 2 y Unknown Passed after medication (ND) 
13y, M Known CD 3 weeks Nausea, emesis
Passed after 
steroid use (ND) 
Thomson, 2010 <16y CD 4 weeks ND Passed after steroid use CD (ND) 
(Transit abnormality) 

























5 days Abdominal pain passed 
Cohen, 2008 ND Known CD ND Ileal pouch endoscopic removal
ND, not described; *Duration of retention or transit abnormalities. ** The patient was finally diagnosed 
as non-specific multiple ulcers of small intestine. 
Table 4. Capsule retention or regional transit abnormalities with symptoms or abnormal 
findings. 
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A novel dissolvable patency capsule will soon be available as a potential screening tool for 
patients deemed to be a high risk for retention. A patency capsule, which similar in size to 
PillCam SB and dissolves spontaneously because it is composed of lactose, has been 
developed by Given Imaging to assess bowel patency and degree of stenosis (Nakamura, 
2008). If passage of the patency capsule is blocked, the capsule dissolves in 40-100h. The 
safety and efficacy of the initial model has been questioned (Gay, 2005), but recently, a new 
patency capsule model with a biodegradable body has been developed. The new patency 
capsule is a reliable indicator of functional patency in suspected or even known cases of 
intestinal stricture, and it can be used prior to conventional CE to predict and minimize the 
risk of retention and impaction (Banerjee, 2007).  
As another rare condition, a previous study reported that a patient having a nervous 
temperament showed the discomfort, headache, and low blood pressure 2 h after capsule 
ingestion (Tokuhara, 2010). Patient temperament might affect outcome, especially among 
children, thus when pediatric patients have a nervous temperament, patient preparation, 
and explanation of the possibility of adverse effects to their legal guardians might be 
necessary. 
4.2 Contraindications 
It is not recommended to use CE in patients with known or suspected gastrointestinal 
obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and 
profile, patients with cardiac pacemakers or other implanted electromedical devices. It is not 
generally recommended to use CE in patients with difficulty of swallowing, but based on 
the development of capsule replacement, it is considerable if the pediatric patient is 
considered to take a benefit by capsule endoscopy even by endoscopic replacement under 
general anesthesia There is no detailed limitation to use CE in small children but it is not 
recommended to use CE under 1.5yr or 10kg of body weight. 
5. Perspective 
Development of capsule endoscopy provides another 2 types of capsule endoscopies 
(PillCam ESO and PillCam COLON) which is for the esophagus and the colon, respectively 
(Eliakim, 2004; Saurin, 2007). The Pillcam ESO capsule differs from the small-bowel capsule 
in that it has a camera at both ends of the capsule and captures a total of 14 images per 
second (7 per second for each camera). The battery life of the Pillcam ESO is approximately 
20 minutes and is approved for esophageal imaging only. The FDA approved the Pillcam 
ESO in November 2004. PillCam ESO and PillCam COLON have been demonstrated of their 
feasibility and usefulness in adult patients with GERD and esophageal varices, and colonic 
neoplasia, respectively. Future application of PillCam ESO and PillCam COLON is expected 
also in pediatric patients. As another interest of issue, therapeutic interventions using a 
capsule endoscope, such as delivery of medication to specific disease sites, smaller size of 
CE, higher quality image, biopsy with remote control are expected in future CE.  
6. Conclusion 
Capsule endoscopy is a non-invasive and effective approach to investigate the entire small 
bowel intestine in the suspected small intestinal diseases of children compared to the 
conventional examination methods (Barium series, computed tomography, push 
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enteroscopy), and provide the evidence in the diagnosis and give the supportive 
informations to evaluate the effect of the treatment and the clinical course. On the other 
hand, a physician and a patient must be aware of that CE is a first-line of surveillance but 
not necessarily a perfect tool to diagnose or exclude a disease thus other examination such 
as double-balloon endoscopy might be needed for histological examination or resection of 
lesions. In addition, especially in known CE, there is a risk of capsule retention which might 
need endoscopic or surgical removal. In those patients who are unable to swallow the 
capsule, endoscopic replacement of capsule is available . Major diagnostic yield is expected 
in patients having indications of suspected IBD, OGIB, and suspected polyps. Abdominal 
pain, malabsorption, protein loss, and growth failure might be included as indication 
especially when they accompanied additional clinical or laboratory signs suggesting 
inflammation. Relatively small number of CE studies in children compared to adult, it needs 
further consideration to use CE in small children at least under 10 years of age as well as 
children over 10 years of age and adults, it is clear that clinical application of CE in pediatric 
population is extending and there is small children who had benefit by the use of CE. For 
the future, together with accumulation of clinical studies, further development of CE such as 
smaller size of CE which is appropriate to small children, increased quality of images, 
option of biopsy, remote control are expected.  
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1. Introduction 
The gold standard for evaluating pathologies of the large bowel, including screening for 
colorectal cancer, is optical colonoscopy, in spite of the fact that it is an invasive procedure 
and needs to be performed by an expert endoscopist. Colon capsule endoscopy is a new 
minimally invasive diagnostic procedure for exploring the large bowel. It does not require 
sedation, air insufflation or intubation. The few available clinical studies on this device have 
shown levels of safety, feasibility and performance as being comparable to those of optical 
colonoscopy. Colon capsule endoscopy is also well tolerated by the patients and it is 
currently considered an   acceptable alternative for cases of "incomplete" colonoscopy, as 
well as for subjects unwilling to undergo the optical colonoscopy procedure, or those with 
contraindications for an invasive procedure. This raises the question of whether colon 
capsule endoscopy can eventually replace optical colonoscopy as a diagnostic tool. On the 
one hand, its has the advantage of being highly likely to increase compliance for undergoing 
colorectal cancer screening among asymptomatic individuals. On the other hand, its 
preparation protocols are even more stringent than those for optical colonoscopy, and the 
detection of suspected or obvious pathology mandates that the individuals return to 
undergo optical colonoscopy. Moreover, since the capsule does not expulse by 10 hours (the 
maximum battery life) for various reasons in approximately 8% of the cases, the colon will 
not have been examined in its entirety. We believe that colon capsule endoscopy will 
eventually replace optical colonoscopy as a first-line procedure when solutions are found for 
those drawbacks 
2. Cololrectal cancer screening  
Colorectal cancer (CRC) is the second leading cause of cancer death, and accounts for 
approximately 9% of cancer deaths overall (Jemel, 2010)  Optical colonoscopy  (OC) is a 
procedure in widespread use and the one advocated as the procedure of choice for 
screening and prevention of CRC by many authors (Brenner et al' ,2010;Baxter et al' 2009)  In 
spite of its being the gold standard for CRC screening, OC has several limitations: only an 
experienced endoscopist is qualified to perform it (Rex,2002), limited endoscopy resources 
may limit its application for large, population-based screening programs, it must examine 
the entire colon, including cecum intubation (Shah,2007;Rex,2006), and it is an invasive 
procedure that requires sedation, with discomfort and embarrassment to the patient, leading 
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procedure in widespread use and the one advocated as the procedure of choice for 
screening and prevention of CRC by many authors (Brenner et al' ,2010;Baxter et al' 2009)  In 
spite of its being the gold standard for CRC screening, OC has several limitations: only an 
experienced endoscopist is qualified to perform it (Rex,2002), limited endoscopy resources 
may limit its application for large, population-based screening programs, it must examine 
the entire colon, including cecum intubation (Shah,2007;Rex,2006), and it is an invasive 
procedure that requires sedation, with discomfort and embarrassment to the patient, leading 
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to low compliance rates (Bujanda,2007). Moreover, previous studies (Barclay,2006; 
Bensen,1999)) have documented variations in OC procedures, adenoma detection rates and 
colonoscope withdrawal times among examiners (Rex 1997; Barclay,2006). The overall 
reported miss rate for neoplastic polyps ranges from 8-24% (Bensen,1999;Rex 1997,). Several 
Canadian case control and cohort studies found that colonoscopy reduced the incidence and 
mortality of distal but not proximal CRC (Singh,2010a; Singh,2010b;Lakoff,2008).  
There are other drawbacks associated with OC. The need for sedation requires that the 
examinee have an escort home, it increases the costs, and it may induce complications, such 
as cardiac arrhythmias, hypotension, oxygen desaturation, and others OC also carries a the 
risk of perforation of about one in 1,000 cases and death in about one in 5,000 cases 
(Orsoni,1997;Weitzmann,2001). It may fail to demonstrate the entire colon in 10–15% of 
cases, and may miss up to 10–20% of polyps <1 cm in size (Shah, 2007; Rex, 2006; Bresselr, 
2004; Picakardt, 2004; Heresbach , 2008;). Finally, the miss rate of OC for large adenomas 
and malignancy has been shown to be about 12% and 5%, respectively (17-19). All these 
negative factors can impact on the compliance in asymptomatic subjects who consider OC 
for colorectal screening.  
3. Colon Capsule Endoscopy (CCE) 
CCE represents a new diagnostic technology for colonic exploration. Its objectives are to 
pass through the entire colon while transmitting images similar to OC, as well as to identify 
colonic pathologies. The ultimate goals are for it to complement or eventually replace the 
diagnostic OC for CRC screening and for diagnosing obscure gastrointestinal (GI) bleeding, 
the cause of positive fecal occult blood tests, iron deficiency anemia, and suspected 
inflammatory bowel disease (i.e., determining the disease extent or even monitoring 
mucosal healing in established cases). It is also intended to provide information in cases of 
incomplete colonoscopy and be applicable when OC poses a significant risk or is 
contraindicated, such as for patients with co-morbidities which preclude sedation or bowel 
preparation.  
3.1 Technical description and operational data 
The CCE system (Given Imaging Ltd., Yoqneam, Israel) consists of a battery-powered video 
capsule with two imagers, one at each end of the capsule. The capsule transmits signals 
through an antenna-lead array to a small data recorder worn around the waist of the 
examinee. The data can then be uploaded to a personal computer-based workstation and 
viewed with the RAPID® software.  
The first generation Pillcam Colon capsule is 11 X 31 mm in size and has two wide-angle 
(156 degrees) imagers, one at each end. The frame acquisition is set at a constant rate of 4 per 
second (i.e., 2 frames per second per camera). The capsule's activity starts automatically 
upon removal from its packaging. Three minutes after being swallowed, the capsule enters 
into a "sleep" mode for one hour and 45 minutes, after which it becomes activated and starts 
recording. 
The second generation Pillcam Colon 2 (Figure 1) is 11.6 X 31.5 mm in size and has two 
wide-angle (176 degrees) imagers, one at each end, yielding an almost 360º coverage. It is 
equipped with an adaptive frame rate (AFR) feature of 4-35 frames that vary depending on 
its rate of movement. The Pillcam Colon 2 captures images at an initial constant rate of 14 
frames per second until the small bowel is reached.  
 





Fig. 1. PillCam®Colon Capsule 2nd generation 
When it identifies the small bowel, the AFR feature is activated and the image acquisition 
function switches to the variable rate mode. The adaptive frame rate feature maximizes 
tissue coverage, optimizes the length of recording, conserves battery power and provides a 
smooth video replay. The main differences between the two models are summarized in 
Table 1 
 
Pillcam Colon 2nd 
generation 
Pillcam Colon 1st 
generation Parameter 
Bidirectional One-way Communication 
Adaptive (4-35) Constant (4 per second) Frame rate (per second) 
Simple Multi-step Two click process Polyp size estimation 
176º 156º Field of view  
Automatic  Light control 
Advanced 1st generation Optics  
Real-time image rate  
control 
Guidance  
(medical staff, patient) 
Storage of capsule video Data recorder 
Table 1. The differences between the two colon capsule    
The data recorder within the capsule of a CCE system has several important features: 
bidirectional communication ability that helps control the frame rate,. a notification feature 
which alerts and helps guide the patient through the process, and 3. a real-time viewing 
capability by means of a liquid crystal diode display (Eliakim ,2006). 
3.2 Clinical data 
Despite the great enthusiasm generated by this new technique, there are only a few clinical 
studies in the literature (Eliakim,2006,2009,2010,;Schoof,2006;Van Gossum,2009;, Sacher-
Huvelin2010; Rokkas,2010; Sieg ,2010 Pilz,2010, Spade 2010,2011a,2011b;Fireman,2007), and 
the reported results in the initial ones on the first CCE generation (Eliakim,2006, 
Schoof,2006; Van Gossum,2009) showed low sensitivity, specificity and predictive values. 
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the reported results in the initial ones on the first CCE generation (Eliakim,2006, 
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The first two pilot studies (Eliakim,2006;Schoof,2006) demonstrated the feasibility and safety 
of CCE, however, a multicenter study that evaluated the detection of polyps and 
malignancy reported that the sensitivity of the technique was limited (Van 
Gossum,2009).The published data on the sensitivity and specificity are summarized in 
Tables 2-6.  
 
Specificity (%) Sensitivity (%) No. Patients CCE Reference 
71 58 545 1
st 
generation Sacher-Huvelin et al. 
54 79 59 1
st 
generation Pilz, et al 
78 72 328 1
st 
generation Van Gossum et al. 
89 73 626 1
st 
generation Rokkas et al. 
75 71 837 1
st 
generation Spada et al.
(2010) 
CCE, colon capsule endoscopy 
*Meta-analysis  
Table 2. Sensitivity and specificity for any type and size of polyp 
These reported results were analyzed and grouped in different subgroups, according to the 
size and type of polyp. For "any" polyp, the sensitivity and specificity ranged between 58-
79% and 54-89%, respectively (Table 2). For polyps ≥6 mm in size, the sensitivity and 
specificity were 39-69% and 73-88%, respectively, for the first generation CCE (Eliakim,2006 
,2010,Schoof,2006;Van Gossum,2009;, Sacher-Huvelin2010; Rokkas, 2010; Pilz,2010, Spade 
2010,2011), and 89% and 76%, respectively, for the second generation CCE (27) (Table 3). 
 
Specificity (%) Sensitivity (%) No. Patients CCE Reference 
88 39 545 1st generation Sacher-Huvelin et al. 
84 64 328 1st generation Van Gossum et al. 
76 50 59 1st generation Pilz et al. 
83 58 91 1st generation Eliakim et al(2009) 
73 60 41 1st generation Schoofs et al.22 
86*  69*  626 1st generation *Rokkas et al.25 
82 68 837 1st generation *Spada et al(2011) 
87 63 40 1st generation Spada et al(2011) 
76 89 104 2nd generation Eliakim et al(2009) 
CCE, colon capsule endoscopy *Significant polyp: >6 mm or ≥3 polyps of any size. 
Table 3. Sensitivity and specificity for polyps ≥6 mm  
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The sensitivity and specificity of CCE for advanced adenoma ranged between 72-73% and 
57-79%, respectively (Table 4), and the sensitivity and specificity for malignant lesions 
ranged between 60-76% and 74-100%, respectively (Table 5). 
 
Reference CCE No. Patients 
 
Sensitivity (%) Specificity (%) 
Sacher-Huvelin et al. 1st generation 545 72 57 
Van Gossum et al. 1st generation 328 *73  79* 
CCE, colon capsule endoscopy*Advanced adenomas (≥6 mm) 
Table 4. Sensitivity and specificity for advanced adenoma 
 
Reference CCE No. Patients  Sensitivity (%) Specificity (%) 
Sacher-Huvelin et al. 1
st 
generation 
545 60 100 
Van Gossum et al. 1
st 
generation 
328 74 74 
Spada et al. (2010) 1
st 
generation 
837 76  
CCE, colon capsule endoscopy*Meta-analysis 
Table 5. Sensitivity and specificity for colorectal cancer 
OC considered the gold standard, in this context it is important to understand that there 
are various limitations, for example the fact that the findings that were demonstrated on 
CCE and not on OC were considered as false positive, a fact which could account for an 
artificial low specificity. The latter is due to the possibility that at least in some cases the 
capsule endoscopy identified lesions that colonoscopy missed. Indeed, in a large multi-
center French study (Sachaer- Huvelin,2010) that offered a repeat colonoscopy for these 
patients the differences in accuracy between CCE and optical colonoscopy were 
minimized.  So  that the CCE specificity might practically represent the supremacy of the 
CCE over OC.  Another cofactor is the fact that in most studies the majority of subjects 
included were known to have an established or suspected colonic disease (past history of 
adenomas or colon cancer, abnormal imaging findings etc.) or a high clinical suspicion of 
colonic disease (rectal bleeding, hematochezia, melena, positive occult blood, change in 
bowel habits, diarrhea or constipation). An example of such study is the one reported by 
by Van Gossum et al (Van Gossum,2009). In other studies, the total number of subjects 
that were recruited was limited and the percentage of subjects that were referred for 
screening was small. For example the article by Eliakim et al. (Eliakim 2009) recruited 
about 104 patients, of whom 32% were referred for screening.  Pilz et al. (Pilz,2010),a total 
of 59 subjects were recruited of whom  only 41% were referred for screening. A study 
which examined the issue of screening and surveillance in a more targeted fashion 
(Sacher-Huvelin,2010) included 545 subjects of whom about 30% were at an average risk 
(screening) and 70% were at an increased risk (surveillance) failed to demonstrate non 
inferiority in relation to colonoscopy. Sensitivity and specificity in this sample was about 
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st 
generation Rokkas et al. 
75 71 837 1
st 
generation Spada et al.
(2010) 
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Table 3. Sensitivity and specificity for polyps ≥6 mm  
 
Capsule Endoscopy - 2011 
 
187 
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39% and 88% respectively for polyps of 6 mm or larger. The researchers concluded that 
the CCE cannot yet replace the optical colonoscopy as a first choice for screening and 
surveillance purposes. 
It should be noted that the reported sensitivity of CT colonography for detecting polyps≥6 mm 
as reported in an article by Johnson et al. (Johnson,2008) is about 78%, a figure which is higher 
than most of those reported for sensitivity for the first generation CCE, however, for the 
second generation CCE.  Eliakim et al. (Eliakim,2009) and Spada et. al. (Spada, 2011) reported  
for sensitivity 89% and 84% respectively(Table 6). 
 
 1st generation 2nd generation# 
Study Van Gossum Eliakim(2009) Spada(2011) 
No site 8 European 5 Israeli 8 European 
No. Patients 320 98 109 
Polyp≥6 mm 
Prevalence 27%(87) 24%(35) 41%(45) 
Sensitivity 64% 89% 84% 
Specificity 84% 76% 64%/92%* 
Polyp ≥10 mm 
Prevalence 16%(50) 14%(20) 29%(32) 
Sensitivity 60% 88% 88% 
Specificity 98% 89% 95% 
*After unblinding  
Table 6. The first vs. 2nd  generation Colon Capsule  
Thus, the sensitivity, specificity and accuracy are insufficient for recommending CCE for 
wide clinical use,— at least for the first generation CCE — as concluded by Van Gossum et 
al (Van Gossum,2009). The technological improvements of the second generation CCE show 
promising and encouraging results, as was shown by a recent publications (Eliakim,2009, 
Spada,2010) (Table 6). More in-depth studies on screening average-risk populations as well 
as surveillance of at-risk populations are warranted, with an eye towards extending the 
indications for CCE. 
4. Preparation protocol 
The colon must be clean of any residual material in order to perform CCE, unlike the case of OC 
where it is possible to suction it. A typical preparation protocol, as described in an article by 
Eliakim et al. (Eliakim,2009) (Table 7), includes a diet based on clear liquids to be followed the 
day before the examination, a split dose of 4 liters of polyethylene glycol (PEG) solution (2 liters 
during the evening before the examination and 2 liters in the morning of the examination), oral 
sodium phosphate boosters and a bisacodyl suppository. The aim of the sodium phosphate and 
bisacodyl additions is to maintain a clean colon and expedite the passage of the capsule down 
the bowel and its excretion within 10 hours following capsule ingestion. 
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DAY BEFORE EXAMINATION  
All day Clear liquid diet 
Evening 2 liters polyethylene glycol 
EXAMINATION DAY  
07:00 2 liters polyethylene glycol 
10:00 Capsule ingestion 
1st booster (at detection of capsule in the 
small bowel) 30 ml sodium phosphate and 1 liter water 
2nd booster (3 hours after 1st booster) 15 ml sodium phosphate and 0.5 liter water 
Suppository (2 hours after 2nd booster) 10 mg bisacodyl 
Table 7. Typical preparation protocol 
Similar protocols have been described in various studies (Table 8). Attempts to replace the 










Yes Yes Yes Tegaserod 1-2 3 Eliakim et al. 
Yes No Yes Domperidone 2 4 Schoofs et al 
Yes No Yes Domperidone 2 4 Van Gossum  et al 
Yes Yes Yes Metoclopramide2 4 Eliakim  et al.(2009) 
PEG, polyethylene glycol; NaP, sodium phosphate 
Table 8. Colonic preparation  
4.1 Preparation quality 
Various studies have addressed the issue of grading the quality of bowel preparation. Colon 
cleanliness is usually categorized into excellent, good, fair, or poor. For ease of reporting and 
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4.1 Preparation quality 
Various studies have addressed the issue of grading the quality of bowel preparation. Colon 
cleanliness is usually categorized into excellent, good, fair, or poor. For ease of reporting and 
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for statistical analyses, most studies use the combinations of good-excellent and poor-fair 
(Table 9). Other studies have reported the quality of preparation as clean, moderate, or poor 
(Eliakim,2009). In addition to cleansing, bowel preparation for CCE also aims to facilitate the 
progress of the capsule through the digestive system as well as to keep certain amounts of 
clear liquids within the colonic lumen in order to allow visualization of the colonic mucosa. 
The latter is also known as the "submarine view", which substitutes for the insufflation and 







Sacher-Huvelin et al. 52 48 
Schoofs et al 88 12 
Eliakim et al(2006) 84.4 15.6 
Van Gossum et al.  72 28 
Spada et al (2010) 70 30 
Spada et al(.2011) 42.5 57.5 
Eliakim et al.( 2009) 78 22 
*Meta-analysis 
Table 9. Colon cleanliness 
As with all other imaging methods of exploring the colon, the quality of bowel preparation 
significantly affects the quality of a CCE study's interpretation and results. Unlike OC, the 
capsule requires a clean colon for a relatively long period of time and, as noted earlier, there is 
no means of remove content. Several studies have addressed the influence of bowel 
preparation on the CCE sensitivity.  One large European multicenter study (Van Gossum 
,2009), which recruited about 328 subjects, found a significant effect of bowel preparation on 
the CCE sensitivity, with a negligible impact on its specificity. Those authors noted that the 
sensitivity and specificity for polyps ≥6 mm in patients with excellent or good bowel 
preparation were 75% and 84%, respectively, compared with 42% and 84% fair or poor 
preparation. For lesions consistent with advanced adenoma, excellent or good bowel 
preparation yielded a sensitivity and specificity of 88% and 78% respectively, while fair to 
poor bowel preparation had a sensitivity and specificity of 44% and 81%, respectively. 
Therefore, it emerges that one of the limitations of CCE is the need for aggressive preparation 
protocol, which has a negative effect on patients' compliance (Van Gossum ,2009). 
5. Capsule egestion  
Capsule egestion while the battery is still operating is an important issue in terms of achieving 
a complete study of the bowel (Table 10). The location of the CCE within the colon upon "wake 
up" was also an important factor for the first generation of the Pillcam colon capsule. 
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At 10 hours 
(%) 
At 8 hours 
(%) 
At 6 hours 
(%) 
Reference 
91   Sacher-Huvelin et al. 
92.8  69.1 Van Gossum et al 
64   Pilz et al 
 81 65 Eliakim et al.(2009) 
Table 10. Capsule egestion 
The absence of information from any location of the CCE distal to the cecum has been 
associated with loss of crucial information and considered as being an incomplete result. 
Although this phenomenon has been reported in only a minority of subjects, it still 
constituted a major pitfall of the procedure. In this context, Van Gossum et al (Van 
Gossum,2009). reported that after one hour and 45 minutes (consistent with the CCE 
"sleeping mode" phase), the capsule was found at or distal to the cecum in 312 of 320 
patients (97.5%), within the cecum in five (1.5%), in the ascending colon in two (0.6 %), and 
the sigmoid colon in one (0.3%). The Pillcam Colon 2 technology has overcome this obstacle 
by its unique AFR feature. 
6. Adverse events 
Minimal side effects were reported in various studies on CCE. Most of them were mild to 
moderate in severity (e.g., nausea, abdominal pain, etc.), and they were mainly related to the 
bowel preparation. In their meta-analysis on CCE, Spada et al.(Spada 2011) reported that the 
rate of these side effects was ranged between 2.6 to 5.6%. 
6.1 Patient satisfaction 
Only limited information is available on patient satisfaction with CCE. When tested on a 
visual analogue scale, the results were only slightly better for CCE compared to OC (Sacher-
Huvelin,2010). Of 53 subjects who underwent colonoscopy in a CCE study published by Pilz 
et al. (Pilz, 2010), 40% preferred the CCE, 38% preferred OC, and 23% had no preference. 
6.2 CCE advantages and drawbacks 
Advantages of this method are not needing sedation, intubation or air insufflation, thus 
obviating the risks of complications associated with an invasive test, especially in cases 
where the capsule yields negative results and colonoscopy is not required. The examination 
itself is free of pain and the examinee can carry on with regular activities. When CCE locates 
abnormal findings and the patient is referred to OC, the endoscopist knows in advance the 
size and location of the lesion. There is certain logistical limitation: in the case of abnormal 
findings on CCE, the patient can be spared undergoing a second cleansing preparation only 
if the CCE video is reviewed promptly and OC can be scheduled at short notice.  
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In terms of disadvantages, OC permits lens clearing by applying water jet, suctioning of 
colonic contents and irrigation capability, thus allowing visualization of the colonic mucosa 
and the interpretation of images obtained during colonoscopy at a lower level of cleanliness 
than that required by CCE. Because CCE lacks these features, a more intensive bowel 
preparation is required. Another reason for a more stringent bowel preparation is the need 
to facilitate capsule passage and allow a certain amount of clear liquids within the colonic 
lumen in order to enable visualization of the mucosa (made possible with the aid of air 
insufflation in OC). This aggressive bowel preparation might well be responsible for low 
compliance rates for undergoing CCE. 
Another disadvantage of the CCE is the lack of therapeutic capabilities, even though several 
studies have shown that polyps <6 mm in size do not need to be removed due to the 
relatively low risk of malignancy (Johnson,2008;Pickhardt,2003). Furthermore, virtual 
colonoscopy does not capture images of polyps <6 mm. Limited battery power which 
sometimes precludes the ability to complete a full study is another drawback. Although the 
second generation CCE can save battery power through its AFR feature and do so without 
losing information (compared with the "sleeping mode" of the first generation CCE), this 
still poses a limitation, especially in cases where the capsule has been delayed in the 
stomach or small intestine. 
The last issue in this respect is the high cost of the CCE system, which is a major factor in 
currently limiting its extensive clinical use. 
6.3 Limitations of the research methodology 
The element of reviewers' experience in interpreting CCE images is a significant factor. 
Gastroenterologists have accumulated considerable experience in OC, while experience with 
CCE is far more limited. Eliakim et al (Eliakim,2006) reported that the specificity values of 
CCE ranged from 83% to 100%, depending on the reviewers' experience. Notably, most 
studies on CCE recruited subjects who were not representative of a typical screening 
population, so that their data could not be used to draw conclusions about the use of CCE in 
the setting of routine screening.  
7. Conclusions 
Based on currently available data, CCE can not be recommended as a substitute for OC, but 
it can serve as a supplementary test in cases of incomplete colonoscopy, when there are 
contraindications to colonoscopy, or for patients who are unwilling to undergo colonoscopy. 
The improvements afforded by the second-generation capsule are promising and 
encouraging, and such enhanced technology will lead to more widespread use that will 
reduce the cost of testing.  Expectations in the future of CCE include self-propelled capsules, 
a more efficient/external energy source, a side imager for extending the field of view and 
minimizing blind areas, and a mouth to anus capsule with the ability for complete 
evaluation of all parts of the digestive system (e.g., in cases of obscure GI bleeding). 
Shortening the period of capsule reading and initial analysis of the images by a 
computerized "reviewer", and expanding the capsule to other fields, such as motility 
assessment, will add to the attractiveness of CCE in the clinical setting. 
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than that required by CCE. Because CCE lacks these features, a more intensive bowel 
preparation is required. Another reason for a more stringent bowel preparation is the need 
to facilitate capsule passage and allow a certain amount of clear liquids within the colonic 
lumen in order to enable visualization of the mucosa (made possible with the aid of air 
insufflation in OC). This aggressive bowel preparation might well be responsible for low 
compliance rates for undergoing CCE. 
Another disadvantage of the CCE is the lack of therapeutic capabilities, even though several 
studies have shown that polyps <6 mm in size do not need to be removed due to the 
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7. Conclusions 
Based on currently available data, CCE can not be recommended as a substitute for OC, but 
it can serve as a supplementary test in cases of incomplete colonoscopy, when there are 
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The improvements afforded by the second-generation capsule are promising and 
encouraging, and such enhanced technology will lead to more widespread use that will 
reduce the cost of testing.  Expectations in the future of CCE include self-propelled capsules, 
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assessment, will add to the attractiveness of CCE in the clinical setting. 
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1. Introduction 
Gastrointestinal (GI) endoscopy has been widely used for detection, differentiation and 
staging for neoplasia in the digestive tract, and has made great progress during the last 
decade (Sivak, 2006). Diagnostic accuracy can be enhanced by better training, more efficient 
techniques, and the development of new image-processing technologies (Cotton et al., 2006; 
Tajiri, 2007); however, diagnosis using conventional endoscopy with optical characteristics 
is essentially limited because it is based on morphological changes and/or discoloration. 
Chromoendoscopy can enhance surface structure and to determine demarcation borders but 
is not enough for screening out of early cancer because it is still depending on endoscopists’ 
expertise and biopsy. Auto-fluorescence imaging system has been applied for lesions which 
have been difficult to morphologically recognize or are indistinct with conventional 
endoscope and this system has potential application for the diagnosis of dysplastic lesions 
and early cancers in the gastrointestinal tract. Optical digital enhancing method such as 
narrow band imaging (NBI), flexible spectral imaging color enhancement (FICE) and i-
SCAN are novel endoscopic techniques which can distinguish neoplastic and non-neoplastic 
lesions without the dye. Magnifying endoscopy in combination with optical digital method 
has an obvious advantage; the analysis of the epithelial pit pattern and the vascular 
network. Some of other techniques are allowing us to visualize cell morphology on the 
micro level reflection of microscopic characteristics. However, we should solve these 
problems; how to combine these technologies in diagnostic strategy, how to apply them into 
the algorithm for therapeutic decision and how to standardize several classifications of 
morphology surrounding them.  
‘Molecular imaging’ is a concept representing the most novel imaging methods in medicine, 
and the definition of the word is controversial. It is broadly defined as ‘the in vivo 
characterization and measurement of a biological process at the cellular molecular level’ 
(Weissleder & Mahmood, 2001) or as the technique that ‘directly or indirectly monitor and 
record the spatiotemporal distribution of molecular and cellular processes for biochemical, 
biological, diagnostic, or therapeutic application’ (Thakur & Lentle, 2005). Positron emission 
tomography (PET) might be included in a wide concept of molecular imaging methods: the 
detection, spatial localization, and quantification of specific molecular targets and events 
that form the basis of pathologies (Mahmood & Wallace, 2007). In the clinical setting of 
medical fields, a major paradigm shift has been rapidly taking place in imaging technology 
represented by PET. Similarly, in the field of GI endoscopy, the authors propose rapid 
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development of ‘endoscopic molecular imaging’, which is considered to be divided into 
three categories: (a) visualization of cell morphology on the micro to nano level; (b) 
reflection of spectroscopic characteristics; and (c) visualization of molecular characteristics. 
The future of endoscopic diagnosis is likely to be affected by a combination of biomarkers 
and technology (Takayama et al., 1998), and ‘endoscopic molecular imaging’ would be 
defined as (c), which has been described as ‘immunoscopy’ (Keller et al., 1998), 
‘bioendoscopy’ (Pasricha & Motamedi, 2002), and ‘optical biopsy’ (Fujimoto et al., 1995). 
These innovations will allow us not only to locate a tumor but also useful to 1) differentiate 
malignant and benign polyps and ulcers, 2) minimize number of biopsies and frequency of 
surveillance, 3) accurate preoperative identification of tumor margin, 4) evaluate 
effectiveness of pharmacological therapy, 5) detect local dysplasia in Barrett’s mucosa or 
ulcerative colitis. These will also allow us to visualize its molecular characteristics (e.g. DNA 
mutations and polymorphisms, gene and/or protein expression), and the activity of specific 
molecules and biological processes that affect tumor behavior and/or its response to 
therapy (Weissleder, 2006).  
Hsiung et al. detected in vivo human colonic dysplasia using a targeted heptapeptide 
topically administered and confocal microendoscopy in 2008 (Hsiung et al., 2008). Recently, 
Goetz et al. used confocal laser endomicroscopy (CRE) and fluorescently labeled epidermal 
growth factor receptor (EGFR) and succeeded in differentiating EGFR expression patterns in 
xenograft tumors and human neoplastic tissue samples (Goetz et al., 2010). These are 
promising future technologies that will play a central role in gastrointestinal oncology. We 
have been attempting to develop a novel imaging method using antibodies labeled with a 
fluorescent marker excitable by infrared rays and imaging modalities. In this section, we 
will describe our results and future directions of endoscopic molecular imaging in 
gastrointestinal oncology. 
2. Characteristics of infrared fluorescence 
Infrared radiation is light with wavelengths between 780 nm and 100 μm, and it has high 
permeability and safety compared to ultraviolet rays. These characteristics have been applied 
to various technologies such as non-destructive analysis of agricultural products, and infrared 
photography has been especially investigated in the medical field (Gibson et al., 1965; Mimura 
& Okuda, 1981). Infrared endoscopy has been used as a special diagnostic tool for examination 
of the gastrointestinal tract with or without intravenous injection of indocyanine green (ICG) 
(Kohso et al., 1990; Ohta et al., 1994; Iseki et al., 2000; Mataki et al., 2003; Ishihara, 2010) ; ICG is 
widely used as a reagent for clinical examination of hepatic function (Fox & Wood, 1960). ICG 
is a fluorescent agent that absorbs infrared rays and produces visible spots at the maximum 
wavelength of 805 nm (Nimura et al., 2004). ICG emits wavelengths of 807-832 nm on 
excitation at around 770 nm (Benson & Kues, 1978; Mordon et al., 1998; Muguruma et al., 
1999). Taking advantage of this characteristic, infrared fluorescence is used for retinal 
angiography (Flower, 1973) and the evaluation of burn depth (Still, 2001) and the patency of 
cardiac venografts (Detter et al., 2002). Recently, this property was applied to gastrointestinal 
blood vessels using a CCD camera (Borotto et al., 1999). In the living body, components or 
elements emit fluorescence of 310-540 nm when excited at 280-370 nm. In addition, there is 
little background noise in the living body (Shealy et al., 1995), especially in the digestive tract, 
which makes infrared fluorescence a likely candidate for development as a novel diagnostic 
system (Ganz, 2004; Okamoto et al., 2005). Several kinds of labeling agents for detecting 
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carcinomas in the digestive tract have been reported (Tatsuta, 1989; Pelegrin, 1991; Ballou et 
al., 1998), some of which fluoresce in visible or ultraviolet rays. However, application of UV is 
not suitable because it damages living tissue (Davies, 1995). ICG seems to be a suitable 
molecule for immunofluorescent diagnosis in the digestive tract such as esophagus, stomach, 
and colon because of its spectral properties and low toxicity.  
3. Fluorescent agents 
Although ICG binds albumin in a non-covalent way in the blood, it lacks a protein-binding 
group to bind antibodies. Therefore, we developed an ICG-N-hydroxysulfosuccinimide ester 
(ICG-sulfo-OSu) (Figure 1A) that has the ability to bind to proteins (Ito et al., 1995). The 
physiochemical characteristics resembled those of ICG: the absorption maximum was 795 nm, 
and it has a specific fluorescence emission at 807 nm upon excitation at 768 nm. However, the 
fluorescence intensity was not sufficient when it was labeled with an antibody. Consequently, 
Nagao et al. developed ICG-acylthiazolidinethione (ICG-ATT) (Figure 1B) (Hirata et al., 1998), 
which consists of the ICG skeleton, an alkyl side chain, and the thiazolidinethione amide 
group. The absorption maximum was 789 nm, and the fluorescent maximum was 830 nm 
upon excitation at 765 nm, reflecting the structure of the original ICG-dye moiety. Both 
materials proved to be near-infrared fluorescent agents (Figure 2), but it is unknown if ICG 
derivatives are toxic to living body in a clinical setting. Although precise toxicity tests have not 
been performed yet, ICG derivatives are expected to be non-toxic because the basic structures 
of these materials are similar to ICG, which is non-toxic.  
 
 
Fig. 1. The chemical structure of ICG-derivative; ICG-sulfo-OSu (A) and ICG-ATT (B). ICG-
sulfo-OSu has an ester group, a characteristic chemical structure capable of biding to various 
antibodies. ICG-ATT is also an infrared fluorescent-labeling reagent useful for proteins and 
amino acid compounds. 
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Fig. 2. Excitation spectrum (dotted line) and emission spectrum (continuous line) of ICG-
sulfo-OSu (A) and ICG-ATT (B). 
4. Labeled antibodies  
First, we labeled an anti-epithelial membrane antigen (EMA) antibody with ICG-sulfo-OSu. 
Although the anti-EMA antibody is not cancer-specific, this antibody is cross-reactive with 
normal epithelium in the digestive tract and has a relatively high sensitivity (Muguruma et 
al., 1998). Therefore, we first confirmed the sensitivity and specificity of 
immunofluorescence of the labeled antibody. Anti-EMA antibody (Dako, Denmark) was 
labeled with ICG-sulfo-OSu by our standardized method. Anti-EMA antibody (2.8 mg) was 
dissolved in 4 ml of 100 mM sodium bicarbonate buffer (pH 8.5), and 40 μl of 6 mM ICG-
sulfo-OSu dissolved in dimethylsulfoxide was added, followed by incubation at 37°C for 1 
hour. Based on our previous study, the molecular ratio of anti-EMA antibody to ICG-sulfo-
OSu was 1:12. The reaction mixture was purified with a Sephadex G-25M column (PD-10, 
Pharmacia, Sweden) using 50 mM phosphate-buffered saline (PBS) as an eluent. The dye-
conjugated antibody was separated from the free dye. The greenish solution of ICG-sulfo-
OSu labeled anti-EMA antibody was immediately freeze-dried. The physiochemical 
characters of the labeled antibody were similar to those of ICG. After confirmation of 
adequate immunofluorescence from this labeled antibody, we attempted to develop a 
cancer-specific labeled antibody. In fact, various cancer-specific antibodies, such as the anti-
CEA antibody, have been used as labeled antibodies for the diagnosis of gastrointestinal 
cancer (Keller et al., 2002). We have also labeled an anti-CEA antibody (Chemicon 
International Inc., CA, USA), which has a high sensitivity for gastrointestinal cancer (Page, 
1986), with ICG-sulfo-OSu. The excitation and emission spectra of ICG-sulfo-OSu labeled 
anti-CEA antibody was also similar to that of ICG (Muguruma et al., 1999). Although the 
labeled anti-CEA antibody showed efficient immunofluorescence, we developed a new 
labeled antibody using a more sensitive tumor marker. Mucin, a glycoprotein containing a 
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large amount of sugar, is the main component of mucus, and the peptide structure of the 
mucin core protein has been clarified (Kim, 1993). The specific expression of mucin in 
various cancers has been reported, and we also studied the staining pattern and evaluated 
its sensitivity in gastrointestinal cancers (Bando et al., 2002). Based on its relatively high 
sensitivity (Nakamori, 1994), we labeled an anti-MUC1 antibody (MY.1E12; kindly provided 
by Prof. Tatsuro Irimura, The University of Tokyo) with ICG-ATT.   
5. Imaging modality 
5.1 Infrared fluorescence microscope 
We developed an infrared fluorescence microscope for observation of tissue sections by 
modifying a conventional infrared microscope (BHSM-IR, Olympus, Japan). The excitation 
filter with a transmission wavelength of 710–790 nm was placed between the halogen lamp 
and the sample, and the barrier filter with a transmission wavelength of 810–920 nm was 
placed between the sample and the charge-coupled device (CCD) camera (Ito, 1997).  
 
 
Fig. 3. Reflected-type imaging system for detecting labeled substances excited by near-infrared 
rays. The light source was placed in the microscope, and samples were irradiated using a half 
mirror. The exciter filter was placed between the halogen lamp and the half mirror, and the 
barrier filter between the half mirror and the ICCD camera. Fluorescent signals were detected 
with the ICCD camera, captured with an image capturing device, and recorded in an image 
storage device. Based on the characteristics of the absorption and fluorescence spectra of ICG-
sulfo-Osu, band pass filters with transmission wavelengths of 710-790 nm and 810-920 nm 
were used as the exciter and barrier filter, respectively. 
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Fluorescent signals were detected by a CCD camera equipped with an image-capturing 
device and recorded in an image-storage device. All the images were processed by 
averaging original images, averaging background images, subtraction, noise filtering, and 
contrast enhancement. However, this transmission-type imaging system cannot be applied 
to an endoscopic system because the specimen is sandwiched between the excitation and 
barrier filters. We therefore developed a reflected-type infrared fluorescence microscopy: the 
light source was placed in the microscope, and the samples were irradiated using a half 
mirror (Figure 3) (Taoka, 1999). The excitation filter was placed between the halogen lamp 
and the half mirror and the barrier filter between the half mirror and the intensified charge 
coupled device (ICCD) camera. Light from the light source passes through the excitation 
filter, and about 50% of the light is reflected and irradiates the sample. About 50% of the 
fluorescence emitted from the sample passes through the barrier filter and is detected by the 
ICCD camera. Although the fluorescent input is reduced by 25% compared with that of 
previous type microscopy, theoretically the ICCD camera enhances the images better than 
the CCD camera equipped with the transmission type. Images were processed by a 
recursive filter, which can also average some images after emphasizing later images, on an 
ICCD controller to decrease noise. The efficiency of image processing using this recursive 
filter was expressed by the following equation: Vn · 1 + (Vin – Vn · 1) / N, where  
Vn = output image, Vn · 1 = the output image 1 frame earlier, Vin = input image, and  
N = constant (4, 16, 64). 
5.2 Infrared fluorescence endoscope  
Based on the results of immunofluorescence using infrared fluorescence microscopy, a 
prototype of infrared fluorescence endoscopy was developed to observe the human 
gastrointestinal tract (Figure 4) (Ito et al., 2001). The system consisted of an infrared 
endoscope (Olympus XGIF-Q40IR, Olympus) coupled with an image-capturing device. The 
light source, a 300 W xenon lamp, was also equipped with an excitation filter and a barrier 
filter, making it possible to observe fluorescence with the infrared excitation light and 
produce normal images under visible light. The ICCD camera was optically connected with 
the scope through an adapter into which the barrier filter was inserted. The new endoscopy 
system with a CCD at its tip has a greatly improved resolution: this system comprises of a 
light source apparatus, an infrared fluorescence endoscope, and image analysis software, 
which is the same as that used for a conventional system (Kimura et al., 2007).  The light 
source apparatus (XCLV-260HP-IRF, Olympus) has three built-in filters; an infrared ray cut 
filter, an infrared ray pass filter, and a RGB filter.  White light produced by a xenon arc lamp 
goes through the infrared ray cut filter or infrared ray pass filter and then through the RGB 
rotation filter.  The infrared ray cut filter is used for conventional observation and the 
infrared ray pass filter for infrared fluorescence observation.  The infrared ray pass filter can 
transmit rays of wavelengths between 540 nm and 560 nm in addition to infrared rays of 
wavelengths between 680 nm and 770 nm.  The reflected light of the former rays allow us to 
know where in the stomach we are looking during infrared fluorescence observation.  The 
RGB rotation filter can transmit light in the near-infrared region as well as the visible region. 
The infrared fluorescence endoscope (XGIFQ-240IRFZ, Olympus) is equipped with both a 
CCD with high resolution for conventional observation and a CCD with high sensitivity for 
infrared fluorescence observation at the top.  These two CCDs can be switched from one to 
another with a single touch of the button of the endoscope in conjunction with the switch 
from one filter to another (the infrared ray cut filter and infrared ray pass filter) in the light 
 
Endoscopic Molecular Imaging in Gastrointestinal Oncology 
 
203 
source apparatus. Infrared rays excite the ICG-derivative-labeled antibody to emit 
fluorescence, which is subjected to barrier filters (825 to 945 nm) placed in front of the CCD 
for infrared fluorescence and is monitored as green signals on a pseudo-color display with 
an image processor (XCV-260HP-IRF, Olympus). 
 
 
Fig. 4. The schema of infrared fluorescence endoscope system. This system consisted of an 
infrared endoscope (Olympus XGIF-Q40IR, OLYMPUS) coupled with an image-capturing 
device. The light source that includes a 300 W xenon lamp which was equipped with an 
excitation filter and a barrier filter, so that it was possible to observe fluorescence with 
infrared excitation light and normal images under visible light. The ICCD camera was 
optically connected with the scope through an adapter into which the barrier filter was 
inserted. 
6. Ex vivo study of immunofluorescence with human stomach 
6.1 Immunofluorescence with microscope system 
Paraffin sections of human gastric mucosa, which had been previously proven to be positive 
in usual immunostaining for the anti-MUC1 antibody, were deparaffinized, and xylene was 
removed. After blocking endogenous peroxidase activity, sections were incubated with 
normal horse serum for 20 min, and then with the labeled antibodies at 500 mg/mL in 0.1M 
PBS for 10 min at room temperature. Observationwas performed under the infrared 
fluorescence imaging device to compare the fluorescence intensity of each preparation. 
Adjacent sections processed in the same way were incubated with the primary antibody, 
and then treated with the secondary antibody and the ABC reagent (avidin biotinylated 
 
New Techniques in Gastrointestinal Endoscopy 
 
202 
Fluorescent signals were detected by a CCD camera equipped with an image-capturing 
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source apparatus. Infrared rays excite the ICG-derivative-labeled antibody to emit 
fluorescence, which is subjected to barrier filters (825 to 945 nm) placed in front of the CCD 
for infrared fluorescence and is monitored as green signals on a pseudo-color display with 
an image processor (XCV-260HP-IRF, Olympus). 
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peroxidase complex) for 30 min. Preparations were visualized by 3-3‘ diaminobenzidine 
(DAB), and counter-stained by hematoxylin and methyl green. Localization of infrared 
fluorescence and DAB coloring was compared in serial sections. Subsequently, 
immunofluorescence of the paraffin sections of human gastric mucosa with ICG ATT-
labeled anti-MUC1 antibody produced stronger fluorescence than that by ICG-sulfo-OSu-
labeled antibody (Figure 5). Localization pattern of infrared fluorescent staining was in good 
agreement with that by the conventional method with oxidized DAB staining, which 




Fig. 5. Images of infrared fluorescent microscopy for gastric cancer specimen reacted with 
ICG-derivative labeled anti-MUC1 antibody. A) ICG-sulfo-OSu labeled anti-MUC1 
antibody, B) ICG-ATT labeled anti-MUC1 antibody. The fluorescence intensity of the 
antigen stained with ICG-ATT labeled antibody was markedly stronger than that treated 
with ICG-sulfo-OSu labeled antibody. 
6.2 Immunofluorescence with endoscope system 
The immunoreactions of CEA with ICG-sulfo-OSu labeled anti-CEA antibody were 
examined in freshly resected human gastric cancer specimens using the infrared 
fluorescence endoscope.  The resected stomach tissue was treated with warm water of 37℃ 
containing 20000 U of Pronase, 1 g of NaHCO3, and 4 mg of dimethylpolysiloxane for 15 
min at room temperature to remove mucus adhering to the mucosa. The sample was treated 
with normal horse serum (blocking serum) for 15 min. The surface of the lesion and normal 
mucosa were then treated with ICG-derivative-labeled antibody for 60 min at room 
temperature (Ito et al., 2001). Then, normal mucosa and the cancerous area were compared 
using the infrared fluorescence endoscope. Infrared fluorescence was observed in the 
cancerous lesion, but not in the non-cancerous areas (Figure 6). Paraffin sections of the 
stomach encompassing the infrared fluorescence-positive site were stained with anti-CEA 
antibody using the ABC method. The immunoreactive staining was positive only in the 
cancerous lesions but was negative in the non-cancerous lesions. In the infrared 
fluorescence-positive sites, the carcinoma tissue was exposed on the mucosal surface.  
 
 




Fig. 6. Infrared fluorescence imaging of freshly resected human gastric cancer tissue using 
ICG-sulfo-OSu-labeled anti-human carcinoembryonic antigen (CEA) antibody and an 
infrared fluorescence endoscope. The cancerous areas were stained with the fluorescent anti-
CEA antibody complex. A) The image observed under visible rays. B) The image observed 
under infrared rays (Ito-S, et al. Endoscopy 33: 849-853, 2001). Reprinted with permission 
 
 
Fig. 7. Infrared fluorescence image of freshly resected human gastric cancer tissue using ICG-
ATT-labeled MUC1 antibody A) The image of a cancerous lesion observed under white light. 
B) The image observed under infrared fluorescence after reaction of ICG-ATT labeled anti-
MUC1 antibody. Strong fluorescence was detected corresponding to the lesion. C) The image 
of a non-cancerous lesion under white light. D) There was no obvious fluorescence under 
infrared fluorescence observation (Ito-S, et al. Biomedical Thermology 23:77–97, 2003). 
Reprinted with permission 
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Subsequently, The same protocol was applied for other series of fresh specimen with gastric 
cancer using with ICG-ATT labeled anti-MUC1 antibody. In the cancerous lesions, the 
immunofluorescence of MUC1 labeled with ICG-ATT was strongly recognized, while there 
was no obvious fluorescence in the normal mucosa (Figure 7A and 7B). Paraffin sections of 
the specimen were stained with MUC1 antibody, and the fluorescence-positive sites and the 
immunoreaction with non-labeled MUC1 antibody corresponded well. 
7. Reinforcement of fluorescence intensity 
Some types of drugs (octylglucosid, OG) are known to be useful as reinforcement agents (Ito 
et al., 1998). The peak fluorescence wavelength lengthened with increasing concentration; an 
increase in the OG concentration from 10 to 100 mM resulted in a shift of the peak 
fluorescence wavelength from 800 to 817 nm. In a study with paraffin sections of human 
gastric cancer, slight fluorescence was observed without OG; however, with 100 mM OG, 
marked fluorescence was observed (Inayama et al., 2003). In another study, we assessed the 
relationship between the fluorescence and protein ratio (F/P ratio) and fluorescence 
intensity (Tadatsu, 2006). During purification of the labeled antibody, the concentration of 
each labeling compound reacting with 1 molecule of the antibody was varied as follows: 4, 
8, 16, and 32 molar equivalents. Subsequently, the intensity of fluorescence was evaluated 
by spectroscopy and infrared fluorescence microscopy. When the fluorescent antibody 
labeled with ICG-ATT was used at an F/P ratio of 2.94 or 4.18, clear and specific fluorescent 
images of the antigen were obtained. When the ICG-ATT-labeled antibody was used at an 
F/P ratio of 6.50 or 6.75, the fluorescence intensity decreased and the fluorescent images of 
the antigen became unclear. Therefore, the lower binding molar ratios of ICG-ATT were 
more useful for labeling the antibody. In previous studies, the whole IgG molecule was 
commonly used for preparation of labeled antibodies. However, labeled IgG displays 
insufficient sensitivity and specificity, probably resulting from nonspecific binding of the Fc 
fragment to target cells or molecular structure-dependent interference between 
fluorochromes. We characterized an Fc-free fluorescence-labeled Fab fragment, which was 
expected to yield more-specific binding to target cells than the whole IgG molecule. An anti-
mucin antibody and ICG-ATT were used as the labeled antibody and labeling compound, 
respectively. Paraffin sections of excised gastric cancer tissues were subjected to staining. 
The labeled whole IgG molecule (ICG-ATT-labeled IgG) and the labeled Fab fragment (ICG-
ATT-labeled Fab) were prepared according to a previous report, and the features of 
fluorescence microscopy images obtained from paraffin sections were compared. The 
fluorescence intensity obtained from paraffin sections of excised gastric cancer tissues 
tended to be greater with ICG-ATT-labeled Fab than with ICG-ATT-labeled IgG. 
Fragmentation of antibodies is considered to contribute to improved sensitivity and 
specificity of labeled antibodies for detection of micro gastrointestinal cancers (Yano, 2006). 
(Figure 8) 
8. In vivo reaction for exogenous antibody  
In vivo immunostaining is essential for utilization of this technique in endoscopic diagnosis; 
however, no method has been established yet (Hayashi, 1999). We examined in vivo 
immunostaining using nude mice.  A human gastric cancer was transplanted into the mice, 
and the tumor was exposed under ether anesthesia. A tissue sample was collected after 
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treatment with an antibody, and immunostaining was performed using the ABC method.  
Where anti-MUC1 mucin antibody had been applied in vivo to the cleaved surface of the 
grafted gastric cancer, the reaction product was demonstrated by the luminosity of the 
neoplastic tissue. In positive controls, strong reactivity was seen, but in the negative control, 
reactivity was not observed (Kusaka et al., 2000). 
 
Fig. 8. The area stained with the unlabeled MUC1 antibody is shown in A.  
Immunofluorescence images of sections treated with ICG-ATT-labeled IgG (B) and ICG-
ATT-labeled Fab (C) are also shown. Stronger fluorescence was detected and the localization 
pattern of infrared fluorescence of the ICG-ATT-labeled Fab antibody was in better 
agreement with that of DAB in conventional immunohistochemistry compared with the 
ICG-ATT-labeled IgG antibody (Yano-H, et al. Photodiagnosis and Photodynamic Therapy 
3: 177-183, 2006). Reprinted with permission 
9. Conclusions 
Molecular imaging was listed as one of the "ten emerging technologies that will change the 
world" by the Massachusetts Institute of Technology (MIT) 2003 Technology Review. 
Recently, in the USA, the National Institutes of Health has launched common fund 
programs in which ‘Molecular Libraries and Imaging’ is included (National Institute of 
Health, 2011). In EU, Diagnostic Molecular Imaging (DiMI) and European Master in 
Molecular Imaging (EMMI) have been organized. DiMI Network of Excellence was one of 
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treatment with an antibody, and immunostaining was performed using the ABC method.  
Where anti-MUC1 mucin antibody had been applied in vivo to the cleaved surface of the 
grafted gastric cancer, the reaction product was demonstrated by the luminosity of the 
neoplastic tissue. In positive controls, strong reactivity was seen, but in the negative control, 
reactivity was not observed (Kusaka et al., 2000). 
 
Fig. 8. The area stained with the unlabeled MUC1 antibody is shown in A.  
Immunofluorescence images of sections treated with ICG-ATT-labeled IgG (B) and ICG-
ATT-labeled Fab (C) are also shown. Stronger fluorescence was detected and the localization 
pattern of infrared fluorescence of the ICG-ATT-labeled Fab antibody was in better 
agreement with that of DAB in conventional immunohistochemistry compared with the 
ICG-ATT-labeled IgG antibody (Yano-H, et al. Photodiagnosis and Photodynamic Therapy 
3: 177-183, 2006). Reprinted with permission 
9. Conclusions 
Molecular imaging was listed as one of the "ten emerging technologies that will change the 
world" by the Massachusetts Institute of Technology (MIT) 2003 Technology Review. 
Recently, in the USA, the National Institutes of Health has launched common fund 
programs in which ‘Molecular Libraries and Imaging’ is included (National Institute of 
Health, 2011). In EU, Diagnostic Molecular Imaging (DiMI) and European Master in 
Molecular Imaging (EMMI) have been organized. DiMI Network of Excellence was one of 
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the largest European research projects funded by the European Commission within the 6th 
Framework Programme (Diagnostic Molecular Imaging, n.d.). EMMI is an international 
program entirely dedicated to in vivo molecular imaging. Supported by the European 
Commission under the SOCRATES programme, this two-year interdisciplinary curriculum 
is brought together by prominent European molecular imaging research groups (European 
Master in Molecular Imaging, n.d.). Given this situation, it is convincing that molecular 
imaging is one of the latest upcoming and nationwide fields that affect human life science. 
Molecular imaging can add various types of information to conventional imaging 
techniques and enable not only detection and localization but also quantification and the 
basis of pathologies (Mahmood and Wallace, 2007). In terms of one specific paradigm of the 
technology, the exogenous administration of targeted probes may provide additional and 
complementary information to native spectro-endomicroscopic image analysis of lesions. It 
also can be used to either image the administered drug directly to access its distribution and 
target binding. 
In general, the incidence of colorectal cancer in the world has been increasing and will occur 
more frequently in the coming generations; a new technology is therefore required that it is 
cost-effective and efficient for both screening and further examinations. It is well known that 
there are many alterations in the molecular pathways of carcinoma; stepwise formation will 
be visualized with various molecules. The fluorescence signal acquired by endoscopy is not 
quantitative by itself, but the intensity of the signal is expected to reveal the depth or 
potential of a cancer. Moreover, amplification or reinforcement strategies are required 
because focal target concentrations are quite low, in the pico- to nanomolar range 
(Weissleder, 1999). Ideal system in this technology should offer a strong signal-to noise 
ratio, quantitative analysis, less invasive modality, real time monitoring and multiplex 
imaging using various fluorescent peptides or antibodies with different optical 
characteristics. Before the application of diagnostic drug to clinical use, pharmacokinetics 
and pharmacodynamics should be tested and these agents have to undergo lengthy 
approval processes; however, no definite barriers are anticipated to prevent its clinical 
application because therapeutic administration of various humanized antibodies has proven 
safe and imaging and therapeutic targets are often same. On the other hand, fluorochromes 
such as ICG are photostable and have been used safely in the human body. With these 
possibilities, it seems apparent that this innovative technology will be realized in 
cooperation with the pharmaceutical industry, chemical company and engineering 
manufacture, hopefully with their investment in the economic market of gastrointestinal 
oncology. 
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1. Introduction 
In the last decades many technologic advances have been done in the field of endoscopic 
imaging in order to achieve, from one side a better visualisation of mucosal layer to 
distinguish neoplastic vs non-neoplastic tissue, and, on the other side, to obtain valuable 
tissue specimen for pathologist to improve diagnostic rate of the procedure. Indeed one of 
the fundamental features of endoscopic procedures consists in the possibility to perform 
direct biopsies in order to achieve histological diagnosis. Although histology is highly 
accurate, it has few limitations: false negative results, delay in reaching the final diagnosis 
and the decision of the correct and best treatment and increased costs in pathology 
procedures with, consequently, the need of repeated procedures. In addiction sensitivity 
and specificity of histology are variable for difficulty to reach specimen adequacy, like in 
biliary duct and pancreatic cysts. Moreover the presence of flogosis or ulcers could alter the 
mucosal architecture and give some false negative/positive results to pathology 
examination. Nevertheless another important limitation of histology is that is a post-mortem 
analysis and it is not able to give us information about in-vivo processes (blood flow, 
mucosal junction exchanges).  
New advances in endoscopic imaging have led, through high resolution endoscopy to 
magnification endoscopy but even if improved they are not able to give us a specific 
diagnosis and, up to now, international guidelines still suggest repeated biopsies and 
histology for surveillance protocol because new techniques are not strong enough to replace 
biopsies. 
Confocal laser endomicroscopy (CLE), a recent advance of endoluminal imaging, allows an 
in-vivo visualization of mucosal layer with a detailed visualization of tissue and subcellular 
structures. 
Since 2004 many papers have been pubblished about the potential role of this new technique, 
have been published and many studies have been introduced to validate this technique. 
CLE has the potential to anticipate the final diagnosis (neoplastic vs non-neoplastic) and 
consequently to guide next therapeutic steps in clinical practice without the delay of a 
pathology response. Moreover it offers the possibility to study mucosal layer to a micron 
resolution giving us an “optical biopsy” and future applications about a role of in-vivo 
study of physiologic and then pathologic processes, like tumoral angiogenesis, flogosis in 
healthy or neoplastic tissue are “work in progress”. 
 
New Techniques in Gastrointestinal Endoscopy 
 
212 
Pasricha, P. J. & Motamedi, M. (2002) Optical biopsies, "bioendoscopy," and why the sky is 
blue: The coming revolution in gastrointestinal imaging. Gastroenterology, 122, 571-
575. 
Pelegrin, A.; Folli, S.; Buchegger, F.; Mach, J. P.; Wagnieres, G. & van den Bergh, H. (1991) 
Antibody-fluorescein conjugates for photoimmunodiagnosis oh human colon 
carcinoma in nude mice. Cancer, 67, 2529-2537. 
Shealy, D. B.; Lipowska, M.; Lipowski, J.; Narayanan, N.; Sutter, S.; Strekowski, L. & 
Patonay, G. (1995) synthesis, chromatographic-separation, and characterization of 
near-infrared-labeled DNA oligomers for use in DNA-sequencing. Analytical 
Chemistry, 67, 247-251. 
Sivak, M. V. (2006) Gastrointestinal endoscopy: past and future. Gut, 55, 1061-1064. 
Still, J. M.; Law, E. J.; Klavuhn, K. G.; Island, T. C. & Holtz, J. Z. (2001) Diagnosis of burn 
depth using laser-induced indocyanine green fluorescence: a preliminary clinical 
trial. Burns, 27, 364-371. 
Tadatsu, Y.; Muguruma, N.; Ito, S.; Tadatsu, M.; Kusaka, Y.; Okamoto, K.; Imoto, Y.; Taue, 
H.; Sano, S. & Nagao, Y. (2006) Optimal labeling condition of antibodies available 
for immunofluorescence endoscopy. Journal of Medical Investigation, 53, 52-60. 
Tajiri, H. (2007) What do we see in the endoscopy world in 10 years’ time? Digestive 
Endoscopy, 19, S174–179. 
Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, 
K.; Miyake, H. & Niitsu, Y. (1998) Aberrant crypt foci of the colon as precursors of 
adenoma and cancer. New England Journal of Medicine, 339, 1277-1284. 
Taoka, S.; Ito, S.; Muguruma, N.; Hayashi, S.; Kusaka, Y.; Ii, K.; Nakamura, K.; Imaizumi, K.; 
Takesako, K. & Shibamura, S. (1999) Reflected illumination-type imaging system 
for the development of infrared fluorescence endoscopy. Digestive Endoscopy, 11, 
321-326. 
Tatsuta, M.; Iishi, H.; Ichii, M.; Baba, M.; Yamamoto, R.; Okuda, S. & Kikuchi, K. (1989) 
Diagnosis of gastric cancers with fluorescein-labeled monoclonal antibodies to 
carcinoembryonic antigen. Lasers in Surgery and Medicine, 9, 422-426. 
Thakur, M. & Lentle, B. C. (2005) Report of a summit on molecular imaging. Radiology, 236, 
753-755. 
Weissleder, R. (1999) Molecular imaging: Exploring the next frontier. Radiology, 212, 609-614. 
Weissleder, R. (2006) Molecular imaging in cancer. Science, 312, 1168-1171. 
Weissleder, R. & Mahmood, U. (2001) Molecular imaging. Radiology, 219, 316-333. 
Yano, H.; Muguruma, N.; Ito, S.; Aoyagi, E.; Kimura, T.; Imoto, Y.; Inoue, S.; Sano, S.; Nagao, 
Y. & Kido, H. (2006) Fab fragment labeled with ICG-derivative for detecting 
digestive tract cancer. Photodiagnosis and Photodynamic Therapy, 3, 177-183. 
13 
New Techniques in Endoscopy:  
Confocal Laser Endomicroscopy 
Helga Bertani, Rita Conigliaro and Flavia Pigò 
Endoscopy Unit, Nuovo Ospedale Civile S. Agostino Estense – Modena, 
Italy 
1. Introduction 
In the last decades many technologic advances have been done in the field of endoscopic 
imaging in order to achieve, from one side a better visualisation of mucosal layer to 
distinguish neoplastic vs non-neoplastic tissue, and, on the other side, to obtain valuable 
tissue specimen for pathologist to improve diagnostic rate of the procedure. Indeed one of 
the fundamental features of endoscopic procedures consists in the possibility to perform 
direct biopsies in order to achieve histological diagnosis. Although histology is highly 
accurate, it has few limitations: false negative results, delay in reaching the final diagnosis 
and the decision of the correct and best treatment and increased costs in pathology 
procedures with, consequently, the need of repeated procedures. In addiction sensitivity 
and specificity of histology are variable for difficulty to reach specimen adequacy, like in 
biliary duct and pancreatic cysts. Moreover the presence of flogosis or ulcers could alter the 
mucosal architecture and give some false negative/positive results to pathology 
examination. Nevertheless another important limitation of histology is that is a post-mortem 
analysis and it is not able to give us information about in-vivo processes (blood flow, 
mucosal junction exchanges).  
New advances in endoscopic imaging have led, through high resolution endoscopy to 
magnification endoscopy but even if improved they are not able to give us a specific 
diagnosis and, up to now, international guidelines still suggest repeated biopsies and 
histology for surveillance protocol because new techniques are not strong enough to replace 
biopsies. 
Confocal laser endomicroscopy (CLE), a recent advance of endoluminal imaging, allows an 
in-vivo visualization of mucosal layer with a detailed visualization of tissue and subcellular 
structures. 
Since 2004 many papers have been pubblished about the potential role of this new technique, 
have been published and many studies have been introduced to validate this technique. 
CLE has the potential to anticipate the final diagnosis (neoplastic vs non-neoplastic) and 
consequently to guide next therapeutic steps in clinical practice without the delay of a 
pathology response. Moreover it offers the possibility to study mucosal layer to a micron 
resolution giving us an “optical biopsy” and future applications about a role of in-vivo 
study of physiologic and then pathologic processes, like tumoral angiogenesis, flogosis in 
healthy or neoplastic tissue are “work in progress”. 
 




The physical principle of the CLE consists in the principle of light interaction with tissue. 
Light interacts with tissue in five different ways (Fig.1): 1- reflection, 2- absorption, 3- single 




Fig. 1. 1- reflection, 2- absorption, 3- single scattering, 4- diffuse scattering, 5- absorption and 
re-emission at a different wave length of fluorescence.  
This last phenomenon can be tissue auto-fluorescence or dye based fluorescence. The light 
source is a blue laser source light with variable wavelength (488 nm - 660 nm). Once the 
light arrives to the tissue a fluorescence signal returns back. Then this fluorescence signal is 
converted in imaging signal from a converter (detector) and then corrected in stabilized 
images from a system software. The last principle, absorption and re-emission at a different 
wavelength of fluorescence, is the basis of CLE and CLE mandates use of fluorescent agents. 
Most studies in humans have been performed with intravenous administration of 
fluoresceine sodium. Fluoresceine quickly distributes within all compartments of the tissue  
can be visualized after few second after fluoresceine injection. It contrasts cellular and 
subcellular details, connettive tissue and vessels architecture at high resolution but does not 
stain nuclei. The safety of the fluoresceine as contrast agent had been demonstrated in 
oftalmology because it has been used for years for ophtalmological imaging of blood 
vessels. Wallace et al. (1) reported a cross-sectional survey study about the safety of 
fluoresceine in CLE procedures. 2272 patients were enrolled and no serious adverse events 
were reported. Minor adverse events occurred in 1.4 % (transient hypotension, nausea, 
injection site erithema, mild epigastric pain) but none of them required additional 
intervention than observation. Acriflavine, another contrast agent, is applied topically and 
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predominantly stains nuclei for human use, in USA and Europe the only FDA and EMEA 
approved contrast is fluoresceine because without nuclear stain it isn’t prone to mutagenic 
effects.  
3. Systems 
Currently two devices are available and approved to perform CLE: one system is inserted in 
the tip of the scope (eCLE, Pentax Corporation, Tokyo, Japan) (Fig.2) and one, a probe-based 
system, is a separate device from the endoscope but capable to be introduced in the working 
channel of any standard endoscope (pCLE, Cellvizio, Mauna KeaTech, Paris, France)  
(Fig.3). 
 eCLE: In this system, the miniaturized confocal scanner has been integrated into the 
distal tip of a new endoscope. A blue laser light source delivers an excitation 
wavelength of 488 nm and light emissions detected at 505- 588 nm. Successive points 
within the tissue are scanned in a raster pattern along X-axis and Y-axis to construct 
serial en-face optical section of 475 x 475 mm at user-controlled variable imaging depth. 
The optical slice thickness is 7 mm with a lateral resolution of 0.7 mm (2). Images on the 
screen approximate a 1000 fold magnification of the tissue in vivo. The advantage of 
this system is that the working channel of the scope is free and it can be used for target 
biopsies or for combined enhancement techniques such as chromoendoscopy. The limit 
of this system is that the calibre of the scope is bigger than a standard 11.8 mm upper 
scope and is stiff. Moreover the lens of the scope is not combined with HD software and 
virtual chromoendoscopy or other system (I-SCAN).  
 
 
Fig. 2. eCLE system, Pentax Corporation, Tokyo, Japan  
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Fig. 3. pCLE, Cellvizio, Mauna KeaTech, Paris, France 
 pCLE: This system probe-based, can be used through the working channel of any 
standard endoscope (colonscope, gastroscope, cholangioscope, bronchoscope, 
ureteroscope…). The advantage of this pCLE is the versatility of the system and the 
possibility to combine it with other advanced “red flag” imaging modalities such as 
virtual chromoendoscopy or magnification. Scanning rates is 12 images/sec. The limits 
of this system pCLE are the slightly low power resolution compared to eCLE (1 mm vs 
0.7mm) and a small field of view (240 – 600 mm). So pCLE system could not be well 
suited to surveying large areas of tissue such as long segments of BE and should ideally 
be combined with a red-flag technique for classification of tissue in a site already 
detected by enhanced endoscopy. However Mauna Kea has developed a post 
acquisition specifically-developed software (“mosaicing”) (fig.4) to paste images 
together and to obtain images similar to histology specimen. 
 




Fig. 4. “Mosaicing” in Cellvizio software 
4. Clinical applications 
Clinical applications of CLE include, potentially, all the current applications of biopsies for 
distinguishing neoplastic vs non-neoplastic tissue.  
Early data suggests a role for CLE: 1-in surveillance program of chronic disease (Barrett’s 
oesophagus and chronic inflammatory bowel disease), 2- in the definition of a known lesion 
(small colonic polyps, undetermined biliary strictures) 3- in therapeutic approach (definition 
of lesion’s margin before EMR or ESD (in oesophagus, stomach or colon) and after resection 
procedure to detect residual tissue. 
4.1 Gastroenterology 
- Barrett’s oesophagus (BE):  Barrett’s oesophagus, considered as an abnormal change in 
squamous epithelium of the oesophagus into an intestinal columnar epithelium (Fig.5), 
is considered a pre-malignant lesion and the most important risk factor for the 
development of oesophageal adenocarcinoma.  
 
 
Fig. 5. Typical Barrett glands with goblet cells and regular arrangement of nuclei are visible. 
The lamina propria contains some regular capillaries and connective tissue and lymphocytes 
and plasma cells as well. The basement membrane is intact and thin. The density of the cells is 
potentially increased in conventional histology due to shrinking artefacts.  
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The incidence of oesophageal adenocarcinoma has been rapidly rising, increasing from 3-fold 
to 6-fold since 1990 (3). International guidelines suggest endoscopic surveillance of BE with 
random 4-quadrant biopsies every 1-2 cm through the extension of intestinal metaplasia for 
detection of dysplasia (high grade/low grade) or early intraepithelial cancer. However, 
surveillance endoscopy has several limitations because dysplastic changes occurring in 
Barrett’s esophagus are not easily identifiable by standard endoscopy. Consequently, the 
current standard of endoscopic practice is to take multiple biopsies because there are no 
features on standard resolution endoscopy that distinguish Barrett’s glandular metaplasia, 
dysplasia or early stage neoplasia. However, there is much controversy about the real efficacy 
of an intense four-quadrant biopsy sampling protocol in detecting Barrett’s dysplasia and 
cancer because the accuracy of standard endoscopy and random biopsies is low and they may 
fail to detect neoplastic lesions.  Moreover biopsies obtained using this technique are prone to 
sampling error and inter-observer agreement is low even between advanced operators and 
even among expert pathologists. Nevertheless, the need for histology confirmation of 
neoplasia eliminates the ability to direct therapy during the index endoscopy because the 
endoscopist cannot see the location of the disease. Thus repeated endoscopies are needed, the 
first for the diagnosis and then for the therapy. A multiple biopsies protocol could also 
interfere with next therapeutic steps; EMR or ESD could be more difficult without adequate 
“lifting sign” due to scar tissue after repeated biopsies. 
This intense surveillance protocol has also many effects on healthcare economy for resource 
management and costs, considering that neoplastic progression in Barrett’s oesophagus has 
a really low incidence (< 1 case in 200 per year).  
Recent published data showed that pCLE was able to detect intraepithelial neoplasia with a 
sensitivity of 75% and specificity of 89-91% (4-8) Fig.6.  
 
 
Fig. 6. pCLE images of healthy squamous epithelium with intrapapillary loop suitable for 
vessels with fluoresceine 
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In the same paper, ranking study population for disease-risk, in the low risk group 
population, pCLE has a NPV nearly 98.8% suggesting the possibility to avoid random 
biopsies. Fig. 7, Fig. 8.  
 
 
Fig. 7. pCLE images of Barrett’s gland with regular columnar-lined epithelial surface. Dark 
mucin Goblet cells (round-shape black cells). 
 
 
Fig. 8. pCLE images of Barrett’s gland with regular columnar-lined epithelial surface. Dark 
mucin Goblet cells (round-shape black cells). 
Another study by Bajbouj et al (5) did not confirm these data and the authors explain the 
differences with previous results with the low frequency of neoplasia detected in the study 
and secondly to strict adherence with diagnostic criteria for neoplasia in their data. The 
prevalence of neoplasia was lower than in the published data using the CLE system or other 
studies evaluating different imaging modalities, which have described prevalence of HG 
dysplasia or early cancers ranging between 24% and 59%. As changes in prevalence impact 
 
New Techniques in Gastrointestinal Endoscopy 
 
218 
The incidence of oesophageal adenocarcinoma has been rapidly rising, increasing from 3-fold 
to 6-fold since 1990 (3). International guidelines suggest endoscopic surveillance of BE with 
random 4-quadrant biopsies every 1-2 cm through the extension of intestinal metaplasia for 
detection of dysplasia (high grade/low grade) or early intraepithelial cancer. However, 
surveillance endoscopy has several limitations because dysplastic changes occurring in 
Barrett’s esophagus are not easily identifiable by standard endoscopy. Consequently, the 
current standard of endoscopic practice is to take multiple biopsies because there are no 
features on standard resolution endoscopy that distinguish Barrett’s glandular metaplasia, 
dysplasia or early stage neoplasia. However, there is much controversy about the real efficacy 
of an intense four-quadrant biopsy sampling protocol in detecting Barrett’s dysplasia and 
cancer because the accuracy of standard endoscopy and random biopsies is low and they may 
fail to detect neoplastic lesions.  Moreover biopsies obtained using this technique are prone to 
sampling error and inter-observer agreement is low even between advanced operators and 
even among expert pathologists. Nevertheless, the need for histology confirmation of 
neoplasia eliminates the ability to direct therapy during the index endoscopy because the 
endoscopist cannot see the location of the disease. Thus repeated endoscopies are needed, the 
first for the diagnosis and then for the therapy. A multiple biopsies protocol could also 
interfere with next therapeutic steps; EMR or ESD could be more difficult without adequate 
“lifting sign” due to scar tissue after repeated biopsies. 
This intense surveillance protocol has also many effects on healthcare economy for resource 
management and costs, considering that neoplastic progression in Barrett’s oesophagus has 
a really low incidence (< 1 case in 200 per year).  
Recent published data showed that pCLE was able to detect intraepithelial neoplasia with a 
sensitivity of 75% and specificity of 89-91% (4-8) Fig.6.  
 
 
Fig. 6. pCLE images of healthy squamous epithelium with intrapapillary loop suitable for 
vessels with fluoresceine 
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In the same paper, ranking study population for disease-risk, in the low risk group 
population, pCLE has a NPV nearly 98.8% suggesting the possibility to avoid random 
biopsies. Fig. 7, Fig. 8.  
 
 
Fig. 7. pCLE images of Barrett’s gland with regular columnar-lined epithelial surface. Dark 
mucin Goblet cells (round-shape black cells). 
 
 
Fig. 8. pCLE images of Barrett’s gland with regular columnar-lined epithelial surface. Dark 
mucin Goblet cells (round-shape black cells). 
Another study by Bajbouj et al (5) did not confirm these data and the authors explain the 
differences with previous results with the low frequency of neoplasia detected in the study 
and secondly to strict adherence with diagnostic criteria for neoplasia in their data. The 
prevalence of neoplasia was lower than in the published data using the CLE system or other 
studies evaluating different imaging modalities, which have described prevalence of HG 
dysplasia or early cancers ranging between 24% and 59%. As changes in prevalence impact 
 
New Techniques in Gastrointestinal Endoscopy 
 
220 
on the variables measured, particularly on the PPV, the authors also face the problem of 
over-interpretation in those studies and the possibility of false positive pCLE findings. A 
prospective multicenter randomized trial had been presented in DDW 2010 with analogue 
results in a study population of around 100 patients. 
An important study is about the inter-observer agreement and Wallace et al. reported a rate of 
86% with a Kappa estimate of 0.72 (CI 95% 0.58-0.86) (6). The observers in this study also rated 
individual features suggestive of neoplasia, such as irregular epithelial thickness, epithelial 
inhomogenity, dark epithelial structures (lack of fluoresceine uptake), crypt/villi fusion and 
irregular vessels. These individual features had good specificity but lower sensitivity than all 




Fig. 9. pCLE images of Barrett’s glands with loss of epithelial lining. No Globet cells 
suggestive for Dysplastic Barrett’s esophagus 
 
 
Fig. 10. pCLE images of irregular vessels suggestive for dysplastic Barrett’s esophagus. 
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Another recent application of confocal endomicroscopy is a role in guiding therapeutic 
endoscopic procedures; 1- to localize and predict pathology, 2- to target biopsies and 
resections in surveillance and treatment, 3- to guide which therapy to use, 4- to assess 
treatment adequacy and gauge need for further treatment (7). 
- Early gastric cancer: Gastric cancer remains the world’s second leading cause of 
cancer-related deaths, with a mortality rate of 16.3 per 100,000 in men and 7.9 per 
100,000 in women (9) and in eastern countries the risk of gastric cancer is dramatically 
high. One of the strategies to improve prognosis, essentially depends on earlier 
detection of pre-neoplastic changes in mucosal layer because intraepithelial neoplasia 
and early gastric cancer have a dramatically better prognosis than advanced one. The 
diagnosis of these lesions is currently based on pathologic assessment. Virtual 
chromoendoscopy and trimodal imaging endoscopy have demonstrated significant 
value for the detection of early gastric neoplasia whereas the detection of 
intraepithelial gastric neoplasia (GIN) has been less mentioned and investigated. 
Considering the higher incidence of GIN compared with early gastric carcinoma 
especially in eastern countries a new technique is highly desirable. Furthermore, 
given the different progression risk of GIN if the dysplasia is a low-grade or high-
grade in screening and surveillance population 
CLE provide an excellent definition of the gastric pit pattern with high diagnostic accuracy 
on detection gastric atrophy and gastric intestinal metaplasia Fig 11. 
 
 
Fig. 11. pCLE images of “early gastric cancer with loss of typical honey-comb structures 
Recently one study has been published to evaluate the role of pCLE before ESD to reduce 
disease recurrence (10). 
- Coeliac disease: Many papers have been published about the role of CLE in the study of 
jejunal mucosa in Coeliac disease. Alterations of villa in terms of length, numbers and 
distribution are easily recognized. Fig. 12. 
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Fig. 12. pCLE images of duodenal villi in healthy duodenum 
- Whipple Disease: Whipple's disease is a rare, systemic infectious disease caused by the 
bacterium Tropheryma whipplei. Diagnosis is made by intestinal biopsy, which reveals 
the presence of the organism as PAS-positive macrophage inclusion. Endoscopy of the 
duodenum and jejunum can reveal pale yellow shaggy mucosa with erythematous 
eroded patches in patients with classic intestinal Whipple's disease, hypercellularity of 
the lamina propria with "foamy macrophages", and a concurrent decreased number of 
lymphocytes and plasma cells, per high power field view of the biopsy. A case report 
about the use of CLE in the diagnosis of Whipple’s Disease has been published (11). 
CLE showed pseudoatrophy and dilation of the villi, the presence of crypts within the 
villi, significant infiltration with inflammatory cells, and the presence of vacuoles or 
signal absence in the tip of the villi. CLE demonstrated moreover foamy macrophages 
in the lamina propria. However, all of these features are not specific for Whipple’s 
disease because they could be found also in Mycobacterium Tubercolosis and other 
infectious disease; the possibility to target biopsies could play a potential role of this 
technique even if the correct diagnosis is reached with the visualization of the bacteria 
with electron microscopy. 
- Inflammatory Bowel disease: The use of CLE in colon disease ranges from classifications of 
colorectal polyps between hyperplastic to neoplastic (adenomatous) to the study of 
inflammatory bowel disease (IBD). In particular patients affected by Ulcerative Colitis 
(UC) are at increased risk of developing colorectal cancer, so guidelines recommend 
endoscopic surveillance including targeted biopsies of suspected lesions and multiple 
random biopsies. However the sensitivity of this protocol for detection of neoplasia is 
still low and is therefore desiderable to replace the inefficient procedure by a more 
efficient method. Chromoendoscopy and virtual chromoendoscopy (NBI) can be used 
to improve detection of dysplastic lesions and can be used to predict histology whereas 
pCLE is an in-vivo histology. Kiesslich et al, using the CLE system reported a sensitivity 
of 97.4%, specificity of 99.4% accuracy of 99.2% to predict the presence of neoplastic 
changes (1) Fig 13. 
 




Fig. 13. pCLE images of typical UC mucosa with fusion of the glands. 
Van den Broek et al (12) reported similar data but lower sensitivity (65%), specificity (82%) 
and accuracy (81%) due probably to a different system, a learning curve in providing images 
and technical skills. Hurlstone et al. (13) assessed the clinical feasibility and predictive 
power of CLE for in-vivo differentiation between ALM and DALM in UC. The study 
evidenced high accuracy of the technique and consequently the possibility to differentiate 
patients eligible for endoscopic treatment from patients fit for surgery. Recently, De Palma 
et al. (14) reported the use of CLE applied in real-time inflammation activity assessment. The 
inflammation activity assessment includes polyps architecture, cellular infiltration and 
vessel architecture. These studies showed that images taken with CLE provide information 
that are equivalent to conventional histology, differentiating between active and non-active 
UC during ongoing colonoscopy Fig 14. 
 
 
Fig. 14. pCLE images in a patient with long-standing UC. Increased intercrypt distance due 
to glands atrophy 
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Recently the use of CLE has been applied also to functional studies in IBD, to  
evaluate epithelial gaps resulting from intestinal cell shedding rate higher than in healthy 
patients undergoing colonoscopy. Liu et al (15) reported that patients with IBD had a 
significantly higher epithelial gap density in the terminal ileum compared with controls 
without IBD. 
- Polyps: Colorectal cancer has been recognized as the second most common cause of 
cancer related death in the United States (16). It progresses through various 
morphological stages, including polyp formation and malignant transformation. 
Different type of polyps have been classified, hyperplastic and adenomatous polyps 
with a malignant potential. Standard endoscopic inspection cannot by itself distinguish 
between neoplastic and non-neoplastic lesions. Thus all detected lesions need to be 
removed and then evaluated by pathologist and this approach still remains the gold 
standard. Almost half of the polyps removed are hyperplastic and this standard 
approach results in unnecessary polypectomies with consequently increased risks and 
costs. The first report of the potential role of CLE in predicting pathology of the colon 
polyps was by Kiesslich et al (1). They reported that intraepithelial neoplasia was 
predicted by CLE with an accuracy of 92% (sensitivity of 97% and specificity of 99%). 
Hurlstone et al (17) subsequently confirmed Kiesslich data, in particular confirmed the 
role of CLE in visualization of high-quality cellular, subsurface vascular and stromal 
imaging enabling prediction of intra-epithelia neoplasia with high level of accuracy 
(99%). Polgase et al (18) also confirmed similar results. Recently Xie published that in 
polyps with diameter > 10 mm the sensitivity of CLE was 97.1% specificity 100%  (19). 
A study by Gomez et al (20), reported also a moderate to good interobserver agreement 
between international collaborative colleagues for distinguishing neoplasia from non-
neoplastic tissue. Buchner et al, (21) defined also a learning curve of the technique to 





Fig. 15. pCLE images showing glands with star-opening of the crypts typical of hyperplastic 
polyps 
 





Fig. 16. pCLE images with long finger-like glands typical of adenomatous polyps. 
- Common bile duct: The pre-operative diagnosis of biliary stenosis and, in particular, 
cholangiocarcinoma is associated with low sensitivity. Cytological brushing and fine 
needle aspiration have a low diagnostic accuracy. Moreover, clinical onset of symptoms 
is often suspicious of malignancy but, if primary sclerosing colangitis is the underlying 
disease, the final diagnosis is challenging. Few case reports and case series about the 
use of pCLE system (cholangioprobe) through a cholangioscope or a catheter 
(graduated dilation catheter) in the CBD have been published up to now showing 
promising results of the technique. Fig.17. 
 
 
Fig. 17. Simulation of Cholangioflex probe introduced in common bile duct through a 
catheter 
Recently, Giovannini et al, (22) reported a phase I-II study  to evaluate the potential role of 
pCLE to detected neoplasia. The accuracy of pCLE was 100% for detection of ampullary 
tumors, 80% for pancreatic cancer and 81% for cholangiocarcinoma. Fig.18-Fig.19. 
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Fig. 19. pCLE images of cholangiocarcinoma with typical thick dark bands and different size 
of branches 
Professor Yank Chen presented promising results in last DDW 2010, from a multicenter 
randomized trial from USA and Europe. He showed a sensitivity of pCLE of 97% with a 
NPV of 80%. Same results have been reported from dr. Meining from Munich in a pilot 
study. Their data are under publications. 
- Pancreas:  One of the major advantages of the probe-based system is the small diameter 
of the fibers that allows through a fine-needle system visualization of pancreatic cysts 
epithelium. Few case reports have been published (23) and presented in last UEGW 
2010 from dr Meining group (Munich) with promising results in the definition of 
neoplastic vs non-neoplastic IPMN or pancreatic cystic lesion. 
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- Eosinophilic esophagitis: The use of the confocal laser endomicroscopy for the diagnosis 
in-vivo of eosinophilic esophagitis has been reported only as case-report.  Fluoresceine 
leakage revealed dilated intercellular spaces and capillary ectasia within the esophageal 
squamous epithelium. In addition, leakage demonstrated by extravasation of 
fluoresceine, became visible. Furthermore small cells within the intercellular spaces 
suspicious of eosinophilis and mild mucosal edema were demonstrated (24).  
5. Future applications 
Urology: Recently pCLE has extended its applications to urology. One in-vivo study has 
been published to date (25).  
Pulmonary disease: Histopathological tissue assessment remains the gold standard for 
accurate diagnosis of many lung conditions. Lesions’ biopsies are usually perfomed through 
blind transbronchial procedure with 1-12% risk of pneumothorax (26) and a 2-9% risk of 
significant bleeding. Tranthoracic biopsy is preferred for peripheral lesions, either 
percutaneously or via thoracotomy or thoracoscopy. The recent miniaturization of the 
confocal laser-scanning microscope enables in vivo imaging of superficial tissue also in lung 
disease. The only commercial system is Cellvizio-Lung .  CLE imaging of mucosal and 
epithelial layers within the body requires the topical or intravenous administration of 
fluorescent contrast agent such as fluoresceine or acriflavine, whereas elastin acts as an 
endogenous fluorescent agent. Thiberville et al. (27) described five distinct lattice 
arrangements of the connective tissue fibres of the normal basement membrane in separate 
areas of the bronchial tree Fig.20. These regular structures became disorganised with a 
decreased fluoresceine signal in pre-malignant and malignant condition. 
 
 
Fig. 20. pCLE images of healthy alveoli 
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Solid organs: A new generation of confocal miniprobes, narrow enough to be introduced 
through a needle have been developed for needle-based confocal laser endomicroscopy 
(nCLE). Their potential role is to perform virtual biopsies of solid organs (liver, pancreas 
and other intraperitoneal structures) accessible only through needle or during laparoscopy, 
EUS or NOTES. The first report by Goetz et al. (28) was in 2008. The authors reported the 
possibility to visualize, with different staining protocols, distinct aspects of the morphology 
and perfusion of the healthy and pathologic liver. A substantial correlation with histology 
was detected with additional information about in-vivo processes imaging: increased 
vessels permeability, common feature of inflammation. Its potential application in liver 
disease could be to perform multiple optical biopsies to find out the most appropriate site to 
obtain specimen to reveal pathognomonic changes potentially yielding instantaneous 
histopathological diagnosis.  Mennone et al (29) also reported the use of nCLE in rat model 
liver. Images obtained provide sufficient detail to distinguish normal from cirrhotic livers in 
rat model. 
Molecular imaging: Some case reports only in animals, about the use of novel biomarkers to 
study angiogenesis in-vivo and consequently to visualize fluorescence –tagged molecular 
agents. 
Bacterial recognition: Recently few case studies have shown that CLE can identify Bacteria 
on the mucosal surface during gastroscopy, Helicobacter Pylori (30) and colonoscopy (31). A 
new confocal endomicroscopy technique has been developed for the identification of E.Coli 
(32). 
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1. Introduction  
Gastrointestinal tumors have major place in the statistics of newly developed cancers every 
year, as the colon cancer is on third place, stomach cancer is on fifth place, and esophageal 
cancer is also in the top ten of tumors according statistics of cancer incidence. Usually the 
tumors are detected on advanced III and IV stage, where the perspectives for the patients 
are not very optimistic (Danon, 2003; Jemal, 2011). Up to now white light endoscopy is the 
main method in detection of gastrointestinal tumors. White-light endoscopy is well-
established and wide used modality. However, despite the many technological advances 
that have been occurred, conventional white light endoscopy is suboptimal and usually 
detects lesions, which already have symptoms of obstruction, bleeding and pain, related to 
tumor growth. Misdiagnoses, related to difficulties in differentiation of inflammatory from 
initial stage adenocarcinoma also have negative effect on the diagnostic accuracy (Da Costa, 
2003). Only experienced gastroenterologists with long practice in endoscopy observations 
could find slight initial changes to dysplastic and neoplastic stages of esophageal, stomach 
or colon mucosa. 
The limitations of standard endoscopy for detection and evaluation of cancerous changes 
in gastrointestinal tract are significant challenge and initiate development of new 
diagnostic modalities. Such detection and visualization techniques, additional to standard 
endoscopy equipment, including optical detection of tissues alterations are investigated 
and their feasibilities for clinical usage are evaluated. Advances in fiber optics, light 
sources, detectors have led to the development of several novel methods for tissue 
evaluation in situ. Optical methods applied for such tissue evaluation often are referred 
under term “optical biopsy”, which indicate their possibilities to make an instant 
diagnosis at endoscopy, previously possible only by using of histological and/or 
cytological analysis (Wang, 2004). 
The new optical approaches are based on light-tissue interactions and differences 
occurred between normal and abnormal tissue sites.  In gastroenterology several optical 
methods are applied recently, such as optical coherent tomography (Tumlinson, 2004), 
chromo-endoscopy, confocal fluorescent microscopy (DaCosta, 2003a; 2003b), Raman 
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diagnostic modalities. Such detection and visualization techniques, additional to standard 
endoscopy equipment, including optical detection of tissues alterations are investigated 
and their feasibilities for clinical usage are evaluated. Advances in fiber optics, light 
sources, detectors have led to the development of several novel methods for tissue 
evaluation in situ. Optical methods applied for such tissue evaluation often are referred 
under term “optical biopsy”, which indicate their possibilities to make an instant 
diagnosis at endoscopy, previously possible only by using of histological and/or 
cytological analysis (Wang, 2004). 
The new optical approaches are based on light-tissue interactions and differences 
occurred between normal and abnormal tissue sites.  In gastroenterology several optical 
methods are applied recently, such as optical coherent tomography (Tumlinson, 2004), 
chromo-endoscopy, confocal fluorescent microscopy (DaCosta, 2003a; 2003b), Raman 
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spectroscopy (Yan, 2005), reflectance spectroscopy (Sun, 2001) and laser- and light-
induced fluorescence spectroscopy (Chissov, 2003). In general, photodiagnostic 
techniques may be very useful for the detection of pre-maliganant dysplasia and early 
malignant changes in gastrointestinal tract. Spectral diagnosis can provide both imaging 
and spectroscopic information; and the techniques divide into those that provide 
morphological data and those that have the potential for molecular and biochemical 
information. Morphological information provides in vivo histology and the techniques 
include optical coherence tomography, light scattering spectroscopy, and confocal 
microscopy. Fluorescence imaging and spectroscopy provide both morphological and 
biochemical data. Raman spectroscopy provides the most powerful tool for obtaining 
precise molecular data. 
Such advanced methods go beyond standard endoscopic techniques and allow receiving 
better image resolution, contrast, higher sensitivity, tissue penetration and could provide 
even biochemical, structural and molecular information about mucosal lesions investigated. 
One of the most sensitive optical detection approaches is light-induced fluorescence 
spectroscopy (LIFS) of gastrointestinal mucosa for neoplasia detection. This technique is 
most widely examined from among of spectroscopic techniques in general, because of its 
rapid and highly sensitive response to early biochemical and morphological changes in the 
tissues.  
Fluorescent diagnosis of tumor tissues becomes a valuable tool in the clinical practice. This 
technique could be applied for detection and evaluation of tumors in different localizations 
using endoscopic equipment. Such combined white-light and fluorescent mode endoscopic 
systems are already developed and introduced in the clinic for the needs of bronchoscopy 
and lung cancer diagnosis, like D-Light system of Karl Storz GmbH,  DAFE system 
(Diagnostic AutoFluorescence Endoscope) of Richard Wolf GmbH, LIFE (Lung Fluorescence 
Endoscopy System) of Xillix Technologies Corp. (DaCosta, 2003; Gabreht, 2007; McMicheal, 
1997; Chissov, 2003). 
However, fluorescent gastroscopes are still on its research and development phases and 
from the best we know the few existing systems, such as Olimpus Evis Lucera, has not 
received yet all approvals for access to the broad clinical market. This system is a 
digestive tract videoscope used for observing of blood vessels in mucous membranes 
under infrared light in the regions 790-820 nm and 905-970 nm. Variation of Xillix 
fluorescent endoscopic system – Xillix-LIFE-GI is applied for autofluorescence detection 
of stomach neoplasia and has approval for Japan and European countries. Several 
fluorescent endoscopy systems are developed and proposed also for applications in the 
practice by different research teams, demonstrating very good clinical results (Chissov, 
2003; Papayan, 2006; Sokolov, 2002), using autofluorescence or exogenous fluorescence 
detection of gastrointestinal neoplasia. 
Despite of the fluorescent endoscopic systems developed mentioned above, the 
fluorescent diagnosis of tumors of the upper part of gastrointestinal tract still is very 
interesting and extensive research and development task worldwide. On the current 
moment detecting the difference in autofluorescence as a gastroendoscopic image still has 
been relatively difficult task because of its faintness. Recent real time gastrointestinal 
fluorescence endoscopy is all based on the use of exogenous fluorophores (DaCosta, 2003; 
Sokolov, 2002; Prost, 2002), that increase the contrast, improve endoscopic resolution  
and sampling, and could be used to receive better 2-D visualization for the needs of 
clinicians. 
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We prepare a general review of the recent techniques, experimental achievements and 
general approaches applied in the field of light-induced fluorescence endoscopy of the 
gastrointestinal tract, as well as will provide below examples from our own research in 
this area. Broad literature survey is carried out to allow precise and extensive comments 
on advantages, drawbacks and future steps needed to be developed in this investigation 
area. 
Advances in spectroscopic instruments will improve imaging’s role as a facilitator of 
research translation. Results received in our studies could serve for development of tools for 
quantifying in vivo tumor growth and origin and for accelerating the transition from pre-
clinical studies to early clinical trials and to routine diagnostic practice. 
2. Principles and methods 
Light-induced fluorescence spectroscopy of biological tissues is based on the physical 
phenomenon that when with a light beam in appropriate spectral region one irradiates some 
biological sample it could re-emit the light with a spectrum, related to its biochemical 
content. These molecules, which are in the tissue and re-emit the light, are called 
fluorophores, and the process itself is called fluorescence. Light sources that can be used 
include incoherent light sources such as Xe or Hg lamps, light-emitting diodes or 
monochromatic laser light. When light penetrate into the tissue, it could cause reflection 
from the tissue layers and non-homogeneities in the tissue; could cause absorption, as well 
as fluorescence. If only endogenous fluorophores, naturally existing in the sample, are used 
to obtain fluorescent signal from the tissue one could observe autofluorescence. If 
fluorescent compound is added (e.g. injected) into the tissue exogenous fluorescence is 
observed (Ell, 2003; Song, 2003, Song, 2005). Fluorescence diagnosis can be achieved by 
measuring either autofluorescence, generated by endogenous molecules, or tissue 
fluorescence following administration of an exogenous agent.  
When fluorescence is observed in situ the resultant spectrum is superposition of several 
overlapping contributions of various fluorophores, which concentrations and special 
distribution vary depend on the stage of tissue pathology. It is typical to observe changes in 
intensity, or appearance/disappearance of fluorescent maxima with progression towards 
neoplasia. These spectral changes could indicate tissue pathological condition and stage of 
the lesion growth. 
In endoscopic fluorescence spectroscopy measurements we could distinguish two major 
directions, see fig. 1: 
1. Depending from the origin of the fluorescent signal detected – autofluorescence and 
exogenous (drug-enhanced) fluorescence; 
2. Depending from the signal detected – point measurements and two-dimensional 
images;  
Point measurements give us spectral data of the fluorescence, usually in terms of intensity of 
the fluorescence signal vs. wavelength, and two-dimensional images allow visualization of 
the mucosal area in terms of fluorescent color maps, which allow determination of 
boundaries and specification of the anatomic place of the pathology.  
Point spectral measurements are more sensitive and allow better differentiation between 
inflammatory and dysplastic areas vs. tumours, as the first ones could have significant 
similarities with the cancer sites, if observed in two-dimensional fluorescent images. This is 
related to diagnostic specificity evaluation using LIFS, as a diagnostic tool and there are 
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different ways to improve the values of LIFS sensitivity and specificity, using spectral 
analysis techniques, which are applied from different research groups to improve their 
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detection high sensitivity and specificity could be achieved, if complex algorithms are 
applied for differentiation of the spectra (Ell, 2003; DaCosta, 2006). However, detecting the 
difference in autofluorescence as a gastroendoscopic image still has been relatively difficult 
task because of spectra similarity and relative faintness of the signals. Recent real time 
gastrointestinal fluorescence endoscopy is all based on the use of exogenous fluorophores 
that increase the contrast, improve endoscopic resolution and sampling, and could be used 
to receive better 2-D visualization. 
2.1 Light-induced autofluorescence detection of gastrointestinal pathologies 
Autofluorescence is a term used to describe fluorescence emission from naturally occurring 
tissue molecules – endogenous fluorophores) such as aromatic amino acids, NADH, 
collagen and porphyrins. Each group of fluorophores is characterized by specific excitation 
and fluorescence emission wavelength ranges (see Table I), although it is common if use one 
excitation wavelength to excite several fluorophores and for their emission bandwidths to 
overlap, resulting in a broad and relatively featureless fluorescence spectrum. Major 
endogenous fluorophores, which produce autofluorescent spectrum observed from 
gastrointestinal mucosa are presented in Table 1, according data from investigations of 
independant research groups (Song, 2003; DaCosta, 2002; Wildi, 2003; Filip, 2011). 
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Fluorophore Origin Optimal excitation wavelength (nm) 
Peak of fluorescence 
emission (nm) 
Tryptophan amino acid 280, 305 340-350 
Tyrosine amino acid 275 300 
Phenylalanine amino acid 260 280 
Collagen structural protein 330-390 390-440 
Elastin structural protein 280, 360 350, 410 
Protein cross-links structural proteins 380-420 460-500 
Pyrodixine vitamin B6 compound 330-340 400 
Ceroid, lipofuscin lipo-pigment granules, oxidation products 340-395 430-460, 540-640 
NADH metabolic co-factor 340 450-470 





390-430, 630 635, 690 
Table 1. Excitation and emission wavelengths of various endogenous fluorophores in 
human tissues 
Different stages of tissue pathologies are associated with alterations in the content, special 
distribution and metabolic activities of these fluorophores, which affect the spectral shape of 
the autofluorescence signal. A number of different pathological processes – mainly 
neoplasia, but also inflammation and ischaemia affect the autofluorescence spectra observed 
from the tissue, due to their influence on metabolic, oxidative condition of the cells and their 
morphology. 
Tumour autofluorescence intensity is strongly reduced, due to several factors: (i) changes in 
the intercellular matrix due to tumour cells size increase vs. normal cells, that lead to 
reduction of collagen and elastin concentration on volume unit and decrease of the 
autofluorescent signal detected from given mucosal area; (ii) metabolic change of NADH, to 
its oxidized form NAD+ in tumour cells, which is non-fluorescent molecule; (iii) thickening 
of the mucosa, which screens off the blue-green autofluorescence from the collagen and 
elastin from submucosa layer; (iv) increase of concentration of optical absorbers in the 
tumour area, such as hemoglobin, due to the neo-vascularization in the tumours, which 
absorb in blue-green spectral region with maxima of absorption at 420-450 nm, peaks at 543 
and 575 nm-for oxy-hemoglobin and one broad peak at 550-580 nm for reduced hemoglobin 
form. 
Spectral shape of the autofluorescent signal is also affected, when neoplasia occur in the 
gastrointestinal tract. Usually when UV – blue light is used for excitation tumour areas 
fluorescence is shifted in red, resulting of endogenous porphyrins concentration raise, 
observed in these tissues, and normal mucosa fluoresce in blue-green spectral region. Many 
authors use the intensity ratios blue/red, green/red or vice-versa to develop diagnostic 
algorithms for evaluation of neoplastic changes in the tissues under investigation (Marcon, 
1999; Mayinger, 2001; DaCosta, 2002; Wildi, 2003; Mayinger, 2003; Song, 2003; Kara, 2005, 
Borisova, 2008; Aihara, 2009). This green/red ratio is used as a basis of XIllix Laser-Induced 
Fluorescence Endoscopy Gastrointestinal (LIFE-GI) (Xillix Technologies Corp., Canada) 
autofluorescence endoscope as a technique for detection of cancerous changes. This system 
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different ways to improve the values of LIFS sensitivity and specificity, using spectral 
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autofluorescence endoscope as a technique for detection of cancerous changes. This system 
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originally used blue light excitation and detected both green and red tissue 
autofluorescence, applying band-pass filters before two image intensifier cameras for 
observation of native fluorescence in the green and red spectral ranges, which are fused to 
create a real time “red-green” image of the pathology (DaCosta, 2006). Generally, there is 
less green fluorescence in neoplastic tissue, than in normal one, while red fluorescence is 
stronger in tumour than in normal tissue. These two systems LIFE-GI and newer LIFE II still 
use fiber endoscopes and not video-endoscopes (Ell, 2003). 
Special attention deserves the influence of hemoglobin absorption on the autofluorescence 
spectra obtained. Its increase is observed in tumor areas due to the vascular growth and the 
distortions in the autofluorescence tissue spectrum induced by this chromophore, which 
molecules absorb light without re-emission of own fluorescence. Hemoglobin is responsible 
for spectral dips at 420 nm and in the region of 540-580 nm. Depending from the 
oxygenation state of hemoglobin in green spectral region one could observe two minima – at 
543 and 575 nm, related to oxy-hemoglobin, or one broad minimum, in the region of 570-580 
nm– related to reduced form of this compound (Vladimirov, 2007; Borisova, 2008). As tumor 
lesions are hypoxic in their advanced stage – this could be used as additional indicator of 
the lesion severity and growth. However, hemoglobin absorption of the autofluorescence 
signal leads to distortion of the signal obtained. Such distortions could be mathematically 
simulated and extracted – to reveal intrinsic autofluorescence of the tissue, unaffected by 
absorption and scattering events. For better processing of the autofluorescence spectra 
received, researchers measured reflectance spectra from the same tissue area and extract 
signal, related to hemoglobin re-absorption of the native fluorescence of the tissue 
(Georgakoudi, 2001; Filip, 2011).  
In the case of autofluorescence detection high sensitivity and specificity could be achieved if 
complex algorithms are applied for differentiation of the spectra (Ell, 2003). However, on the 
current moment detecting the difference in autofluorescence as a gastroendoscopic image 
still has been relatively difficult task because of its faintness. The main advantage of the 
autofluorescence technique is the fact that it is not necessary to administrate chemical 
substance to the patient before fluorescence observations. Signal obtained is unstructured 
broad superposition of the fluorescent spectra of several intrinsic fluorophores, which do 
not allow easy recognition of the lesion type and need powerful mathematical algorithms 
for diagnostic differentiation of the normal/abnormal tissues. Significant disadvantages of 
exogenous fluorescent drugs usage are related to considerable medical and legal 
implications, as well as significant additional costs needed to obtain registration and 
approval for an exogenous fluorophore to be used as a medication. The advent of powerful 
light sources and highly sensitive detectors will lead to the development of autofluorescence 
endoscopy clinical systems. But on this moment real time gastrointestinal fluorescence 
endoscopy is based mainly on use of exogenous fluorophores. 
2.2 Light-induced exogenous fluorescence detection of gastrointestinal pathologies 
Tissue fluorescence could be enhanced following application of exogenous fluorescent drug, 
which is highly selective to cancerous and dysplastic tissues. Drug-mediated fluorescence is 
advantageous from the point of view of better visualization of the tumor area, with strong 
fluorescent signal, less ambiguous relative to autofluorescence and simpler and even 
cheaper instrumentation that could be used for exogenous fluorophores detection (Song, 
2003). Other advantage is related to the a priori knowledge about optical properties of 
exogenous fluorophore – its excitation and emission spectra are well known and its 
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applicability is related mainly to its selective localization within tissues of interest, mode of 
administration and low side effects to the patients. Of course, cost related to the process of 
registration and approval of such exogenous fluorophore is significant drawback for faster 
introduction of such fluorescence systems in clinical practice. 
Up to date, photosensitizers, used in photodynamic therapy, such as porphyrin derivative 
(HpD), delta-aminolevulinic acid (5-ALA), chlorines, have been exploited, and many of 
them fluoresce and demonstrate good selectivity for neoplasm. These drugs are also the 
most interesting for the investigators, as possible compounds applicable for exogenous 
fluorescence diagnosis of gastrointestinal tract.  
Most typical photosensitizers used for fluorescent detection of gastrointestinal neoplasia are 










5-ALA/ PpIX  
5-aminolevulinic 
acid/ proto-
porphyrin IX or 
hematoporphyrin 
derivative (HpD)
405, 514, 630 635, 690, 704 
Barrett esophagus, low- and high-grade 
colon dysplasia, esophageal squamous cell 
cancer adenocarcinoma, stomach carcinoma  
(Brand, 2002; Ortner, Messmann, 2003; Song, 
2005; Vladimirov, 2007; Ishizuka, 2011) 
chlorin (chlorin 
e6, mTHPC) 660 665 
Esophageal squamous cell carcinoma 
(Gossner, 1998; Bourre, 2002) 
phthalocyanines 
(PCs) 410, 530, 670 675-685, 740 
Stomach carcinoma, esophageal 
adenocarcinoma  
(Chissov, 2003) 
Table 2. Excitation and emission wavelengths of various exogenous photosensitizers and 
their gastrointestinal neoplasia diagnostic application. 
These compounds could be applied either for point spectroscopy or for imaging. 
Photosensitizers have high selectivity to neoplastic tissues and could accumulate 
significantly more in tumours. These compounds have strong fluorescence in red spectral 
region, 630-740 nm, where autofluorescence signal is very low, which allow better 
visualization and differentiation during video-endoscopic observations. 
In the most of the studies 5-ALA/PpIX is applied as fluorescent marker for tumor 
detection in esophagus and stomach. Less popular are fluorescent drugs, based on 
phthalocyanines and chlorines, applied for diagnosis as well as for therapeutic procedures 
based on photodynamic effect appearance in the tumor cells after light irradiation. Results 
achieved with 5-ALA/PpIX show very good correlation between fluorescence signals and 
histology examination of the lesions investigated. Rapid lesions border determination 
using exogenous fluorescence signal could be obtained in 1-D scanning spectroscopic 
mode. Our own results from in vivo detection show very good differentiation between 
normal and abnormal tissues in 1-D spectroscopic regime and moderate discrimination in 
2-D imaging using 5-ALA (Borisova, 2008b). Simple spectral discrimination algorithms 
allow to improve the differentiation between normal/cancerous mucosa, as well as to 
decrease the false positive results, related to the Protoporphyrin IX accumulation not only 
in tumor but in inflammatory cells of the esophagus and stomach. 
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applicability is related mainly to its selective localization within tissues of interest, mode of 
administration and low side effects to the patients. Of course, cost related to the process of 
registration and approval of such exogenous fluorophore is significant drawback for faster 
introduction of such fluorescence systems in clinical practice. 
Up to date, photosensitizers, used in photodynamic therapy, such as porphyrin derivative 
(HpD), delta-aminolevulinic acid (5-ALA), chlorines, have been exploited, and many of 
them fluoresce and demonstrate good selectivity for neoplasm. These drugs are also the 
most interesting for the investigators, as possible compounds applicable for exogenous 
fluorescence diagnosis of gastrointestinal tract.  
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their gastrointestinal neoplasia diagnostic application. 
These compounds could be applied either for point spectroscopy or for imaging. 
Photosensitizers have high selectivity to neoplastic tissues and could accumulate 
significantly more in tumours. These compounds have strong fluorescence in red spectral 
region, 630-740 nm, where autofluorescence signal is very low, which allow better 
visualization and differentiation during video-endoscopic observations. 
In the most of the studies 5-ALA/PpIX is applied as fluorescent marker for tumor 
detection in esophagus and stomach. Less popular are fluorescent drugs, based on 
phthalocyanines and chlorines, applied for diagnosis as well as for therapeutic procedures 
based on photodynamic effect appearance in the tumor cells after light irradiation. Results 
achieved with 5-ALA/PpIX show very good correlation between fluorescence signals and 
histology examination of the lesions investigated. Rapid lesions border determination 
using exogenous fluorescence signal could be obtained in 1-D scanning spectroscopic 
mode. Our own results from in vivo detection show very good differentiation between 
normal and abnormal tissues in 1-D spectroscopic regime and moderate discrimination in 
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New Techniques in Gastrointestinal Endoscopy 
 
238 
For diagnostic purposes, delta-aminolevulinic acid is currently the compound that attracting 
greatest interest. 5-ALA is not a photosensitizer by itself, but a precursor in heme 
biosynthesis. In neoplastic cells activity of ferrochelatase, enzyme, attaching Fe2+ to the 
protoporphyrin IX, is strongly reduced, which lead to selective accumulation in malignant 
cells of this compound, which has photosensitizing properties, see figure 2. This effect could 
be observed using autofluorescence as well, but the concentration of PpIX in the tumour is 
much less than if 5-ALA is exogenously administered.  Preliminary studies suggest that 
protoporphyrin IX (PpIX) fluorescence resulting from exogenously administered 5-
aminolevulinic acid (5-ALA) may improve the detection of dysplastic mucosa in the GI tract 
(Brand, 2002). 5-ALA is a natural precursor of heme, which induces the formation of 
endogenous PpIX.  
The administration of exogenous ALA results in the accumulation of PpIX in tissue due to 
feedback inhibition of the final step of the heme biosynthetic cycle. Enzymatic differences in 
dysplastic tissue (e.g., decreased ferrochelatase activity) lead to an increase in PpIX 
concentration and following higher intensity red fluorescence.  
This mechanism of 5-ALA transformation to photosensitive PpIX is used not only for 
gastrointestinal tumor detection and photodynamic therapy, but as well for skin, bladder, 
bronchi, brain, lung cancer diagnosis and treatment. ALA-induced PpIX fluorescence has 
also been used successfully as a marker for dysplasia in many organs (Svanberg, 2004). 
Exogenous fluorescence detection of different mucosal neoplasia becomes a valuable tool for 
early detection and determination of malicious lesions during standard endoscopic 
observation. Real time fluorescent system, based on exogenous fluorescence detection of 5-
ALA/PpiX is developed by Storz company in Germany, so called D-Light system. Excitation 
lamp applied is filtered by short pass filter (<440 nm), and the blue light is delivered to the 
tissue investigated via illumination bundle of standard fibroscope. The fluorescent light is 
collected by endoscope imaging bundle and detected by video camera after second high-
pass filter (>450 nm), which reduced strongly the excitation light coming into the detector 
(Ell, 2003).   
 
  5-ALA      
Fig. 2. Structural formulas of the compounds delta-aminolevulinic acid and protoporphyrin 
IX and the time of transformation of 5-ALA to Pp IX 
Up to now only two gastroscopic systems- one based on autofluorescence - Xillix LIFE-GI 
and other based on exogenous 5-ALA/PpIX fluorescence - Storz D-Light with possibilities 
for fluorescence imaging detection are appeared on the market. In contrast, broad 
possibilities for choice of fluorescent bronchoscopes and cystoscopes exist, as the systems 
6-8 h, depending 
from the organ 
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are built in such way to allow fluorescent detection of tumors for example in bronchi or 
bladder. One of the technical problems, related to gastrointestinal applications are the 
losses of excitation and fluorescent signals through longer gastrointestinal endoscopes, 
which fade the images that could be observed. For detection of the fluorescence signal 
from gastrointestinal tract most of the researchers apply optical fibers through 
instrumental channel of the standard endoscopic equipment, which allow fluorescence 
detection of suspicious areas. We also applied such approach in our investigations; 
therefore we will present here only point spectral measurements. The 2-D pictures 
obtained from the common endoscopic video-equipment are relatively dim due to low 
level of the fluorescent light and in the improvement of the fluorescent video image is 
following step in our investigations. 
However, results achieved from point measurements already show very good correlation 
between fluorescence signals and histology examination of the lesions investigated. Rapid 
lesions border determination using exogenous fluorescence signal could be obtained. Other 
important issue in such investigations is the contrast between inflammatory and tumor 
areas, where one could observe very good differentiation, achieving of a contrast higher 
then three times in the intensity of the 5-ALA/PpIX fluorescence in the tumor area vs. 
inflammation (Borisova, 2008a). 
2.3 Advantages and drawbacks of fluorescence techniques for gastrointestinal 
tumours detection 
As mentioned above technological advances in fiber optics, light sources, detectors, and 
molecular biology have stimulated the development of numerous optical methods that 
promise to significantly improve our ability to visualize and evaluate human epithelium in 
vivo (Wang, 2004).  
The majority of gastrointestinal malignancies, especially adenocarcinoma, arise from 
epithelial surfaces. A common phenotype of all epithelial cancers is the progression from 
normal mucosa, through a stage of dysplasia, to cancer (Ell, 2003; Wildi, 2003; Song, 2003). 
The diagnosis of dysplasia based on standard endoscopy with multiple biopsies is still 
limited. S. M. Wildi and M. B. Wallace, 2003 discussed that in many cases dysplasia is 
invisible to the eye of the endoscopist, very common in flat lesions. Because of that is the 
need of numerous random biopsies and histological examination is the standard procedure. 
Although, such strategy could misses some dysplastic areas. Some visible lesions usually are 
not distinguished endoscopically from the surrounding nondysplastic tissue. On the other 
hand, the histological evaluation of biopsy specimens is difficult, especially differentiation 
between low grade and high grade dysplasia. There is significant inter-observer 
disagreement between pathologists in diagnosing dysplasia. 
Different methods such as chromoendoscopy, magnifying endoscopy, and optical-based 
spectroscopic and imaging modalities can increase the possibility to detect endoscopically 
precursor lesions and early stage of gastrointestinal cancer with combination of target 
biopsies (Ell, 2003; Ishizuka, 2011; Marcon, 1999; Song, 2003; Wildi, 2003; Wang, 2004,). They 
have the potential to overcome the limitations of standard endoscopic procedures by 
assessing wide neoplastic regions. These modalities may also provide a more accurate 
assessment of the extent of neoplastic lesions than conventional endoscopy, which is critical 
for success of the new endoscopic therapy, such as endoscopic mucosal resection (Wang, 
2004). Nevertheless, all of these new techniques are also associated with various limitations 
and standardization. 
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are built in such way to allow fluorescent detection of tumors for example in bronchi or 
bladder. One of the technical problems, related to gastrointestinal applications are the 
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A great advantage of different autofluorescence techniques is that they can be implemented 
in vivo and give information about tissue in its native state. The detection of occult 
dysplastic or cancerous lesions is more accurate than standard endoscopy with biopsies 
(Wildi, 2003; Song, 2003). In addition, the results of C. Ell, 2003 showed that absence of 
dysplasia, early cancer, or inflammation was detected in fluorescence negative areas of 
Barrett’s mucosa, and consequently no false negative fluorescence findings were obtained. 
The data of L.-M. Wong Kee Song and B. C. Wilson, 2005 showed that targeted biopsies 
performed under LIFE endoscope in patients with short-segment Barrett esophagus 
identified more sites with high grade dysplasia than conventional biopsies obtained under 
standard endoscopy. On the opposite of these results, other study showed that both 
techniques had an equal sensitivity for high grade dysplasia and early cancer (Kobayashi, 
2001). Fluorescence spectroscopy is associated with low rate of sensitivity and specificity of 
‘low risk’ (non-dysplastic Barrett), and discriminating ‘high-risk’ (high grade dysplasia) 
from low grade dysplasia.  False-positives results occur in the presence of inflammatory or 
reactive changes (Ell, 2003). The reported diagnostic accuracy have depends on the sample 
size and wavelength(s) selection. One other advantage of the fluorescence spectroscopy is 
the easy passage of the probes through the accessory channel of standard diagnostic 
endoscopes and highly predictable geometry between fibers that provide the source of light 
and those that deliver collected light to the detector (Wildi, 2003). On the other hand, 
spectroscopic techniques are limited by the small surface area they examine at the tip of the 
probe compared to standard endoscopy (Song, 2003, 2005). In parallel with point 
spectroscopy, real-time fluorescence imaging prototypes, such as fiberoptic endoscopes or 
videoendoscopes, have been developed, providing a field of view, similar to that of a 
conventional endoscope. The application of drug-enhanced fluorescence imaging in the 
upper GI tract increase the sensitivity for detection of Barrett’s type dysplasia, but low 
specificity was found (Song, 2003). The fluorescence imaging with 5-ALA have similar 
limitations to autofluorescence imaging about a relative high number of false-positives 
results in cases with inflammation and metaplasia (Ell, 2003). In addition, the optimal dose 
of 5-ALA and whether topical application is capable of being as effective as oral 
administration is not estimated yet.  
So, the potential clinical use of fluorescent endoscopy is wide-area surveillance, as in Barrett’s 
esophagus and chronic inflammatory bowel diseases. T. Wang and J. Van Dam, J., 2004 
discussed that these methods of optical biopsy are unlikely to replace conventional biopsy 
with histopathological interpretation of excised tissue, but they are likely to provide a more 
accurate and efficient approach to target biopsy of diseased tissue, thus reducing the number 
of conventional biopsies required, increasing surveillance intervals, and reducing cost. L.-M 
Wong Kee Song and K. Wang, 2003, also discussed that optical-based techniques for diagnosis 
of premalignant lesions, as well as early gastrointestinal cancer remains “controversial”. 
Although they are promising modalities for detection of dysplastic or early neoplastic lesions. 
There is a need of technical optimization and confirmation of the preliminary results by future 
large number, prospective, randomized, controlled, cross-over clinical trials, as well as 
comparing the potential of drug-enhanced fluorescence detection relative to autofluorescence 
and to standard biopsy surveillance. The optimal technique may be a combination of optical 
modalities (multimodal optical diagnosis) with maximal diagnostic sensitivity and specificity. 
For instance, a lesion could be detected by a wide area surveillance technique such as 
autofluorescence imaging, and further characterized by a spectroscopic technique, such as 
exogenous fluorescence, Raman and/or confocal endoscopy.   
 
Light-Induced Fluorescence Techniques for Gastrointestinal Tumour Detection 
 
241 
C. Ell, 2003 discussed that fluorescent endoscopy may increase the detection of neoplastic 
lesions in the stomach but the clinical indications for fluorescence endoscopy is limited to 
patients with Barrett’s esophagus. Spectroscopic procedures still have higher sensitivity and 
specificity rates for identifying neoplastic lesions than imaging fluorescence systems. From 
the clinical point of view, only real time endoscopic fluorescence imaging systems represent 
a practicable solution. The systems that are currently available still have weaknesses, and 
will need to undergo thorough clinical evaluation once they have been technically 
optimized. In comparison with incoherent light sources, laser-based methods seem to be too 
elaborate and expensive, and the former are likely to replace them. In addition, fluorescence 
detection will have to be possible in the future using high resolution video endoscopes.  
According to the report of the American Society for Gastrointestinal Endoscopy (ASGE) 
Technology Committee, (Song, 2011), autofluorescence imaging, using probe-based 
spectroscopic devices and fiberoptic autofluorescence imaging (AFI) endoscopes have 
limited clinical value because of poor image quality related to fiberoptic technology. On the 
other hand video-endoscopic AFI systems is an improvement over earlier fiberoptic 
systems, but still have image quality inferior to high-resolution endoscopy. Improvements 
in image resolution, noise reduction, and color contrast may be achieved by further 
intensifying the autofluorescence signal and by optimizing the excitation and/or detection 
wavelength algorithms. In addition to steady-state fluorescence detection schemes, time-
resolved fluorescence imaging, which measures fluorescence decay as a function of time, 
may be a future method to help further enhance lesion detection. Quantitative analysis of 
AFI images and development of autofluorescence indices for tissue discrimination have the 
potential to improve diagnostic accuracy and complement, if not supplement, the visual 
interpretation of images. Ultimately, autofluorescence combined with the detection of a 
fluorescent contrast agent that has high affinity for a targeted tissue receptor (ie, molecular 
beacon) may be the optimal solution for fluorescence-based diagnosis. In addition to 
technological developments, randomized controlled trials are needed to assess the accuracy 
of AFI relative to high-definition white light imaging and other competing technologies, 
such as electronic mucosal enhancement techniques (eg, narrow-band imaging, multi band 
imaging). Inter-observer agreement and validation studies in non-enriched patient 
populations are also needed before AFI can be recommended for routine endoscopic 
practice. The report concluded that AFI may enhance lesion detection or differentiation in 
the GI tract, the technique currently lacks sufficient specificity to make it useful as a stand-
alone diagnostic modality during endoscopic practice. AFI may be a valuable tool when 
used as part of a multimodal imaging scheme, but this will require further technical 
advances and validation in prospective, randomized trials. 
3. Light-induced point fluorescence spectroscopy of gastrointestinal 
tumours 
Major spectral features observed during endoscopic investigations of gastrointestinal tumor, 
could be distinct as the next regions, according their origin and spectral region appearance, 
after application of 5-ALA and fluorescent excitation at 405 nm, as follow: 
1. 450-650 nm region, where tissue autofluorescence is observed;  
2. 630-710 nm region, where fluorescence of PpIX is clearly pronounced;  
3. 530-580 nm region, where minima in the autofluorescence signal are observed, related 
to re-absorption of oxy-hemoglobin in this spectral area.  
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Normal mucosa has bright autofluorescence, related mainly to the emission of co-enzymes, 
phospholipids, collagen, elastin, and protein cross-links. The intensity of autofluorescence in 




        (a)                                                                         (b) 
Fig. 3. Fluorescence signal detected from normal esophagus (a) and stomach (b) walls and 
carcinoma, as typical example of the spectral features observed with exogenous photosensitizer 
delta-ALA/protoporphyrin IX and 405 nm excitation is applied (Borisova et al, 2008a). 
Normal esophagus and stomach autofluorescence lies in blue-green spectral area, which 
could be observed using video-endoscopy system such as D-Light (Filip, 2011) or 
autofluorescence endoscopic systems (Kara, 2005). 
3.1 LIFS of gastrointestinal tumours – experimental results 
Fluorescence intensity varies strongly from patient to patient; therefore most reasonable is 
the intra-patient comparison of the fluorescence intensity of normal tissue areas vs. 
suspicious ones. Even in the frames of one pathological area the intensity could vary, see fig. 
4 (Borisova, 2008c). One of the disadvantages discussed in the most of the papers is related 
to false-positive results, which could be obtained when inflammations appear in the 
esophageal or stomach walls. Inflammatory areas reveal red fluorescence, due to some 
selectivity of 5-ALA/PpIX in the inflammatory cells, where heme synthesis is delayed. 
Indeed, when video-observation is applied, it is not easy to differentiate the red signal 
coming from inflammatory area and from neoplastic lesion, but when point spectroscopy is 
applied, one could observe significant differences in the intensity levels of 5-ALA/PpIX 
fluorescence at 635 nm. Therefore, point spectroscopy allows to reach higher specificity of 
the diagnosis (Georgakoudi, 2001, Ortner, 2003), than video-endoscopic observation 
(Endlicher, 2001; Messmann, 2003).  
If compare relative intensities of normal and abnormal tissues sites for esophagus and 
stomach (see fig. 3b), the high level of the autofluorescence signal in the long wavelength 
spectral range (>600 nm) of the stomach wall, lead to problems in 2-D video-observation of 
the stomach tumor fluorescence. The values of the area of the autofluorescence spectrum of 
normal mucosa for the region >600 nm in comparison with the same region for tumor 
fluorescence are comparable and the ratio values between total areas of normal vs. tumor 
spectra in the region 600-800 nm vary from 0,7 to 1,1 for different patients.  
 




Fig. 4. Fluorescence spectra obtained in vivo from different suspicious areas of an esophageal 
mucosa of one patient, after 6 h ALA/PpIX application, using 405 nm excitation – 
inflammatory mucosa and different points on tumor lesion (Borisova et al., 2008c). 
This effect could not be avoided by application of filter before CCD camera, as the long-pass 
filter (>600 nm) passed both signals – from normal mucosa autofluorescence and from 
exogenous 5-ALA/PpIX tumor fluorescence, see fig.5. 
 
 
Fig. 5. Comparison of the integrated fluorescence signal for the region 600-780 nm, calculated 
for all cases detected from stomach normal mucosa, inflammation, and carcinoma. Data are 
represented with the mean values of the areas calculated (Borisova et al., 2008b). 
As the human eye make an integration of the spectral signal when compare intensities, in  
2-D image the endoscopist will observe similar by color and light intensity areas, which also 
lead to specificity reduction, when video-endoscopic observation is applied (see table 3). 
These specificity values could reach 51% (Messmann, 2003) or even 27% (Endlicher, 2001), 
which makes them absolutely useless for 2-D diagnosis. If a long-wavelength filter is 
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applied to reject the autofluorescence from the normal mucosa sites red “tail” of the 
autofluorescence from the normal mucosa will be still detected and the contrast could not be 
improved. In that case only spectral data could increase the fluorescence detection 
sensitivity and specificity. 
This problem is still unsolved in the existing imaging systems for gastroscopic observations, 
but could be solved partially by change of excitation wavelength applied and this task is in a 
process of solving in our further investigations using longer wavelengths for excitation of 
PpIX (using peaks of absorption at 509 nm, 544 nm or 584 nm), where autofluorescence is 
not so strong factor, as well as back scattered excitation light from the mucosal surface does 
not lie in the spectral region of PpIX fluorescence itself. Drawback of this approach is the 
fact that fluorescence effectiveness is much less, when use excitation on these wavelengths, 
than at 405 nm, where the strongest absorption of PpIX is observed. 
When inflammatory areas occurred in the organ under investigation false-positive red 
fluorescence is observed in video channel of the endoscope due to the accumulation of PpIX 
in the both tumor and inflammatory areas. The contrast between the fluorescent signals at 
635 nm between tumor regions and inflammations observed in all patients, where such 
comparison was possible, usually is higher than two (Borisova, 2009). In such way one could 
be sure in general that using point fluorescence detection approach, he could distinguish 




Fig. 6. Dimensionless ratio (•) R=I635/I560 calculated for all cases detected from normal 
mucosa, inflammation, dysplasia and tumor of stomach. Lines represent the mean values of 
this ratio calculated (Borisova et al., 2009). 
The fluorescent intensities of the maximum at 635 nm of inflammatory area detected from 
stomach wall are close to the lowest signals received from tumors. Therefore, an additional 
criterion could be applied for better differentiation of inflammation from tumor. We used 
for these goals a dimensionless ratio R=I635/I560, see fig.6. Using this simple algorithm very 
good differentiation tumor/inflammation is obtained that could be applied for clinical 
practice needs. Moreover, similar approaches are proposed for differentiation of normal and 
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cancerous sites from other research groups, for gastrointestinal tumors, cancer detection in 
bronchi and lungs. Using green and red band-pass filters two complimentary images are 
received and ratio between them is calculated to receive more contrast image and to 
improve sensitivity and specificity of the fluorescent endoscopy approach (Sokolov, 2002, 
2005; Goujon, 2001). 
3.2 LIFS of gastrointestinal tumours – sensitivity and specificity peculiarities 
When new diagnostic approach is introduced into the medical practice, major indicators of 
its clinical applicability are the values of sensitivity and specificity of such newly developed 
method. As we already mentioned, when discussed advantages and drawbacks of light-
induced fluorescence diagnostics – this technique, nevertheless if autofluorescence, or drug-
enhanced exogenous fluorescence detection is applied, is only complimentary on its recent 
level of development. In some next stage of its development, when more sensitive detectors, 
or more complicate mathematical algorithms for image analysis are applied in video-
endoscopes used for gastrointestinal tumor observations, this high sensitive method could 
found primary place as a diagnostic tool.  
Nowadays, all reports on exogenous fluorescence diagnostics related to evaluation of 
statistical diagnostic values show an excellent sensitivity of fluorescent diagnostic technique 
and moderate, even poor specificity values. We stopped our attention on few reasons for 
such low values of the specificity: 
i. false-positive red fluorescence, due to selectivity of exogenous photosensitizers, not 
only to tumor cells, but also to inflammatory areas; 
ii. significant autofluorescence signal in the spectral range above 600 nm, which lead to 
problems with differentiation during 2-D video observation of lesion fluorescent 
images; 
As we will see from the comparison of the results, obtained from other research groups (see 
table 3), other possible reasons for low specificity values of this technique, up to now are: 
iii. strong dependence on the fluorescent drug concentration to the contrast tumor/normal 
mucosa observed; 
iv. drug application influence on the selective accumulation of the fluorophore into tumor 
area – intravenous, using spray catheter, enema, orally, etc. 
In table 3 are presented data from investigations, which allow observing the general 
tendencies and influences on the sensitivity and specificity values obtained, depending from 
the initial conditions applied. 
Messmann and group, 2003,  applied 5-ALA using three different ways – orally, using spray 
catheter and enema for detection of low-grade and high-grade colon dysplasia. Endoscopic 
observations were performed using fibrescopes, connected to a light source delivering 
white, or blue light (D-light, Storz, Germany) and the evaluations of SE and SP were based 
on the observed real time fluorescence pictures. According observations, optimal way of 
application is using spray catheter, as there sensitivity is 100%, and moderate but relatively 
higher value of specificity is reached – 62 %. Authors called the fluorescent technique 
“promising” for detection of LGD and HGD in ulcerative colitis, but observed high rate of 
false-positive fluorescent signals related to inflammatory areas. Unequal absorption of 5-
ALA using enema or spray catheter also need to be taken into account and cannot be 
excluded as possible source of methodological errors. Authors stress on the fact that they 
received high percentages for the negative predictive values, which allow concluding an 
indication that there is almost no colon dysplasia in a negative fluorescence observations.  
 
New Techniques in Gastrointestinal Endoscopy 
 
244 
applied to reject the autofluorescence from the normal mucosa sites red “tail” of the 
autofluorescence from the normal mucosa will be still detected and the contrast could not be 
improved. In that case only spectral data could increase the fluorescence detection 
sensitivity and specificity. 
This problem is still unsolved in the existing imaging systems for gastroscopic observations, 
but could be solved partially by change of excitation wavelength applied and this task is in a 
process of solving in our further investigations using longer wavelengths for excitation of 
PpIX (using peaks of absorption at 509 nm, 544 nm or 584 nm), where autofluorescence is 
not so strong factor, as well as back scattered excitation light from the mucosal surface does 
not lie in the spectral region of PpIX fluorescence itself. Drawback of this approach is the 
fact that fluorescence effectiveness is much less, when use excitation on these wavelengths, 
than at 405 nm, where the strongest absorption of PpIX is observed. 
When inflammatory areas occurred in the organ under investigation false-positive red 
fluorescence is observed in video channel of the endoscope due to the accumulation of PpIX 
in the both tumor and inflammatory areas. The contrast between the fluorescent signals at 
635 nm between tumor regions and inflammations observed in all patients, where such 
comparison was possible, usually is higher than two (Borisova, 2009). In such way one could 
be sure in general that using point fluorescence detection approach, he could distinguish 




Fig. 6. Dimensionless ratio (•) R=I635/I560 calculated for all cases detected from normal 
mucosa, inflammation, dysplasia and tumor of stomach. Lines represent the mean values of 
this ratio calculated (Borisova et al., 2009). 
The fluorescent intensities of the maximum at 635 nm of inflammatory area detected from 
stomach wall are close to the lowest signals received from tumors. Therefore, an additional 
criterion could be applied for better differentiation of inflammation from tumor. We used 
for these goals a dimensionless ratio R=I635/I560, see fig.6. Using this simple algorithm very 
good differentiation tumor/inflammation is obtained that could be applied for clinical 
practice needs. Moreover, similar approaches are proposed for differentiation of normal and 
 
Light-Induced Fluorescence Techniques for Gastrointestinal Tumour Detection 
 
245 
cancerous sites from other research groups, for gastrointestinal tumors, cancer detection in 
bronchi and lungs. Using green and red band-pass filters two complimentary images are 
received and ratio between them is calculated to receive more contrast image and to 
improve sensitivity and specificity of the fluorescent endoscopy approach (Sokolov, 2002, 
2005; Goujon, 2001). 
3.2 LIFS of gastrointestinal tumours – sensitivity and specificity peculiarities 
When new diagnostic approach is introduced into the medical practice, major indicators of 
its clinical applicability are the values of sensitivity and specificity of such newly developed 
method. As we already mentioned, when discussed advantages and drawbacks of light-
induced fluorescence diagnostics – this technique, nevertheless if autofluorescence, or drug-
enhanced exogenous fluorescence detection is applied, is only complimentary on its recent 
level of development. In some next stage of its development, when more sensitive detectors, 
or more complicate mathematical algorithms for image analysis are applied in video-
endoscopes used for gastrointestinal tumor observations, this high sensitive method could 
found primary place as a diagnostic tool.  
Nowadays, all reports on exogenous fluorescence diagnostics related to evaluation of 
statistical diagnostic values show an excellent sensitivity of fluorescent diagnostic technique 
and moderate, even poor specificity values. We stopped our attention on few reasons for 
such low values of the specificity: 
i. false-positive red fluorescence, due to selectivity of exogenous photosensitizers, not 
only to tumor cells, but also to inflammatory areas; 
ii. significant autofluorescence signal in the spectral range above 600 nm, which lead to 
problems with differentiation during 2-D video observation of lesion fluorescent 
images; 
As we will see from the comparison of the results, obtained from other research groups (see 
table 3), other possible reasons for low specificity values of this technique, up to now are: 
iii. strong dependence on the fluorescent drug concentration to the contrast tumor/normal 
mucosa observed; 
iv. drug application influence on the selective accumulation of the fluorophore into tumor 
area – intravenous, using spray catheter, enema, orally, etc. 
In table 3 are presented data from investigations, which allow observing the general 
tendencies and influences on the sensitivity and specificity values obtained, depending from 
the initial conditions applied. 
Messmann and group, 2003,  applied 5-ALA using three different ways – orally, using spray 
catheter and enema for detection of low-grade and high-grade colon dysplasia. Endoscopic 
observations were performed using fibrescopes, connected to a light source delivering 
white, or blue light (D-light, Storz, Germany) and the evaluations of SE and SP were based 
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Table 3. Sensitivity and specificity received using LIFS of gastrointestinal tract for different 
localisations using autofluorescent or exogenous fluorescent detection of lesions 
Interesting investigation, related to the optimisation of exogenous fluorophore 
concentration is carried out by Endlicher and group (Endlicher, 2001) for detection of low-
grade and high-grade dysplasia in Barrett esophagus. Again, the observations are made in 
2-D regime, not as point spectral measurements, which explain partially the moderate 
values of specificity received, 4-6 hours after oral application of 5-ALA to the patients. The 
lower and upper limits of 5-ALA concentrations applied reveal that number of fluorescent 
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negative biopsies in the patients’ group sensitized with 30 mg/kg was extremely low, due to 
the high background fluorescence. In contrary, when 5 mg/kg 5-ALA is applied to the 
patients, only weak fluorescence appear and therefore the number of positive biopsies is 
lower in that group. Additionally false positive fluorescence was induced mainly by 
inflammatory areas and metaplasia, as well as from reflux of bile into the esophagus, which 
was associated with intensive red fluorescence. Optimal values for 5-ALA oral applications 
are received for 15-20 mg/kg dose. Researchers also observed that while local sensitization 
caused no side effects, systemic application of 5-ALA with doses higher than 20 mg/kg 
could cause mild nausea or vomiting in a few of the patients, as well as transient increases in 
liver enzymes in two patients from 58 examined persons. Skin photosensitivity using 5-ALA 
is relatively low and disappears after several hours after systemic administration, but 
disappear totally after 18 hours for all patients. 
In the second part of the table 3 are presented results from investigations using 
autofluorescence as a diagnostic tool. When autofluorescence detection is applied high 
values for sensitivity and specificity (higher than 90 %) are reported from all research 
groups. Autofluorescence spectroscopy is characterized with high values for both these 
diagnostic parameters. The biggest problem of this technique is the visualization of the 
pathologies, useful for the clinicians, which still waits for its technical solution. Point 
spectral data detected are useful and informative for the physicists and engineers, who work 
on the development of this technique for its introduction into the clinical practice. But these 
data are not so exciting for the clinicians, who prefer to visualize their objects of interest, 
developing 2-D images, based on real or pseudo-color maps, based on the optical properties 
of the investigated tissues. Xillix LIFE-GI system is one possible answer of such need, but 
still not optimized for daily clinical observations.  
4. Conclusions 
Theoretically spectral diagnosis can provide imaging and point spectroscopic information in 
both - morphological and biochemical data modes with extreme sensitivity and specificity. 
Advances in spectroscopic instruments will improve imaging’s role as a facilitator of 
research translation. Results received in the recent studies could serve for development of 
tools for quantifying in vivo tumor growth and origin and for accelerating the transition 
from pre-clinical studies to early clinical trials and to routine diagnostic practice. Beyond all 
doubts, application of new, more sensitive tool for diagnostics of esophageal and stomach 
neoplasia could potentially make fluorescence surveillance clinically and cost effective 
procedure. 
Despite of the fluorescent endoscopic systems developed and already discussed under 
clinical and laboratorial investigations, the fluorescent diagnosis of tumors of the 
gastrointestinal tract is still very challenging and extensive research and development task 
worldwide. With the optimization of the procedures and evaluation of diagnostic added 
value of the technique, through development of appropriate algorithms based on 
fluorescence properties of the investigated sites, a novel high sensitive diagnostic tool could 
be successfully applied as complementary to the standard white light endoscopy.  
But on this moment real time gastrointestinal fluorescence video-endoscopy rely on the use 
of exogenous fluorophores and contrast, which would be observed after exogenous 
fluorophore application. Most popular precursor of a photosensitizer is delta-aminolevulinic 
acid/Protoporphyrin IX (5-ALA/PpIX) that is also used as fluorescent marker for dysplasia 
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negative biopsies in the patients’ group sensitized with 30 mg/kg was extremely low, due to 
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tools for quantifying in vivo tumor growth and origin and for accelerating the transition 
from pre-clinical studies to early clinical trials and to routine diagnostic practice. Beyond all 
doubts, application of new, more sensitive tool for diagnostics of esophageal and stomach 
neoplasia could potentially make fluorescence surveillance clinically and cost effective 
procedure. 
Despite of the fluorescent endoscopic systems developed and already discussed under 
clinical and laboratorial investigations, the fluorescent diagnosis of tumors of the 
gastrointestinal tract is still very challenging and extensive research and development task 
worldwide. With the optimization of the procedures and evaluation of diagnostic added 
value of the technique, through development of appropriate algorithms based on 
fluorescence properties of the investigated sites, a novel high sensitive diagnostic tool could 
be successfully applied as complementary to the standard white light endoscopy.  
But on this moment real time gastrointestinal fluorescence video-endoscopy rely on the use 
of exogenous fluorophores and contrast, which would be observed after exogenous 
fluorophore application. Most popular precursor of a photosensitizer is delta-aminolevulinic 
acid/Protoporphyrin IX (5-ALA/PpIX) that is also used as fluorescent marker for dysplasia 
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and tumor detection in many other anatomical sites. 5-ALA/PpIX has low toxicity, very 
good selectivity to the tumor tissues and reveals high contrast normal/abnormal tissue, 
which makes it preferable form of exogenous fluorophore for clinical applications.  
Results achieved with 5-ALA/PpIX show very good correlation between fluorescence 
signals and histology examination of the lesions investigated. The lack of fluorescence peaks 
in the red spectral area for normal mucosa is an indication for selective accumulation of 5-
ALA/PpIX only in abnormal sites and gives high contrast when lesion borders are 
determined from clinicians during video observation in the process of diagnostic procedure. 
Rapid lesions border determination using exogenous fluorescence signal is obtained in such 
way. However, more detailed investigation about differences in the accumulation of 5-
aminolevulinic acid/protoporphyrin IX in neoplastic and inflammatory areas will be useful 
to evaluate and optimize the contrast between these tissue conditions.  
In conclusion, optical spectroscopic and imaging modalities, such as fluorescence 
endoscopy, narrow band imaging, optical coherence tomography, and confocal endoscopy, 
are still under evaluation and should be considered research tools at the current time. 
Although promising, instrument optimization, diagnostic reproducibility, and validation 
through large-scale prospective comparative trials are needed before optical spectroscopic 
and imaging techniques are considered part of routine endoscopic practice. Ultimately, 
whether and to what extent fluorescence endoscopy will find its place in clinical 
gastroenterology will only be decided in comparison with the other imaging options 
available (high resolution endoscopy, magnification endoscopy, chromo-endoscopy, etc). 
Additionally the cost effectiveness of spectroscopic screening needs to be further assessed in 
prospective studies. 
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1. Introduction 
In recent years endoscopic diagnosis has evolved to include new endoscopic techniques that 
enhance visualization of gastrointestinal mucosa. This has improved diagnostic accuracy, as 
well as patient surveillance and management. Magnifying endoscopy is an endoscopic 
imaging technique that enhances visualisation of fine mucosal structures and capillary 
patterns. Studies utilizing magnification in conjunction with chromoendoscopy in the 
identification of intestinal metaplasia, dysplasia, early carcinoma in the upper 
gastrointestinal tract, as well as different patterns in colonic polyps, have elucidated its 
usefulness.  The interpretation of the images and patterns seen with these new endoscopic 
methods, or inter-observer agreement, remains a challenge in clinical practice. Magnifying 
endoscopy is useful in predicting the histological diagnosis during the endoscopic 
examination itself, but requires a careful, time consuming, inspection of the mucosa. In this 
chapter we discuss different patterns observed by magnifying chromoendoscopy as well as 
the current challenges in performing the endoscopic procedures and in interpretation of 
images.  
2. Technique of magnifying endoscopy and chromoendoscopy 
2.1 Equipment 
Standard endoscopic findings have a poor correlation with histopathologic diagnosis.  
Because of the patchy distribution of lesions within the mucosa, the sensitivity of random 
biopsies technique is low. New endoscopic methods have been developed to improve 
diagnostic sensitivity by enhancing the detection of suspicious lesions, followed by targeted 
biopsies. High resolution endoscopes provide better quality visualization. Magnifying 
endoscopes enlarge the image by using a movable lens, allowing for improved imaging of 
fine mucosal structures and microvascular architecture. Magnifying gastroscopes have an 
adjustable focus system that provides the capacity to obtain conventional images as well as 
close-up views. A transparent cap is affixed to the tip of the endoscope in order to maintain 
a distance of 2-3 mm between mucosa under examination and the endoscope. This helps to 
retain a focused image and permits a proper analysis of mucosal details by the endoscopist. 
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We use magnifying endoscopy in conjunction with chromoscopy in order to improve 
visualization of mucosal details. Acetic acid is weak acid with a pH of 2.5 that produces 
reversible intracellular cytoplasmic protein denaturation. The chemical response of the 
mucosa to acetic acid creates an observed whitening over time. The application of acetic acid 
highlights the surface of the mucosa and highlights subtle mucosal patterns. Methylene blue 
is a vital stain that is taken up by absorbent tissues such as the small intestinal epithelium. 
We used it for improved detection of intestinal metaplasia in the esophagogastric junction or 
in the gastric mucosa. The amount of dye that we use is 5 to 10 ml for the examination of 
esophageal mucosa and 10 to 20 ml in the gastric mucosa. An application of a limited 
amount of dye and repeated suctioning are necessary in order to avoid aspiration during the 
procedure. 
2.3 Method 
We perform conventional endoscopy, followed by magnification chromoendoscopy to identify 
different patterns corresponding to normal or modified mucosa and to establish the practical 
usefulness of these methods. Informed consent is obtained from all patients before performing 
all endoscopic examinations. All magnification endoscopy procedures are performed using an 
Olympus Gif-Q 160Z high-magnification endoscope which provides up to 115 times 
magnification. A transparent cap is attached to the endoscopic tip in order to maintain good 
focus. Initially, we examine the esophagus, stomach and duodenum by conventional 
endoscopy to identify visible changes of the mucosa. After that, the dye is spread onto the 
surface of the mucosa and we switch to the magnification function of the endoscope to 
examine modified areas and surrounding normal mucosa. We use a spray catheter inserted 
through the biopsy channel of the scope to spread the dye on the mucosa. We rotate the scope 
during the dye application for uniform coverage of the mucosa. Excess dye and water is 
removed by suction before starting the magnification. Previous white light endoscopic 
examination allows proper identification of some lesions and may help to narrow the area 
necessary to be surveyed in a focused, magnified endoscopic examination. Later, targeted 
biopsies from areas with modified patterns are obtained for correlation with histopathological 
findings. It is important to examine the entire mucosa before taking biopsies, as the presence of 
post-biopsy bleeding can interfere with obtaining subsequent magnified image. We take 
endoscopic photographs with relevant conventional and magnified views. Registered images 
are evaluated by three endoscopists. Previous published reports on normal magnified mucosa 
and modified mucosa with associated patterns are used for proper evaluation. The diagnosis 
of lesions is established by magnifying chromoendoscopy from the viewpoint of the fine 
mucosal pattern (so called, pit pattern) and the minute vessels. We study the correlation 
between mucosal patterns and the histological conditions. We classify the magnifying 
endoscopic pattern as follows: normal patterns and abnormal (modified) patterns. 
Corresponding biopsies are analyzed in Department of Pathology. 
2.4 Patient selection 
We perform magnifying endoscopy in patients with suspected esophageal or gastric lesions. 
As a first step, we perform conventional upper endoscopies. We identify patients with 
modified esophagogastric junction mucosa, atrophic gastritis, gastric polyps or other gastric 
lesions: erosions, nodular appearance of the mucosa, ulcer scars, superficial elevated lesions 
or flat lesions. Patients with advanced cancer, malignant lymphoma are excluded.  
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An analysis of fine mucosal details and vasculature requires patient cooperation. This can be 
achieved by adequately sedation during the procedure. Occasionally, patient agitation 
creates esophageal and gastric motion and it is difficult to maintain a focused image. This 
can result in both prolongation of the procedure and an inadequate endoscopic survey. 
Additionally, dye application and careful examination of mucosal and vascular details 
increase the time necessary for the entire procedure. We have found that an experienced 
anesthesiologist can reliably ensure adequate sedation utilizing Propofol during the 
endoscopic examination. Mucus or secretions, as well as gastric and esophageal peristalsis, 
may interfere with obtaining good, relevant images.  
3. Clinical applications 
3.1 The esophagus 
We select patients with presumed Barrett’s esophagus on conventional endoscopy and 
modified esophagogastric junction for dye application and magnification. We examine the 
distal esophagus and esophagogastric junction with magnification. We first identify intra-
epithelial papillary capillary loop (IPCL) in the squamous epithelium (Fig.1).  
 
 
Fig. 1. Magnified view of intra-epithelial papillary capillary loop (IPCL) 
3.1.1 Barrett’s esophagus (BE) 
Barrett’s esophagus is characterized by the replacement of the squamous epithelium of the 
esophagus by columnar epithelium. According to international guidelines, only patients 
with specialized columnar epithelium, that means intestinal metaplasia, are advised to 
undergo periodic endoscopic surveillance for the detection of dysplasia or early carcinoma 
(American Society for Gastrointestinal Endoscopy [ASGE], 2006). In clinical practice, 4-
quadrant random biopsies are taken every 1 and 2 cm from the columnar-lined esophagus 
for the detection of early premalignant and malignant lesions. Previous reports emphasized 
the risk for the patients with cardiac–type mucosa in the columnar-line esophagus for 
development of esophageal adenocarcinoma (Sampliner, 2002). Riddell & Odze showed that 
patients with esophageal columnar metaplasia, without goblet cells, are also at risk for the 
development of carcinoma. These patients should be also included in surveillance programs 
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and guidelines for the diagnosis of BE should be revisited (Riddell & Odze, 2009). Kerkhof 
et al. demonstrated that the length of columnar-lined esophagus is one of the most 
important predictors for the presence of intestinal metaplasia, in addition to male gender 
and hiatal hernia size (Kerkhof et al., 2007). Thus, increasing the length of columnar 
metaplasia raises the chance of detecting goblet cells in biopsies. The detection of goblet cells 
in BE decreases in the case of short-segment BE (Jones et al., 2002). We perform magnified 
examinations in patients with long-segment BE (Fig.2), which is easily suspected based on 
conventional endoscopic appearance. The real challenge, however, is to diagnose columnar 
metaplasia that measures less than 1 cm in length. The endoscopic appearance of ultrashort 
BE is impossible to differentiate from an irregular Z-line with conventional endoscopy. 
Areas with intestinal metaplasia and dysplasia are difficult to detect with conventional 
endoscopy and a random biopsy technique is used in clinical practice. Mucosal changes, 
especially in the situation of short BE or ultrashort BE, are sometimes not easily identified. 
Sampling errors create the major limitations in the diagnosis accuracy. 
 
 
Fig. 2. Long-segment Barrett’s esophagus: methylene blue selectively stains specialized 
columnar epithelium 
Magnification chromoendoscopy has been shown to improve the detection of Barrett’s 
esophagus. Several classification systems for the mucosal patterns have been proposed. Endo 
et al. identified 5 different patterns by using methylene blue magnification chromoendoscopy 
for the detection of BE: small/round pattern, straight, long oval, tubular and villous pattern. 
Round and straight pattern corresponded to gastric epithelium, whereas area showing tubular 
and villous pattern contained intestinal-type epithelium (Endo et al., 2002). Guelrud et al. used 
magnifying endoscopy in conjunction with chromoendoscopy with acetic acid to detect 
characteristic patterns in the esophagogastric junction, including intestinal metaplasia. They 
named this technique enhanced-magnification endoscopy. The result was the detection of four 
different patterns in the distal esophagus: round, reticular, villous and ridged. Areas showing 
villous or ridged pattern corresponded with the detection of intestinal metaplasia (Guelrud et 
al., 2001). Hoffman et al. demonstrated the usefulness of magnifying endoscopy with acetic 
acid in the detection of BE, with fewer biopsies needed for diagnosis compared with a random 
biopsy technique (Hoffman et al., 2006). We perform magnifying endoscopy with methylene 
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blue application to identify different patterns in the esophagogastric junction. For the detection 
of BE, we first identify the proximal margin of gastric folds on conventional endoscopy. On 
magnified examination, we search for the identification of the transition from circular pattern 
corresponding with cardiac mucosa, to a modified pattern: villous or tubular pattern 
corresponding to intestinal metaplasia. The application of methylene blue allows a good 
demarcation of modified areas, including the small islands of columnar metaplasia, almost 
invisible on white light examination. The goal of the examination is the detection of modified 
patterns, that correspond with metaplastic and dysplastic mucosa. We identify different types 
of mucosal patterns: round pattern, circular pattern and oval pattern, tubular pattern and 
villous pattern. The presence of circular and oval patterns is associated with cardiac-type 
mucosa (Fig.3). Round pattern corresponds to fundic epithelium (Fig.4). Tubular and villous 
patterns exhibit intestinal metaplasia by histologic evaluation (Fig.5, Fig.6, Fig.7).  
 
 
Fig. 3. Circular or oval pits corresponding to cardiac-type mucosa 
 
 
Fig. 4. Round pits regular in shape and arrangement corresponding to fundic mucosa 
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blue application to identify different patterns in the esophagogastric junction. For the detection 
of BE, we first identify the proximal margin of gastric folds on conventional endoscopy. On 
magnified examination, we search for the identification of the transition from circular pattern 
corresponding with cardiac mucosa, to a modified pattern: villous or tubular pattern 
corresponding to intestinal metaplasia. The application of methylene blue allows a good 
demarcation of modified areas, including the small islands of columnar metaplasia, almost 
invisible on white light examination. The goal of the examination is the detection of modified 
patterns, that correspond with metaplastic and dysplastic mucosa. We identify different types 
of mucosal patterns: round pattern, circular pattern and oval pattern, tubular pattern and 
villous pattern. The presence of circular and oval patterns is associated with cardiac-type 
mucosa (Fig.3). Round pattern corresponds to fundic epithelium (Fig.4). Tubular and villous 
patterns exhibit intestinal metaplasia by histologic evaluation (Fig.5, Fig.6, Fig.7).  
 
 
Fig. 3. Circular or oval pits corresponding to cardiac-type mucosa 
 
 
Fig. 4. Round pits regular in shape and arrangement corresponding to fundic mucosa 
 




Fig. 5. Tubular pattern corresponding to intestinal metaplasia in a long- segment BE 
 
 
Fig. 6. Tubular pattern corresponding to intestinal metaplasia in a short-segment BE 
 
 
Fig. 7. Villous pattern corresponding to intestinal metaplasia in a short-segment BE 
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We use enhanced magnifying endoscopy for the diagnosis of short-segment BE. We observe 
a whitish discoloration of epithelium, followed by a clear differentiation between columnar 
and squamous epithelium two minutes after acetic acid application: the squamous 
epithelium remains white, while columnar epithelium becomes reddish (Fig.8). We identify 
small islands of columnar mucosa at the esophagogastric junction after dye application. A 
focused magnification on these areas allows the identification of different patterns and 
targeted biopsies (Fig.9). 
 
 
Fig. 8. The acetowhitening reaction in a case of short-segment BE: columnar epithelium 
becomes reddish and swollen 
 
 
Fig. 9. Small islands of columnar epithelium are clearly detected; the villous pattern 
corresponds to intestinal metaplasia 
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This method has limitations because it requires additional time, experience in performance, 
as well as experience in the interpretation of different mucosal patterns. Dye may not 
uniformly spread on the mucosa (Fig.10). We identify areas with irregular patterns, 
corresponding to dysplastic BE. These areas are appropriate for targeted biopsies and 
subsequent surveillance (Fig.11). 
 
 
Fig. 10. Heterogenous stained areas in patient with dysplasia  
 
 
Fig. 11. Distorsion of the cerebriform pattern in a patient with long-segment BE; the detection 
of an irregular/distorded pattern is followed by focused biopsies for the diagnosis of dysplasia 
Some studies show that magnifying endoscopy improves the detection of neoplasia in BE. An 
irregular mucosal pattern, an irregular vascular pattern and the presence of abnormal blood 
vessels are findings reported to be predictors for high-grade dysplasia (HGD) or early 
neoplasia in BE. Sharma et al. reported the detection of an irregular/distorted pattern in 
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patients with BE which corresponded to HGD on biopsy specimens. They did not identify a 
specific pattern corresponding to low-grade dysplasia (LGD) in these patients (Sharma et al., 
2003). Vascular patterns are better identified with narrow band imaging (NBI) than with 
chromoendoscopy, because the blood vessels may be masked by the use of stains. The 
observation of capillary patterns by NBI improves the diagnostic value for detecting 
specialized intestinal epithelium and superficial Barrett’s adenocarcinoma (Goda et al., 2007). 
3.2 The stomach  
In the stomach, we analyze two different anatomical findings by magnification: the mucosal 
structure and the microvascular architecture. Small round pits of uniform shape are identified 
in normal gastric body mucosa. The capillary loops surround the necks of gastric pits and have 
a honeycomb-like appearance under magnification. The collecting venules, which drain from 
the mucosal surface towards the submucosa, have a starfish-like appearance. The normal 
magnified view of gastric mucosa was previously described and the evaluation of normal 
patterns is useful for the detection of any inflammatory or malignant changes of the mucosa 
(Kato et al., 2005). When we identify a mucosal lesion by conventional endoscopy we magnify 
suspicious areas, as well as normal appearing surrounding mucosa. In selected cases, we use 
dyes such as methylene blue or acetic acid for better visualization of fine mucosal structure 
and a clearer demarcation between normal and pathologic mucosa. 
3.2.1 Normal gastric mucosa 
Magnified endoscopic findings of normal gastric mucosa are different in the gastric body and 
antral areas. A honeycomb-like appearance of subepithelial capillary network (SECN) and 
collecting venules (CV) are specific findings of the microvascular architecture in the gastric 
body (Fig.12). The microvascular architecture of the gastric body mucosa was first described in 
vivo by Yagi. (Yagi, 2001). Gastric antrum demonstrates a different pattern, without the 
detection of CVs, due to their location in a deeper part of the lamina propria than in the gastric 
body. The microvascular architecture of the antral mucosa shows a coil-shaped SECN (Fig.13).  
 
 
Fig. 12. Normal gastric body: regular round pits, honeycomb-like SECN and regular 
arrangement of CVs 
 
New Techniques in Gastrointestinal Endoscopy 
 
260 
This method has limitations because it requires additional time, experience in performance, 
as well as experience in the interpretation of different mucosal patterns. Dye may not 
uniformly spread on the mucosa (Fig.10). We identify areas with irregular patterns, 
corresponding to dysplastic BE. These areas are appropriate for targeted biopsies and 
subsequent surveillance (Fig.11). 
 
 
Fig. 10. Heterogenous stained areas in patient with dysplasia  
 
 
Fig. 11. Distorsion of the cerebriform pattern in a patient with long-segment BE; the detection 
of an irregular/distorded pattern is followed by focused biopsies for the diagnosis of dysplasia 
Some studies show that magnifying endoscopy improves the detection of neoplasia in BE. An 
irregular mucosal pattern, an irregular vascular pattern and the presence of abnormal blood 
vessels are findings reported to be predictors for high-grade dysplasia (HGD) or early 
neoplasia in BE. Sharma et al. reported the detection of an irregular/distorted pattern in 
Magnifying Endoscopy and  
Chromoendoscopy in Upper Gastrointestinal Tract: Clinical Applications 
 
261 
patients with BE which corresponded to HGD on biopsy specimens. They did not identify a 
specific pattern corresponding to low-grade dysplasia (LGD) in these patients (Sharma et al., 
2003). Vascular patterns are better identified with narrow band imaging (NBI) than with 
chromoendoscopy, because the blood vessels may be masked by the use of stains. The 
observation of capillary patterns by NBI improves the diagnostic value for detecting 
specialized intestinal epithelium and superficial Barrett’s adenocarcinoma (Goda et al., 2007). 
3.2 The stomach  
In the stomach, we analyze two different anatomical findings by magnification: the mucosal 
structure and the microvascular architecture. Small round pits of uniform shape are identified 
in normal gastric body mucosa. The capillary loops surround the necks of gastric pits and have 
a honeycomb-like appearance under magnification. The collecting venules, which drain from 
the mucosal surface towards the submucosa, have a starfish-like appearance. The normal 
magnified view of gastric mucosa was previously described and the evaluation of normal 
patterns is useful for the detection of any inflammatory or malignant changes of the mucosa 
(Kato et al., 2005). When we identify a mucosal lesion by conventional endoscopy we magnify 
suspicious areas, as well as normal appearing surrounding mucosa. In selected cases, we use 
dyes such as methylene blue or acetic acid for better visualization of fine mucosal structure 
and a clearer demarcation between normal and pathologic mucosa. 
3.2.1 Normal gastric mucosa 
Magnified endoscopic findings of normal gastric mucosa are different in the gastric body and 
antral areas. A honeycomb-like appearance of subepithelial capillary network (SECN) and 
collecting venules (CV) are specific findings of the microvascular architecture in the gastric 
body (Fig.12). The microvascular architecture of the gastric body mucosa was first described in 
vivo by Yagi. (Yagi, 2001). Gastric antrum demonstrates a different pattern, without the 
detection of CVs, due to their location in a deeper part of the lamina propria than in the gastric 
body. The microvascular architecture of the antral mucosa shows a coil-shaped SECN (Fig.13).  
 
 
Fig. 12. Normal gastric body: regular round pits, honeycomb-like SECN and regular 
arrangement of CVs 
 





Fig. 13. Normal antral mucosa: the SECN is coil-shaped  
The first description in vivo of the characteristic pattern of the gastric antrum was by Yao. 
(Yao & Oishi, 2001). We observe these specific patterns of gastric mucosa free from 
pathological changes in order to be able to distinguish them from abnormal situations 
associated with modified mucosa due to inflammation, atrophy or neoplasia. 
3.2.2 Chronic gastritis 
Different findings on magnifying endoscopy are reported to be associated with modified 
gastric mucosa as a result of inflammation or atrophy. The proper evaluation of mucosal 
changes is an important step in detection of premalignant lesions and subsequent 
surveillance for some of these patients. Four different patterns are described in association 
with normal mucosa, Helicobacter pylori (HP)- infected stomach and gastric atrophy: type 1 
shows regular round pits, honeycomb-like SECN with regular arrangement of CVs; type 2 
shows regular round pits and honeycomb-like SECN, with the loss of CVs; type 3 shows 
enlarged white pits surrounded by erythema, with the loss of normal SECN and CVs; type 4 
shows the loss of round pits and SECN, with an irregular arrangement of CVs 
(Anagnostopoulos et al., 2007). The authors reported the correspondence between type 1 
and normal gastric mucosa, type 2 or 3 and HP- infected gastric mucosa. Type 4 pattern 
corresponds to mucosal atrophy. The visibility of collecting venules is affected by HP- 
induced inflammation and atrophy. We identify a magnified appearance of large white pits 
with surrounding erythema in cases of HP induced gastritis. Collecting venules are not 
visible (Fig.14). Several studies report the use of magnification endoscopy for the evaluation 
of mucosal patterns of the gastric body after successful eradication of HP. Yagi K et al. 
described the characteristic features of the gastric mucosa in this situation: (i) disappearance 
of swelling and/or erithema between gastric pits; (ii) white pits change to pinhole-like pits; 
and (iii) collecting venules became visible (Yagi et al., 2002). Using magnifying technique, 
we are able to identify HP-infected mucosa during the endoscopic procedure and are also 
able to evaluate the efficiency of the eradication therapy.  
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Fig. 14. Helicobacter pylori- induced gastritis: enlarged white pits surrounded by erythema 
In case of atrophic gastritis, we notice an irregular arrangement of collecting venules with 
the disappearance of normal SECN pattern (Fig.15). Magnifying endoscopic observation is 
helpful for the identification of patients with extensive atrophy. These patients are selected 
for dye application and targeted inspection, followed by biopsying suspicious areas for the 
detection of intestinal metaplasia or gastric dysplasia (Fig.16, Fig.17).  
 
 
Fig. 15. Atrophic gastritis: the disappearance of normal SECN and round pits, irregular 
arrangement of CVs 
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Fig. 16. Area with modified pattern corresponding to intestinal metaplasia 
 
 
Fig. 17. Islands of intestinal metaplasia in the area of atrophic gastritis identified after 
methylene blue application  
3.2.3 Premalignant lesions: Intestinal metaplasia, low-grade dysplasia (LGD) 
It is well known that the prognosis of patients with gastric cancer depends on the stage at 
diagnosis. As a multistep process in gastric carcinogenesis has been defined, early 
detection and vigilant surveillance of these histopathologic lesions are mandatory: 
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atrophic gastritis, intestinal metaplasia and dysplasia. The methods for detection and 
surveillance are different in different parts of the world and an ideal technique, biopsy 
protocol, and optimum time interval between endoscopic procedures, have not yet been 
defined. Some authors emphasize the benefits of annual surveillance of patients with 
atrophic gastritis or intestinal metaplasia in detecting cancer at an early stage, with 
improvement in survival (Whiting et al., 2002). The diagnosis of premalignant lesions and 
the performance of surveillance depend upon random biopsy technique. The updated 
Sydney System recommended taking two antral biopsies, two corporal biopsies and one 
biopsy from the incisura angularis (Dixon et al., 1996). This prescribes a considerable 
effort in order to evaluate the risk of the patient for the development of gastric cancer. 
Magnification chromoendoscopy may optimize the evaluation of premalignant gastric 
lesions (Areia et al., 2008).  Topographic mapping for the detection of extensive intestinal 
metaplasia or more advanced lesions such as dysplasia or carcinoma should be consider 
when evaluating the patient’s risk (Correa et al., 2010). As previously discussed, not all 
patients are suitable for the magnifying examination of the entire gastric mucosa. A full 
magnified survey of the normal appearing mucosa can be a technical challenge and 
lengthens the procedure. A focus on areas of modified mucosa, followed by targeted 
magnifying examination of suspicious areas, could improve the detection of early pre-
neoplastic and neoplastic lesions. We have tried to identify the specific endoscopic 
patterns associated with intestinal metaplasia and dysplasia on histopathological 
evaluation. We apply a mucolytic agent (10% N-acetylcisteine) onto the mucosa. After 
that, a solution of methylene blue 1% is sprayed over the mucosa. Three minutes later, we 
wash the mucosa with water and remove the excess methylene blue and water. Using this 
technique, we obtain areas of mucosa with blue homogeneous staining and magnify these 
particularly areas as well as the surrounding mucosa (Fig.18). Blue stained areas are 




Fig. 18. Blue stained areas detected after methylene blue application 
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Fig. 18. Blue stained areas detected after methylene blue application 
 





Fig. 19. Focused magnification on homogenous stained areas 
Keeping in mind that dysplasia and carcinoma may develop in areas of intestinal 
metaplasia, we perform focused magnification in these areas (Fig.19). We identify specific 
pit patterns in stained areas: round and tubular pits, blue small pits (Fig.20, Fig.21). 
Targeted biopsies are taken from these areas and histopathological evaluation confirm the 
presence of intestinal metaplasia. 
 
 
Fig. 20. Blue small pits in areas with intestinal metaplasia 
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Fig. 21. Tubular pits in areas with intestinal metaplasia 
In some cases we obtain a heterogeneous staining mucosa with an unclear pattern (Fig. 22, 
Fig.23). It is difficult to achieve reliable inter-observer agreement in these cases where 
different patterns are not clearly identified. Uneven spreading of the dye across the mucosa 
often causes these unclassified findings and affects the diagnosis accuracy. Targeted 
biopsies are mandatory to clarify the diagnosis because the detection of irregular patterns is 
highly suspicious for the diagnosis of dysplasia. 
 
 
Fig. 22. Heterogenous stained area obtained after methylene blue application 
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Fig. 22. Heterogenous stained area obtained after methylene blue application 
 





Fig. 23. Heterogenous stained area showing the loss of the clear pattern 
Mucosal patterns corresponding to intestinal metaplasia and dysplasia were previously 
defined by Dinis-Ribeiro et al. The authors identified three groups of endoscopic patterns 
after methylene blue staining, as follows: Group I (nonmetaplastic, nondysplastic 
mucosa), Group II (metaplastic mucosa) and Group III (dysplastic mucosa) (Dinis-Ribeiro 
et al., 2003).  
We are sometimes faced with the clinical situation of a patient with previously detected 
LGD on random biopsies where subsequent follow-up endoscopies with biopsies failed to 
detect any dysplasia. A surveillance strategy based on magnifying endoscopy with targeted 
biopsies should offer a better assurance for these patients, compared to a conventional 
examination with random biopsies (Fig.24). This is particularly true since the main concern 
in cases of the random diagnosis of LGD is the failure of the detection of a synchronous 
lesion such as HGD or even carcinoma. 
International guidelines recommend the surveillance of patients with LGD and the 
treatment (surgical or endoscopic) for patients with HGD (ASGE, 2006). Surveillance of 
patients with LGD is challenging given the large surface area that must to be evaluated, the 
difficulty of reliably re-locating suspicious mucosal sites seen on prior endoscopies, as well 
as inter-observer variability. We recommended surveillance based on magnifying 
examination of gastric mucosa and focused biopsies in our patients with LGD. The 
management and surveillance of patients with premalignant lesions remain controversial in 
different part of the world. In the United States the surveillance of patients with gastric 
intestinal metaplasia is not recommended (ASGE, 2006). On the other hand, studies from the 
United Kingdom show the benefit of performing surveillance in patients with premalignant 
lesions for the early detection of gastric cancer (Whiting et al., 2002). Magnifying 
chromoendoscopy provides the ability to evaluate the extension of gastric atrophy and 
intestinal metaplasia. This may yet prove to be a reliable way to follow the evolving risk to 
the patient. Specific recommendations should be considered for each individual patient, 
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based upon the detection of dysplasia and the extent and severity of premalignant lesions 
(atrophic gastritis and intestinal metaplasia).  
 
 
Fig. 24. Area with lack of visible structure in a patient with LGD 
3.2.4 High-grade dysplasia (HGD) and early gastric cancer (EGC) 
Several reports describe the magnification findings of early gastric cancer (Fig.25). Since 
endoscopic treatment for gastric cancer was developed, the proper evaluation of the lesion,  
 
 
Fig. 25. Area showing the loss of regular SECN pattern (EGC) 
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Fig. 25. Area showing the loss of regular SECN pattern (EGC) 
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with regards to invasion, lateral spreading, and histopathological features, has become even 
more essential. Otsuka et al. classified the characteristic patterns of EGC as follows: (i) a small 
regular pattern of sulci and ridges; (ii) an irregular pattern of sulci and ridges; and (iii) a lack 
ofvisible structure. The presence of irregular minute vessels and the variation in the caliber of 
vessels are specific vascular patterns in EGC. The fine observation provides information about 
histological characteristics of the detected lesions. Small regular patterns were observed more 
frequently in differentiated adenocarcinoma; lack of visible structure and irregular patterns 
were characteristic to undifferentiated adenocarcinoma (Otsuka et al., 2004).  
In differentiated carcinoma, the regular SECN pattern disappeared and irregular 
microvessels proliferated within the cancerous mucosa. It was a clear demarcation line 
between the cancerous and non-cancerous mucosa. The detection of an irregular shape and 
distribution of microvessels makes the difference between early cancer and focal gastritis 
(Fig.26). Irregular microvessels are tumorous vessels. The demarcation line between cancer 
and normal mucosa allowed the evaluation of the margin of the carcinoma before 
endoscopic resection. In case of undifferentiated carcinoma, magnification endoscopic 
findings show the loss of the regular SECN pattern. According to Yao et al., the analysis of 
vascular architecture by magnifying endoscopy could be a new diagnostic system for the 
early detection of gastric cancer. Characteristic microvascular patterns were identified for 
different histopathological type of carcinoma (Yao et al., 2004).  
 
 
Fig. 26. Irregular shape and arrangement of microvessels (EGC) 
The distinction between a flat reddened lesion due to inflammation (chronic gastritis) or 
EGC of superficial flat type is sometimes impossible by conventional endoscopy. The 
examination of fine mucosal structure and microvascular architecture by magnification 
allows the detection of irregular microvessels and the loss of the regular SECN pattern in 
case of HGD (Fig.27). We have encountered situations where the differentiation between 
modified mucosa due to inflammation or malignant transformation has been difficult. In 
one such case, under magnification, we detected the loss of regular SECN pattern, but no 
irregular microvessels. The histopathological evaluation subsequently demonstrated chronic 
gastritis with intestinal metaplasia (Fig.28). 
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Fig. 27. Area with abnormal microvessels and variation of vessel caliber (HGD) 
 
 
Fig. 28. Disappearance of the regular SECN pattern, without the detection of abnormal 
microvessels (chronic gastritis with intestinal metaplasia) 
To summarize, some lesions are difficult to recognize as cancerous or non-cancerous based 
upon conventional or magnified examination. The detection of a modified pattern requires 
targeted biopsies in order to clarify the diagnosis. Gastric mucosa can be modified in 
various situations such as inflammation, atrophy, dysplasia or cancer. We must keep in 
mind that all of these alter the endoscopic appearance of the mucosa on magnification. That 
is way the interpretation of different patterns can be so difficult. We found that an 
examination of the mucosal and vascular architecture improves our accuracy in the 
endoscopic detection of gastric neoplasia.  
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histological characteristics of the detected lesions. Small regular patterns were observed more 
frequently in differentiated adenocarcinoma; lack of visible structure and irregular patterns 
were characteristic to undifferentiated adenocarcinoma (Otsuka et al., 2004).  
In differentiated carcinoma, the regular SECN pattern disappeared and irregular 
microvessels proliferated within the cancerous mucosa. It was a clear demarcation line 
between the cancerous and non-cancerous mucosa. The detection of an irregular shape and 
distribution of microvessels makes the difference between early cancer and focal gastritis 
(Fig.26). Irregular microvessels are tumorous vessels. The demarcation line between cancer 
and normal mucosa allowed the evaluation of the margin of the carcinoma before 
endoscopic resection. In case of undifferentiated carcinoma, magnification endoscopic 
findings show the loss of the regular SECN pattern. According to Yao et al., the analysis of 
vascular architecture by magnifying endoscopy could be a new diagnostic system for the 
early detection of gastric cancer. Characteristic microvascular patterns were identified for 
different histopathological type of carcinoma (Yao et al., 2004).  
 
 
Fig. 26. Irregular shape and arrangement of microvessels (EGC) 
The distinction between a flat reddened lesion due to inflammation (chronic gastritis) or 
EGC of superficial flat type is sometimes impossible by conventional endoscopy. The 
examination of fine mucosal structure and microvascular architecture by magnification 
allows the detection of irregular microvessels and the loss of the regular SECN pattern in 
case of HGD (Fig.27). We have encountered situations where the differentiation between 
modified mucosa due to inflammation or malignant transformation has been difficult. In 
one such case, under magnification, we detected the loss of regular SECN pattern, but no 
irregular microvessels. The histopathological evaluation subsequently demonstrated chronic 
gastritis with intestinal metaplasia (Fig.28). 
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Fig. 27. Area with abnormal microvessels and variation of vessel caliber (HGD) 
 
 
Fig. 28. Disappearance of the regular SECN pattern, without the detection of abnormal 
microvessels (chronic gastritis with intestinal metaplasia) 
To summarize, some lesions are difficult to recognize as cancerous or non-cancerous based 
upon conventional or magnified examination. The detection of a modified pattern requires 
targeted biopsies in order to clarify the diagnosis. Gastric mucosa can be modified in 
various situations such as inflammation, atrophy, dysplasia or cancer. We must keep in 
mind that all of these alter the endoscopic appearance of the mucosa on magnification. That 
is way the interpretation of different patterns can be so difficult. We found that an 
examination of the mucosal and vascular architecture improves our accuracy in the 
endoscopic detection of gastric neoplasia.  
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3.2.5 Gastric polyps 
Proper diagnosis and management of patients with gastric polyps involves a histopathologic 
evaluation of the polyp and also of the surrounding mucosa (Carmack et al., 2009). That 
entails many biopsy samples, both from the lesion and from unaffected mucosa. Magnified 
endoscopic findings corresponding to gastric polyps are described by Tajiri at al. 
Hyperplastic polyps show a reddish, coarse pattern on magnifying endoscopy. Gastric 
adenomas show a white, minute, regular mucosal pattern (Tajiri at al., 2002). We identify 
specific patterns corresponding to gastric polyps (Fig.29, Fig.30). The true extension of 
premalignant lesions such as atrophic gastritis and intestinal metaplasia are identified after 
methylene blue or acetic acid application. 
 
 
Fig. 29. Minute, regular pattern in gastric adenoma 
 
 
Fig. 30. Reddish, coarse pattern in hyperplastic polyps 
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In the case of a patient with multiple polypoid lesions in the body of the stomach, magnified 
examination allowed the identification of a specific, modified pattern (Fig. 31). The 
histopathological evaluation established the diagnosis: gastric carcinoids. We detected 




Fig. 31. Irregular pattern in gastric carcinoid 
 
 
Fig. 32. Irregular arrangement of the CVs in the surrounding mucosa (atrophic gastritis) 
In conclusion, the evaluation of the mucosa that surrounds gastric polyps is recommended 
when consider management recommendations. We identify characteristic endoscopic 
features that serve as useful tools for improving the diagnostic accuracy and ease of 
surveillance in these patients.  
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3.3 Normal duodenal mucosa and celiac disease 
Magnification endoscopy allows the identification of details of the villous structure of the 
normal duodenal mucosa (Fig.33, Fig.34).  
 
 
Fig. 33. Normal duodenal mucosa on magnifying endoscopy 
 
 
Fig. 34. Magnified view of villi after methylene blue application 
Scalloping and reduced number of duodenal folds, mosaic appearance and mucosal grooves 
are all characteristic conventional endoscopic features of the duodenal mucosa in patients 
with celiac disease (Fig.35). Because of the patchy distribution of the disease, in some 
situations targeted biopsies increase diagnostic accuracy. The detection of villous atrophy 
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was improved by the use of magnification endoscopy (Cammarota et al., 2004). Enhanced 
magnification endoscopy revealed 4 mucosal patterns: I, normal; II, stubbed; III, ridged and 
IV, foveolar. Patterns II, III and IV corresponded to villous atrophy. This method was 
superior to standard endoscopy in detecting patchy areas of partial mucosal atrophy (Lo et 
al., 2007). By using magnifying endoscopy, we identify areas with short duodenal villi and 
we take biopsies samples from these areas (Fig.36, Fig.37). Histopathological evaluation 
confirms the presence of villous atrophy in these areas. This can be a method to avoid 
random biopsies and delays in diagnosis in patients with malabsorption syndrome.  
 
 
Fig. 35. Cobblestoning appearance becomes more visible after methylene blue application 
(celiac disease)  
 
 
Fig. 36. Patchy atrophy with stunted villi (celiac disease) 
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Fig. 37. Detection of foveolar pattern in a patient with celiac disease 
4. Challenges and future directions 
Magnification chromoendoscopy is a valuable useful tool for the detection and surveillance 
of inflammatory and neoplastic lesions of the upper gastrointestinal tract. Authors have 
described major challenges in the use of magnification chromoendoscopy. There are few 
endoscopists specifically trained in these techniques. There is a lack of standardization in 
methods and terminologies, as well as an absence of a unified classification of mucosal 
patterns (Canto, 2005; Sharma, 2005). The procedure requires additional time and the 
interpretation of different endoscopic images is quite challenging in some situations. Novel 
endoscopic techniques, with better visualization of mucosal changes, in the future may offer 
further answers to important questions regarding the risk of the patient and appropriate 
surveillance strategies. Magnifying endoscopy combined with NBI improve the diagnosis 
sensitivity of the early cancer by enhancing the visualization of microvascular network. The 
detection of irregular microvascular pattern and the evaluation of the extent of cancer might 
relate to optical biopsy (Kaise et al., 2007). 
5. Conclusion 
Different endoscopic techniques require time and attention from the endoscopist because 
of the variation in the interpretation of images. Not all patients are appropriate for a 
magnifying examination. The prior detection of suspicious endoscopic areas by 
conventional endoscopy, followed by focused magnification and targeted biopsies from 
areas exhibiting modified patterns, could improve diagnostic accuracy. Later examination 
of different patterns and images recorded on videotapes, as well as correlation with 
subsequent histopathological findings, are key steps in learning and interpreting mucosal 
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changes. The goals of endoscopic magnifying examination in conjunction with 
chromoscopy for esophageal evaluation are an improvement in detection, particularly the 
detection of short-segment BE and small islands of metaplastic mucosa, as well as the 
early detection of malignant transformation with the diagnosis of dysplasia and better 
surveillance of these patients by targeted biopsies. Risk stratification, based upon the 
detection of premalignant gastric lesions, could be of value in developing surveillance 
strategies. Although the method of magnifying endoscopy cannot replace histology-based 
decision for surveillance, it may help to decide whether follow-up endoscopies should be 
performed in patients with previously detected dysplasia or in patients with gastric 
atrophy and intestinal metaplasia, without dysplasia. We consider that intensive 
surveillance should be focused on patients with extensive gastric atrophy, intestinal 
metaplasia and in patients with dysplasia. Magnifying endoscopy allows the detection 
and the evaluation of extension of all of these lesions. Our work is mainly focused on the 
clinical application of the method in order to achieve standardized terminologies and 
criteria. 
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1. Introduction   
Autofluorescence imaging (AFI) endoscopy for detection of early neoplastic lesions has 
recently received considerable attention in the field of clinical gastroenterology (van den 
Broek et al., 2008; Matsuda et al., 2008; Inoue et al., 2010). The main source of 
autofluorescence eruption under blue light excitation has been considered to be submucosal 
collagen, not the mucosal layer in human (Izuishi et al., 1999; Huang et al., 2004). In this 
report, we describe a rare case in which highly fluorescent mucosal macrophages made a 
superficial-type colonic adenoma remarkably easy to detect. To the best of our knowledge, 
there has been no case report documenting that the mucosal macrophages are the main 
contributors to colonic autofluorescence detected at autofluorescence colonoscopy. 
2. Brief case report 
A 74-year-old man with chronic renal failure was referred to our department in July 2006 for 
evaluation of positive fecal occult blood test. He had been receiving long-term hemodialysis 
since 1997. White light (WL) colonoscopic examination revealed a superficial-type neoplastic 
lesion in the descending colon (Fig. 1A). An inspection with AFI (CF-FH260AZI, Olympus 
Medical Systems Corp., Tokyo, Japan) (excitation: 390–470 nm; emission: 500–630 nm; green 
reflection: 540–560 nm) showed remarkably strong autofluorescence signal in normal 
colonic lumen (Fig. 1B). Unusual cobblestone appearance of the strong autofluorescence 
signal in the non-neoplastic lesion around the neoplasia was observed. Submucosal vessels 
commonly seen under AFI examination were not apparent (See Fig. 1C for comparison.). 
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Since the autofluorescence intensity of the neoplastic lesion was reduced, the superficial-
type neoplasia was clearly recognized. On hematoxylin and eosin (H&E) staining, the non-
neoplastic lesion showed slight nonspecific colitis with epithelial hyperplasia (Fig. 2D) and 
findings for the neoplastic lesions were consistent with tubular adenoma with high-grade 




Fig. 1. A, A WL image of the colonic mucosa and the superficial-type colonic tumor 
(arrows). B, An AFI image of the surrounding mucosa with strong autofluorescence signal 
and the tumor with reduced autofluorescence signal (arrows). Uncommon cobblestone 
appearance of the intense autofluorescence signal in the non-neoplastic lesion clearly reveals 
the tumor. C, An AFI image in a classic case of superficial-type colonic tumor (arrows), 
shown for comparison. Note that cobblestone appearance of the autofluorescence signal is 
not apparent and submucosal vessels are clearly visible in non-neoplastic lesion. D, H&E-
staining of the superficial-type colonic tumor for this patient. 
Stereomicroscopic images for a mucosal cross-section of a biopsied non-neoplastic colonic 
specimen showed intense autofluorescence signals with granular pattern (arrowheads in Fig. 
2A) on the luminal zone of the mucosal layer (upper left panel of Fig. 2A, WL image; upper 
right panel, autofluorescence image: excitation: 436 nm; emission > 455 nm; lower left panel, 
autofluorescence image: excitation: 405 nm; emission > 430 nm; lower right panel, 
autofluorescence image: excitation: 365 nm; emission > 400 nm). Immunohistochemical 
investigation of the non-neoplastic mucosa showed that cells containing the granular 
autofluorescence signals were positive for CD68, a marker for macrophages (Fig. 2B and 2C). 
Normalized fluorescence spectra of colonic mucosal cross-sections for this patient and in a 
classic case are shown (Fig. 3, 4, and 5). The emission peaks of the spectra with excitation at 436 
nm, 405 nm and 365 nm for our patient were around 480 nm (Fig. 3A, 4A, and 5A).  
Highly Fluorescent Macrophages in Colonic  




Fig. 2. Evaluation of the source of autofluorescence eruption in the non-neoplastic mucosa.  
A, Stereomicroscopic image of a biopsied colonic specimen (upper left panel, WL image; upper 
right panel, autofluorescence image: excitation: 436 nm [D436/10x; Chroma Technology Corp., 
Rockingham, VT]; emission: > 455 nm [E455LP v2; Chroma Technology Corp.]; lower left 
panel, autofluorescence image: excitation: 405 nm [D405/20x; Chroma Technology Corp.]; 
emission: > 430 nm [HQ430LP; Chroma Technology Corp.]; lower right panel, 
autofluorescence image: excitation: 365 nm [D365/10x; Chroma Technology Corp.]; emission: 
> 400 nm [E400LP v2; Chroma Technology Corp.]). Strong autofluorescence signals 
(arrowheads) with granular pattern are observed in the luminal zone of the mucosal layer.  
B, A low-magnification confocal image of autofluorescence (arrowheads) (excitation: 440 nm; 
emission: 450-510 nm) obtained with differential interference contrast (DIC) imaging in a 6-μm 
thin-sliced section. C, High-magnification confocal images of autofluorescence (left panel) 
(arrowhead) (excitation: 440 nm; emission: 450-510 nm) and CD68 immunostaining (middle 
panel) in a thin-sliced section. Nuclei were detected with TO-PRO3 iodide (blue) (right panel). 
D, Histological appearance of H&E-stained tissue sections of the non-neoplastic mucosa. 
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Fig. 3. Comparison of fluorescence spectra with excitation at 436 nm. A, A normalized 
fluorescence spectrum of a colonic mucosal cross-section for this patient. B, A normalized 
fluorescence spectrum of a colonic mucosal cross-section in a classic case, shown for 
comparison. The fluorescence spectra (>455 nm) (E455LP v2; Chroma Technology Corp.) 
excited at 436 nm (D436/10x; Chroma Technology Corp.) were analyzed by using a 
multichannel spectrophotometer (MCPD-7000; Otsuka Electronics, Osaka, Japan). 
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Fig. 4. Comparison of fluorescence spectra with excitation at 405 nm. A, A normalized 
fluorescence spectrum of a colonic mucosal cross-section for this patient. B, A normalized 
fluorescence spectrum of a colonic mucosal cross-section in a classic case, shown for 
comparison. The fluorescence spectra (>430 nm) (HQ430LP; Chroma Technology Corp.) 
excited at 405 nm (D405/20x; Chroma Technology Corp.) were analyzed by using the 
multichannel spectrophotometer. 
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Fig. 5. Comparison of fluorescence spectra with excitation at 365 nm. A, A normalized 
fluorescence spectrum of a colonic mucosal cross-section for this patient. B, A normalized 
fluorescence spectrum of a colonic mucosal cross-section in a classic case, shown for 
comparison. The fluorescence spectra (> 400 nm) (E400LP v2; Chroma Technology Corp.) 
excited at 365 nm (D365/10x; Chroma Technology Corp.) were analyzed by using the 
multichannel spectrophotometer. 
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The autofluorescence intensity of a neoplastic lesion becomes attenuated under blue light 
excitation as a mucosal lesion progresses from normal status to early malignant disease, and 
this difference can be exploited to detect early neoplastic disease in the gastrointestinal tract 
(Huang et al., 2004; Haringsma et al., 2001). It is reported that the main source of tissue 
fluorescence is submucosal collagen and that the autofluorescence of the mucosal layer is 
weak in human, although the mucosal layer is the important source of autofluorescence in 
rat colons  (Izuishi et al., 1999; Huang et al., 2004; Nakano et al., 2008; Nakano et al., in 
press). The attenuated autofluorescence in neoplastic lesions has been believed to be caused 
by a decrease in submucosal collagen-fluorescence due to the masking effect of mucosal 
thickening by neoplastic cells. In our patient, macrophages located in the luminal zone of 
the mucosal layer had stronger autofluorescence signals than the submucosal stroma. 
Therefore, the boundary of the tumor could be clearly recognized under AFI colonoscopy 
because of minimal scattering effect. DaCosta showed that macrophages in the lamina 
propria contribute to mucosal autofluorescence and suggested that lipofuscin granules in 
macrophages are fluorescent (DaCosta, 2000). In our case, however, the autofluorescence 
signal in macrophages was unusually strong and Schmorl reaction for lipofuscin and 
melanin was negative. We also performed fluorescence spectral and lifetime analyses, and 
Raman spectroscopic analyses (Nakano et al., in press; Harada et al., in press; Murayama et 
al., 2009; Harada et al., 2009; Ogawa et al., 2009), but it was not possible to identify the 
fluorophore in macrophages in our patient. 
Abbreviations: WL, white light; AFI, autofluorescence imaging; DIC, differential 
interference contrast.  
4. Conclusion 
In conclusion, we report a rare case in which highly fluorescent mucosal macrophages were 
detected under AFI colonoscopy. The unusual cobblestone appearance of the intense 
mucosal autofluorescence in the non-neoplastic lesion markedly enhanced visualization of 
the tumor in comparison with more typical cases.  
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1. Introduction 
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approximately 20% of the cases, parts of the small intestine cannot be observed due to the 
delayed passage of the capsule through the small intestine, and thus it is necessary to 
shorten the passage time [3][4]. Currently, there is no consensus on the preparation of 
patients to improve the passage of CEs through their digestive tract, and the establishment 
of a standardized preparatory treatment is necessary. The purpose of this study was to 
investigate whether the pre-exam administration of Daikenchuto shortens the time during 
which a CE remains in the small intestine, and to improve the speed at which the capsules 
reach the large intestine. 
2. Patients and methods 
Patients: All outpatients who underwent CE at our hospital between May 2009 and April 
2010 were included in this study. All patients who were enrolled before December 14, 
2009 were in the control group, and all patients after that date were in the DKT group. 
The purpose of the capsule endoscopy was explained to all patients, and informed 
consent was obtained from all patients. The inclusion criteria for this study were patients 
with confirmed or suspected intestinal diseases and patients without suspected organic 
narrowing of the lumen of the small intestine. The exclusion criteria were patients with a 
narrowed lumen of the small intestines that could delay CE passage, patients with 
implanted electronic devices (e.g. cardiac pacemakers), and patients with confirmed or 
suspected pregnancy. 
This study included 135 patients, with 83 males and 52 females, and their age varied from 14 
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Methods: The recommended daily dose of Daikenchuto is 15.0 g, and contains 1.25 g of a 
dried mixture of herbs (50% ginger root, 30% ginseng, and 20% sansho) and 10.0 g of a 
dried sugary substance. Thirty patients who received 7.5 g per day of DKT (TJ-100, 
manufactured by Tsumura, Tokyo) between lunch and dinner on the day before the exam 
and at 7:00 a.m. on the day of the exam (DKT group) were compared to 105 patients who 
did not receive any DKT (control group). A PillCamSB (Given Imaging, Israel) was used 
for both DKT and control groups. The PillCamSB1 and PillCamSB2 are the same size (11 x 
26 mm) and shape. 
The patients were instructed to consume special food according to the modified Brown's 
method [5] for lunch and dinner (Sanwa Kagaku Kenkyusho, Nagoya) on the day before the 
exam, and nothing by mouth on the morning of the exam. Upon arrival, the patients took 40 
minutes to ingest 900 mL of a magnesium citrate solution along with 10 mL of a simethicone 
solution before swallowing the capsule endoscope. The patients were allowed to drink 
water 2 hours later, and to eat either noodles or special food 4 hours later. The data 
recorders were disconnected 8 hours later. 
The location of the capsule was confirmed by a real-time viewer (Given Imagings) one hour 
later in the first 16 patients of the DKT group. If the capsule was still in the stomach, then 
the patients received 10 mg of metoclopramide intravenously [6]. A Rapid Reader 4 was 
initially used for the image analyses, and a Rapid Reader 5 (both manufactured by Given 
Imagings) was used from October 14, 2009 onwards. The image data for the stomach, 
duodenum, and appendix were entered, and the time during when the capsule remained in 
the stomach and small intestine was calculated [13]. Two physicians specialized in 
endoscopic exams interpreted the radiograms independently from each other. 
We defined the overall CE observation time as the time from when the CE was orally 
ingested until the time when the CE reached the ileocecal junction. The time during when 
the CE remained in the small intestines was defined as the time from when the CE exited 
and entered the duodenum until the time the CE reached the ileocecal junction in this 
study. 
3. Statistical analyses 
Modified Kaplan-Meier curves were used to investigate the time during when the CE 
remained in the small intestine. Therefore, the event in the Kaplan-Meier curve was defined 
as the arrival of the CE at the large intestine. The difference in time during when the CEs 
remained in the small intestines between the DKT and control groups was investigated 
using a log-rank test. Chi-square analysis was used to calculate the difference in the CE 
completion rates between the two groups. Our focus in the Cox proportional hazard model 
was from the time when the CE entered the duodenum to the time when the CE exited the 
small intestine, from the point of DKT pharmacological effectiveness. 
In order to detect observations with an extremely short time during when the CE remained 
in the small intestines (CEs inappropriate for accurate visual information to be included in 
this exam), all patients who completed the exam were plotted using histograms, and the 
distribution characteristics of the two groups were compared. An alpha level of 0.05 (one-
sided test for Chi-square tests and two-sided tests for all others) was used in all statistical 
tests. 
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The patient background for both groups was as follows: 1) the male to female ratio was 
18:11 in the DKT group and 59:40 in the control group (p=0.36 Chi-square test); 2) the mean 
age was 60.7±16.3 years in the DKT group and 59.6±17.9 years in the control group (p=0.58 
Student t-test); 3) underlying diabetes mellitus was found in 1 patient in the DKT group and 
2 patients in the control group; 4) a history of abdominal surgery was found in 5 patients in 
the DKT group and 6 patients in the control group; and 6) metoclopramide was 
administered to 12 patients in the DKT group and 4 patients in the control group. There 
were no statistically significant differences in background between the two groups; 
therefore, the control group was determined to be appropriate for this study. Three patients 
with missing data, 2 patients who were unable to swallow the capsule, and 1 patient with 
pharyngeal obstruction [7] in the control group as well as 1 patient in the DKT group whose 
narrowing of the intestinal lumen was confirmed during CE were excluded from the 
analyses. 
The remaining curves from both groups during the first three hours were not parallel or 
even crossing-over between the groups, suggesting DKT not equally affecting to all 
patients. However, more effectively it seems to accelerating the patients with slower 
peristalsis (log-rank P=0.016) (Fig. 1). The proportion of patients with a successful CE 
observation was significantly higher in the DKT group than in the control group 
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DKT group non-DKT group Total (N)
Proportion of 
success cases (N) 96.5% (28) 72.7% (72) 100.0% (100)
Proportion of    
failure cases (N) 3,4% (1) 27.2% (27) 100.0 (28)
Total  (N) 100.0% (29) 100.0 % (99) 100% (128)
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Table 1. Comparative study between DKT and non-DKT group in CE successful proportion   
The Cox proportional model for the time during when the CEs remained in the small 
intestines revealed that the crude successful ratio between the control group and the DKT 
group was 1:2.2 (P＝0.0008), and the adjusted successful ratio was 1:2.0 (P = 0.0078) after 
adjusting for age, gender, and metoclopramide use. In other words, we observed a two-
fold in the successful intestinal passage using the current CE system (Table 2).  
A comparison of the distribution characteristics of the time during when the capsules 
remained in the small intestine between the DKT and control groups showed that they 
were almost identical to patients in the control group with successful exam completion, 
and there were no patients with poor observation conditions due to diarrhea (Fig. 2). No 
patients experienced adverse effects such as liver dysfunction, jaundice or stomach ache 




(RR) (95% CI) P value
DKT 2.20 (1.39-3.49) 0.0008 Crude RR 
Adjusted   RR** DKT 2.00 (1.20-3.35) 0.0078 
*protective factor for CE successful  completion
**adjusted with Metoclopramide, aging(+1) and sex  
DKT: Tsumura Daikenchuto 
Table 2. Evaluation of DKT for CE successful completion analyzed using Cox proportional 
model  
.
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Consumed time for passing through intestine                                                                 
(Cases subjected only for successfully reaching ceacum)
 
DKT: Tsumura Daikenchuto 
Fig. 2. Comparative study for the trasit time distribution between DKT and non-DKT group  
5. Discussion 
In order to improve the CE successful complete rate, some GI prokinetic agents such as 
metoclopramide [8][9], mosapride [10], erythromycin [11][12], and chewing gum [13] have 
been used to prepare patients. Our study is the first of its kind to report the relationship 
between DKT use as a prokinetic agent and a reduced time that the capsules remained in the 
small intestine, as well as a better CE successful completion rate. 
DKT has been known in Japan to be effective in treating patients with lowered GI peristalsis, 
such as post-operative ileus [14][15]. The mechanisms for promoting bowel motility remain 
largely unknown. However, basic research has shown that one of the ingredients in DKT, 
sansho (Zanthoxylum piperitum), promotes acetylcholine release from the ends of the 
parasympathetic nerves at the neuromuscular junction in the digestive tract, and hence the 
distal part of intestine as well as the large intestine are affected [16][17][18] . In addition, it 
also works directly on vanilloid receptors (a type of capsaicin receptor) in the intestinal 
mucosa, and increases peristalsis by releasing substance P [19]. DKT has also been reported 
to increase the release of motilin, which increases the peristalsis of the digestive tract [20]. 
Metoclopramide use did not contribute to a significantly shortened time during when the 
CE remained in the small intestine that led to successful completion of the exam (data not 
shown). Previous studies did not provide any evidence that metoclopramide use 
contributed to a more successful CE or a shortened time during when the CEs remained in 
the lower half of the small intestines [8]. 
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In this study, we performed: (1) a comparison of the simple successful exam completion 
rates, (2) an investigation of the temporal properties of the CE survival curves throughout 
the exam using modified Kaplan-Meier curves (the difference starts to appear after the first 
three hours), and (3) a determination of the effectiveness of DKT in successfully completing 
CEs with a battery life of 8 hours. 
There were no significant differences in the CE remaining curves between the DKT and 
control groups during the first 3 hours of the exam, suggesting no clinical effect on patients 
with originally active peristalsis. Significant differences in the rate of arrival at the large 
intestine appeared between the 4th and 5th hours, suggesting affecting patients with slower 
peristalsis. Interestingly, there was no significant difference in the passage from the oral 
swallowing till stomach exiting between the DKT and control groups (P=0.884). This fits 
with the basic pharmacological studies mentioned above which reported that DKT acts on 
the distal part of the small intestines and the large intestine.  
There are some limitations to this study. Since the number of patients in the study is not 
large, the results may be equivocal enough due to low statistical power. There may also be a 
possible information bias since the patients were not blinded, and knew that they took DKT. 
Although this prospective study did not use convenience sampling and adjusted for gender, 
age, and metoclopramide use, the presence of possible potential confounders still cannot be 
ignored because of the non-randomized controlled assignment. However, in a general 
hospital, it is difficult to conduct randomized studies for various reasons, and this 
represents the satisfactory clinical research that was ethically and logistically feasible, and 
acceptable as an exploratory study. Further randomized controlled trial study should be 
warranted in any case.  
CE is a non-invasive and effective procedure to evaluate lesions in the small intestine. To 
avoid adverse effects from preparation, DKT should be given in the smallest amounts at the 
time closest to the exam. The recommended daily dose of DKT is 15.0 g, but the 7.5 g / day 
dose used in our study showed satisfactory effects. If the CE passed through the small 
intestines too quickly, then the exam quality could have possibly been compromised. 
However, we did not observe excessive peristalsis such as diarrhea induced by our 
preparation method. The capsule technology was upgraded during the study. This was 
solely to improve the quality of the images taken, and we do not believe that it affected the 
study results since the size and shape of the capsules did not differ. The PillCam SB2 had 
longer than 8 hours of image recording time. Thus, it was possible to extend the exam time if 
the real time viewer showed that the CE had not reached the large intestine by the end of 
the 8 hour exam period. However, we suspected that the time during when the CE remains 
in the small intestines beyond 8 hours varies greatly, and decided to end the exam at 8 hours 
for convenience. We did not encounter any problems with discovering minute lesions that 
may have been adversely affected by the granules of DKT. We are currently dissolving the 
DKT in hot water before administering it to patients.  
6. Conclusion 
The pre-CE administration of DKT may become a standardized method to prepare patients 
for capsule endoscopy, and multi-site randomized studies should be conducted in the 
future. These study results suggested that DKT can improve the speed at which the CE 
reaches the large intestine without compromising exam accuracy by promoting peristalsis of 
the small intestine. 
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1. Introduction 
Colorectal carcinoma ranks third in frequency among all cancers. With regards to cancer 
related mortality, colorectal carcinoma is known as the second cause (Levin et al., 2003). This 
condition accounts for 10% of all cancer related mortalities in women and men. Overall, 
lifetime risk for the development of colorectal carcinoma is still 5%. (Eddy, 1990) The well-
known risk factors are age, inheritance, inflammatory bowel disease, and environmental 
and dietary factors. Despite these risk factors, any individual factors could not be 
demonstrated in 75-80% of cases. Nevertheless, it is reported that most of the colorectal 
cancers originate from polyps.  
Colonic polyps are described as overgrowths of colonic mucosa regardless of histological 
findings (Van Dan, 1995). Vast majority of colorectal carcinomas originate from 
adenomatous polyps. This theory called adenoma-carcinoma sequence has been widely 
accepted (Hawk & Levin, 2005). Colonic polyps are divided as: non-neoplastic, which has no 
risk or low risk of developing cancer (hamartomatous, inflammatory, hyperplastic); and 
neoplastic which has low risk of developing cancer (tubular adenoma, villous adenoma, 
tubulovillous adenoma). Histopathological analysis has an important place in the 
discrimination of polyps (Erdem et al., 2005; Netzer et al., 1998). The size of the polyps has 
an important role for the occurrence of invasive cancer (Altparmak et al., 2001). Small 
polyps with size less than 1 cm have a low rate of developing invasive cancer. However, this 
rate increases, as the polyps get larger (Su et al., 2005; Yamaji et al., 2004). Colonic polyps are 
overgrowths with a slow progress that carry a small risk of malignant transformation. 
However, colonic polyps constitute an important predisposition to colon cancer, and 
therefore these neoplasms should be removed when detected. 
Understanding the fact that development of colorectal carcinoma starts with mucosal 
lesions, the visualization of colon, early diagnosis of the lesions and the initiation of 
treatment have gained much importance. The determination of precancerous adenomatous 
polyps and cancer at an early stage with screening reduces mortality and morbidity 
associated with colon cancer (Chao et al., 2004; Van Dan, 1995). Thus, American Cancer 
Association emphasized the importance of screening in colon cancer (Jemal et al., 2002). It is 
possible to detect and treat polyps at a very early stage with various screening methods. 
This feature different from some other types of cancer enables prevention or early 
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management of colorectal cancer (Eddy, 1990; Towler et al., 1998). Colonoscopy is the gold 
standard in the diagnosis of colorectal polyps (Roberts-Thomson et al., 2008). The most 
important advantage of this method is that it may also be used for treatment while being 
used in diagnosis. However, conventional colonoscopy has a serious complication risk of 
perforation, even if this risk is less than 1%. If any intervention was performed, the 
complication rate may increase up to 5%. (Consolo et al., 2008; Waye et al., 1992) 
2. Virtual colonoscopy 
In the last few years, the early diagnosis and cure rates of this condition is rather increased 
with the aid of screening methods. Digital rectal examination, occult blood test in stool, 
flexible sigmoidoscopy, double contrast barium enema and colonoscopy are among the 
routine screening methods of colorectal cancer. The American Cancer Society has included 
colorectal cancer screening in their guidelines. Screening the whole colon for colorectal 
cancer called as “total colon examination” is substantially emphasized in these guidelines. In 
association with this procedure, conventional colonoscopy, and double contrast barium 
enema are widely performed (Byers et al., 1997; Levin et al., 2003). Inadequate colon 
cleaning and air insufflations, and missing small polyps between the mucosal folds are 
among the limitations of double contrast barium enema. Flexible endoscopy has important 
advantages, such as high sensitivity in the diagnosis of colorectal polyps and opportunity of 
taking a biopsy (Chao et al., 2004; Colucci et al., 2003; Van Dam, 1995). It has taken the place 
of double contrast barium enema because of its superior efficiency. Despite its efficacy in the 
evaluation and treatment of colonic pathology, colonoscopy also has disadvantages such as 
being invasive, risk of perforation and hemorrhage, low patient tolerance, sedation 
requirement, perforation risk, and conditions in which the evaluation can not be properly 
finished (Anderson et al., 1992; Consolo et al., 2008; Detsky, 2001; Kim et al., 2007; White et 
al., 2009).  
Patient intolerance is among the most important problems with the existing screening 
methods. With the technological developments in computed tomography (CT) systems, this 
problem has led the emergence of computed tomographic colonography (CTC) also termed 
as “virtual colonoscopy” technique (Hock et al., 2011). The American Cancer Society has 
described virtual colonoscopy as a promising screening technique in 1997 (Byers et al., 
1997). Indeed, the idea of virtual colonoscopy has been initiated with the discovery of 
computed tomography (CT) by Godfrey Hounsfield in 1973 (Hounsfield, 1973). Following 
that, virtual colonoscopy was used in patients who cannot tolerate the conventional 
colonoscopy procedure. (Bakir et al., 2004; Ferrucci, 2001; Labianca & Merelli, 2010; White et 
al., 2009). The positive results regarding patient tolerance with this minimally invasive 
technique confirmed this idea.  
In the first step, two-dimensional (2D) high-resolution images in the axial plane are obtained 
with this screening technique. Then, three-dimensional (3D) images are constructed similar 
to conventional colonoscopy by digital software systems. After adequate colonic distention 
is ensured, CT examination is performed, preferentially with multi-detector systems. Data 
acquisition is performed first in the supine, and afterwards in the prone position. Imaging in 
two different positions, enables mobilization of the feces and fluid to the dependent wall 
and increases the accuracy of the CTC procedure. The multi-detector systems with higher 
resolution, significantly decreased scan time (within a single breath-hold) and thinner 
collimation have improved the sensitivity and specificity of CTC.  Thin collimation is a must 
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for an adequate CTC examination, in order to obtain high-quality three-dimensional images 
and multi-planar reformats. Another important point is that the scan should be completed 
in a single breath-hold period; otherwise motion artefacts might decrease the resolution 
(Pickhardt, 2007; Mang et al.,  2007; Tolan et al., 2007; Wu et al., 2011) 
3. Preparation and technique 
Bowel cleansing and preparation is an important step of this procedure. There are a few 
recommendations for bowel cleansing. It is well known that adequate patient education 
and bowel preparation increase the sensitivity of this technique significantly. In the 
presence of an adequately cleansed bowel, the residual stool particles may result in false 
positive interpretation. Unlike colonoscopy, the residual fluid cannot be aspirated during 
the CTC examination. Therefore, the presence of fluid may cause in false negative results. 
Since the first introduction of CTC into the imaging practice, bowel preparation 
techniques have been changed and modified. Fecal and fluid tagging methods have been 
developed in addition to bowel cleansing, which have been shown to increase the 
accuracy of this examination (Taylor et al., 2003). Approximately 24-48 hours before the 
examination, patients are informed to start a clear liquid diet. Bowel cleansing is generally 
performed using various agents such as sodium phosphate, polyethylene glycol, fleet 
enemas (phosphasoda) or magnesium citrate. In general, while phosphasoda is preferred 
in younger patients, polyethylene glycol is used in older age in order to avoid side effects 
(Bielen et al., 2003).  
Adequate distention of the colon should be achieved for a high-quality CTC and accurate 
interpretation. In order to perform colonic distention, a rectal tube is inserted just before the 
examination. Prior to the rectal tube insertion, digital rectal examination should be 
performed and then the tube is inserted in the left decubitus position. Foley catheters and 
rectal tubes can be used for this purpose. It has been reported that catheters as thin as 20 F 
are adequate for optimal distention. The large caliber balloon rectal catheter is generally 
used in barium studies. However, it was not recommended due to the increased risk of 
colonic perforation. Both room air and CO2 are suitable to use during colonic insufflation. 
Using room air with a plastic handheld insufflator is practical and cost-effective and most 
centers use this method. On the other hand, some authors prefer the use of CO2, with the 
suggestion that it is rapidly absorbed from colonic mucosa with less post-procedure patient 
discomfort. The insufflation of CO2 or compressed air can be performed by manual means or 
automatically with an insufflator. The use of an insufflator enabling the control of both the 
intra-rectal pressure and the volume of gas delivered, is generally preferred because of its 
safety. The amount of gas delivered depends on the colonic length of the patient and the 
competency of ileocecal valve. After the insufflation is performed, a scout image of the 
abdomen is obtained, to evaluate the need for more insufflation. (Fig 1). During the 
insufflation process, antispasmodic agents may be administered to reduce the discomfort 
and spasms and to provide better distention. Yet, there is no consensus about the use of anti-
spasmodic agents, and some authors disagree the use of these agents routinely, since they 
believe that administration of these agents increases the patients discomfort and may cause 
side effects. In most of the centers, antispasmolytics are not used routinely, but indicated 
when marked patient discomfort occurs (Bielen et al., 2003; Mang et al., 2007; Pickhardt et al 
2003; Taylor et al., 2003; Tolan et al., 2007). After this procedure, the colonic pathway is 
determined (Fig 2)  
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Fig. 1. After the insufflation is performed, a scout image of the abdomen is obtained, to 
evaluate the need for more insufflation 
 






Fig. 2. Virtual colonoscopic pathway view of colon. (H: Head, F:Foot, R:Right, L:Left, A: 
Anterior, P:Posterior) 
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Fig. 3. Extracolonic pathologies can be seen in virtual colonoscopy (sigmoid colon 
carcinoma) 
4. Advantages and disadvantages of virtual colonoscopy 
Virtual colonoscopy has many advantages such as the evaluation of extracolonic structures 
and moving inside the colon with a “fly-through” view as if a conventional colonoscopy 
examination. (Kim et al., 2007; Macari et al., 2011; Pedersen et al., 2003; Pescatore et al., 2000; 
Pickhardt et al., 2011; Pilch-Kowalczyk et al., 2004; Roberts-Thomson et al., 2008; Sutherland 
et al., 2011; White et al., 2009)(Fig 3,4). Virtual examinations carry the advantages including 
being relatively noninvasive, safe, and acceptable by clinicians (Ekci & Yildirim, 2009; 
Johnson & Dackman., 2000; Leksowski el al., 2011; McHugh et al., 2011; Vining, 1996). All 
these advantages may facilitate the detection of polyps with certain size. (Table 1) Probably, 
the most important disadvantage of the virtual colonoscopy is that it is only possible to 
detect the presence of polyp, and that biopsy cannot be performed or polyps cannot be 
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removed with this procedure (Byers  et al., 1997; Dachman & Yoshida, 2003; Ignjatovic et al., 
2010; Fenlon, 2002; Levin  et al., 2003; Pilch-Kowalczyk et al., 2004). (Table 2). Polyps appear 
as intraluminal nodular filling defects on 3D endoluminal images. Their shape is mostly 
round or oval, but may also have lobulated features. Most of the polyps are sessile; some of 
them are pedunculated characterized with a stalk. It is noteworthy to mention that some of 
the pedunculated polyps may change position among prone and supine images, in this case 
the presence of the stalk helps to prevent diagnostic confusion with fecal residue (Chang et 
al., 2011; Ignjatovic et al., 2010; Liedenbaum et al., 2010; Taylor et al., 2003). The 
differentiation of polyps and fecal residue is one of the most important diagnostic 
challenges in evaluation of CTC. At this point, combined evaluation of both 2D and 3D 
images is mandatory. On 3D views, both entities are seen as luminal filling defects, on the 
other hand fecal residue mostly contain air density foci that can readily be seen on 2D 
images. Another important clue is the change in position of fecal material among supine and 
prone images (Ferrucci 2001; Wu et al.,2011; Taylor et al., 2003). 
 
  
Fig. 4. “Fly-through” view in colon 
Diverticula are relatively common findings on CTC, which appear as air-filled sacs on 2D, 
and as “complete dark ring” on 3D endoluminal images. This “complete dark ring” 
appearance is important, since polyps different from diverticula are well defined at their 
free-profile margin only. On the other hand, when diverticula are filled with fecal material, 
differentiation might be difficult, since they will be seen as polypoid structures bulging to 
the lumen from the diverticular orifice (Taylor et al., 2003; Ferrucci 2001). 
Pseudo lesions observed with virtual colonoscopy are residual fecal material, ileocecal 
valve, bulbous and irregular interhaustral folds, inadequate colon distention and extrinsic 
compression defects (Fig 5). Another disadvantage of virtual colonoscopy is the false 
negative or false positive rates. The most common reasons are inadequate colon preparation, 
inadequate distention and bulbous haustral fold (Hara et al., 2001; Halligan et al., 2006; 
Ferrucci, 2001; Roberts-Thomson et al., 2008). Screening in prone or supine position or 
administration of IV contrast agent might be helpful to avoid confusing polyps with 
residual fecal material. (Fletcher et al., 1998; Stuart & Andrea, 2007). Attempts have been 
made to further increase the accuracy of CTC, with the so-called  “tagging” methods. They 
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include basically fecal and fluid tagging. In the tagging methods, laxative dose is reduced 
and the preparation is accompanied with oral contrast material in order to “tag” the possible 
residual stool and fluid. From the patient point of view, the tagging methods, enabling less 
laxative dosage, increase patient compliance by reducing the uncomfortable symptoms 
related to bowel cleansing. It is well known that fluid and fecal tagging improve the 
diagnostic performance by reducing the number of false-positive and false-negative results. 
During the tagging process, the ingested bowel contents are marked with contrast and in 
turn, they are easily differentiated from real lesions. The polyps, as expected, do not absorb 
the ingested contrast material and remain in their original soft tissue density which make 
them easily distinguishable from bowel contents that are admixed and coated with contrast 
(Bielen et al., 2003; Pickhardt, 2007 ). Most of the studies suggest increased diagnostic 
accuracy of CTC with the use of tagging methods (Dachmann et al., 2007; Liedenbaum et al., 
2011; McFarland & Brink., 1999).  
 
 Minimally invasive
 High patient comfort 
 No sedation is needed 
 The examination is less time consuming and causes less pain 
 Allows evaluation of extracolonic organs  
 Provides evaluation of metastases at the same time in cancer cases  
 Detection of polyps hiding behind the haustral fold is easier  
 The images may be reevaluated for many times after the procedure  
 Provides “fly-through” view as if a normal colonoscopy screening 
 Provides evaluation of the proximal aspect of strictures in obstructed lesions where it is not 
possible to get access with conventional colonoscopy  
 The images might be evaluated by different specialists independent from time and place 
 It may be performed in patients having additional systemic disorders where conventional 
colonoscopy is contraindicated   
 It may be performed in acute angle sigmoid cases where the conventional colonoscopy 
failed to proceed 
Table 1. Potential advantages of virtual colonoscopy  
 
 Exposure to radiation
 No possibility of biopsy 
 The further assessment of the detected lesions should be performed with conventional 
colonoscopy 
 Compared to conventional colonoscopy, it provides less detail of colonic mucosa and lack of 
color makes it harder to evaluate the color changes of mucosa 
 Detection sensitivity is low in polyps less than 5mm and flat adenomas  
 It is an expensive procedure 
 The evaluation and reporting is relatively time consuming 
 It carries the risk of giving false negative or false positive results 
 If the colon is not adequately insufflated, the colonic evaluation is hard or almost impossible  
 The excess gas insufflations cause pain. Therefore, it should be given under physician 
control and as required  
 Colonic cleansing is crucial (If this procedure is not properly carried out, residual fecal 
material might mimic or hide lesions) 
 The procedure requires an experienced radiologist for both performing and interpretation 
Table 2. Disadvantages of virtual colonoscopy 
 




Fig. 5. Residual fecal material 
For the “tagging” procedure, only barium, only iodine, or their combination can be used, the 
latter resulting in both fecal and fluid tagging. The optimal “tagging formula” is still under 
debate as to which agents to be used in which dosages (Chang  et al., 2011; Pickhardt et al., 
2003; Pickhardt, 2007). 
Another important factor affecting the rate of polyp detection in CTC is the slice thickness. 
Studies comparing the efficiency of 3 mm and 5 mm slices have reported that the image 
clarity of 5 mm slices was less than that of 3 mm slices and that 5 mm slices were less 
sensitive to polyps sized less than 5 mm. (Hara et al., 1997; Rogalla et al., 2002). It was 
concluded that the use of slices less than 3 mm was beneficial in CTC. (Stuart&Andrea, 
2007). With the technological improvements, this technique yielded images with better 
resolution, thereby obtaining significantly higher polyp detection rates (Aschoff et al., 2004; 
Dachman et al., 2007; Vining, 1996) (Fig 6).  
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Fig. 6. Colonic polyps’ view on 3D CTC images 
The modality of choice in the detection of colonic polyps is still fiberoptic colonoscopy. 
Fiberoptic colonoscopy is the only modality that allows detection and at the same time, 
excision of the polyps. For adenomatous lesions measuring more than 1 cm, this technique 
has high sensitivity (> 95 %) and specificity (100%). A false negative rate of 6 % has been 
reported (Dachman&Yoshida, 2003; Dachman et al., 2007). The sensitivity of virtual 
colonoscopy in the detection of polyps measuring more than 1 cm is, 90-94% (Oto et al., 
2003). Studies comparing conventional and virtual colonoscopy have shown that these two 
modalities have similar sensitivity values for polyps measuring more than 7 mm (Menardo, 
2004), while virtual colonoscopy has limited efficiency for the detection of polyps less than 5 
mm (Aschoff et al., 2004). In another study comparing these two modalities in terms of 
detection of colonic adenomas measuring more than 6 mm, the sensitivity of virtual 
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colonoscopy was reported as 88.7%, and the sensitivity of optic colonoscopy was 92.3%. And 
in the same study the sensitivity values for lesions measuring more than 10 mm were 
reported as 93.8% and 87.5%, respectively (Pickhardt et al., 2003). Gottlieb (Gottlieb, 2004), 
evaluated patients who had undergone virtual colonoscopy, followed by optic colonoscopy 
and the author reported a 10% false negative rate of optic colonoscopy in the detection of 
polyps dependent on the operator, whereas lower false negative rates were reported for 
virtual colonoscopy.  
The sensitivity rates of optic and virtual colonoscopy are getting closer to each other, 
parallel to the technological advances.  The varying sensitivity values of virtual colonoscopy 
for polyps measuring 1-5 mm most probably depend on; the adequacy of bowel cleansing, 
CT acquisition technique, the administration of intravenous contrast medium, the relation of 
the lesion with mucosal folds, and experience of the radiologist. Among these issues, 
experience of the radiologist is very important in terms of high diagnostic performance. 
There are highly different and variable accuracy values reported among different readers, 
which in turn needs to be standardized with reader training. Various reports indicate that 
increased reader education and experience provides better accuracy in terms of CTC 
evaluation (Burling et al., 2007; Haycock et al., 2010; Philip et al.,2011). 
5. Conclusion 
In conclusion, the size and location of the polyps can be successfully detected by virtual 
colonoscopy, but it is noteworthy to indicate that conventional colonoscopy is inevitable for 
pathologic diagnosis. Due to the above-mentioned reasons, we believe that virtual 
colonoscopy is suitable for screening purposes, and cannot replace the necessity for 
conventional colonoscopy for definitive diagnosis. However, with technological advances 
the application of virtual colonoscopy may contribute significantly to the diagnosis of 
colonic diseases.  
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